Unnamed: 0,title,date,stock,sentiment
549047.0,Gilead Sciences: Co. Said To Refinance $2.5B Loan Facility,2020-06-10 13:44:00-04:00,GILD,neutral
549048.0,Gilead Sciences Option Alert: Jun 19 $80 Calls Sweep (2) near the Ask: 300 @ $1.121 vs 22172 OI; Earnings 7/28 After Close [est] Ref=$78.32,2020-06-10 09:39:00-04:00,GILD,positive
549049.0,A Peek Into The Markets: US Stock Futures Mixed; All Eyes On Fed Decision,2020-06-10 06:01:00-04:00,GILD,neutral
549050.0,Singapore Approves Gilead's Remdesivir as COVID-19 Treatment,2020-06-10 05:23:00-04:00,GILD,positive
549051.0,A Look Into Gilead Sciences' Price Over Earnings,2020-06-09 10:35:00-04:00,GILD,neutral
549052.0,Gilead's Remdesivir Slows Disease Progression in Monkeys with COVID-19,2020-06-09 06:50:00-04:00,GILD,neutral
549053.0,4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize,2020-06-08 18:26:00-04:00,GILD,neutral
549054.0,Astrazeneca CEO Soriot Said To Have Called Gilead CEO On May 9; Proposed Exploring Merger On A Call,2020-06-08 17:08:00-04:00,GILD,neutral
549055.0,PreMarket Prep Stock Of The Day: Gilead Sciences,2020-06-08 12:20:00-04:00,GILD,neutral
549056.0,3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor,2020-06-08 10:10:00-04:00,GILD,neutral
549057.0,EMA Receives Application For Conditional Authorization Of First COVID-19 Treatment In EU,2020-06-08 10:06:00-04:00,GILD,neutral
549058.0,"'Gilead, AstraZeneca not in merger talks' CNBC's Faber Reports",2020-06-08 09:19:00-04:00,GILD,neutral
549059.0,Gilead Sciences shares are trading higher following a Bloomberg article suggesting AstraZeneca has approached the company regarding a merger.,2020-06-08 07:12:00-04:00,GILD,positive
549060.0,A Peek Into The Markets: US Stock Futures Up; OPEC+ Agrees To Extend Output Cuts,2020-06-08 06:01:00-04:00,GILD,positive
549061.0,AstraZeneca Approached Gilead With A Deal That Could Be The Biggest On Record: Report,2020-06-08 03:56:00-04:00,GILD,neutral
549062.0,AstraZeneca Approaches Gilead Regarding Potential Record Health-Care Merger,2020-06-07 08:47:00-04:00,GILD,neutral
549063.0,"Bulls And Bears Of The Week: Gilead, Shopify, Tesla And More",2020-06-06 14:26:00-04:00,GILD,neutral
549064.0,Galapagos And Gilead Highlight Presentation Of Analyses From Phase 2 EQUATOR Clinical Program Of Efficacy Of Filgotinib In Psoriatic Arthritis,2020-06-05 16:03:00-04:00,GILD,positive
549065.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,GILD,positive
549066.0,Gilead Says Indian Licensees are Free to Set Price of Remdesivir,2020-06-04 05:42:00-04:00,GILD,positive
549067.0,"Gilead, Galapgos Announce Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in Finch 1 and 3 Studies in Rheumatoid Arthritis",2020-06-04 05:34:00-04:00,GILD,positive
549068.0,"Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy",2020-06-03 11:20:00-04:00,GILD,neutral
549069.0,"STAT News' Adam Feuerstein Retweets Tweet From Memorial Sloan-Kettering Doctor, Peter Bach, On Gilead Remdesivir Reanalysis Data",2020-06-03 09:15:00-04:00,GILD,neutral
549070.0,"SVB Leerink Upgrades Gilead From Market Perform To Outperform, Raises PT From $85 To $94",2020-06-03 07:16:00-04:00,GILD,neutral
549071.0,Gilead shares are trading lower on continued momentum after the company reported data from its Phase 3 Trial of Remdesivir showing odds of improvement in clinical status with 10-day course were trending toward but not reaching statistical significance.,2020-06-02 13:06:00-04:00,GILD,negative
549072.0,"'Gilead Drug Remdesivir's Use Against Coronavirus Could Become Obsolete, Analyst Says' -Barrons Report",2020-06-02 10:57:00-04:00,GILD,negative
549073.0,"'Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions' -Reuters",2020-06-02 08:40:00-04:00,GILD,neutral
549074.0,Gilead's Remdesivir Cleared for Use in India for Severe Covid Cases,2020-06-02 05:20:00-04:00,GILD,negative
549075.0,Mark Genovese Joins Gilead to Lead Clinical Development of Company's Inflammation Programs,2020-06-01 16:05:00-04:00,GILD,neutral
549076.0,"BioSig Shares Spike To Session High On Volume; 8-K Filing Shows Co. Subsidiary ViralClear Filed Protocol Of Planned Study To Evaluate Safety, Efficacy Of Merimepodib In Combo With Remdesivir For Patients With Advanced Coronavirus To ClinicalTrials.gov",2020-06-01 13:51:00-04:00,GILD,positive
549077.0,Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19,2020-06-01 11:14:00-04:00,GILD,neutral
549078.0,Gilead shares are trading lower after the company reported data from its Phase 3 Trial of Remdesivir showing odds of improvement in clinical status with 10-day course were trending toward but not reaching statistical significance.,2020-06-01 09:43:00-04:00,GILD,negative
549079.0,"'Gilead study of remdesivir in moderate #COVID19 patients out: patients on 5-day course were 65% more likely to have clinical improvement at Day 11 vs standard of care, but effect for those on 10-day course was not statistically significant' -Tweet",2020-06-01 08:45:00-04:00,GILD,positive
549080.0,Gilead Says Odds Of Improvement In Clinical Status With 10-day Course Of Remdesivir Were Trending Toward But Not Reaching Statistical Significance,2020-06-01 08:37:00-04:00,GILD,negative
549081.0,UPDATE: Gilead Study Demonstrated That Patients In The 5-day Remdesivir Treatment Group Were 65 Percent More Likely To Have Clinical Improvement At Day 11 Compared With Those In The Standard Of Care Group,2020-06-01 08:32:00-04:00,GILD,positive
549082.0,Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19; Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone,2020-06-01 08:31:00-04:00,GILD,positive
549083.0,Mylan's Pakistan Partner AGP to Sell Remdesivir to Treat Covid-19 Within Two Months,2020-05-31 09:25:00-04:00,GILD,positive
549084.0,Gilead Seeks Marketing Authorization From India,2020-05-29 15:12:00-04:00,GILD,neutral
549085.0,"Gilead's Kite Pharma Reports Yescarta Data Showing Response Rates In Relapsed, Refractory Indolent Non-Hodgkin Lymphoma To Be Presented At ASCO",2020-05-29 08:10:00-04:00,GILD,neutral
549086.0,"Gilead Reports Updated Results From Single-Arm, Open-Label Phase 1b Trial Of Magrolimab In Combo With Azacitidine In Previously Untreated Patients With Higher-Risk Myelodysplastic Syndrome",2020-05-29 08:07:00-04:00,GILD,neutral
549087.0,"Tigress Financial's Ivan Feinseth Notes Many Co.'s Working To Produce Coronavirus Vaccines/Treatments; Says If Remdesivir Is Ramped Up, Gilead May Need To Work With Others To License And Produce It, And It May Not Be As Profitable",2020-05-28 11:52:00-04:00,GILD,negative
549088.0,"The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer",2020-05-28 08:24:00-04:00,GILD,neutral
549089.0,BDR Pharmaceuticals Sought India Approval to Manufacture Remdesivir Without Gilead Agreement,2020-05-28 05:25:00-04:00,GILD,positive
549090.0,Roche Initiates Phase III Clinical Trial of Actemra/Roactemra Plus Remdesivir in Hospitalised Patients With Severe Covid-19 Pneumonia in collaboration with Gilead,2020-05-28 05:19:00-04:00,GILD,negative
549091.0,Gilead And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer Immunotherapies; Arcus To Receive $175M Up Front And $200M Equity Investment Plus Up To $1.6B In Potential R&D Funding+Milestones,2020-05-27 07:13:00-04:00,GILD,negative
549092.0,UK Clears Gilead's Remdesivir For Some Coronavirus Patients,2020-05-26 15:46:00-04:00,GILD,positive
549093.0,"CORRECTION: UK Health Minister Hancock Says Anti-Viral Drug Remdesivir Is Probably Biggest Step Forward In Treatment Since Crisis Began; Prior Headline Named Hancock US Health Minister, This Was Incorrect",2020-05-26 15:13:00-04:00,GILD,negative
549094.0,"'Gilead Could Sell $1.1 Billion of Remdesivir This Year, Analyst Writes' -Barrons Report",2020-05-26 12:51:00-04:00,GILD,neutral
549095.0,UK Health Minister Hancock Says Anti-Viral Drug Remdesivir Is Probably Biggest Step Forward In Treatment Since Crisis Began,2020-05-26 12:15:00-04:00,GILD,negative
549096.0,"Benzinga's Top Upgrades, Downgrades For May 26, 2020",2020-05-26 09:42:00-04:00,GILD,positive
549097.0,10 Biggest Price Target Changes For Tuesday,2020-05-26 08:02:00-04:00,GILD,neutral
549098.0,"SunTrust Robinson Humphrey Upgrades Gilead Sciences to Hold, Raises Price Target of $73",2020-05-26 06:07:00-04:00,GILD,neutral
549099.0,UK Health Ministry Says Selected NHS Patients to Access Gilead's Coronavirus Treatment Remdesivir,2020-05-26 05:59:00-04:00,GILD,neutral
549100.0,Investigators Found Remdesivir Was Most Beneficial for Hospitalized Patients With Severe Disease Requiring Supplemental Oxygen; Findings Less Conclusive in Other Patient Subgroups,2020-05-22 18:17:00-04:00,GILD,positive
549101.0,"NIH Says Peer-reviewed Data Shows Gilead''s Remdesivir for Covid-19 Improves Time to Recovery; Says Remdesivir is Superior to Standard of Care for Treatment of Covid-19, According to Report Published in New England Journal of Medicine",2020-05-22 18:16:00-04:00,GILD,positive
549102.0,Fauci On Remdesivir Study: Study Showed Advantage Of Diminishing Time Of Recovering From COVID-19,2020-05-22 12:15:00-04:00,GILD,positive
549103.0,Gilead Sciences Option Alert: Jun 19 $75 Calls Sweep (39) near the Ask: 854 @ $2.185 vs 17286 OI; Ref=$72.88,2020-05-22 10:17:00-04:00,GILD,positive
549104.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,GILD,neutral
549105.0,"Gilead, Galapagos Report Topline Results From Phase 2b/3 Trial Of Filgotinib In Moderate To Severe Active Ulcerative Colitis",2020-05-20 16:02:00-04:00,GILD,neutral
549106.0,Gilead Sciences Option Alert: Jul 17 $80 Calls Sweep (32) near the Ask: 508 @ $2.09 vs 5144 OI; Ref=$73.8899,2020-05-20 13:43:00-04:00,GILD,positive
549107.0,Gilead Sciences Option Alert: May 29 $75 Calls Sweep (2) near the Ask: 300 @ $1.45 vs 2555 OI; Ref=$73.31,2020-05-20 12:38:00-04:00,GILD,positive
549108.0,"'Gov. Abbott announced El Paso hospitals would receive 12 cases of Remdesivir...' -Tweet From El Paso, Texas' KVIA ABC 7 News",2020-05-20 11:31:00-04:00,GILD,neutral
549109.0,"In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs",2020-05-19 09:38:00-04:00,GILD,positive
549110.0,"RBC Analyst Earlier Warned Gilead's Remdesivir Is Unlikely To Yield Monetary Results Co. Hoped, Notes Co. Planning To Give Away 1.5M Doses For Free",2020-05-18 15:08:00-04:00,GILD,positive
549111.0,Gilead Sciences Option Alert: Jan 15 $125 Calls Sweep (26) above Ask!: 300 @ $0.686 vs 2223 OI; Ref=$74.881,2020-05-18 12:42:00-04:00,GILD,positive
549112.0,"Barron's Picks And Pans: Cisco, Gilead, Netflix, Wayfair And More",2020-05-17 11:00:00-04:00,GILD,neutral
549113.0,Gilead Sciences Option Alert: Jan 15 $90 Calls Sweep (3) near the Ask: 350 @ $4.651 vs 8065 OI; Ref=$75.96,2020-05-15 15:52:00-04:00,GILD,positive
549114.0,"VBI Vaccines Shares At Session Highs; 'Why Big Investors Aren't Betting It All on a Coronavirus Cure' -WSJ Article; Mentions Gilead, VBI Vaccines, INOVIO",2020-05-14 14:56:00-04:00,GILD,positive
549115.0,'#COVID19 No data disclosed for #remdesivir #hydroxychroloquine in the DISCOVERY trial in France.' -Tweet From Andy Biotech. BZ NOTE: Content In Tweet From ~2 Hours Ago,2020-05-14 12:11:00-04:00,GILD,neutral
549116.0,"Gilead, Co.'s Kite Pharma Highlight Acceptance Of 9 Abstracts During ASCO 2020",2020-05-13 17:01:00-04:00,GILD,positive
549117.0,Gilead Sees Some Results On Remdesivir In 'Few Weeks',2020-05-13 15:00:00-04:00,GILD,neutral
549118.0,"Hetero Enters Into a Licensing Agreement With Gilead Sciences, Inc. for the Manufacturing and Distribution of ""Remdesivir"" in 127 Countries, Including India, for COVID-19",2020-05-13 14:01:00-04:00,GILD,positive
549119.0,Roivant Sciences Says Breathe Trial Participants Will Be Permitted To Use Investigational Antivirals Including Remdesivir,2020-05-13 13:14:00-04:00,GILD,neutral
549120.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,GILD,neutral
549121.0,"4 Key Takeaways From Senate's Online Hearing On US Coronavirus Strategy, Reopening Economy",2020-05-13 07:36:00-04:00,GILD,neutral
549122.0,Gilead Shares Drop As It Agrees To 'Royalty-Free' Coronavirus Drug Licence With Generic Drugmakers In 127 Countries,2020-05-13 01:30:00-04:00,GILD,positive
549123.0,"UPDATE: Under The Terms Of The License Agreement Signed With Gilead, Mylan Has Rights To Manufacture And Distribute Remdesivir In 127 Low- And Middle-Income Countries, Including India.",2020-05-12 16:19:00-04:00,GILD,positive
549124.0,Mylan To Supply Investigational Antiviral Remdesivir For The Potential Treatment Of Coronavirus/COVID-19,2020-05-12 16:17:00-04:00,GILD,neutral
549125.0,Gilead Confirms Non-Exclusive Voluntary License Deal For Distribution Of Remdesivir With 5 Generic Makers In 127 Countries,2020-05-12 14:40:00-04:00,GILD,neutral
549126.0,Here's A Bullish Options Play On Gilead,2020-05-12 14:28:00-04:00,GILD,positive
549127.0,"'Gilead strikes licensing agreements w 5 cos (Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan) to manufacture remdesivir in 127 countries, royalty-free until WHO declares end of global public health emergency' -Tweet",2020-05-12 14:22:00-04:00,GILD,positive
549128.0,Jubilant Life Sciences Signs Non-Exclusive License Deal For Selling Gilead's Remdesivir In 127 Countries Including India; BZ NOTE: Jubilant Not Publicly Traded In US,2020-05-12 12:18:00-04:00,GILD,positive
549129.0,FDA Commissioner: We've Learned A Lot Of Lessons From The 'Remdesivir Situation',2020-05-12 11:49:00-04:00,GILD,neutral
549130.0,Fauci: Remdesivir Study Was Statistically Significant But Modest Success,2020-05-12 10:31:00-04:00,GILD,positive
549131.0,"'Distribution of Key Drug Was Flawed, Says White House Official' -Yesterday WSJ Report",2020-05-12 08:39:00-04:00,GILD,neutral
549132.0,UPDATE: European Medicines Authority Says Has Added Treatment Duration Of 5 Days For Gilead's Remdesivir Alongside 10-Day Course,2020-05-11 14:52:00-04:00,GILD,positive
549133.0,European Medicine Authority Recommends Expanding Gilead's Remdesivir Compassionate Use To Patients Not On Mechanical Ventilation,2020-05-11 14:47:00-04:00,GILD,positive
549134.0,"Gilead shares are trading higher. Strength potentially due to optimism surrounding the company's Remdesivir, which is being evaluated as a potential coronavirus treatment candidate.",2020-05-11 12:25:00-04:00,GILD,positive
549135.0,Biotech Stock Rally Is Crushing Short Sellers,2020-05-11 12:15:00-04:00,GILD,negative
549136.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,GILD,neutral
549137.0,NYC Mayor Bill de Blasio  Tweets: This week the FDA approved the use of Remdesivir to treat severely ill COVID-19 patients. The initial clinical trials shows it decreased hospital stays from 15 to 11 days. That's promising.,2020-05-10 15:12:00-04:00,GILD,positive
549138.0,"HHS Announces Shipments of Donated Remdesivir for Hospitalized Patients With Covid-19 from a Donation by Gilead Sciences to the U.S. Which Was Finalized on May 3, 2020",2020-05-09 09:55:00-04:00,GILD,neutral
549139.0,UPDATE: NIAID Says Investigators Currently Expect Enrolling 1K+ Patients In Remdesivir Plus Baricitinib Trial,2020-05-08 14:14:00-04:00,GILD,neutral
549140.0,"UPDATE: NIH's National Institute Of Allergy And Infectious Diseases Says Remdesivir Trial Is Expected To Open At ~100 US, Int'l. Sites",2020-05-08 14:12:00-04:00,GILD,neutral
549141.0,US National Health Institutes Clinical Trial Testing Remdesivir Plus Anti-Inflammatory Adults With Coronavirus In US,2020-05-08 14:11:00-04:00,GILD,neutral
549142.0,Iranian Linked Hackers Attacked Gilead,2020-05-08 13:16:00-04:00,GILD,negative
549143.0,White House Says Task Force's Birx Will Offer Consultation Regarding Gilead's Coronavirus Drug,2020-05-08 12:57:00-04:00,GILD,neutral
549144.0,Gilead Issues Press Release Highlighting Approval Of Veklury In Japan For Patients With Severe Coronavirus Infection,2020-05-07 11:45:00-04:00,GILD,positive
549145.0,3 Biotech ETFs Up 10% Or More Over The Last Month,2020-05-07 11:36:00-04:00,GILD,neutral
549146.0,Gilead Sciences Option Alert: May 15 $80 Calls Sweep (4) near the Ask: 725 @ $0.96 vs 14381 OI; Ref=$77.35,2020-05-07 11:28:00-04:00,GILD,positive
549147.0,Japan Health Ministry Official: Remdesivir Will Be Used For Coronavirus/Covid-19 Patients With Severe Conditions,2020-05-07 08:24:00-04:00,GILD,negative
549148.0,Japan Approves Gilead Sciences' Drug Remdesivir As Coronavirus/COVID-19 Treatment,2020-05-07 07:58:00-04:00,GILD,positive
549149.0,"EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says",2020-05-06 12:42:00-04:00,GILD,neutral
549150.0,Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss,2020-05-06 10:49:00-04:00,GILD,negative
549151.0,"Gilead Says Possibility That Co May Experience Delays With NDA for Filgotinib for Treatment of RA Filed With FDA and With NDA, MAA for Kte-x19 for Treatment of Relapsed or Refractory Mantle Cell Lymphoma",2020-05-06 06:23:00-04:00,GILD,neutral
549152.0,Gilead Says Anticipate Accelerating Remdesivir Investments in Future Quarters,2020-05-06 06:13:00-04:00,GILD,neutral
549153.0,"Gilead Sciences Says Incurred ~$50M of Manufacturing Scale-up, Clinical Trial Costs for Remdesivir During Q1",2020-05-06 06:12:00-04:00,GILD,neutral
549154.0,"Coronavirus Has Been Circulating Since Late 2019, UK Research Says",2020-05-06 01:04:00-04:00,GILD,neutral
549155.0,"Gilead In Talks With Some Chemicals, Pharma Companies About Ability To Produce Remdesivir For Europea, Asia, Developing World Through At Least 2022",2020-05-05 17:35:00-04:00,GILD,positive
549156.0,"UPDATE: Gilead Negotiating Long-Term Voluntary Licenses With Several Generic Drugmakers In India, Pakistan To Produce Remdesivir For Developing Countries",2020-05-05 17:34:00-04:00,GILD,neutral
549157.0,"Gilead Will Further Accelerate, Maximize Access To Remdesivir, Negotiating On Long-Term Voluntary Licenses With Drugmakers",2020-05-05 17:21:00-04:00,GILD,neutral
549158.0,Japanise Health Minister Says Gilead's Remdesivir May Be Approved In Japan On Thursday,2020-05-05 12:24:00-04:00,GILD,positive
549159.0,"'With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake' -STAT News $",2020-05-05 07:26:00-04:00,GILD,neutral
549160.0,"WHO Expert Says It Has Not Received Any Data From The US Relevant To The Purported Origin Of The Virus, Need To Understand More About Virus",2020-05-04 13:12:00-04:00,GILD,neutral
549161.0,WHO Says We Welcome The Recent Data From Randomized Control Trial Done In US With Gileads Remdesivir Says 'There Are Signals Of Hope There For The Potential Use Of The Drug',2020-05-04 13:09:00-04:00,GILD,positive
549162.0,"4 Sector ETFs For May: 2 To Buy, 2 To Avoid",2020-05-04 08:22:00-04:00,GILD,negative
549163.0,A Peek Into The Markets: US Stock Futures Down; Dow Futures Fall Over 300 Points,2020-05-04 06:00:00-04:00,GILD,neutral
549164.0,"7 Stocks To Watch For May 4, 2020",2020-05-04 04:41:00-04:00,GILD,neutral
549165.0,"Remdesivir To Be Available For Coronavirus Patients This Week, Gilead CEO Says",2020-05-03 23:16:00-04:00,GILD,neutral
549166.0,Trump Says Gilead is Pushing Fast on Coronavirus Drug,2020-05-03 19:40:00-04:00,GILD,neutral
549167.0,"Gilead CEO O'Day Says Co Has Donated Its Remdesivir Supplies to Federal Government' Says Government to Determine Where Treatments Go, Based on Need",2020-05-03 11:00:00-04:00,GILD,neutral
549168.0,"Benzinga's Bulls And Bears Of The Week: Ford, Gilead, Microsoft, Intel And More",2020-05-03 08:18:00-04:00,GILD,neutral
549169.0,"Barron's Picks And Pans: Berkshire Hathaway, Carvana, Madison Square Garden And More",2020-05-02 15:45:00-04:00,GILD,neutral
549170.0,Reuters Issues Correction: Says Vice President Pence Says The 1.5 Million (Not 1 Million) Vials Of Remdesivir Will Start Being Distributed To Hospitals On Monday,2020-05-01 16:44:00-04:00,GILD,neutral
549171.0,"Markets Have Best Month Since 1987, But End Week On Low Note",2020-05-01 16:30:00-04:00,GILD,neutral
549172.0,Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19,2020-05-01 16:27:00-04:00,GILD,positive
549173.0,"Gilead Says Set A Goal Of Producing At Least 500,000 Treatment Courses By October, 1M Treatment Courses By December 2020 And 'Millions More In 2021'",2020-05-01 16:24:00-04:00,GILD,neutral
549174.0,Gilead Says Authorization Allows 5-Day And 10-Day Treatment Durations,2020-05-01 16:21:00-04:00,GILD,neutral
549175.0,"Gilead Clarifies: 'Remdesivir remains an investigational drug and has not been approved by FDA'; Notes 'The authorization is temporary and does not take the place of the formal new drug application submission, review and approval process'",2020-05-01 16:21:00-04:00,GILD,positive
549176.0,Gilead PR Highlights FDA Emergency Authorization For Remdesivir; Says 'Authorization Enables Broader Use of Remdesivir to Treat Hospitalized Patients with Severe COVID-19 Disease in the United States',2020-05-01 16:20:00-04:00,GILD,positive
549177.0,Vice President Pence Says 1M Vials Of Remdesivir Will Start Being Distributed To Hospitals On Monday,2020-05-01 15:56:00-04:00,GILD,neutral
549178.0,FDA Letter To Gilead Authorizing Emergency Use For Remdesivir (Full Letter),2020-05-01 15:55:00-04:00,GILD,negative
549179.0,(PDF) FDA Fact Sheet For Remdesivir,2020-05-01 15:50:00-04:00,GILD,neutral
549180.0,Gilead Shares Spike On Reports Of FDA Emergency Use Authorization For Remdesivir; Down ~4.3% For The Session,2020-05-01 15:50:00-04:00,GILD,negative
549181.0,FDA's Hahn Says 'This Is An Important Clinical Advance',2020-05-01 15:48:00-04:00,GILD,positive
549182.0,FDA Commissioner Hahn: Gilead Drug Authorized For Use In Hospitalized Patients,2020-05-01 15:48:00-04:00,GILD,neutral
549183.0,Trump Says Gilead CEO Calls It An Important First Step And Is Donating 1 Million Vials Of Remdesivir,2020-05-01 15:44:00-04:00,GILD,positive
549184.0,Trump Says Gilead Has Emergency Use Authorization From FDA,2020-05-01 15:41:00-04:00,GILD,negative
549185.0,Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir,2020-05-01 15:00:00-04:00,GILD,positive
549186.0,"UPDATE: Morgan Stanley Maintains Equal-Weight On Gilead Sciences, Raises Target To $77 Notes 'Base business stable, we continue to expect near-term updates on remdesivir'",2020-05-01 11:51:00-04:00,GILD,positive
549187.0,"UPDATE: SunTrust Robinson Humphrey Downgrades Gilead Sciences To Sell, Maintains $70 Target On 'Lack of visibility to growth'; Notes 'We don't know what a sustainable revenue stream from remdesivir will look like'",2020-05-01 11:28:00-04:00,GILD,positive
549188.0,UPDATE: Raymond James Downgrades Gilead Sciences To Market Perform 'Because We Aren't Going to Wild Guess Remdesivir NPV',2020-05-01 11:17:00-04:00,GILD,neutral
549189.0,"Benzinga's Top Upgrades, Downgrades For May 1, 2020",2020-05-01 09:40:00-04:00,GILD,positive
549190.0,"SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $85",2020-05-01 09:30:00-04:00,GILD,neutral
549191.0,"Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $90",2020-05-01 08:49:00-04:00,GILD,neutral
549192.0,"Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $77",2020-05-01 08:09:00-04:00,GILD,neutral
549193.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,GILD,neutral
549194.0,Gilead CEO Says Company Will Continue to Try to Make New Drug Accessible and Affordable to Patients Around the World,2020-05-01 07:54:00-04:00,GILD,neutral
549195.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-01 07:42:00-04:00,GILD,neutral
549196.0,Gilead Sciences shares are trading lower after several firms downgraded the company's stock following the company's Q1 earnings results. The company also sees its business in the short term will be impacted by coronavirus due to fewer patients accessing treatment.,2020-05-01 07:19:00-04:00,GILD,neutral
549197.0,Gilead Says It Will Produce 1M Courses Of Coronavirus Experimental Drug 'Remdesivir' By December,2020-05-01 06:59:00-04:00,GILD,neutral
549198.0,JP Morgan Downgrades Gilead Sciences to Neutral,2020-05-01 06:43:00-04:00,GILD,positive
549199.0,SunTrust Robinson Humphrey Downgrades Gilead Sciences to Sell,2020-05-01 06:18:00-04:00,GILD,neutral
549200.0,Raymond James Downgrades Gilead Sciences to Market Perform,2020-05-01 06:12:00-04:00,GILD,neutral
549201.0,Gilead Sciences Announces Plans To Be Able To Produce Several Million Remdesivir Treatment Courses In 2021,2020-04-30 16:56:00-04:00,GILD,neutral
549202.0,Gilead Announced Number Of Treatment Courses Expected To Be Available May Actually Be Higher Based On Recent Topline Results From First Simple Study,2020-04-30 16:55:00-04:00,GILD,positive
549203.0,Gilead Announced It Anticipates More Than 1M Treatment Courses Will Be Manufactured By December 2020; Treatment Courses Projections Assume A 10-day Dosing Duration,2020-04-30 16:54:00-04:00,GILD,neutral
549204.0,Gilead Sciences Commits ~$50M Of Spending To Combat Coronavirus,2020-04-30 16:26:00-04:00,GILD,negative
549205.0,"Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus",2020-04-30 16:21:00-04:00,GILD,neutral
549206.0,"After Hours Stocks We're Watching: AMZN, WDC, AMGN, GILD, V, SKY, LOCO",2020-04-30 16:07:00-04:00,GILD,neutral
549207.0,Gilead Says While Coronavirus Did Not Impact Its First Quarter Results in It Anticipates That Its Business In The Short Term Will Be Impacted Due To Fewer Patients Accessing Treatment For Conditions Such As HIV And HCV,2020-04-30 16:05:00-04:00,GILD,neutral
549208.0,"Gilead Sciences Q1 EPS $1.680 Beats $1.570 Estimate, Sales $5.548B Beat $5.450B Estimate",2020-04-30 16:02:00-04:00,GILD,neutral
549209.0,Gilead Sciences Option Alert: May 15 $70 Puts at the Bid: 2500 @ $0.521 vs 15919 OI; Earnings 4/30 After Close Ref=$81.95,2020-04-30 14:06:00-04:00,GILD,positive
549210.0,"UK's Vallance: Remdesivir Has Shown Promise In Studies, Says Total Number Of Infections Coming Down",2020-04-30 12:50:00-04:00,GILD,positive
549211.0,Gilead Sciences Option Alert: Jun 19 $95 Calls at the Bid: 1500 @ $3.17 vs 7992 OI; Earnings 4/30 After Close Ref=$82.61,2020-04-30 12:44:00-04:00,GILD,positive
549212.0,"Apple And Amazon Up To Bat this Afternoon As Investors Ponder Microsoft, Facebook Results",2020-04-30 09:54:00-04:00,GILD,positive
549213.0,"FDA Commissioner Hahn Says Is Moving At 'Lightning Speed' On Gilead's Remdesivir, Says Wants To Have 'Totality Of Data' To Target Drug",2020-04-30 09:20:00-04:00,GILD,neutral
549214.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,GILD,positive
549215.0,"Earnings Scheduled For April 30, 2020",2020-04-30 04:16:00-04:00,GILD,neutral
549216.0,Trump Says He Wants FDA To Go As Quickly As Possible To Approve Gilead's Remdesivir,2020-04-29 17:04:00-04:00,GILD,neutral
549217.0,Fed Has Market's Back As It Pledges To Keep Rates Low Until Economy Can Swim On Its Own,2020-04-29 15:40:00-04:00,GILD,negative
549218.0,FDA Announcement Allowing Emergency Use Of Gilead's Experimental Coronavirus Drug Remdesivir Could Come As Soon As Wednesday,2020-04-29 14:02:00-04:00,GILD,negative
549219.0,"CFRA Maintains Sell on Gilead Sciences, Raises Price Target to $74",2020-04-29 13:27:00-04:00,GILD,neutral
549220.0,NIH Reports Median Time To Recovery Was 11 Days For Patients Treated With Remdesivir Compared With 15 Days For Those Who Received Placebo,2020-04-29 13:15:00-04:00,GILD,neutral
549221.0,"NIH Reports Prelim Results Suggested A Survival Benefit, With A Mortality Rate Of 8.0% For Group Receiving Remdesivir Versus 11.6% For Placebo Group",2020-04-29 13:14:00-04:00,GILD,positive
549222.0,NIH Clinical Trial Shows Remdesivir Accelerates Recovery From Advanced Coronavirus; Preliminary Results Indicate That Patients Who Received Remdesivir Had A 31% Faster Time To Recovery Than Those Who Received Placebo,2020-04-29 13:14:00-04:00,GILD,positive
549223.0,Fauci: FDA 'Working As We Speak' To Get Remdesivir To Market,2020-04-29 12:59:00-04:00,GILD,neutral
549224.0,"Fauci Says China Study On Remdesivir Was Not Adequate, Underpowered",2020-04-29 12:58:00-04:00,GILD,negative
549225.0,Here's How Much Investing $100 In Gilead Sciences Stock Back In 2010 Would Be Worth Today,2020-04-29 12:36:00-04:00,GILD,positive
549226.0,Fauci Says Has No Timeline On Gilead Working With FDA For Remdesivir Approval,2020-04-29 12:12:00-04:00,GILD,positive
549227.0,"'Fauci says Gilead reports the anti-viral reduced duration of COVID-19 from 15 to 11 days. ""A drug can block this virus,"" said Fauci about the results of the drug trial. He says the mortality rate also fell from 11% to 8%' -Tweet From CBS White House",2020-04-29 12:09:00-04:00,GILD,negative
549228.0,"'Fauci says Gilead reports the anti-viral reduced duration of COVID-19 from 15 to 11 days. ""A drug can block this virus,"" said Fauci about the results of the drug trial. He says the mortality rate also fell from 11% to 8%' -Tweet From CBS White House",2020-04-29 12:09:00-04:00,GILD,negative
549229.0,Fauci: Data Shows Remdesivir 'Clear Cut' Positive Effect,2020-04-29 11:55:00-04:00,GILD,positive
549230.0,SVBLeerink On Gilead Expects 'to learn more about these results during Gilead's earnings call tomorrow and we believe the focus of the discussion with primarily revolve around timelines for further clinical readouts as well as supply and manufacturing',2020-04-29 11:52:00-04:00,GILD,positive
549231.0,"SVBLeerink Maintains Market Perform, $68 Target On Gilead Notes 'We remain optimistic about the potential for remdesivir to provide meaningful clinical benefit across a relatively broad spectrum of moderate to severe COVID-19 illness'",2020-04-29 11:52:00-04:00,GILD,positive
549232.0,Why Gilead Stock Is Trading Higher Today,2020-04-29 11:43:00-04:00,GILD,neutral
549233.0,"STAT News Reporter Adam Feuerstein Responds To Tweet On Lancet Report On Remdesivir Trial, Says 'This Is The Negative China Study...We Reported On Last Week;' Lancet Study Suggests Drug Not Associated With Significant Clinical Benefits",2020-04-29 11:15:00-04:00,GILD,negative
549234.0,"UPDATE: JMP Reiterates Market Outperform Rating, $10 Price Target On BioCryst Pharma; BZ NOTE: BioCryst Shares Currently Trading At $3.72",2020-04-29 10:55:00-04:00,GILD,positive
549235.0,BioCryst Pharma Shares At Intraday High As Traders Circulate JMP Research Note Highlighting 'expect BCRX shares to trade up on [remdesivir] news',2020-04-29 10:54:00-04:00,GILD,positive
549236.0,"Hearing Gilead Drug Results Will Likely Be Discussed At White House Coronavirus Briefing, National Institutes For Health Will Release Results Later Today",2020-04-29 10:53:00-04:00,GILD,neutral
549237.0,P/E Ratio Insights for Gilead Sciences,2020-04-29 10:20:00-04:00,GILD,neutral
549238.0,"Alphabet, Boeing Shares Get A Lift Following Earnings, While GE Falls Short",2020-04-29 10:01:00-04:00,GILD,positive
549239.0,Gilead Sciences Option Alert: Fri $80 Calls at the Ask: 1000 @ $3.32 vs 6362 OI; Earnings 4/30 After Close Ref=$81.245,2020-04-29 09:57:00-04:00,GILD,positive
549240.0,UPDATE: Jefferies Says While Gilead Data Positive 'on balance there are a couple of factors to fill out the picture that are important to know in detail',2020-04-29 09:23:00-04:00,GILD,positive
549241.0,"Jefferies Says Gilead News On Remdesivir Will Be Taken As Good News Over Short Term, Sees FDA Probably Accelerating Some Sort Of Approval, Expanded Use For Drug",2020-04-29 09:22:00-04:00,GILD,positive
549242.0,Gilead shares are trading higher after a study of the company's remdesivir by the National Institute of Allergy and Infectious Diseases met its primary endpoint. Remdesivir is being evaluated as a potential coronavirus treatment candidate.,2020-04-29 09:22:00-04:00,GILD,positive
549243.0,Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial,2020-04-29 09:21:00-04:00,GILD,positive
549244.0,"'Today, the world gets the first real sign that a new medicine, remdesivir from Gilead Sciences, will help the world emerge from the Covid-19 pandemic...' -Tweet From STAT News' Adam Feuerstein",2020-04-29 08:59:00-04:00,GILD,positive
549245.0,"UPDATE: Gilead Says 'At Day 14, 64.5% (n=129/200) of patients in the 5-day treatment group and 53.8% (n=106/197) of patients in the 10-day treatment group achieved clinical recovery'",2020-04-29 08:51:00-04:00,GILD,neutral
549246.0,Gilead Says Plans To Submit Full Data For Remdesivir In Peer-Reviewed Journal In Coming Weeks,2020-04-29 08:47:00-04:00,GILD,neutral
549247.0,UPDATE: Gilead Says No New Safety Signals Were Identified With Remdesivir,2020-04-29 08:47:00-04:00,GILD,positive
549248.0,UPDATE: Gilead Says Phase 3 Trial Of Remdesivir Showed Patients Receiving 10-Day Treatment Course Achieved Similar Improvement In Clinical Status vs Those Taking 5-Day Treatment Course,2020-04-29 08:47:00-04:00,GILD,positive
549249.0,Gilead Shares To Resume Trade At 9 a.m. EDT,2020-04-29 08:39:00-04:00,GILD,positive
549250.0,S&P 500 Futures Spike ~15 Points Following Positive Gilead Data On Remdesivir,2020-04-29 08:31:00-04:00,GILD,positive
549251.0,"Gilead Reports Data From National Institute of Allergy and Infectious Diseases, Says 'We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing'",2020-04-29 08:30:00-04:00,GILD,neutral
549252.0,"REMINDER: Results From Gilead's Coronavirus Anti-Viral, Remdesivir, Expected This Week",2020-04-29 08:27:00-04:00,GILD,neutral
549253.0,Gilead Shares Halted News Pending,2020-04-29 08:26:00-04:00,GILD,positive
549254.0,Gilead Sciences Option Alert: Aug 21 $115 Calls Sweep (55) near the Ask: 320 @ $2.074 vs 8159 OI; Earnings 4/30 After Close Ref=$79.3902,2020-04-28 14:53:00-04:00,GILD,positive
549255.0,'Experts worry next studies of Gilead Covid-19 drug may add uncertainty' -STAT,2020-04-27 14:20:00-04:00,GILD,negative
549256.0,Japan PM Abe Says Approval For Remdesivir Expected 'Soon',2020-04-27 10:52:00-04:00,GILD,positive
549257.0,"UPDATE: UBS Downgrades Gilead Sciences To Neutral, Raises Price Target From $77 To $80 'on valuation & as risk/reward into remdesivir (RDV) phase 3 readout appears balanced'",2020-04-27 10:40:00-04:00,GILD,neutral
549258.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2020",2020-04-27 09:32:00-04:00,GILD,positive
549259.0,UBS Downgrades Gilead Sciences to Neutral,2020-04-27 07:15:00-04:00,GILD,neutral
549260.0,Hearing Japan May Approve Gilead's Remdesivir for Coronavirus in May,2020-04-27 06:46:00-04:00,GILD,neutral
549261.0,Japan PM Abe Says Gilead's Coronavirus Drug Candidate Remdesivir May Soon Get Approval,2020-04-27 06:22:00-04:00,GILD,positive
549262.0,"Gilead Sues U.S., Claiming It Secretly Obtained Patents on HIV Research That Led to Truvada",2020-04-26 20:10:00-04:00,GILD,neutral
549263.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,GILD,negative
549264.0,China Tried to Patent Potential Coronavirus Drug Remsvidir the Day After Beijing Confirmed Virus Was Transmissable Between Humans,2020-04-26 11:14:00-04:00,GILD,neutral
549265.0,"Bulls And Bears Of The Week: Amazon, Boeing, Disney, Netflix And More",2020-04-25 15:20:00-04:00,GILD,positive
549266.0,CORRECTION: Lead Researcher For Gilead Remdesivir Trial Says Sees Trial Results Possibly By Mid May; Initial Headline Incorrectly Suggested 'Mid Day',2020-04-24 14:12:00-04:00,GILD,neutral
549267.0,Gilead Sciences Option Alert: Fri $76.5 Calls at the Ask: 994 @ $2.701 vs 218 OI; Earnings 4/30 After Close Ref=$79.12,2020-04-24 14:08:00-04:00,GILD,positive
549268.0,"UPDATE: Lead Researcher For Gilead Remdesivir Trial Says Sees Trial Results Possibly By Mid May, Prelim. Results Could Come Earlier",2020-04-24 13:33:00-04:00,GILD,neutral
549269.0,Gilead Shares Spike To Session High; Report A Lead Researcher Has Said US Gov't. Trial Of Remdesivr Is 'Running Ahead Of Schedule',2020-04-24 13:32:00-04:00,GILD,positive
549270.0,Crude Oil Bounce Gives Energy Stock A Lift As Market Volatility Ebbs,2020-04-24 10:05:00-04:00,GILD,negative
549271.0,Baird Analyst Says 'Don't Give Up' Yet On Gilead's Remdesivir,2020-04-24 09:50:00-04:00,GILD,neutral
549272.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 24, 2020: GILD, DKNG, FFIV, ADC, SGMS",2020-04-24 07:46:00-04:00,GILD,positive
549273.0,Why Gilead Stock Is Trading Lower Today,2020-04-23 14:58:00-04:00,GILD,negative
549274.0,Gilead Sciences Option Alert: May 1 $64 Puts Sweep (7) near the Bid: 350 @ $0.585 vs 61 OI; Earnings 4/30 After Close Ref=$75.99,2020-04-23 13:56:00-04:00,GILD,positive
549275.0,"Hearing SunTrust Defending Gilead, Says Remdesivir Could Still Work In Patients With Moderate Severity Coronavirus Infection",2020-04-23 13:42:00-04:00,GILD,neutral
549276.0,Hearing Author Of Gilead Study Disputes Characterization Drug 'Flopped',2020-04-23 13:39:00-04:00,GILD,negative
549277.0,"WHO Says Draft Document On Gilead's Remdesivir Was Inadvertently Posted On Website, Says Manuscript Undergoing Peer Review, WHO Is Waiting For Final Version Before Commenting",2020-04-23 13:27:00-04:00,GILD,neutral
549278.0,Gilead Sciences Option Alert: Fri $85 Calls Sweep (11) near the Ask: 969 @ $0.29 vs 4919 OI; Earnings 4/30 After Close Ref=$75.9249,2020-04-23 13:23:00-04:00,GILD,positive
549279.0,Gilead shares are trading lower after the company reportedly ended its Remdesivir study due to low enrollment and said study results were inconclusive.,2020-04-23 13:23:00-04:00,GILD,negative
549280.0,"UPDATE: Gilead Calls Study Results 'Inconclusive,' Says Trends In Data Suggest Potential Benefit Via Remdesivir",2020-04-23 13:11:00-04:00,GILD,positive
549281.0,UPDATE: Gilead Says Remdesivir Study Was 'Underpowered' To Enable Statistically Meaningful Conclusions,2020-04-23 13:11:00-04:00,GILD,positive
549282.0,"UPDATE: Gilead Says Investigators In Remdesivir Study Did Not Provide Permission For Publication Of Results, Confirms Study Terminated Early Due To Low Enrollment",2020-04-23 13:10:00-04:00,GILD,negative
549283.0,"Gilead Confirms Remdesivir Data Was Prematurely Posted, Says Has Been REmoved",2020-04-23 13:10:00-04:00,GILD,neutral
549284.0,Gilead Sciences Option Alert: Jun 19 $110 Calls Sweep (4) near the Ask: 863 @ $1.601 vs 14400 OI; Earnings 4/30 After Close Ref=$78.0397,2020-04-23 13:02:00-04:00,GILD,positive
549285.0,Gilead Sciences Option Alert: May 15 $80 Calls Sweep (11) near the Ask: 550 @ $5.0 vs 15829 OI; Earnings 4/30 After Close Ref=$77.81,2020-04-23 12:59:00-04:00,GILD,positive
549286.0,'I do not believe this gilead news. It is from the chinese trials ...This is not from Gilead' -Tweet From CNBC's Jim Cramer,2020-04-23 12:55:00-04:00,GILD,neutral
549287.0,"Gilead Shares Resume Following Circuit Breaker Halt, Shares Have Rebounded ~4.6% From Session Low, Down 1.9% For Session",2020-04-23 12:53:00-04:00,GILD,positive
549288.0,"'Data on Gilead's remdesivir, released by accident, show no benefit for coronavirus patients' -STAT News",2020-04-23 12:51:00-04:00,GILD,negative
549289.0,"UPDATE: FT Report On Gilead's Remdesivir Says Study Was Ended Due To Low Enrollment, Results Didn't Given Meaningful Conclusions",2020-04-23 12:49:00-04:00,GILD,negative
549290.0,S&P 500 Futures Plunge ~30 Points Following Report Gilead's Remdesivir 'Flops' In First Trial,2020-04-23 12:46:00-04:00,GILD,neutral
549291.0,Gilead Shares Plunge As Hearing Co.'s Remdesivir 'Flops' In First Trial,2020-04-23 12:46:00-04:00,GILD,positive
549292.0,Gilead Sciences Option Alert: Fri $80 Calls Sweep (6) near the Ask: 500 @ $3.0 vs 3935 OI; Earnings 4/30 After Close Ref=$82.365,2020-04-23 09:33:00-04:00,GILD,positive
549293.0,Gilead Sciences Option Alert: Jun 19 $110 Calls Sweep (27) near the Ask: 1095 @ $2.046 vs 2252 OI; Earnings 4/30 After Close Ref=$81.06,2020-04-22 15:43:00-04:00,GILD,positive
549294.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,GILD,negative
549295.0,"Gilead, Kite And oNKo-innate Announce Research Collaboration To Discover Cancer Immunotherapies Focused On Natural Killer (NK) Cells",2020-04-21 16:15:00-04:00,GILD,negative
549296.0,How The COVID-19 Pandemic Could End,2020-04-20 16:33:00-04:00,GILD,neutral
549297.0,Gilead Sciences Option Alert: Fri $90 Calls Sweep (6) near the Ask: 428 @ $1.85 vs 7491 OI; Earnings 4/30 After Close Ref=$84.33,2020-04-20 09:38:00-04:00,GILD,positive
549298.0,Gilead Sciences Option Alert: May 15 $90 Calls at the Ask: 398 @ $4.201 vs 10729 OI; Earnings 4/30 After Close Ref=$83.15,2020-04-20 09:33:00-04:00,GILD,positive
549299.0,"Benzinga's Top Upgrades, Downgrades For April 20, 2020",2020-04-20 09:32:00-04:00,GILD,positive
549300.0,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,2020-04-20 06:09:00-04:00,GILD,neutral
549301.0,"Wells Fargo Downgrades Gilead Sciences to Equal-Weight, Announces $87 Price Target",2020-04-20 05:24:00-04:00,GILD,positive
549302.0,"BMO Capital Downgrades Gilead Sciences to Market Perform, Announces $79 Price Target",2020-04-20 05:22:00-04:00,GILD,neutral
549303.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,GILD,neutral
549304.0,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",2020-04-19 17:22:00-04:00,GILD,positive
549305.0,"Indexes End Week Higher As White House Rolls Out State-By-State Coronavirus Strategy, Investors Digest First Round Of Earnings Reports",2020-04-18 12:43:00-04:00,GILD,neutral
549306.0,Why Peloton Stock Lost Ground Friday,2020-04-17 16:14:00-04:00,GILD,negative
549307.0,Ross Gerber Says Tesla Is Pushing Ahead Of Competitors During COVID-19 Pandemic,2020-04-17 15:35:00-04:00,GILD,neutral
549308.0,National Institutes Of Health Gives Formal Statement On Gilead's Remdesivir In Monkeys,2020-04-17 15:25:00-04:00,GILD,neutral
549309.0,Gilead Shares Relatively Quiet As Hearing National Institutes For Health Suggest Co.'s Remdesivir Coronavirus Anti-Viral Treatment Prevent COVID-19 Progression In Monkeys,2020-04-17 15:25:00-04:00,GILD,positive
549310.0,A Strong But Cautious Start To The Second Quarter,2020-04-17 14:03:00-04:00,GILD,positive
549311.0,CFRA Downgrades Gilead Sciences to Sell,2020-04-17 13:52:00-04:00,GILD,neutral
549312.0,Why Amazon Is Trading Down Friday,2020-04-17 12:57:00-04:00,GILD,positive
549313.0,"Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone",2020-04-17 12:49:00-04:00,GILD,neutral
549314.0,58 Stocks Moving In Friday's Mid-Day Session,2020-04-17 12:31:00-04:00,GILD,neutral
549315.0,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting",2020-04-17 09:46:00-04:00,GILD,neutral
549316.0,Gilead Sciences Option Alert: May 15 $80 Puts Sweep (6) near the Bid: 577 @ $4.542 vs 1435 OI; Earnings 4/30 After Close Ref=$84.38,2020-04-17 09:45:00-04:00,GILD,positive
549317.0,Former FDA Commissioner Says Gilead's Remdesivir Could Have Enough Data For Emergency Use Authorization,2020-04-17 09:16:00-04:00,GILD,negative
549318.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 17, 2020: GILD, NOK, INVH, THMO, LOGM",2020-04-17 07:55:00-04:00,GILD,positive
549319.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,GILD,positive
549320.0,Gilead Sciences shares are trading higher after a report noted that data from a clinical trial on the company's remdesivir drug suggests coronavirus patients are responding to treatment.,2020-04-17 07:31:00-04:00,GILD,positive
549321.0,"'""My hunch is that it's going to work earlier in the disease so if it's introduced early in the disease it can be an effective drug. It's not a slam dunk by any means. I don't think it's a cure for the virus,"" says @ScottGottliebMD...'",2020-04-17 07:27:00-04:00,GILD,positive
549322.0,"Hearing Raymond James Downplaying Gilead Data On Remdesivir, Says Recent Comments On Data Congruent With Prior New England Journal Of Medicine Cohort Which Implied Potential Modest To No Benefit Compared Historically",2020-04-17 07:15:00-04:00,GILD,positive
549323.0,36 Stocks Moving in Friday's Pre-Market Session,2020-04-17 07:11:00-04:00,GILD,neutral
549324.0,S&P Futures Rise 2.5%; Report Suggests Gilead's Remdesivir Shows Promise in Treating Covid-19; President Trump Unveils Plan for U.S. Economy Restart; Boeing to Reopen Next Week,2020-04-17 05:50:00-04:00,GILD,positive
549325.0,Gilead Says Expect Data From Phase 3 Study in Patients With Severe Covid-19 Infection to Be Available at End of April,2020-04-16 21:12:00-04:00,GILD,negative
549326.0,"Gilead Says Understand the Urgent Need for a Covid-19 Treatment and the Resulting Interest in Data on Our Investigational Antiviral Drug Remdesivir; Says Anecdotal Reports Do Not Provide Statistical Power Necessary to Determine Safety, Efficacy Profile of Remdesivir as Treatment for Covid-19",2020-04-16 21:11:00-04:00,GILD,positive
549327.0,"Big Stocks Moving After Hours As Market Cheers Gilead, 'Reopening' Updates",2020-04-16 19:30:00-04:00,GILD,positive
549328.0,Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock,2020-04-16 19:10:00-04:00,GILD,positive
549329.0,7 Stocks Moving In Thursday's After-Hours Session,2020-04-16 16:54:00-04:00,GILD,neutral
549330.0,Gilead Sciences shares are trading higher after a report noted that data from a clinical trial on the company's remdesivir drug suggests coronavirus patients are responding to treatment.,2020-04-16 16:25:00-04:00,GILD,positive
549331.0,'Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment' -STAT News,2020-04-16 16:18:00-04:00,GILD,neutral
549332.0,Gilead Sciences Option Alert: Aug 21 $110 Calls Sweep (7) near the Ask: 321 @ $1.772 vs 10932 OI; Earnings 4/30 After Close [est] Ref=$76.2501,2020-04-16 13:46:00-04:00,GILD,positive
549333.0,Gilead Sciences Option Alert: Aug 21 $80 Calls Sweep (33) near the Ask: 530 @ $5.947 vs 6241 OI; Earnings 4/30 After Close [est] Ref=$74.66,2020-04-16 10:19:00-04:00,GILD,positive
549334.0,Arcus Bio Shares Volatile After Hours Amid Report Gilead To Hold Talks To Take Stake In Co.,2020-04-15 16:12:00-04:00,GILD,positive
549335.0,Why Gilead's Stock Is Trading Lower Today,2020-04-15 15:42:00-04:00,GILD,negative
549336.0,Gilead's Spokesperson Confirms Remdesivir Trial In China In Patients With Severe Disease Was 'Terminated Early Due To Low Enrollment'; Trial In China In Patients With Moderate Disease Now Listed On Clinicaltrials.gov As Suspended,2020-04-15 14:51:00-04:00,GILD,negative
549337.0,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,2020-04-15 13:09:00-04:00,GILD,positive
549338.0,Gilead Sciences shares are trading lower after trials of the company's potential coronavirus candidate Remdesivir were suspended in China due to low enrollment.,2020-04-15 11:49:00-04:00,GILD,negative
549339.0,Gilead Shares Fall To Pre-Market Low As Hearing Co. Trial For Remdesivir In China Has Been Suspended,2020-04-15 08:57:00-04:00,GILD,negative
549340.0,"Gilead Shares Spike To Session High, Quickly Pare Gain, Following Comment From Trump Co.'s Remdesivir Is Showing 'Good Progress'",2020-04-14 12:51:00-04:00,GILD,positive
549341.0,Gilead Sciences Option Alert: Jun 19 $90 Calls Sweep (2) near the Ask: 344 @ $2.42 vs 5076 OI; Earnings 4/30 After Close [est] Ref=$76.3,2020-04-14 12:36:00-04:00,GILD,positive
549342.0,Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use,2020-04-13 16:05:00-04:00,GILD,positive
549343.0,Gilead Sciences Option Alert: Fri $71 Calls Sweep (9) near the Ask: 384 @ $3.9 vs 337 OI; Earnings 4/30 After Close [est] Ref=$74.39,2020-04-13 14:07:00-04:00,GILD,positive
549344.0,Gilead Sciences Option Alert: Fri $85 Calls Sweep (3) near the Ask: 7494 @ $0.12 vs 15594 OI; Earnings 4/30 After Close [est] Ref=$74.42,2020-04-13 13:48:00-04:00,GILD,positive
549345.0,"India Today Journalist Tweets: '2 out of 3 #COVID19 patients have benefitted from Remdesivir drug - an observational study has found @ICMRDELHI director Dr Raman GangaKhedkar,' Says Need For Ventilator/Oxygen Was Found To Have Reduced After Administration",2020-04-13 07:38:00-04:00,GILD,positive
549346.0,Gilead shares are trading higher after the company said its coronavirus treatment showed an improvement in 68% of cases.,2020-04-13 06:52:00-04:00,GILD,positive
549347.0,"The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates",2020-04-12 10:05:00-04:00,GILD,neutral
549348.0,Gilead Canada Reports Submission Of Supplemental New Drug Submission To Health Canada For Descovy For HIV Pre-Exposure Prophylaxis,2020-04-09 08:01:00-04:00,GILD,neutral
549349.0,"UPDATE: RBC Issues Report On Gilead: 'New Remdesivir Trial Changes Aim To Maximize Odds, Though Suggests Dramatic Effects Unlikely'",2020-04-08 12:40:00-04:00,GILD,neutral
549350.0,"Gilead Shares Tick Lower As Traders Circulate Comment From RBC Suggesting co. Updated Its ClinicalTrials.gov Listing For 2 Trials For Remdesivir For Coronavirus Treatment To Increase Enrollment, Revise Primary, Secondary Endpoints",2020-04-08 12:39:00-04:00,GILD,positive
549351.0,Gilead Analyst Sees Over 50% Chance Of Success For Remdesivir In Mild-To-Moderate COVID-19,2020-04-07 11:50:00-04:00,GILD,positive
549352.0,10 Short Squeeze Candidates If The Market Rally Continues,2020-04-07 11:36:00-04:00,GILD,neutral
549353.0,Gilead Sees Volume Spike As Traders Circulate German Website Suggesting Spokesperson For Federal Institute For Drugs And Medical Devices Confirmed 'Corona patients who are particularly seriously ill may...be treated with not yet approved remdesivir',2020-04-07 10:51:00-04:00,GILD,negative
549354.0,"Jim Cramer, On CNBC's 'Squawk On The Street,' Says He Is More Bullish On Regeneron Than Gilead",2020-04-07 09:38:00-04:00,GILD,neutral
549355.0,"Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Raises Price Target to $86",2020-04-07 06:53:00-04:00,GILD,negative
549356.0,"Trump Says Spoke With Pharmaceutical Companies; Says 10 Different Therapeutic Agents Are In Active Trials, Says Will Be 'Fairly Quick Process' And Says A Second Company Was Approved To Start Vaccine Trials",2020-04-06 18:02:00-04:00,GILD,positive
549357.0,"STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump",2020-04-06 17:06:00-04:00,GILD,neutral
549358.0,Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment,2020-04-06 15:32:00-04:00,GILD,neutral
549359.0,'Data for Gilead's potential coronavirus therapy are coming soon. Here's what you need to know' -Article From STAT News,2020-04-06 15:20:00-04:00,GILD,neutral
549360.0,Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery,2020-04-06 06:16:00-04:00,GILD,neutral
549361.0,Gilead To Donate 1.5M Doses Of Experimental Coronavirus Treatment: 'The Right Thing To Do',2020-04-05 16:03:00-04:00,GILD,neutral
549362.0,"Barron's Picks And Pans: Post-Pandemic Ideas, Safe Dividends And More",2020-04-04 14:25:00-04:00,GILD,positive
549363.0,"What's The Difference Between Coronavirus, SARS-CoV-2 and COVID-19?",2020-04-03 16:22:00-04:00,GILD,neutral
549364.0,UPDATE: EMA Gives Recommendations On Compassionate Use Of Gilead's Remdesivir For COVID-19 Coronavirus Infection,2020-04-03 08:51:00-04:00,GILD,positive
549365.0,"European Medicines Agency (European Equivalent Of FDA) Says Gilead's Remdesivir Shown To Be Active Against COVID-19, 2 SARS-, MERS-Coronavirus Infections, But Notes 'Currently Only Limited Data On Use' in COVID-19 Patients",2020-04-03 08:50:00-04:00,GILD,negative
549366.0,Gilead Sciences Option Alert: Fri $81 Calls Sweep (16) near the Ask: 356 @ $0.283 vs 9594 OI; Earnings 4/30 After Close [est] Ref=$75.59,2020-04-02 14:47:00-04:00,GILD,positive
549367.0,Gilead Sciences shares are trading higher. The company on Wednesday announced it is initiating two phase 3 randomized studies as a potential coronavirus treatment.,2020-04-02 14:43:00-04:00,GILD,positive
549369.0,"RNC Genter Capital CEO Likes Tech, Health Care, Financials In Volatile Market",2020-04-02 10:32:00-04:00,GILD,positive
549370.0,Gilead Initiates Two Phase 3 Randomised Studies To Evaluate The Safety And Efficacy Of Its Investigational Treatment Remdesivir For Coronavirus,2020-04-01 07:28:00-04:00,GILD,positive
549371.0,"'$GILD says it's starting two more remdesivir studies vs Covid-19, in 15 UK hospitals.' -Jacob Plieth",2020-04-01 07:26:00-04:00,GILD,neutral
549372.0,Gilead Sciences Option Alert: Apr 9 $85 Calls Sweep (24) near the Ask: 1031 @ $0.653 vs 571 OI; Earnings 4/30 After Close [est] Ref=$75.37,2020-03-31 10:31:00-04:00,GILD,positive
549373.0,"Gilead shares are trading higher after the company said it would expand access to its experimental coronavirus treatment, Remdesivir.",2020-03-30 09:07:00-04:00,GILD,positive
549374.0,Gilead Reports HSR Waiting Period For Forty Seven Deal Expired; Sees Tender Offer Closing Beginning In Apr. 2020,2020-03-30 08:31:00-04:00,GILD,neutral
549375.0,Ex-FDA Chief Gottlieb Expects Coronavirus Therapeutic Option By Summer,2020-03-29 18:40:00-04:00,GILD,neutral
549376.0,"Barron's Picks And Pans: Tech Picks, SoftBank, REITs, Tesla And More",2020-03-29 10:29:00-04:00,GILD,neutral
549377.0,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,2020-03-27 02:59:00-04:00,GILD,neutral
549378.0,Gilead shares are trading higher as the global coronavirus outbreak continues. The company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate.,2020-03-26 15:41:00-04:00,GILD,positive
549379.0,"Gilead Asks FDA To Rescind Orphan Drug Designation For Remdesivir, Says It Is Confident It Can Maintain Expedited Timeline",2020-03-25 13:25:00-04:00,GILD,positive
549380.0,"Zoom Video, Teladoc Lead The Coronavirus Short Squeeze Candidates",2020-03-25 12:10:00-04:00,GILD,neutral
549381.0,"Gilead Sciences shares are trading lower, not currently seeing company-specific news. Movement appears market related as equities experience volatility amid US stimulus progress.",2020-03-25 11:44:00-04:00,GILD,positive
549382.0,5 Stocks Moving In Monday's After-Hours Session,2020-03-23 16:42:00-04:00,GILD,neutral
549383.0,Gilead Sciences shares are trading higher as traders circulate word the company received FDA Orphan Drug Designation for Remdesivir as a treatment for the coronavirus.,2020-03-23 16:13:00-04:00,GILD,positive
549384.0,Traders Circulate Word Gilead Receives FDA Orphan Drug Designation For Remdesivir As Treatment For Coronavirus,2020-03-23 16:03:00-04:00,GILD,neutral
549385.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,GILD,negative
549386.0,"Gilead shares are trading higher amid continued coronavirus concerns, as the company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate. UPDAE Shares have since reversed and are now trading lower.",2020-03-23 08:10:00-04:00,GILD,positive
549387.0,Why BofA Has Low Expectations For Gilead's Remdesivir As Potential Coronavirus Treatment,2020-03-20 14:52:00-04:00,GILD,negative
549388.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,GILD,negative
549389.0,Piper Sandler Upgrades Gilead Sciences to Overweight,2020-03-20 05:24:00-04:00,GILD,negative
549390.0,"'250 patients have received $GILD's remdesivir through expanded access, new FDA info says' -Tweet From Pharma Pink Sheet Reporter",2020-03-19 15:52:00-04:00,GILD,neutral
549391.0,FDA Approves EPCLUSA For Pediatric Patients With Any Strain Of Hepatitis C,2020-03-19 14:40:00-04:00,GILD,positive
549392.0,"UPDATE: Jefferies Notes Trumps Public Announcement Of Fast Track Potential For New Coronavirus Therapies For Compassionate Use Only, Calls 'Not Material,' And 'A Relatively Minor Disappointment Vs Growing Investor Expectations' For Gilead",2020-03-19 13:25:00-04:00,GILD,positive
549393.0,Hearing Jefferies Has Called Trump's Coronavirus Fast Track 'Somewhat Disappointing' For Gilead,2020-03-19 13:22:00-04:00,GILD,negative
549394.0,Gilead Sciences Option Alert: Apr 17 $82.5 Calls Sweep (25) near the Ask: 331 @ $8.643 vs 1043 OI; Earnings 4/30 After Close [est] Ref=$81.9,2020-03-19 12:29:00-04:00,GILD,positive
549395.0,FDA's Hahn Clarifies Remdesivir Is Going Through Normal FDA Process,2020-03-19 12:25:00-04:00,GILD,positive
549396.0,"Gilead shares are trading higher amid continued coronavirus concerns, as the company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate. Piper Sandler analysts said they believe the drug could soon receive approval.",2020-03-19 10:00:00-04:00,GILD,positive
549397.0,Analyst Says Gilead's Remdesivir Could Be Approved 'Within Months' For COVID-19 Treatment,2020-03-19 07:50:00-04:00,GILD,positive
549398.0,Tweet From STAT News' Adam Feuerstein Includes Some Details Of Piper Sandler Note On Gilead's Remdesivir Potentially Being Approved For Broad Use In 'Coming Months',2020-03-18 15:14:00-04:00,GILD,positive
549399.0,Hearing Piper Analyst Suggesting Gilead's Remdesivir Could Be Approved For Coronavirus Infection 'Very Soon',2020-03-18 14:55:00-04:00,GILD,positive
549400.0,DZ Bank Upgrades Gilead Sciences to Buy,2020-03-18 11:04:00-04:00,GILD,neutral
549401.0,"Gilead Sciences shares are trading higher amid continued global coronavirus concerns, as the company's experimental drug remdesivir is being evaluated as a potential coronavirus treatment candidate.",2020-03-18 10:27:00-04:00,GILD,positive
549402.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,GILD,positive
549403.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,GILD,negative
549404.0,Gilead Highlights New Clinical Study Data For GS-6207 Presented At CROI 2020,2020-03-11 15:10:00-04:00,GILD,neutral
549405.0,How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?,2020-03-10 17:24:00-04:00,GILD,neutral
549406.0,Treatment With Gilead's Vesatolimod Is Evaluated For Safety And Virologic And Immunologic Response Versus Placebo In Phase 1B HIV Functional Cure Study,2020-03-10 14:34:00-04:00,GILD,positive
549407.0,Gilead Presents 96-Week DISCOVER Trial Data Demonstrating 'Favorable Renal and Bone Safety Profile of Descovy for HIV PrEP in At-Risk Populations',2020-03-10 11:33:00-04:00,GILD,positive
549408.0,"Gilead Sciences shares are trading lower, not currently seeing company-specific news. Weakness potentially related to profit taking, as the company is working on a coronavirus treatment and has performed well amid the outbreak.",2020-03-10 10:27:00-04:00,GILD,positive
549409.0,Gilead Shares Unaffected Amid Co. Press Release Highlighting New Data On Biktarvy Presented At CROI 2020,2020-03-09 14:53:00-04:00,GILD,positive
549410.0,TD Ameritrade Index Shows Retail Investors Were Pessimistic In February,2020-03-09 14:16:00-04:00,GILD,negative
549411.0,Investor Movement Index Summary: February 2020,2020-03-09 13:57:00-04:00,GILD,neutral
549412.0,Gilead Sciences shares are trading lower after RBC Capital downgraded the stock from Top Pick to Outperform.,2020-03-09 10:58:00-04:00,GILD,positive
549413.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2020",2020-03-09 10:07:00-04:00,GILD,positive
549414.0,"RBC Capital Downgrades Gilead Sciences to Outperform, Announces $86 Price Target",2020-03-09 06:46:00-04:00,GILD,neutral
549415.0,Gilead Sciences Option Alert: May 15 $90 Calls Sweep (66) near the Ask: 1794 @ $4.846 vs 7861 OI; Earnings 4/30 After Close [est] Ref=$79.01,2020-03-06 14:23:00-05:00,GILD,positive
549416.0,Gilead Sciences Option Alert: Mar 20 $79 Calls Sweep (25) near the Ask: 1668 @ $3.937 vs 599 OI; Earnings 4/30 After Close [est] Ref=$79.175,2020-03-06 14:12:00-05:00,GILD,positive
549417.0,Gilead Sciences shares are trading higher after hearing that Evercore said data from Gilead China on the coronavirus could arrive this month.,2020-03-06 14:03:00-05:00,GILD,positive
549418.0,Hearing Evercore Saying Data From Gilead China On Coronavirus Could Arrive This Month,2020-03-06 13:22:00-05:00,GILD,neutral
549419.0,Gilead Sciences Option Alert: Jan 15 $110 Calls Sweep (18) near the Ask: 535 @ $2.08 vs 2732 OI; Earnings 4/30 After Close [est] Ref=$76.93,2020-03-05 10:04:00-05:00,GILD,positive
549420.0,Gilead Sciences Option Alert: May 15 $80 Calls Sweep (2) near the Ask: 503 @ $4.0 vs 12396 OI; Earnings 4/30 After Close [est] Ref=$75.56,2020-03-04 12:02:00-05:00,GILD,positive
549421.0,"National Institutes For Health Head Fauci Says We Should Know Within Several Months Whether Gilead's Antiviral Coronavirus Treatment Works, Sees Implementation 'Imminent' Afterward",2020-03-03 10:40:00-05:00,GILD,neutral
549422.0,"Gilead Sciences shares are trading lower. NOTE: The company on Monday announced it will acquire Immuno-oncology therapy developer Forty Seven for $95.50/share in cash, or around $4.9 billion total.",2020-03-03 08:02:00-05:00,GILD,neutral
549423.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,GILD,positive
549424.0,Pfizer Works On Compounds That May Help Stop Coronaviruses,2020-03-03 06:53:00-05:00,GILD,positive
549425.0,How The COVID-19 Outbreak Is Benefiting Biotech Investors,2020-03-02 14:27:00-05:00,GILD,neutral
549426.0,Mid-Afternoon Market Update: Dow Jumps 800 Points; China Pharma Shares Spike Higher,2020-03-02 14:26:00-05:00,GILD,positive
549427.0,"How To Approach The Market This Week: PreMarket Prep Recap For March 2, 2020",2020-03-02 12:22:00-05:00,GILD,neutral
549428.0,Mid-Day Market Update: Crude Oil Rises Over 3%; Novavax Shares Plunge,2020-03-02 12:10:00-05:00,GILD,negative
549429.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.,2020-03-02 11:18:00-05:00,GILD,positive
549430.0,Mid-Morning Market Update: Markets Open Higher; Gilead To Buy Forty Seven For $4.9B,2020-03-02 10:16:00-05:00,GILD,neutral
549431.0,Gilead Confirms Deal To Buy Biotech Forty Seven For $4.9B,2020-03-02 09:13:00-05:00,GILD,neutral
549432.0,"Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 2, 2020: GILD, BIDU, CODX, MRKR, APDN",2020-03-02 07:51:00-05:00,GILD,positive
549433.0,Gilead to Acquire Forty Seven for $95.50/Share Cash,2020-03-02 06:57:00-05:00,GILD,neutral
549434.0,"Barron's Picks And Pans: COVID-19 Stocks, Intel, Tesla And More",2020-03-01 14:45:00-05:00,GILD,neutral
549435.0,Gilead Sciences shares are trading lower after DZ Bank downgraded the stock from Buy to Hold. NOTE: Many stocks in the healthcare sector are trading lower with the overall market amid continued coronavirus fears.,2020-02-28 11:11:00-05:00,GILD,negative
549436.0,Gilead Sciences Option Alert: Jun 19 $80 Calls Sweep (4) near the Ask: 1000 @ $2.5 vs 8423 OI; Ref=$68.2,2020-02-28 10:13:00-05:00,GILD,positive
549437.0,Gilead Eyes Takeover Of Cancer Biotech Forty Seven: Report,2020-02-28 09:16:00-05:00,GILD,negative
549438.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,GILD,neutral
549439.0,DZ Bank Downgrades Gilead Sciences to Hold,2020-02-28 05:59:00-05:00,GILD,neutral
549440.0,Forty Seven Shares Spike Sharply Higher After Hours As Hearing Co. Had Discussions About Various Options With Gilead,2020-02-27 16:15:00-05:00,GILD,positive
549441.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-27 10:24:00-05:00,GILD,neutral
549442.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2020",2020-02-27 09:37:00-05:00,GILD,positive
549443.0,"Barclays Initiates Coverage On Gilead Sciences with Underweight Rating, Announces $62 Price Target",2020-02-27 08:08:00-05:00,GILD,neutral
549444.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-27 07:40:00-05:00,GILD,neutral
549445.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,GILD,positive
549446.0,Gilead Sciences shares are trading higher after the company announced it has initiated 2 Phase 3 studies of remdesivir in adults diagnosed with the Coronavirus.,2020-02-27 07:20:00-05:00,GILD,positive
549447.0,"Gilead to Widen Testing of Antiviral Drug in Hong Kong, South Korea, other Asian Markets",2020-02-27 06:12:00-05:00,GILD,neutral
549448.0,Gilead Reports Initiation Of 2 Phase 3 Studies Of Remdesivir For Coronavirus,2020-02-26 17:01:00-05:00,GILD,neutral
549449.0,Shares of several healthcare and biotech companies are trading higher. Not seeing any news to justify the price action.,2020-02-26 14:28:00-05:00,GILD,positive
549450.0,Gilead Sciences Option Alert: Mar 20 $80 Calls Sweep (9) near the Ask: 1000 @ $1.301 vs 23681 OI; Ref=$72.32,2020-02-26 12:00:00-05:00,GILD,positive
549451.0,Gilead Sciences Option Alert: Mar 20 $72.5 Calls Sweep (78) near the Ask: 1382 @ $3.116 vs 9226 OI; Ref=$72.16,2020-02-26 11:52:00-05:00,GILD,positive
549452.0,Shares of several healthcare and biotech companies are trading higher. Movement appears market related as equities have rebounded this session following recent selloffs.,2020-02-26 11:19:00-05:00,GILD,positive
549453.0,24 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-26 08:01:00-05:00,GILD,neutral
549454.0,NIAID's Fauci Says The Earliest A Coronavirus Vaccine Could Be Tested And Available To Public Would Be A Year Or A Year And A Half,2020-02-25 15:20:00-05:00,GILD,neutral
549455.0,Gilead Shares On Watch As NIAID's Fauci Discusses Trials For Co.'s Candidate,2020-02-25 15:19:00-05:00,GILD,positive
549456.0,"National Institutes Of Health Says Those With Confirmed Coronavirus Infection With Mild, Cold-Like Symptoms Or No Apparent Symptoms Will Not Be Included In Remdesivir Trial; Must Have Laboratory-Confirmed Coronavirus Infection",2020-02-25 11:15:00-05:00,GILD,negative
549457.0,Clinical Trial of Remdesivir To Treat Coronavirus Begins Study; Enrolling Hospitalized Adults With Coronavirus In Nebraska,2020-02-25 11:10:00-05:00,GILD,positive
549458.0,"Gilead Sciences shares are trading lower, potentially selling off from Monday strength. Shares gained on Monday after the WHO said the company's experimental drug may be a coronavirus treatment candidate.",2020-02-25 10:04:00-05:00,GILD,positive
549459.0,Gilead Sciences Option Alert: Mar 20 $70 Calls Sweep (3) near the Ask: 506 @ $4.394 vs 19554 OI; Ref=$73.0738,2020-02-25 09:35:00-05:00,GILD,positive
549460.0,Hearing US Will Start Testing Gilead's Remedesivir To Treat Coronavirus,2020-02-25 08:58:00-05:00,GILD,positive
549461.0,Gilead Shares Volatile But Largely Unaffected Following Earlier Bloomberg Article 'Gilead's Drug Leads Global Race for Coronavirus Treatment',2020-02-25 08:29:00-05:00,GILD,positive
549462.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,GILD,negative
549463.0,"Chip Stocks, Apple, Airlines Among Hardest Hit As Stocks Plunge On Coronavirus Spread",2020-02-24 17:21:00-05:00,GILD,neutral
549464.0,PreMarket Prep Stock Of The Day: Gilead Sciences,2020-02-24 12:24:00-05:00,GILD,neutral
549465.0,"Gilead Sciences Option Alert: Jan, 2022 $100 Calls Sweep (2) near the Ask: 500 @ $2.8 vs 4912 OI; Ref=$72.95",2020-02-24 10:41:00-05:00,GILD,positive
549466.0,Gilead Sciences Option Alert: Mar 20 $70 Calls Sweep (2) near the Ask: 500 @ $4.5 vs 18026 OI; Ref=$72.8664,2020-02-24 09:58:00-05:00,GILD,positive
549467.0,Gilead Sciences Option Alert: Mar 20 $80 Calls at the Ask: 1000 @ $1.4 vs 20677 OI; Ref=$73.93,2020-02-24 09:32:00-05:00,GILD,positive
549468.0,Shares of Gilead Sciences are trading higher amid the non-Chinese spread of coronavirus due to the company's ongoing trial to treat coronavirus.,2020-02-24 08:25:00-05:00,GILD,positive
549469.0,Gilead Sciences Option Alert: Mar 20 $80 Calls Sweep (44) near the Ask: 528 @ $0.62 vs 23628 OI; Ref=$69.25,2020-02-21 13:40:00-05:00,GILD,positive
549470.0,"Gilead shares are trading higher. The company's collaboration partner Galapagos said it expects Filgotinib approval in the US, Europe and Japan.",2020-02-21 11:34:00-05:00,GILD,positive
549471.0,Gilead Sciences Option Alert: Mar 20 $65 Calls Sweep (2) near the Ask: 1014 @ $4.5 vs 8617 OI; Ref=$68.6795,2020-02-21 10:49:00-05:00,GILD,positive
549472.0,Gilead Sciences Option Alert: Mar 20 $70 Calls Sweep (3) near the Ask: 500 @ $1.861 vs 14420 OI; Ref=$68.63,2020-02-21 10:45:00-05:00,GILD,positive
549473.0,"Gilead Shares Rise 1.5% Premarket; Galapagos Announced Co, Gilead Expect Approval of First Product Candidate, Filgotinib, in RA in the U.s., Europe, and Japan",2020-02-21 05:33:00-05:00,GILD,positive
549474.0,Gilead Sciences Option Alert: Mar 20 $75 Calls Sweep (28) near the Ask: 500 @ $0.52 vs 14425 OI; Ref=$67.3588,2020-02-19 14:28:00-05:00,GILD,positive
549475.0,"Gilead to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020",2020-02-19 05:19:00-05:00,GILD,positive
549476.0,Gilead Sciences Option Alert: Feb 21 $72.5 Calls Sweep (47) near the Ask: 970 @ $0.242 vs 13430 OI; Ref=$66.425,2020-02-12 10:14:00-05:00,GILD,positive
549477.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,GILD,positive
549478.0,U.S. FDA Grants Priority Review For Kite's KTE-X19 Biologics License Application In Relapsed Or Refractory Mantle Cell Lymphoma; NOTE: Kite Is A Gilead Co.,2020-02-10 08:31:00-05:00,GILD,positive
549479.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,GILD,neutral
549480.0,Gilead Sciences shares are trading higher on reports suggesting China has started enrolling coronavirus patients in a clinical trial of the company's Remdesivir.,2020-02-07 09:20:00-05:00,GILD,positive
549481.0,GileadSciences Said it Will make Remdesivir Available to More 2019nCoV Patients via Proper Channels if Drug Proves Potentially Safe and Effective in Preliminary Trials,2020-02-07 05:19:00-05:00,GILD,positive
549482.0,China Began Enrolling CoronavirusPatients in Clinical Trial of Remdesivir on Thursday,2020-02-07 05:16:00-05:00,GILD,neutral
549483.0,74 Stocks Moving In Thursday's Mid-Day Session,2020-02-06 12:38:00-05:00,GILD,neutral
549484.0,Gilead Sciences shares are trading higher after Chinese scientists applied to patent the company's remdesivir to help treat the coronavirus.,2020-02-06 11:09:00-05:00,GILD,positive
549485.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2020",2020-02-06 09:35:00-05:00,GILD,positive
549486.0,"Bernstein Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $70",2020-02-06 05:38:00-05:00,GILD,negative
549487.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,GILD,neutral
549488.0,"'We are aware of reports of the Wuhan Institute for Virology's patent application. Our focus at this time, is on rapidly determining the potential for remdesivir as a treatment for 2019-nCoV and accelerating manufacturing'",2020-02-05 13:14:00-05:00,GILD,neutral
549489.0,"UPDATE: B of A Maintains Neutral On Gilead, Raises Target To $72 Notes 'Overall, we believe that 2020 guidance looks conservative, but we remain concerned over the lack of clear growth drivers that could meaningfully accelerate product sales'",2020-02-05 12:50:00-05:00,GILD,positive
549490.0,"Benzinga's Top Upgrades, Downgrades For February 5, 2020",2020-02-05 09:55:00-05:00,GILD,positive
549491.0,Gilead shares are trading lower after the company reported worse-than-expected Q4 EPS and issued soft FY20 guidance.,2020-02-05 09:18:00-05:00,GILD,neutral
549492.0,"Credit Suisse Maintains Underperform on Gilead Sciences, Raises Price Target to $60",2020-02-05 08:53:00-05:00,GILD,positive
549493.0,"B of A Securities Maintains Neutral on Gilead Sciences, Raises Price Target to $72",2020-02-05 08:09:00-05:00,GILD,positive
549494.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,GILD,neutral
549495.0,"Raymond James Downgrades Gilead Sciences to Outperform, Lowers Price Target to $80",2020-02-05 05:14:00-05:00,GILD,negative
549496.0,"Remdesivir & Chloroquine were Found Effective in Inhibiting Recently Emerged Coronavirus (2019-nCoV) in Vitro; Result was Published in Cell Research, said Wuhan Institute of Virology on its website Tue",2020-02-04 19:00:00-05:00,GILD,positive
549497.0,"'$GILD on call: No knowledge of additional #coronavirus responses to remdesivir. Waiting for clinical data. On manufacturing capacity: ""We are investing heavily to be prepared as best we can.""' -Tweet From STAT's Adam Feuerstein",2020-02-04 17:22:00-05:00,GILD,positive
549498.0,Gilead Raises Quarterly Dividend From $0.63 To $0.68/Share,2020-02-04 16:02:00-05:00,GILD,neutral
549499.0,"Gilead Sees FY20 Product Sales $21.8B-$22.2B, Adj. EPS $6.05-$6.45 vs $7.01 Estimate",2020-02-04 16:02:00-05:00,GILD,neutral
549500.0,"Gilead Sciences Q4 Adj. EPS $1.3 Misses $1.67 Estimate, Sales $5.796B Beat $5.71B Estimate",2020-02-04 16:02:00-05:00,GILD,negative
549501.0,Gilead Sciences Option Alert: Feb 21 $72.5 Calls Sweep (37) near the Ask: 531 @ $0.513 vs 10294 OI; Earnings 2/4 After Close Ref=$67.39,2020-02-04 09:36:00-05:00,GILD,positive
549502.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,GILD,negative
549503.0,First Shipment of Gildead's Remdesivir May Arrive in China on Tuesday,2020-02-04 05:08:00-05:00,GILD,neutral
549504.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,GILD,neutral
549505.0,"Earnings Scheduled For February 4, 2020",2020-02-04 04:21:00-05:00,GILD,neutral
549506.0,Gilead Sciences Option Alert: Mar 20 $67.5 Calls Sweep (35) near the Ask: 692 @ $2.297 vs 11796 OI; Earnings 2/4 After Close Ref=$66.66,2020-02-03 14:34:00-05:00,GILD,positive
549507.0,Gilead Sciences Option Alert: Mar 20 $75 Calls Sweep (35) near the Ask: 719 @ $0.5 vs 244 OI; Earnings 2/4 After Close Ref=$66.8,2020-02-03 13:12:00-05:00,GILD,positive
549508.0,PreMarket Prep Recap: Bulls Regain Early Control Of The Markets,2020-02-03 12:32:00-05:00,GILD,neutral
549509.0,61 Stocks Moving In Monday's Mid-Day Session,2020-02-03 12:25:00-05:00,GILD,neutral
549510.0,'Gilead Sciences says remdesivir not yet approved to treat coronavirus' -China's Global Times,2020-02-03 12:24:00-05:00,GILD,positive
549511.0,Gilead Sciences Option Alert: May 15 $75 Calls at the Ask: 500 @ $0.761 vs 914 OI; Earnings 2/4 After Close Ref=$65.7449,2020-02-03 11:11:00-05:00,GILD,positive
549512.0,Gilead Sciences Option Alert: Feb 21 $70 Calls Sweep (4) near the Ask: 721 @ $1.061 vs 27477 OI; Earnings 2/4 After Close Ref=$67.245,2020-02-03 09:36:00-05:00,GILD,positive
549513.0,Gilead Sciences Option Alert: Feb 21 $70 Calls Sweep (119) above Ask!: 1094 @ $0.594 vs 27477 OI; Earnings 2/4 After Close Ref=$68.2778,2020-02-03 09:31:00-05:00,GILD,positive
549514.0,Gilead's Experimental Antiviral Drug To Be Screened In Human Trials In China For Coronavirus,2020-02-03 09:19:00-05:00,GILD,neutral
549515.0,18 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,GILD,neutral
549516.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,GILD,neutral
549517.0,Gilead Sciences shares are trading higher following reports the company's Remdesivir will undergo a trial for treatment of Coronavirus.,2020-02-03 07:08:00-05:00,GILD,positive
549518.0,"Gilead Shares Selling Off Over the Last 30 Minutes, the Stock Traded Higher Early Monday Following a Weekend Report the Company's Remdesivir Would Undergo a Trial for Coronavirus",2020-02-03 06:39:00-05:00,GILD,positive
549519.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,GILD,neutral
549520.0,Beijing's China-Japan Friendship Hospital will Lead a Clinical Trial on the Treatment of Coronavirus Gilead's Remdesivir in Wuhan,2020-02-02 08:55:00-05:00,GILD,positive
549521.0,Coronavirus Case Treated With Gilead Drug May Spur Wider Tests,2020-02-02 08:52:00-05:00,GILD,neutral
549522.0,Hearing Gilead Working with China to Determine if its Remdesivir Can be Used to Treat Corona Virus,2020-01-31 13:51:00-05:00,GILD,positive
549523.0,Gilead Sciences Option Alert: Fri $64.5 Calls at the Ask: 3770 @ $0.451 vs 6889 OI; Earnings 2/4 After Close Ref=$64.205,2020-01-28 10:58:00-05:00,GILD,positive
549524.0,Gilead Sciences Option Alert: Mar 20 $62.5 Calls Sweep (50) near the Ask: 984 @ $3.051 vs 1043 OI; Earnings 2/4 After Close Ref=$63.61,2020-01-27 12:36:00-05:00,GILD,positive
549525.0,Gilead Sciences Option Alert: Fri $64.5 Calls Sweep (15) near the Ask: 505 @ $0.461 vs 3302 OI; Earnings 2/4 After Close Ref=$63.69,2020-01-27 12:17:00-05:00,GILD,positive
549526.0,Gilead Says There Are Currently No Antiviral Data For Remdesivir That Show Activity Against Wuhan Coronavirus,2020-01-23 13:54:00-05:00,GILD,negative
549527.0,Gilead Says Co Is In Discussions Regarding Potential Use Of Remdesivir As An Investigational Treatment For Ongoing Wuhan Coronavirus Outbreak,2020-01-23 13:53:00-05:00,GILD,neutral
549528.0,"Gilead Says Co Is In Active Discussions With Researchers, Clinicians In U.S. And China Regarding Ongoing Wuhan Coronavirus Outbreak",2020-01-23 13:52:00-05:00,GILD,positive
549529.0,Gilead Shares Spike To Session High Hearing Company Assessing Its Ebola Drug As A Coronavirus Treatment,2020-01-23 13:34:00-05:00,GILD,positive
549530.0,Guggenheim Securities Downgrades Gilead Sciences to Neutral,2020-01-21 09:33:00-05:00,GILD,positive
549531.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,GILD,positive
549532.0,Gilead Sciences Option Alert: Fri $63 Calls Sweep (52) above Ask!: 1040 @ $0.3 vs 232 OI; Earnings 2/3 After Close [est] Ref=$63.09,2020-01-17 09:41:00-05:00,GILD,positive
549533.0,Gilead Sciences CEO Says To Focus On Small To Medium Sized Bolt-On Acquisitions,2020-01-13 12:53:00-05:00,GILD,neutral
549534.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,GILD,neutral
549535.0,Gilead Sciences Licenses Portfolio Of HIV Antibodies From The Rockefeller University,2020-01-09 08:32:00-05:00,GILD,neutral
549536.0,Xencor And Gilead Enter License Agreement For Use Of XmAb Antibody Technologies In Investigational Agents For HIV,2020-01-08 08:04:00-05:00,GILD,positive
549537.0,Investor Movement Index Summary: December 2019,2020-01-07 07:40:00-05:00,GILD,neutral
549538.0,HOOKIPA Says it has Made Strong Progress in its Collaboration with Gilead for Cures to Hepatitis B and HIV,2020-01-06 07:14:00-05:00,GILD,positive
549539.0,Gilead Sciences Option Alert: Jan 17 $65 Calls at the Ask: 1500 @ $1.311 vs 32458 OI; Earnings 2/3 After Close [est] Ref=$65.1002,2020-01-03 13:57:00-05:00,GILD,positive
549540.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2020",2020-01-03 11:33:00-05:00,GILD,positive
549541.0,Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes,2020-01-02 10:41:00-05:00,GILD,neutral
549542.0,"Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%",2020-01-01 11:58:00-05:00,GILD,neutral
549543.0,Gilead Sciences Option Alert: Feb 21 $70 Calls at the Ask: 5863 @ $0.761 vs 14359 OI; Earnings 2/3 After Close [est] Ref=$64.5295,2019-12-31 10:09:00-05:00,GILD,positive
549544.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,GILD,neutral
549545.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,GILD,negative
549546.0,"Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval",2019-12-24 05:11:00-05:00,GILD,positive
549547.0,Gilead Reports China's National Medical Products Admin. Approved Vosevi For Treatment Of Chronic Hep C Infection Who Require Re-Treatment,2019-12-20 08:32:00-05:00,GILD,positive
549548.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,GILD,positive
549549.0,Gilead Reports Submission Of Filgotinib New Drug Application Under Priority Review For Rheumatoid Arthritis Treatment,2019-12-19 16:30:00-05:00,GILD,neutral
549550.0,"Micron Yesterday, Nike Today: Earnings Keep Rolling In As Week Winds Down",2019-12-19 09:45:00-05:00,GILD,neutral
549551.0,Gilead Sciences Option Alert: Jan 17 $70 Calls Sweep (21) near the Ask: 514 @ $0.693 vs 65480 OI; Earnings 2/3 After Close [est] Ref=$66.4952,2019-12-16 10:40:00-05:00,GILD,positive
549552.0,Gilead's Phase 2 ATLAS Study in Patients with Bridging Fibrosis and Compensated Cirrhosis Missed its Primary Endpoint,2019-12-16 08:03:00-05:00,GILD,negative
549553.0,"Bernie Sanders  Tweet: We could eradicate HIV/AIDS in America. What's standing in the way? The greed of the pharmaceutical industry.  An $8 HIV drug in Australia costs $2,000 in America. That is immoral. We need affordable, generic HIV medicine. Now",2019-12-14 19:59:00-05:00,GILD,negative
549554.0,Bristol-Myers Squibb Wins Patent Royalty Fight Against Gilead; Co. Awarded $585M In Damages Plus Royalty,2019-12-13 14:31:00-05:00,GILD,positive
549555.0,Gilead Sciences shares are trading lower after Credit Suisse downgraded the stock from Neutral to Underperform and lowered the price target from $67 to $63.,2019-12-13 11:49:00-05:00,GILD,positive
549556.0,"Credit Suisse Downgrades Gilead Sciences to Underperform, Lowers Price Target to $63",2019-12-13 07:01:00-05:00,GILD,positive
549557.0,Gilead Sciences Option Alert: Jan 17 $70 Calls Sweep (41) above Ask!: 864 @ $1.087 vs 44382 OI; Earnings 2/3 After Close [est] Ref=$67.575,2019-12-12 14:01:00-05:00,GILD,positive
549558.0,Gilead Sciences Option Alert: Jan 17 $70 Calls Sweep (21) near the Ask: 608 @ $1.048 vs 44382 OI; Earnings 2/3 After Close [est] Ref=$67.535,2019-12-12 13:58:00-05:00,GILD,positive
549559.0,'Activists Say A Patent Office Lawyer's Tweets Showed 'Bias' In Favor Of Gilead In HIV Drug Case' - STAT,2019-12-12 13:20:00-05:00,GILD,positive
549560.0,Gilead Sciences Option Alert: Feb 21 $70 Calls at the Ask: 4230 @ $2.351 vs 10716 OI; Earnings 2/3 After Close [est] Ref=$67.6259,2019-12-12 12:56:00-05:00,GILD,positive
549561.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,GILD,positive
549562.0,Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company's Second CAR T Cell Therapy,2019-12-11 16:09:00-05:00,GILD,neutral
549563.0,Gilead's Kite And Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination Of Yescarta And Mavrilimumab In Relapsed Or Refractory Large B-Cell Lymphoma,2019-12-11 08:32:00-05:00,GILD,neutral
549564.0,Gilead's Kite Presents Results From Pivotal ZUMA-2 Trial In Relapsed Or Refractory Mantle Cell Lymphoma; Results Showed 93 Percent of Patients Treated With Investigational KTE-X19 Achieved Response,2019-12-09 14:49:00-05:00,GILD,neutral
549565.0,Gildead's Kite Presents Findings From Real-World Use Of Yescarta Study,2019-12-09 14:48:00-05:00,GILD,neutral
549566.0,Gilead Shares Unaffected Following Earlier Article From UK's Guardian 'Sanders and Ocasio-Cortez say company seeking HIV patent extension 'deceitful and immoral'',2019-12-09 10:55:00-05:00,GILD,negative
549567.0,Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment at ASH 2019,2019-12-07 14:24:00-05:00,GILD,positive
549568.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,GILD,neutral
549569.0,Gilead Sciences shares are trading higher. Currently not seeing any news to justify the price action.,2019-11-25 10:56:00-05:00,GILD,positive
549570.0,Gilead Sciences Option Alert: Jan 17 $65 Calls Sweep (87) near the Ask: 4354 @ $1.248 vs 47976 OI; Ref=$62.565,2019-11-14 10:58:00-05:00,GILD,positive
549571.0,Galapagos Says Received Transparency Notice from Gilead; Gilead Holds 25.10% of Galapagos Shares,2019-11-14 06:14:00-05:00,GILD,positive
549572.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,GILD,positive
549573.0,"SunTrust Robinson Humphrey Initiates Coverage On Gilead Sciences with Hold Rating, Announces $70 Price Target",2019-11-12 06:27:00-05:00,GILD,neutral
549574.0,"Gilead, Galapagos Announce New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Durable Efficacy and Safety Profile",2019-11-09 17:10:00-05:00,GILD,positive
549575.0,Gilead Highlights Presentation Of Data On GS-6207 As Potential Component Of Long-Acting HIV Therapy,2019-11-08 08:12:00-05:00,GILD,neutral
549576.0,Gilead To Present New Data From Viral Hepatitis Research Programs At The Liver Meeting 2019,2019-11-08 08:11:00-05:00,GILD,neutral
549577.0,"Former Google, Pharma Execs Start Ritual-Based Cannabis Company",2019-11-07 17:15:00-05:00,GILD,neutral
549578.0,Gilead Sciences shares are trading lower after the company exercised warrants for 2.62 million shares of Galapagos.,2019-11-07 10:19:00-05:00,GILD,positive
549579.0,Gilead Therapeutics Exercises Warrants for 2.62M Shares of Galapagos,2019-11-06 16:32:00-05:00,GILD,positive
549580.0,Gilead Presents 96-Week Discover Trial Data Supporting Non-inferior Efficacy And Key Safety Differences Of Descovy For PrEP Compared With Truvada For PrEP,2019-11-06 06:48:00-05:00,GILD,positive
549581.0,US Appeals Court Upholds Lower Court Ruling That Tossed $2.54B Jury Verdict For Merck In Patent Case Against Gilead,2019-10-30 09:54:00-04:00,GILD,negative
549582.0,Gilead Sciences Option Alert: Jan 17 $65 Calls Sweep (22) near the Ask: 12532 @ $1.638 vs 31930 OI; Ref=$63.015,2019-10-28 14:05:00-04:00,GILD,positive
549583.0,Gilead and Glympse Bio Announce the Companies Enter Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development,2019-10-28 08:03:00-04:00,GILD,neutral
549584.0,"Benzinga's Top Upgrades, Downgrades For October 25, 2019",2019-10-25 12:44:00-04:00,GILD,positive
549585.0,Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes,2019-10-25 12:41:00-04:00,GILD,neutral
549586.0,"UPDATE: Raymond James On Gilead Notes 'therefore filgotinib and M&A will need to be the main growth drivers going forward';'both can be and while the base business doesn't look like a major growth business to us anymore on net, it is still stable', Huge",2019-10-25 11:07:00-04:00,GILD,positive
549587.0,"UPDATE: Raymond James Maintains Strong Buy On Gilead, Lowers Target To $81 Notes 'our investment thesis is admittedly drifting'; Doesn't 'think Biktarvy + PrEP + Yescarta are enough anymore to drive growth in the face of continued pressure on HCV'",2019-10-25 11:07:00-04:00,GILD,positive
549588.0,Hearing Dealreporter Says Gilead Could Be Eyeing Intercept Pharma,2019-10-25 09:38:00-04:00,GILD,neutral
549589.0,"Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $80",2019-10-25 09:31:00-04:00,GILD,negative
549590.0,10 Biggest Price Target Changes For Friday,2019-10-25 09:28:00-04:00,GILD,neutral
549591.0,Maxim Group Downgrades Gilead Sciences to Hold,2019-10-25 08:43:00-04:00,GILD,neutral
549592.0,"BMO Capital Maintains Outperform on Gilead Sciences, Lowers Price Target to $81",2019-10-25 08:39:00-04:00,GILD,negative
549593.0,Gilead Sciences shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also narrowed its FY19 sales guidance below analyst estimates.,2019-10-25 08:35:00-04:00,GILD,neutral
549594.0,"Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to $81",2019-10-25 08:08:00-04:00,GILD,positive
549595.0,"Maxim Downgrades Gilead To Hold, Lowers Price Target To $66",2019-10-25 07:53:00-04:00,GILD,negative
549596.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,GILD,positive
549597.0,Gilead Sciences shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also narrowed its FY19 sales guidance below analyst estimates.,2019-10-24 16:41:00-04:00,GILD,neutral
549598.0,"Gilead Narrows FY19 Sales Guidance From $21.6B-$22.1B To $21.8B-$22.1B vs $22.32B Estimate, Reaffirms EPS At $3.90-$4",2019-10-24 16:03:00-04:00,GILD,neutral
549599.0,"Gilead Sciences Q3 Adj. EPS $1.75 Beats $1.74 Estimate, Sales $5.604B Miss $5.61B Estimate",2019-10-24 16:02:00-04:00,GILD,negative
549600.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,GILD,neutral
549601.0,"Earnings Scheduled For October 24, 2019",2019-10-24 04:05:00-04:00,GILD,neutral
549602.0,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,2019-10-21 11:16:00-04:00,GILD,neutral
549603.0,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",2019-10-20 08:08:00-04:00,GILD,positive
549604.0,"Bank of America Reinstates Neutral on Gilead Sciences, Announces $70 Price Target",2019-10-17 07:22:00-04:00,GILD,neutral
549605.0,"Gilead Sciences Appoints Andrew Dickinson As CEO Effective November 1, 2019",2019-10-15 08:43:00-04:00,GILD,positive
549606.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,GILD,positive
549607.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,GILD,positive
549608.0,"Gilead, Galapagos Report Efficacy, Safety Results Of Filgotinib Through 52 Weeks In FINCH 1, 3 Studies In RA",2019-10-10 18:01:00-04:00,GILD,positive
549609.0,"Gilead To Report Q3 Earnings On Thurs., Oct. 24, 2019 After Market Close",2019-10-10 16:20:00-04:00,GILD,neutral
549610.0,Gilead Sciences Option Alert: Fri $62.5 Calls Sweep (91) near the Ask: 983 @ $0.391 vs 359 OI; Earnings 10/24 After Close Ref=$62.4786,2019-10-10 09:39:00-04:00,GILD,positive
549611.0,"Jim Cramer Shares His Thoughts On Roku, Gilead And More",2019-10-09 11:35:00-04:00,GILD,positive
549612.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,GILD,positive
549613.0,"The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration",2019-10-08 07:11:00-04:00,GILD,negative
549614.0,Gilead  Submits NDA for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan,2019-10-08 04:26:00-04:00,GILD,neutral
549615.0,Gilead Highlights New Data From HIV Clinical Development Program At IDWeek,2019-10-04 08:31:00-04:00,GILD,neutral
549616.0,Gilead Receives FDA Approval For Descovy In HIV Pre-Exposure Prophylaxis,2019-10-03 14:50:00-04:00,GILD,positive
549617.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,GILD,negative
549618.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,GILD,neutral
549619.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,GILD,positive
549620.0,'Fast Money Halftime Report' Picks For September 26,2019-09-26 17:55:00-04:00,GILD,neutral
549621.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,GILD,negative
549622.0,Gilead Sciences and Elton John AIDS Foundation to Partner to Positively Impact People Affected with HIV,2019-09-09 07:38:00-04:00,GILD,positive
549623.0,Alberta Provides Access To Biktarvy For The Treatment Of HIV,2019-08-26 11:57:00-04:00,GILD,neutral
549624.0,Gilead And Galapagos Complete Closing Of Transformative Research And Development Collaboration,2019-08-23 16:02:00-04:00,GILD,neutral
549625.0,"Gilead Sciences Says ""Strongly Believe"" That The Patents Granted To Hhs Since 2015 For Prep And Pep Are Not Valid",2019-08-21 13:58:00-04:00,GILD,positive
549626.0,Gilead Statement On Petitions To U.S. Patent And Trademark Office On Hiv Prep Patents; Will Continue To Invest In Programs To Accelerate Access To Prep,2019-08-21 13:58:00-04:00,GILD,neutral
549627.0,Gilead Reports EMA Validated Marketing Application For Filgotinib For Treatment Of RA,2019-08-15 16:01:00-04:00,GILD,positive
549628.0,Gilead Reports Its Canada Unit Reported Quebec Public Drug Insurance Plan Will Be Provided For Eligible Patients With Access To Biktarvy Tablets,2019-08-15 08:02:00-04:00,GILD,neutral
549629.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,GILD,positive
549630.0,Gilead Reports China National Medical Products Admin. Approved Biktarvy For Treatment Of HIV-1 Infection,2019-08-09 08:31:00-04:00,GILD,positive
549631.0,Agenus Reports $7.5M Payment Triggered Following Acceptance Of Investigational New Drug Application Filing For AGEN2373,2019-08-08 10:05:00-04:00,GILD,positive
549632.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,GILD,neutral
549633.0,Gilead Sciences Statement on FDA Advisory Committee's Recommendation on Descovy for PrEP,2019-08-07 20:48:00-04:00,GILD,neutral
549634.0,"Gilead Shares Unaffected As FDA Panel Has Voted 16-2 In Favor Of co.'s Descovy For Pre-Exposure Prep Of HIV In Men, Transgender Women",2019-08-07 15:47:00-04:00,GILD,positive
549635.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,GILD,neutral
549636.0,Gilead Sciences Option Alert: Sep 20 $65 Calls Sweep (2) near the Ask: 527 @ $1.5 vs 3258 OI; Ref=$63.23,2019-08-06 12:43:00-04:00,GILD,positive
549637.0,Gilead's Sciences Canada Unit Highlights Ontario Drug Benefit Program Will Provide Eligible Patients With Access To Biktarvy Tablets,2019-08-06 08:26:00-04:00,GILD,positive
549638.0,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.,2019-08-05 12:43:00-04:00,GILD,negative
549639.0,Gilead Sciences Option Alert: Aug 9 $67.5 Calls Sweep (2) near the Ask: 700 @ $0.401 vs 536 OI; Ref=$65.71,2019-07-31 10:00:00-04:00,GILD,positive
549640.0,Gilead Sciences shares are trading lower despite better-than-expected Q2 results and raised guidance.,2019-07-31 09:52:00-04:00,GILD,neutral
549641.0,"Credit Suisse Maintains Neutral on Gilead Sciences, Lowers Price Target to $67",2019-07-31 08:59:00-04:00,GILD,positive
549642.0,"Raymond James Maintains Strong Buy on Gilead Sciences, Raises Price Target to $86",2019-07-31 07:51:00-04:00,GILD,positive
549643.0,Gilead Ticks Higher After Q2 Earnings Beat,2019-07-30 16:20:00-04:00,GILD,neutral
549644.0,Gilead Raises FY19 Product Sales Guidance From $21.3B-$21.8B To $21.6B-$22.1B,2019-07-30 16:02:00-04:00,GILD,neutral
549645.0,"Gilead Sciences Q2 Adj. EPS $1.82 Beats $1.72 Estimate, Sales $5.685B Beat $5.51B Estimate",2019-07-30 16:02:00-04:00,GILD,neutral
549646.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,GILD,positive
549647.0,"15 Stocks To Watch For July 30, 2019",2019-07-30 04:38:00-04:00,GILD,neutral
549648.0,"Earnings Scheduled For July 30, 2019",2019-07-30 04:05:00-04:00,GILD,neutral
549649.0,RBC On Gilead: 'A Compelling Opportunity To Build A Long-Term Position',2019-07-29 11:04:00-04:00,GILD,positive
549650.0,"UPDATE: RBC On Gilead Also Notes 'high conviction that with new leadership and many overhangs out of the way, shares will begin to better reflect the value of future cash flows from their marketed products and pipeline, which we believe is worth $91'",2019-07-29 10:08:00-04:00,GILD,positive
549651.0,"UPDATE: RBC Upgrades Gilead To Top Pick, Announces $91 Target As Firm Notes 'We have increasingly high confidence GILD's HIV franchise will provide steady annual revenues of ~$16B/year over the medium term'",2019-07-29 10:07:00-04:00,GILD,positive
549652.0,"Benzinga's Top Upgrades, Downgrades For July 29, 2019",2019-07-29 09:55:00-04:00,GILD,positive
549653.0,RBC Capital Upgrades Gilead Sciences to Top Pick,2019-07-29 07:33:00-04:00,GILD,positive
549654.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,GILD,negative
549655.0,Gilead Highlights Presentation Of Data In Ongoing HIV Cure Research Program,2019-07-23 16:00:00-04:00,GILD,neutral
549656.0,Gilead Reports Presented Added Results From DISCOVER Trial Of Descovy At International AIDS Society Conference on HIV Science,2019-07-23 11:06:00-04:00,GILD,neutral
549657.0,Gilead Presents New Data On Biktarvy For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance,2019-07-22 12:01:00-04:00,GILD,neutral
549658.0,STAT News Article Highlights CAR-T Therapy Innovations,2019-07-22 11:17:00-04:00,GILD,neutral
549659.0,Gilead Highlights Presentation Of Proof-Of-Concept Data For GS-6207 Capsid Inhibitor In People Living With HIV,2019-07-22 11:02:00-04:00,GILD,negative
549660.0,DURECT Soars On Out-Licensing Deal With Gilead For Up To $170M,2019-07-22 09:23:00-04:00,GILD,neutral
549661.0,DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product; DURECT To Receive Upfront Payment Of $25M With Potential For Up To $75M In Development And Regulatory Milestones,2019-07-22 08:03:00-04:00,GILD,positive
549662.0,"Gilead Will Buy Exclusive Global Rights To Develop, Commercialize Novel Small Molecules Against 3 Undisclosed Targets From Novartis, Novartis Will Receive Upfront Payment, Eligible For Added $291M",2019-07-19 08:31:00-04:00,GILD,positive
549663.0,"Gilead To Report Q2 Earnings On Tue., Jul. 30, 2019 After Market Close",2019-07-16 16:09:00-04:00,GILD,neutral
549664.0,52 Biggest Movers From Yesterday,2019-07-16 05:15:00-04:00,GILD,neutral
549665.0,Mid-Afternoon Market Update: Carolina Trust BancShares Rises On Acquisition News; Callon Petroleum Shares Tumble,2019-07-15 14:56:00-04:00,GILD,positive
549666.0,Mid-Day Market Update: Crude Oil Down 1%; Galapagos Shares Spike Higher,2019-07-15 12:58:00-04:00,GILD,negative
549667.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-15 12:47:00-04:00,GILD,neutral
549668.0,Mid-Morning Market Update: Markets Edge Lower; Citigroup Beats Q2 Estimates,2019-07-15 10:15:00-04:00,GILD,negative
549669.0,Galapagos Notches $3.95B Upfront Investment From Gilead,2019-07-15 10:01:00-04:00,GILD,neutral
549670.0,Gilead Sciences shares are trading higher after Wells Fargo upgraded the stock from Market Perform to Outperform and raised the price target from $68 to $88.,2019-07-15 09:57:00-04:00,GILD,positive
549671.0,10 Biggest Price Target Changes For Monday,2019-07-15 09:48:00-04:00,GILD,neutral
549672.0,"Benzinga's Top Upgrades, Downgrades For July 15, 2019",2019-07-15 09:38:00-04:00,GILD,positive
549673.0,"Wells Fargo Upgrades Gilead Sciences to Outperform, Raises Price Target to $88",2019-07-15 07:01:00-04:00,GILD,positive
549674.0,Galapagos Shares RIse $23 Premarket Following Announcement of $1.1B Equity Investment from Gilead,2019-07-15 04:01:00-04:00,GILD,positive
549675.0,"Gilead, Galapagos Announce 10-year Global R&D Collaboration",2019-07-14 20:47:00-04:00,GILD,neutral
549676.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,GILD,negative
549677.0,"Gilead Reports Strategic Collaboration With Renown Institute For Health Innovation For Collection, Analyzing Of Genetic, Electronic Health Data",2019-07-11 08:37:00-04:00,GILD,positive
549678.0,"Gilead, Lyndra Therapeutics Partner On Ultra-Long-Acting HIV Drugs",2019-07-09 09:54:00-04:00,GILD,neutral
549679.0,"Lyndra Therapeutics, Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics",2019-07-09 04:08:00-04:00,GILD,neutral
549680.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,GILD,positive
549681.0,Gilead Sciences Option Alert: Jul 26 $71.5 Calls Sweep (28) near the Ask: 596 @ $0.339 vs 1144 OI; Earnings 7/24 After Close [est] Ref=$68.65,2019-07-05 13:54:00-04:00,GILD,positive
549682.0,"The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug",2019-07-02 07:29:00-04:00,GILD,positive
549683.0,Gilead Announces Intent to Submit NDA to FDA for Filgotinib This Year,2019-07-01 19:03:00-04:00,GILD,neutral
549684.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,GILD,neutral
549685.0,"The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership",2019-06-25 07:15:00-04:00,GILD,neutral
549686.0,"Gilead, Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies",2019-06-24 19:03:00-04:00,GILD,positive
549687.0,"Gilead Reports Strategic Collaboration With Nurix To Develop Novel Therapies For Cancer, Other Diseases",2019-06-19 08:30:00-04:00,GILD,negative
549688.0,"Abcellera Reports Therapeutic Antibody Discovery Collaboration With Gilead, Will Receive Upfront, Research Payments",2019-06-13 06:16:00-04:00,GILD,neutral
549689.0,"WHO Emergency Committee Meeting To Decide If Ebola Outbreak Constitutes An Int'l. Emergency Will Begin Jun. 14, 2019",2019-06-12 11:15:00-04:00,GILD,negative
549690.0,Gilead Sciences Option Alert: Jun 28 $66 Calls Sweep (3) near the Ask: 500 @ $1.301 vs 838 OI; Earnings 7/24 After Close [est] Ref=$66.67,2019-06-12 09:33:00-04:00,GILD,positive
549691.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,GILD,neutral
549692.0,"Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing",2019-06-11 14:29:00-04:00,GILD,neutral
549693.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,GILD,neutral
549694.0,Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.,2019-06-07 12:31:00-04:00,GILD,negative
549695.0,ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study,2019-06-06 11:44:00-04:00,GILD,neutral
549696.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,GILD,positive
549697.0,"Gilead Sciences shares are trading higher after Kite, a Gilead company, announced positive data from the ZUMA-1 trial of Yescarta.",2019-06-03 15:09:00-04:00,GILD,positive
549698.0,"Gilead's Kite Highlights New Yescarta Data From ZUMA-1, Showed 'High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment'",2019-06-03 09:02:00-04:00,GILD,neutral
549699.0,"Biocartis, Kite Sign Agreement for Development of Assays Supporting Kite's Therapies; Financial Terms Not Disclosed",2019-06-01 07:31:00-04:00,GILD,positive
549700.0,Gilead's Kite Reports Clinical Collaboration With Humanigen To Evaluate Investigational Combination of Yescarta® with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,2019-05-31 08:35:00-04:00,GILD,neutral
549701.0,"Gilead, Galapagos Highlights Will Present Latest Data From Filgotinib At EULAR 2019",2019-05-29 16:32:00-04:00,GILD,neutral
549702.0,Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding',2019-05-28 11:08:00-04:00,GILD,negative
549703.0,"UPDATE: Goldman Downgrades Gilead To Sell, Lowers Target To $60 As Firm Notes 'Nearer-term we expect the company's top line growth to decelerate'",2019-05-28 09:56:00-04:00,GILD,positive
549704.0,10 Biggest Price Target Changes For Tuesday,2019-05-28 09:52:00-04:00,GILD,neutral
549705.0,Gilead Sciences shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered the price target from $70 to $60.,2019-05-28 09:52:00-04:00,GILD,negative
549706.0,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",2019-05-28 09:15:00-04:00,GILD,positive
549707.0,A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Economic Data,2019-05-28 07:24:00-04:00,GILD,negative
549708.0,"Goldman Sachs Downgrades Gilead Sciences to Sell, Lowers Price Target to $60 Price Target",2019-05-28 06:33:00-04:00,GILD,negative
549709.0,"Alpine Immune Sciences 8-K Shows Gilead's Kite Pharma Provided Co. Notice Of Termination Of License, Research Deal",2019-05-24 07:49:00-04:00,GILD,positive
549710.0,Gilead And Kratos Defense: 'Fast Money Halftime Report' Picks From May 23,2019-05-23 14:39:00-04:00,GILD,positive
549711.0,"Benzinga's Top Upgrades, Downgrades For May 23, 2019",2019-05-23 09:01:00-04:00,GILD,positive
549712.0,"Citigroup Upgrades Gilead Sciences, Inc. - Common Stock to Buy",2019-05-23 07:08:00-04:00,GILD,neutral
549713.0,"Credit Suisse Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Neutral Rating, Announces $70 Price Target",2019-05-21 07:09:00-04:00,GILD,positive
549714.0,"Hearing Credit Suisse Initiates Coverage On Gilead With Neutral Rating, $70 Price Target",2019-05-20 17:06:00-04:00,GILD,positive
549715.0,"Temasek Liquidates Positions In Boeing, Tencent Music, Gilead, Takes Small Stake In Microsoft",2019-05-15 06:39:00-04:00,GILD,neutral
549716.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,GILD,positive
549717.0,"Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.",2019-05-13 10:35:00-04:00,GILD,negative
549718.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,GILD,positive
549719.0,'Drugmaker Gilead reaches multiyear agreement with White House to donate HIV prevention med PrEP' -CNBC,2019-05-10 07:59:00-04:00,GILD,positive
549720.0,Gilead To Invest $109M In Goldfinch Bio For Kidney Drug Collaboration,2019-05-08 14:12:00-04:00,GILD,neutral
549721.0,"UPDATE: Goldfinch To Receive $55M In Upfront Payments From Gilead, Added $54M To Support Development Of KGA Platform For Diabetic Kidney Disease",2019-05-08 07:08:00-04:00,GILD,positive
549722.0,Gilead Sciences Reports Strategic Collaboration With Goldfinch Bio To Develop Novel Therapies For Kidney Disease,2019-05-08 07:07:00-04:00,GILD,positive
549723.0,Gilead Sciences shares are trading higher after the company reported better-than-expected Q1 EPS and reaffirmed 2019 guidance.,2019-05-03 10:18:00-04:00,GILD,positive
549724.0,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen",2019-05-03 07:49:00-04:00,GILD,positive
549725.0,Gilead Reaffirms FY19 Guidance,2019-05-02 16:02:00-04:00,GILD,neutral
549726.0,"Gilead Sciences Q1 Adj. EPS $1.76 Beats $1.61 Estimate, Sales $5.258B Miss $5.31B Estimate",2019-05-02 16:01:00-04:00,GILD,negative
549727.0,What's The Buzz Around Novartis' Gene Therapy Zolgensma?,2019-05-02 09:22:00-04:00,GILD,neutral
549728.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,GILD,positive
549729.0,"Earnings Scheduled For May 2, 2019",2019-05-02 04:43:00-04:00,GILD,neutral
549730.0,"Alphabet's Eric Schmidt, Diane Greene To Leave Board This June",2019-05-01 08:13:00-04:00,GILD,negative
549731.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,GILD,neutral
549732.0,Gilead Reports CFO Robin Washington To Step Down; Was Named To Alphabet's Board,2019-04-30 16:27:00-04:00,GILD,neutral
549733.0,"Bernstein Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Outperform Rating",2019-04-26 09:01:00-04:00,GILD,neutral
549734.0,"Bernstein Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Outperform Rating, Announces $82 Price Target",2019-04-26 08:29:00-04:00,GILD,neutral
549735.0,Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment,2019-04-25 10:13:00-04:00,GILD,negative
549736.0,Gilead Announces Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis Due To NASH Did Not MEet PRe-Specified Week 48 Endpoint,2019-04-25 08:02:00-04:00,GILD,neutral
549737.0,'Gilead defied a government HIV patent. The Justice Department has opened a review.' -Washington Post,2019-04-24 12:52:00-04:00,GILD,positive
549738.0,"Gilead Reports Its Kite Pharma Co. Planning New Facility In Frederick County On 20-Acre Site, Maryland To Produce Cell Therapies For People With Cancer",2019-04-24 08:34:00-04:00,GILD,negative
549739.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,GILD,positive
549740.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,GILD,negative
549741.0,"Jim Cramer Shares His Thoughts On AMD, Gilead, Nvidia And More",2019-04-18 07:30:00-04:00,GILD,positive
549742.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,GILD,negative
549743.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,GILD,negative
549744.0,Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis,2019-04-16 07:04:00-04:00,GILD,positive
549745.0,"Gilead Sciences, Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH",2019-04-12 04:22:00-04:00,GILD,neutral
549746.0,"Gilead Highlights Will Present New Data On HBV, Hep C Medicines At The International Liver Congress Thurs.",2019-04-11 09:19:00-04:00,GILD,neutral
549747.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,GILD,positive
549748.0,Gilead Presents New Data in NASH at the International Liver Congress 2019,2019-04-11 03:45:00-04:00,GILD,neutral
549749.0,'Gilead Sciences to lay off one-fifth of sales force as financial pressures build' -STAT,2019-04-10 15:43:00-04:00,GILD,negative
549750.0,"UBS Upgrades Gilead, Sees EPS Upside In 2019",2019-04-10 11:17:00-04:00,GILD,neutral
549751.0,Gilead Sciences shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised the price target from $75 to $77.,2019-04-10 10:39:00-04:00,GILD,positive
549752.0,10 Biggest Price Target Changes For Wednesday,2019-04-10 09:37:00-04:00,GILD,neutral
549753.0,"Benzinga's Top Upgrades, Downgrades For April 10, 2019",2019-04-10 09:04:00-04:00,GILD,positive
549754.0,"A Peek Into The Markets: US Stock Futures Climb Ahead Of CPI, Fed Minutes",2019-04-10 07:19:00-04:00,GILD,neutral
549755.0,"UBS Upgrades Gilead Sciences to Buy, Raises Price Target to $77",2019-04-10 06:55:00-04:00,GILD,neutral
549756.0,Gilead Sciences Option Alert: May 17 $70 Calls Sweep (35) near the Ask: 534 @ $1.309 vs 7580 OI; Earnings 4/30 After Close [est] Ref=$67.56,2019-04-05 10:34:00-04:00,GILD,positive
549757.0,Gilead Reports Submission Of Supplemental New Drug Application To FDA For Once-Daily Descovy For HIV Pre-Exposure Prophylaxis,2019-04-05 08:31:00-04:00,GILD,neutral
549758.0,Congo Health Ministry Says Has Recorded 15 New Confirmed Cases Of Ebola,2019-03-29 13:55:00-04:00,GILD,neutral
549759.0,Gilead Sciences shares are trading higher after the company's filgotinib met its primary and key secondary endpoints in a phase 3 Finch 1 rheumatoid arthritis study.,2019-03-29 11:46:00-04:00,GILD,positive
549760.0,"The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead",2019-03-29 07:42:00-04:00,GILD,positive
549761.0,Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 Finch 1 Rheumatoid Arthritis Study,2019-03-28 17:07:00-04:00,GILD,neutral
549762.0,The Precision Biosciences IPO: What You Need To Know,2019-03-27 16:23:00-04:00,GILD,neutral
549763.0,6 Gene Therapy M&A Targets On The Radar,2019-03-27 12:45:00-04:00,GILD,neutral
549764.0,Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress 2019,2019-03-27 06:10:00-04:00,GILD,neutral
549765.0,"Gilead Reports Japan's Ministry of Health, Labour, Welfare Approves Co.'s Biktarvy For Treatment Of HIV-1 Infection",2019-03-26 08:35:00-04:00,GILD,positive
549766.0,Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo,2019-03-22 10:49:00-04:00,GILD,neutral
549767.0,"Benzinga's Top Upgrades, Downgrades For March 15, 2019",2019-03-15 09:19:00-04:00,GILD,positive
549768.0,"BMO Capital Initiates Coverage On Gilead Sciences with Outperform Rating, Announces $78 Price Target",2019-03-15 06:52:00-04:00,GILD,neutral
549769.0,Gilead Sciences Option Alert: Apr 18 $70 Calls Sweep (33) near the Ask: 991 @ $0.301 vs 5924 OI; Earnings 4/30 After Close [est] Ref=$65.63,2019-03-13 12:01:00-04:00,GILD,positive
549770.0,"Agenus Reports Acceptance Of Co.'s IND Filing For AGEN1423 Partnership With Gilead, Triggering Cash Payment Of $7.5M",2019-03-13 08:33:00-04:00,GILD,positive
549771.0,"Gilead Highlights Data From Two Studies Supporting Further Development Of GS-6207, A Novel, Investigational HIV-1 Capsid Inhibitor As A Component Of Future Long-Acting HIV Therapies",2019-03-07 17:31:00-05:00,GILD,positive
549772.0,UPDATE: Gilead Says Biktarvy Showed No Treatment-Emergent Resistance,2019-03-06 17:32:00-05:00,GILD,negative
549773.0,"Gilead Reports Presented New Data On Biktarvy, TAF-Based Regimens For Treatment Of HIV-1: Through Week 48, Biktarvy Maintained High Rates Of Virologic Suppression With Low Incidence Of Study Drug-Related Adverse Events,",2019-03-06 17:32:00-05:00,GILD,negative
549774.0,Gilead Announces Its DISCOVER Trial Meets Primary And Secondary Endpoints And Will Support Supplemental Regulatory Filing For Descovy For Pre-Exposure Prophylaxis,2019-03-06 14:11:00-05:00,GILD,positive
549775.0,Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial,2019-02-19 10:36:00-05:00,GILD,positive
549776.0,Gilead Reports Received Approval In Canada For YESCARTA CAR T Therapy For Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy,2019-02-19 08:06:00-05:00,GILD,positive
549777.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,GILD,neutral
549778.0,"Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage",2019-02-15 09:01:00-05:00,GILD,neutral
549779.0,Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure,2019-02-13 16:22:00-05:00,GILD,negative
549780.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-02-12 12:18:00-05:00,GILD,neutral
549781.0,"Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech",2019-02-12 12:12:00-05:00,GILD,negative
549782.0,8 Biggest Price Target Changes For Tuesday,2019-02-12 09:57:00-05:00,GILD,neutral
549783.0,UPDATE: Raymond James Lowers Gilead Target From $90 To $85 As Firm Notes 'Gilead's Phase 3 trial in F4 NASH patients (STELLAR4) failed' And Firm Has 'very little reason to suspect STELLAR3 in F3 NASH (data 2Q19E) will be any different',2019-02-12 09:21:00-05:00,GILD,negative
549784.0,Gilead's Failed NASH Drug Trial Drags Stock Lower,2019-02-12 09:07:00-05:00,GILD,negative
549785.0,"Benzinga's Top Upgrades, Downgrades For February 12, 2019",2019-02-12 09:05:00-05:00,GILD,positive
549786.0,26 Stocks Moving In Tuesday's Pre-Market Session,2019-02-12 08:25:00-05:00,GILD,neutral
549787.0,Shares of Gilead Sciences are trading lower after the company announced its Phase 3 STELLAR-4 study did not meet its primary endpoint. The stock was subsequently downgraded by several banks.,2019-02-12 08:17:00-05:00,GILD,neutral
549788.0,"The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares",2019-02-12 08:04:00-05:00,GILD,negative
549789.0,"Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to $85",2019-02-12 07:52:00-05:00,GILD,positive
549790.0,A Peek Into The Markets: US Stock Futures Point To Higher Wall Street Open,2019-02-12 07:01:00-05:00,GILD,neutral
549791.0,"Citigroup Downgrades Gilead Sciences to Neutral, Lowers Price Target to $75",2019-02-12 06:54:00-05:00,GILD,negative
549792.0,"Wells Fargo Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $68",2019-02-12 06:39:00-05:00,GILD,positive
549793.0,7 Stocks Moving In Monday's After-Hours Session,2019-02-11 16:46:00-05:00,GILD,neutral
549794.0,Gilead Sciences shares are trading lower after the company reported the topline data from its STELLAR-4 Phase 3 study did not meet its primary endpoint.,2019-02-11 16:41:00-05:00,GILD,neutral
549795.0,Gilead Reports Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis Due To NASH Did Not Meet Primary Endpoint,2019-02-11 16:32:00-05:00,GILD,neutral
549796.0,"For Sale: Performance Stocks, Slightly Worn",2019-02-07 15:03:00-05:00,GILD,negative
549797.0,January's Market Bounce Resulted In Some Unexpected Retail Trading Trends,2019-02-05 16:45:00-05:00,GILD,neutral
549798.0,Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4,2019-02-05 15:26:00-05:00,GILD,neutral
549799.0,Investor Movement Index January Summary,2019-02-05 13:14:00-05:00,GILD,neutral
549800.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-02-05 12:35:00-05:00,GILD,neutral
549801.0,Gilead Sciences shares are trading lower after the company reported Q4 EPS of $1.44 versus $1.70 estimate; sales declined 3.8% year over year due to weakness in its hepatitis C segment.,2019-02-05 10:39:00-05:00,GILD,negative
549802.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-02-05 07:53:00-05:00,GILD,neutral
549803.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,GILD,positive
549804.0,"12 Stocks To Watch For February 5, 2019",2019-02-05 04:25:00-05:00,GILD,neutral
549805.0,'$GILD's comment on M&A: late stage opportunities are few and far between.' -Tweet From Notable Biotech Investor Brad Loncar,2019-02-04 17:05:00-05:00,GILD,positive
549806.0,Gilead Sciences shares are trading lower after the company reported Q4 EPS of $1.44 versus the $1.70 estimate.,2019-02-04 16:20:00-05:00,GILD,neutral
549807.0,Gilead Raises Qtr. Dividend From $0.57 To $0.63/Share,2019-02-04 16:15:00-05:00,GILD,neutral
549808.0,"Gilead Sees FY19 GAAP EPS $1.40-$1.50, Product Sales $21.3B-$21.8B",2019-02-04 16:06:00-05:00,GILD,neutral
549809.0,"Gilead Sciences Q4 EPS $1.44 May Not Compare To $1.70 Estimate, Sales $5.795B Beat $5.48B Estimate",2019-02-04 16:05:00-05:00,GILD,neutral
549810.0,Q4 Earnings Preview For Gilead Sciences,2019-02-04 07:32:00-05:00,GILD,neutral
549811.0,"8 Stocks To Watch For February 4, 2019",2019-02-04 04:50:00-05:00,GILD,neutral
549812.0,"Earnings Scheduled For February 4, 2019",2019-02-04 04:02:00-05:00,GILD,neutral
549813.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,GILD,neutral
549814.0,Analysts Cut AbbVie Price Targets After Earnings Miss,2019-01-28 10:59:00-05:00,GILD,negative
549815.0,Agenus Closes $150 Million Immuno-oncology Transaction With Gilead,2019-01-24 08:43:00-05:00,GILD,neutral
549816.0,Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year,2019-01-18 09:15:00-05:00,GILD,neutral
549817.0,"UPDATE: Nektar Says Gilead Will Be Responsible For Preclinical Studies, Costs",2019-01-08 11:40:00-05:00,GILD,positive
549818.0,UPDATE: Nektar Research Collab With Gilead Will Be For Exploration Of Combo Between Co.'s NKTR-225 And Gilead's Effector-Memory T Cells With Antiretroviral Therapies,2019-01-08 11:40:00-05:00,GILD,positive
549819.0,"Nektar Therapeutics 8-K Shows Pres, CEO Will Make Presentation At JP Morgan Healthcare Conference; Will Outline Research Collab With Gilead; Will Show $1.92B In Cash, Equivalents as Of Dec. 31, 2018",2019-01-08 11:37:00-05:00,GILD,positive
549820.0,Gilead Received Approval for Epclusa in Japan,2019-01-08 04:23:00-05:00,GILD,positive
549821.0,5 Top-Selling Drugs With Growth Potential In 2019,2019-01-07 15:04:00-05:00,GILD,positive
549822.0,Gilead Sciences at JP Morgan Conference Says To Focus On HIV In 2019,2019-01-07 12:36:00-05:00,GILD,positive
549823.0,Gilead. Yuhan Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis,2019-01-06 17:58:00-05:00,GILD,positive
549824.0,Oppenheimer Upgrades Gilead Sciences to Outperform,2019-01-03 09:50:00-05:00,GILD,neutral
549825.0,26 Stocks Moving In Thursday's Pre-Market Session,2019-01-03 08:23:00-05:00,GILD,neutral
549826.0,Gilead shares are trading up on news that Bristol-Myers will acquire Celgene in a $74 billion deal.,2019-01-03 07:13:00-05:00,GILD,positive
549827.0,Gilead Sciences Option Alert: Feb 15 $65 Calls Sweep (27) near the Ask: 536 @ $2.739 vs 4625 OI; Earnings 2/5 After Close [est] Ref=$63.63,2019-01-02 12:19:00-05:00,GILD,positive
549828.0,Gilead Sciences Option Alert: Mar 15 $65 Calls Sweep (17) near the Ask: 590 @ $3.25 vs 329 OI; Earnings 2/5 After Close [est] Ref=$63.4,2019-01-02 12:10:00-05:00,GILD,positive
549829.0,Gilead Sciences Option Alert: Mar 15 $65 Calls Sweep (28) near the Ask: 508 @ $3.151 vs 329 OI; Earnings 2/5 After Close [est] Ref=$63.43,2019-01-02 11:58:00-05:00,GILD,positive
549830.0,28 Stocks Moving In Monday's Pre-Market Session,2018-12-24 08:02:00-05:00,GILD,neutral
549831.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,GILD,neutral
549832.0,Raymond James: Gilead In NASH For The Long Haul,2018-12-20 09:43:00-05:00,GILD,neutral
549833.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,GILD,positive
549834.0,"Gilead, Agenus Report Collaboration Deal To Develop Immuno-Oncology Therapies; Agenus To Receive $150M",2018-12-20 07:31:00-05:00,GILD,neutral
549835.0,"Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $86",2018-12-19 08:08:00-05:00,GILD,neutral
549836.0,Gilead Sciences And Scholar Rock Announce Collaboration To Develop Novel Therapies For Fibrotic Diseases; Scholar Rock Will Receive $80M Upfront As Well As Up To $1.425B In Potential Milestones,2018-12-19 08:04:00-05:00,GILD,positive
549837.0,"Guggenheim Reinstates Buy on Gilead Sciences, Announces $86",2018-12-18 07:25:00-05:00,GILD,neutral
549838.0,Gilead Sciences Option Alert: Jan 18 $75 Calls at the Ask: 600 @ $0.37 vs 25755 OI; Earnings 2/5 After Close [est] Ref=$66.87,2018-12-17 11:52:00-05:00,GILD,positive
549839.0,Gilead Sciences Option Alert: Jan 18 $50 Calls Sweep (2) near the Ask: 700 @ $19.076 vs 2396 OI; Earnings 2/5 After Close [est] Ref=$69.07,2018-12-12 12:54:00-05:00,GILD,positive
549840.0,"Stocks That Will Be Trading Ex Dividend Thurs., Dec. 13, 2018",2018-12-12 11:15:00-05:00,GILD,neutral
549841.0,"New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James",2018-12-11 14:49:00-05:00,GILD,neutral
549842.0,"Gilead Shares Down 1.7% To Below $68 Level Mon.; Co. Announced Late Sun. Roche Exec Daniel O'Day Will Replace John Milligan As CEO, Also Be Named Chair",2018-12-10 12:50:00-05:00,GILD,positive
549843.0,Roche Executive Daniel O'Day to Succeed John Milligan as Gilead CEO,2018-12-09 20:32:00-05:00,GILD,positive
549844.0,Gilead Reports China National Medical Products Administration Approved Harvoni As Hepatitis C Treatment,2018-12-04 08:36:00-05:00,GILD,positive
549845.0,Gilead Reports China National Medical Products Administration Approved Descovy As HIV Treatment,2018-12-04 08:34:00-05:00,GILD,positive
549846.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,GILD,neutral
549847.0,Gilead's Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia at ASH 2018,2018-12-04 04:56:00-05:00,GILD,neutral
549848.0,Kite Announces Encouraging Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia at ASH 2018,2018-12-03 20:09:00-05:00,GILD,positive
549849.0,Gilead's  Kite Announces Two-Year Data for Yescarta in Patients With Refractory Large B-Cell Lymphoma at ASH 2018; Median Duration Of Complete Response Was Not Reached; Median Overall Survival Was Not Reached,2018-12-02 18:41:00-05:00,GILD,negative
549850.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,GILD,neutral
549851.0,Gilead Sciences shares are trading higher amid reports of an Ebola outbreak in The Congo; Gilead developed the Remdesivir antiviral which is undergoing clinical trials to treat Ebola.,2018-11-30 14:02:00-05:00,GILD,positive
549852.0,Japan Tobacco Terminates Agreements With Gilead Sciences Under Which Gilead Grants An Exclusive License To JT To Develop And Commercialize Six Anti-HIV Drugs In Japan,2018-11-29 04:32:00-05:00,GILD,positive
549853.0,9 Policy Catalysts For Health Care Investors To Watch Before Year's End,2018-11-25 09:35:00-05:00,GILD,positive
549854.0,Gilead Announces China National Medical Products Administration (NMPA) Approves Vemlidy for Chronic Hepatitis B Virus Infection,2018-11-19 04:02:00-05:00,GILD,positive
549855.0,Gilead Reports Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis At The Liver Meeting,2018-11-09 08:00:00-05:00,GILD,neutral
549856.0,"IMX Dips In October, But Investors Remain Bullish",2018-11-06 14:25:00-05:00,GILD,neutral
549857.0,Investor Movement Index October Summary,2018-11-06 10:50:00-05:00,GILD,neutral
549858.0,Gilead Sciences shares are down 6.0% after the company announced partnership with Tango Therapeutics; Gildead will pay $50M upfront.,2018-10-31 12:54:00-04:00,GILD,positive
549859.0,"Gilead Sciences and Tango Therapeutics Announce Collaboration to Develop Immuno-Oncology Therapies, Gilead to Make a $50M Upfront Payment",2018-10-31 08:32:00-04:00,GILD,neutral
549860.0,Gilead Reports 96-Week Results From Phase 3 Study Of Biktarvy For Treatment Of HIV-1 In Adults New To HIV Therapy: 'Showed High Efficacy and High Barrier to Resistance',2018-10-30 06:39:00-04:00,GILD,negative
549861.0,"Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to $94",2018-10-26 11:21:00-04:00,GILD,positive
549862.0,"Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $88",2018-10-26 10:38:00-04:00,GILD,negative
549863.0,10 Biggest Price Target Changes For Friday,2018-10-26 09:47:00-04:00,GILD,neutral
549864.0,"Benzinga's Top Upgrades, Downgrades For October 26, 2018",2018-10-26 09:22:00-04:00,GILD,positive
549865.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,GILD,negative
549866.0,"PiperJaffray Downgrades Gilead Sciences to Neutral, Lowers Price Target to $75",2018-10-26 06:53:00-04:00,GILD,negative
549867.0,Gilead Sciences Raises FY18 Sales Guidance From $20B-$21B To $20.8B-$21.3B vs $21.43B Est.,2018-10-25 16:07:00-04:00,GILD,neutral
549868.0,"Gilead Sciences, Inc. Q3 Adj. EPS $1.84 Beats $1.63 Estimate, Sales $5.5B Beat $5.38B Estimate",2018-10-25 16:05:00-04:00,GILD,neutral
549869.0,A Preview Of Gilead's Q3 Earnings,2018-10-25 08:24:00-04:00,GILD,neutral
549870.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,GILD,negative
549871.0,"Earnings Scheduled For October 25, 2018",2018-10-25 04:48:00-04:00,GILD,neutral
549872.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,GILD,neutral
549873.0,"Gilead, Galapagos Announce FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life",2018-10-20 19:48:00-04:00,GILD,positive
549874.0,Gilead Sciences Option Alert: Oct 19 $77.5 Calls Sweep (19) near the Ask: 539 @ $0.986 vs 4073 OI; Earnings 10/25 After Close Ref=$76.18,2018-10-04 14:38:00-04:00,GILD,positive
549875.0,Gilead Reports 96-Week Results From Phase 3 Study Of Biktarvy For Treatment Of HIV-1 In Adults New To HIV Therapy: 'Showed High Efficacy and a Demonstrated Tolerability Profile',2018-10-03 08:31:00-04:00,GILD,neutral
549876.0,"Gilead Subsidiary, Kite, And HiFiBiO Therapeutics Announce Research Collaboration o Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) Cancer Treatment; HiFiBio Will Receive $10M Upfront Payment",2018-10-02 08:34:00-04:00,GILD,negative
549877.0,"Cantor Fitzgerald Initiates Coverage On Gilead Sciences with Overweight Rating, Announces $87 Price Target",2018-10-01 08:18:00-04:00,GILD,negative
549878.0,Traders Circulating FDA.gov Adverse Event Reporting System Doc Showing Case For Multiple Instances Of Co.'s HIV Treatment Potentially Causing Transplacental Defects; Gilead Shares Move Lower,2018-09-26 12:52:00-04:00,GILD,negative
549879.0,Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni for the Treatment of Chronic Hepatitis C,2018-09-24 08:31:00-04:00,GILD,neutral
549880.0,"Stocks Trading Ex Dividend For Thurs., Sep. 13, 2018",2018-09-14 07:09:00-04:00,GILD,neutral
549881.0,"Stocks Trading Ex Dividend For Thurs., Sep. 13, 2018",2018-09-13 09:42:00-04:00,GILD,neutral
549882.0,"Why Gilead, Galapagos Shares Are Trading Higher",2018-09-12 13:30:00-04:00,GILD,positive
549883.0,Fast Money Picks For September 12,2018-09-12 08:49:00-04:00,GILD,neutral
549884.0,Gilead Reports Collaboration With Precision BioSciences For Development Of Therapies Against Hep B Virus Using ARCUS Genome Editing,2018-09-12 08:31:00-04:00,GILD,neutral
549885.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,GILD,positive
549886.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-09-12 08:17:00-04:00,GILD,neutral
549887.0,Gilead and Galapagos Announce Filgotinib Meets Primary and 'All Key Secondary' Endpoints In Phase 3 Study In Rheumatoid Arthritis,2018-09-11 16:06:00-04:00,GILD,neutral
549888.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,GILD,neutral
549889.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,GILD,positive
549890.0,"Gilead,  Galapagos  Announce  Tortuga  Phase  2  Study  of Filgotinib  in  Ankylosing  Spondylitis  Achieves  Primary  Endpoint",2018-09-06 04:26:00-04:00,GILD,neutral
549891.0,UPDATE: Terms Of Gilead Licensing Deal For Trianni Not Disclosed,2018-09-04 16:06:00-04:00,GILD,neutral
549892.0,Gilead Reports Licensing Deal With Trianni For Use Of Trianni Transgenic Human Monoclonal Antibody Discovery Platform,2018-09-04 16:05:00-04:00,GILD,neutral
549893.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,GILD,neutral
549894.0,Gilead's Yescarta Resceives European Marketing Authorization,2018-08-27 06:37:00-04:00,GILD,neutral
549895.0,"Sierra Oncology Acquires Momelotinib, Will Pay Gilead $3M Upfront With Potential Milestone Payments Of Up To $195M",2018-08-22 07:01:00-04:00,GILD,negative
549896.0,The Highs And Lows Of Earnings Season Dominate July's IMX Results,2018-08-07 16:10:00-04:00,GILD,negative
549897.0,Investor Movement Index July Summary,2018-08-07 09:12:00-04:00,GILD,neutral
549898.0,Gilead Sciences' Genvoya for the Treatment of HIV-1 is Approved by the China National Drug Administration,2018-08-06 06:09:00-04:00,GILD,positive
549899.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,GILD,neutral
549900.0,"Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class'",2018-07-27 10:29:00-04:00,GILD,neutral
549901.0,Gilead Sciences Option Alert: Sep 21 $82.5 Calls Sweep (32) near the Ask: 863 @ $1.15 vs 3235 OI; Ref=$77.79,2018-07-26 10:45:00-04:00,GILD,positive
549902.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2018",2018-07-26 08:58:00-04:00,GILD,positive
549903.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,GILD,negative
549904.0,"Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $85",2018-07-26 08:15:00-04:00,GILD,neutral
549905.0,Baird Downgrades Gilead Sciences to Neutral,2018-07-26 06:23:00-04:00,GILD,neutral
549906.0,Gilead Reaffirms FY18 Net Product Sales Guidance $20B-$21B vs $20.81B Estimate,2018-07-25 16:04:00-04:00,GILD,neutral
549907.0,UPDATE: Gilead Raises FY18 GAAP EPS From $1.41-$1.51 To $1.50-$1.60,2018-07-25 16:03:00-04:00,GILD,neutral
549908.0,Gilead Raises FY18 Outlook,2018-07-25 16:01:00-04:00,GILD,neutral
549909.0,"Gilead Sciences Q2 Adj. EPS $1.91 Beats $1.56 Estimate, Sales $5.5B Beat $5.21B Estimate",2018-07-25 16:01:00-04:00,GILD,neutral
549910.0,Gilead Sciences Announces CEO John F. Milligan to Step Down,2018-07-25 16:00:00-04:00,GILD,neutral
549911.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,GILD,positive
549912.0,Gilead Sciences Q2 Earnings Preview,2018-07-25 07:55:00-04:00,GILD,neutral
549913.0,"Earnings Scheduled For July 25, 2018",2018-07-25 04:23:00-04:00,GILD,neutral
549914.0,Gilead Highlights New Data On Impact Of Truvada For Pre-Exposure Prophylaxis on the Number of HIV Diagnoses in the United States At Int'l. AIDS Conference: Prevalence Increased From 7 To 68.5 Per 1K People,2018-07-24 08:06:00-04:00,GILD,positive
549915.0,"The Week Ahead: FANG Earnings Continue, Fox Vote On Disney Deal, More IPOs",2018-07-23 12:41:00-04:00,GILD,neutral
549916.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,GILD,neutral
549917.0,Celgene Shares Spike ~0.6% Following Trader Circulation Of Questionable Chatter Of Interest From Gilead,2018-07-20 09:53:00-04:00,GILD,positive
549918.0,Gilead Reports Kite Pharma And Gadeta Entered Strategic Collaboration To Develop Novel Gamma Delta TCR Therapies In Various Cancers,2018-07-19 08:41:00-04:00,GILD,positive
549919.0,"Gilead's Kite, Gadeta Report Strategic Partnership to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors",2018-07-19 08:31:00-04:00,GILD,positive
549920.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,GILD,positive
549921.0,Gilead Reports Received Approval In Canada For BIKTARVY For Treatment Of HIV-1 Infection,2018-07-12 07:19:00-04:00,GILD,positive
549922.0,3 Stocks With Bullish Setups For The Rest Of The Week,2018-07-11 07:06:00-04:00,GILD,neutral
549923.0,"Novartis, Roche, Gilead Have Cancelled Some Drug Price Increases",2018-07-10 14:46:00-04:00,GILD,negative
549924.0,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,2018-07-09 14:39:00-04:00,GILD,positive
549925.0,Gilead Sciences Option Alert: Jul 20 $74.5 Calls Sweep (5) near the Ask: 500 @ $1.371 vs 81 OI; Earnings 7/25 After Close Ref=$74.4,2018-07-06 10:35:00-04:00,GILD,positive
549926.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,GILD,neutral
549927.0,"EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Utlragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta",2018-06-29 07:50:00-04:00,GILD,positive
549928.0,"Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock",2018-06-28 14:42:00-04:00,GILD,neutral
549929.0,"Benzinga's Top Upgrades, Downgrades For June 28, 2018",2018-06-28 09:08:00-04:00,GILD,positive
549930.0,"Raymond James Initiates Coverage On Gilead Sciences with Strong Buy Rating, Announces $93 Price Target",2018-06-28 08:32:00-04:00,GILD,positive
549931.0,European Commission Grants Marketing Authorization for Gilead's Biktarvy,2018-06-25 08:12:00-04:00,GILD,positive
549932.0,A Look Back At What's Happened To Each Sector Through The First Half Of 2018 (Part 1),2018-06-19 11:54:00-04:00,GILD,neutral
549933.0,Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate,2018-06-12 11:47:00-04:00,GILD,positive
549934.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: TherapeuticsMD, Charles River, OSI Systems, Odonate Therapeutics, Syros, Alnylam, Gilead, and Celgene",2018-06-06 07:29:00-04:00,GILD,neutral
549935.0,Gilead Option Alert: Jul 20 $70 Calls Sweep (24) near the Ask: 827 @ $2.05 vs 4507 OI; Earnings 7/25 After Close [est] Ref=$69.86,2018-06-04 13:24:00-04:00,GILD,positive
549936.0,Gilead Shares Spike Higher After the Company Says a Study of an Experimental Therapy Eliminated Eliminated Woman's Breast Cancer,2018-06-04 11:06:00-04:00,GILD,negative
549937.0,Gilead's Kite Rports ZUMA-1 Data Suggest Patient Response To Yescarta At 3 Months Could Be Predictive Of Longer-Term Response In refractory B-Cell Lymphoma,2018-06-04 09:04:00-04:00,GILD,neutral
549938.0,Gilead's Kite Reports Initial Results From Phase 1 Study Of T-Cell Receptor Cell Therapy In HPV-16-Positive Solid Tumors: NCI Study Shows Investigational Therapy Induces Response In Patients with Epithelial Cancers,2018-06-04 09:03:00-04:00,GILD,positive
549939.0,Cramer: Gilead Is Dead Money,2018-06-01 07:53:00-04:00,GILD,negative
549940.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,GILD,positive
549941.0,"PiperJaffray Assumes Gilead Sciences at Overweight, Announces Price Target $85",2018-05-31 08:11:00-04:00,GILD,negative
549942.0,UPDATE: Galapagos Will Receive a $15M Payment from Gilead For This Progression of Filgotinib From Phase 2 to a Phase 2b/3 SELECTION Study,2018-05-30 16:02:00-04:00,GILD,neutral
549943.0,Gilead and Galapagos Announce Filgotinib in Phase 2 EQUATOR Study Met Primary Edpoint,2018-05-30 16:01:00-04:00,GILD,neutral
549944.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,GILD,positive
549945.0,Gilead Announces China Drug Administration Approves Epclusa for Chronic Hepatitis C Virus Infection,2018-05-30 03:52:00-04:00,GILD,positive
549946.0,Tesaro Shares Spike ~$0.70 Over Last Min. As Hearing Speculation Gilead Is In Advanced Talks To Buy Co.,2018-05-22 10:44:00-04:00,GILD,positive
549947.0,"UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals",2018-05-17 12:38:00-04:00,GILD,negative
549948.0,"Gilead Option Alert: Jun 21, 2019 $75 Calls Sweep (26) at the Ask: 962 @ $4.35 vs 383 OI; Ref=$67.58",2018-05-17 10:54:00-04:00,GILD,positive
549949.0,"Hearing FDA Names Drugmakers Accused Of Blocking Generic Rivals Including Gilead, Celgene, Novartis",2018-05-17 09:21:00-04:00,GILD,negative
549950.0,U.S. Food and Drug Administration Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents,2018-05-15 11:00:00-04:00,GILD,positive
549951.0,"Gilead's Kite Pharma Reports New Global Facilities, Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline",2018-05-15 08:33:00-04:00,GILD,negative
549952.0,"Gilead, Match Group, Biotech, Ethereum: 'Fast Money' Picks For May 14",2018-05-14 07:13:00-04:00,GILD,neutral
549953.0,55 Biggest Movers From Yesterday,2018-05-03 04:42:00-04:00,GILD,neutral
549954.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-05-02 13:30:00-04:00,GILD,neutral
549955.0,21 Stocks Moving In Wednesday's Pre-Market Session,2018-05-02 08:11:00-04:00,GILD,neutral
549956.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,GILD,neutral
549957.0,"16 Stocks To Watch For May 2, 2018",2018-05-02 05:38:00-04:00,GILD,neutral
549958.0,9 Stocks Moving In Tuesday's After-Hours Session,2018-05-01 17:12:00-04:00,GILD,neutral
549959.0,Gilead Reaffirms FY18 Outlook,2018-05-01 16:01:00-04:00,GILD,neutral
549960.0,"Gilead Sciences Q1 EPS $1.48 Misses $1.64 Estimate, Sales $5.088B Miss $5.38B Estimate",2018-05-01 16:01:00-04:00,GILD,negative
549961.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,GILD,neutral
549962.0,"15 Stocks To Watch For May 1, 2018",2018-05-01 05:02:00-04:00,GILD,neutral
549963.0,"Earnings Scheduled For May 1, 2018",2018-05-01 04:59:00-04:00,GILD,neutral
549964.0,Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases,2018-04-30 16:20:00-04:00,GILD,neutral
549965.0,"The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More",2018-04-30 12:56:00-04:00,GILD,neutral
549966.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,GILD,neutral
549967.0,Gilead Sciences Reports European CHMP Adopted Positive Opinion For Co.'s Biktarvy,2018-04-27 06:36:00-04:00,GILD,positive
549968.0,"Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises",2018-04-25 12:11:00-04:00,GILD,positive
549969.0,Watching Gilead Shares As Traders Circulating Earlier STAT News Article 'NIH is sued for plans to award license for CAR-T therapy to Gilead',2018-04-20 12:48:00-04:00,GILD,positive
549970.0,"Gilead Subsidiary Kite Acquires Certain Facilities From Astellas, No Terms Disclosed",2018-04-18 18:02:00-04:00,GILD,neutral
549971.0,"Gilead Combination Therapy Data Presented from First 12-Week Study, Says Enrollment Complete for Phase 3 STELLAR Trials of ASK1 Inhibitor Selonsertib",2018-04-13 10:16:00-04:00,GILD,negative
549972.0,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,2018-03-20 11:29:00-04:00,GILD,neutral
549973.0,Gilead Sciences Tweets: Gilead's Norbert Bischofberger to step down; John McHutchison appointed Chief Scientific Officer and Andrew Cheng appointed Chief Medical Officer,2018-03-12 09:31:00-04:00,GILD,neutral
549974.0,Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather',2018-03-09 11:28:00-05:00,GILD,neutral
549975.0,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,2018-03-07 11:31:00-05:00,GILD,neutral
549976.0,An Eventful February Took Its Toll On TD Ameritrade's Investor Index,2018-03-06 16:17:00-05:00,GILD,neutral
549977.0,Investor Movement Index February Summary,2018-03-06 11:55:00-05:00,GILD,neutral
549978.0,Gilead Reports Phase 3 Study Data Evaluating Women Who Switched To Biktarvy From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen,2018-03-05 16:01:00-05:00,GILD,positive
549979.0,UPDATE: Gilead Says 'No Patients in Biktarvy Treatment Arm Demonstrated Treatment-Emergent Resistance Through 48 Weeks',2018-03-05 12:08:00-05:00,GILD,negative
549980.0,"UPDATE: Gilead Says 'Through 48 Weeks, Biktarvy Found to Be Non-Inferior to Abacavir-Containing Regimen in Virologically Suppressed Adults Living With HIV'",2018-03-05 12:08:00-05:00,GILD,neutral
549981.0,"Gilead Highlights Results From Phase 3 Study Of Patients Who Switched To Biktarvy From Abacavir, Dolutegravir, Lamivudine Regimen",2018-03-05 12:08:00-05:00,GILD,neutral
549982.0,7 Biotech Stocks With Clinical Trial Outcomes In March,2018-03-05 12:01:00-05:00,GILD,neutral
549983.0,Gilead Announces Data Support Continued Clinical Investigation of GS-9620 and GS-9722 as Part of an HIV Eradication Strategy,2018-03-04 16:30:00-05:00,GILD,positive
549984.0,"Teva Pharma and Natco Pharma Submit ANDAs to the FDA Requesting Permission to Manufacture Generic Sovaldi, Argue Gilead's Patents are Not Valid",2018-02-27 06:32:00-05:00,GILD,negative
549985.0,"Gilead Form 4 Filing Late Wed. Showed Sale Of 14,435 Shares By Exec VP, Corporate & Medical Affairs, Gregg Alton, On Feb. 20",2018-02-22 10:35:00-05:00,GILD,positive
549986.0,"Gilead's Kite, Sangamo Therapeutics Partner To Develop Generation Engineered Cell Therapies For Cancer Treatment, Sangamo To Receive Upfront Payment Of $150M With $3.01B In Potential Milestone Payments",2018-02-22 07:10:00-05:00,GILD,negative
549987.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,GILD,neutral
549988.0,"Gilead, Merck Quiet As Traders Circulate Reuters Article From Feb. 17th Titled 'Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict'",2018-02-20 10:23:00-05:00,GILD,positive
549989.0,"Gilead Shares Unaffected, AbbVie Shares Move Lower Amid Capitol Forum Report 'Rep. Khanna and Other Democrats Urge HHS to Take Patents, Pave Way for Cheaper HCV Generics'",2018-02-15 09:59:00-05:00,GILD,positive
549990.0,Traders Circulating Speculation Gilead Pursuing Galapagos Takeover,2018-02-12 09:46:00-05:00,GILD,neutral
549991.0,"BMO Capital Maintains Market Perform on Gilead Sciences, Raises price target to $88.00",2018-02-08 09:21:00-05:00,GILD,neutral
549992.0,Najarian Brothers See Unusual Options Activity In Procter & Gamble And Gilead,2018-02-07 17:02:00-05:00,GILD,neutral
549993.0,"With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline",2018-02-07 14:37:00-05:00,GILD,neutral
549994.0,Gilead Reports FDA Approved Biktarvy For Treatment Of HIV-1 Infection,2018-02-07 14:22:00-05:00,GILD,positive
549995.0,"Leerink Swann Maintains Market Perform on Gilead Sciences, Lowers price target to $83.00",2018-02-07 12:35:00-05:00,GILD,negative
549996.0,TD Ameritrade Investors Had A Record-Breaking January,2018-02-06 17:40:00-05:00,GILD,neutral
549997.0,8 Stocks Moving In Tuesday's After-Hours Session,2018-02-06 17:07:00-05:00,GILD,neutral
549998.0,"Gilead Sciences Shares Up 2.4% After Hours As Company Reports Positive Q1 Earnings, 10% Q1 Dividend Increase",2018-02-06 16:14:00-05:00,GILD,positive
549999.0,Gilead Sciences Raises Qtr. Dividend From $0.52 to $0.57/Share,2018-02-06 16:03:00-05:00,GILD,neutral
550000.0,"Gilead Sciences Reports Q4 EPS $1.78 vs $1.67 Est., Sales $5.9B vs $5.73B Est.",2018-02-06 16:01:00-05:00,GILD,neutral
550001.0,Investor Movement Index January Summary,2018-02-06 13:24:00-05:00,GILD,neutral
550002.0,Earnings Outlook For Gilead Sciences,2018-02-06 12:26:00-05:00,GILD,neutral
550003.0,"12 Stocks To Watch For February 6, 2018",2018-02-06 04:53:00-05:00,GILD,neutral
550004.0,"Earnings Scheduled For February 6, 2018",2018-02-06 04:22:00-05:00,GILD,neutral
550005.0,The Week Ahead: IPOs Ramp Up Just As Earnings Season Fades,2018-02-05 13:22:00-05:00,GILD,neutral
550006.0,"Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypal, Starbucks, Wynn And More",2018-02-04 13:28:00-05:00,GILD,positive
550007.0,Alphabet Earnings Preview: What Might Be Expected For Q4?,2018-02-01 10:32:00-05:00,GILD,neutral
550008.0,Attention Biotech Investors: February PDUFA Catalysts Come Calling,2018-01-31 15:30:00-05:00,GILD,neutral
550009.0,FDA Watchlist: Catalysts To Look Out For This February,2018-01-31 11:04:00-05:00,GILD,neutral
550010.0,Vetr Crowd Downgrades Gilead Sciences,2018-01-30 13:49:00-05:00,GILD,neutral
550011.0,Gilead Sciences Outlook Brightens; Citi Upgrades,2018-01-30 12:59:00-05:00,GILD,positive
550012.0,"Benzinga's Top Upgrades, Downgrades For January 30, 2018",2018-01-30 09:31:00-05:00,GILD,positive
550013.0,Citigroup Upgrades Gilead Sciences to Buy,2018-01-30 07:49:00-05:00,GILD,neutral
550014.0,Jefferies On Gilead: 'We See Better Days Ahead',2018-01-26 13:48:00-05:00,GILD,positive
550015.0,"Benzinga's Top Upgrades, Downgrades For January 26, 2018",2018-01-26 09:14:00-05:00,GILD,positive
550016.0,"The Market In 5 Minutes: GDP, Intel's Beat, XFL's Return, Bitcoin And Japan",2018-01-26 09:02:00-05:00,GILD,neutral
550017.0,Jefferies Upgrades Gilead Sciences to Buy,2018-01-26 07:08:00-05:00,GILD,neutral
550018.0,"Gilead To Report Q4 Earnings On Tues., Feb. 6 After Market Closes",2018-01-23 16:30:00-05:00,GILD,neutral
550019.0,Pharma M&A Picks Up Momentum,2018-01-23 13:56:00-05:00,GILD,neutral
550020.0,Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal,2018-01-23 11:13:00-05:00,GILD,neutral
550021.0,Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?,2018-01-23 10:58:00-05:00,GILD,positive
550022.0,5 Stocks With Clear Technical Trading Signals Right Now,2018-01-22 15:11:00-05:00,GILD,positive
550023.0,The Top 10 Value Stocks In The S&P 500,2018-01-19 13:12:00-05:00,GILD,positive
550024.0,"Gilead's Kite Pharma Reports Clinical Collaboration To Evaluate Investigational Combo Of Yescarta, Pfizer's Utomilumab In Large B-Cell Lymphoma",2018-01-18 08:38:00-05:00,GILD,neutral
550025.0,5 Biggest Price Target Changes For Tuesday,2018-01-16 10:17:00-05:00,GILD,neutral
550026.0,"Benzinga's Top Upgrades, Downgrades For January 16, 2018",2018-01-16 10:03:00-05:00,GILD,positive
550027.0,"The Market In 5 Minutes: Auto Show Highlights, Bitcoin Tumbles, Northrop Vs. Lockheed",2018-01-16 09:00:00-05:00,GILD,neutral
550028.0,Wells Fargo Upgrades Gilead Sciences to Outperform,2018-01-16 06:46:00-05:00,GILD,positive
550029.0,Wells Fargo Upgrades Gilead Sciences to Outperform; Raises PT to $96 from $84 -Reuters,2018-01-16 04:24:00-05:00,GILD,positive
550030.0,Pete Najarian Sees Unusual Options Activity In Gilead And KKR & Co.,2018-01-09 15:08:00-05:00,GILD,neutral
550031.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,GILD,positive
550032.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,GILD,positive
550033.0,"Gilead Shares Spike Higher Over $72, $73 Levels; Stock Up 2.5%",2018-01-02 10:05:00-05:00,GILD,positive
550034.0,4 Biotech Stocks Ready To Crush The Market In 2018,2017-12-27 12:41:00-05:00,GILD,positive
550035.0,Gilead Option Alert: Jan 19 $73 Calls Sweep (12) at the Ask: 522 @ $1.68 vs 267 OI; Ref=$73.13,2017-12-27 12:11:00-05:00,GILD,positive
550036.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,GILD,neutral
550037.0,Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy,2017-12-20 12:23:00-05:00,GILD,positive
550038.0,"Benzinga's Top Upgrades, Downgrades For December 20, 2017",2017-12-20 09:14:00-05:00,GILD,positive
550039.0,"The Market In 5 Minutes: Historic Tax Bill Looms Large, Bitcoin Cash, Amazon Boxes, And More",2017-12-20 09:01:00-05:00,GILD,neutral
550040.0,Credit Suisse Downgrades Gilead Sciences to Neutral,2017-12-20 06:29:00-05:00,GILD,positive
550041.0,Credit Suisse Downgrades Gilead to Neutral from Outperform; Lowers PT to $80 from $82 -Reuters,2017-12-20 04:22:00-05:00,GILD,positive
550042.0,"Galapagos Shares Briefly Spike Higher, Turn Positive As Traders Circulate Report Gilead Could Be Interested In Co.",2017-12-19 10:26:00-05:00,GILD,positive
550043.0,Galapagos Announced Earlier Receipt Of Transparency Notification From Gilead Sciences,2017-12-18 08:52:00-05:00,GILD,neutral
550044.0,Galapagos Exercises Co-promotion Option for Filgotinib with Collaboration Partner Gilead Sciences in Eight European Countries,2017-12-14 16:31:00-05:00,GILD,neutral
550045.0,Gilead Sciences Reports Executive Chair John Martin Will Transition To Chair Of Board,2017-12-14 16:30:00-05:00,GILD,neutral
550046.0,"ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More",2017-12-13 12:31:00-05:00,GILD,neutral
550047.0,Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher,2017-12-13 10:24:00-05:00,GILD,neutral
550048.0,Kite Announces Data from ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory ALL at #ASH2017,2017-12-12 04:22:00-05:00,GILD,neutral
550049.0,3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise,2017-12-11 12:52:00-05:00,GILD,positive
550050.0,Gilead's Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta in Patients With Refractory Large B-cell Lymphoma at #ASH2017,2017-12-10 11:51:00-05:00,GILD,neutral
550051.0,Gilead Option Alert: Dec 15 $71.5 Calls Sweep (19) at the Ask: 500 @ $2.281 vs 99 OI; Ref=$73.62 Signals,2017-12-08 10:46:00-05:00,GILD,positive
550052.0,"Wall Street's M&A Chatter From December 7: Entellus Medical-Stryker, Sucampo, Silicon Labs-Sigma Designs",2017-12-08 07:52:00-05:00,GILD,neutral
550053.0,"UPDATE: Gilead Says Deal For Cell Design Labs Made Up Of Initial Upfront Payment Of ~$175M, Added Payments Of Up To $322M 'upon the occurrence of certain events, including the achievement of development and approval milestones'",2017-12-07 17:02:00-05:00,GILD,positive
550054.0,Gilead Sciences Reports Deal With Subsidiary Kite To Acquire Cell Design Labs For ~$567M,2017-12-07 17:00:00-05:00,GILD,neutral
550055.0,Gilead Sciences Announces a $100M Commitment to Fight HIV/AIDS in Southern US,2017-12-04 06:33:00-05:00,GILD,neutral
550056.0,GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV,2017-12-01 12:38:00-05:00,GILD,neutral
550057.0,Maim Upgrades Gilead Sciences to Buy from Hold -Reuters,2017-12-01 04:44:00-05:00,GILD,neutral
550058.0,CMS Head Verma Says Agency Considering Ways To Curb Costs For Expensive New Medications,2017-11-30 16:47:00-05:00,GILD,neutral
550059.0,Maxim Explains Why Gilead Sciences Is A Now A Buy,2017-11-30 13:58:00-05:00,GILD,neutral
550060.0,"Benzinga's Top Upgrades, Downgrades For November 30, 2017",2017-11-30 09:04:00-05:00,GILD,positive
550061.0,Maxim Group Upgrades Gilead Sciences to Buy,2017-11-30 08:50:00-05:00,GILD,neutral
550062.0,"X-Chem, Gilead Report Drug Discovery Collaboration To Screen Proprietary Dex Libraries To Discover Therapeutic Leads Against Targets In Antiviral, Added Therapeutic Areas",2017-11-28 08:22:00-05:00,GILD,neutral
550063.0,"Amazon, Gilead, Nordstrom: Fast Money Picks For November 28",2017-11-28 07:24:00-05:00,GILD,positive
550064.0,Portfolio Manager Says Now Is A Great Time To Buy Biotech,2017-11-15 15:13:00-05:00,GILD,positive
550065.0,"As Gilead's Outlook Dims, Argus Downgrades",2017-11-13 10:15:00-05:00,GILD,neutral
550066.0,Argus Downgrades Gilead Sciences to Hold,2017-11-13 08:13:00-05:00,GILD,neutral
550067.0,"Lightning Round: Jim Cramer Advises His Viewers On Gilead, Exxon Mobil And More",2017-11-09 07:30:00-05:00,GILD,neutral
550068.0,A Big Biotech ETF Is About To Get Cheaper,2017-11-08 15:28:00-05:00,GILD,neutral
550069.0,"Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead",2017-11-07 09:06:00-05:00,GILD,positive
550070.0,"Gilead Sciences Says In Sept 2017, Post-Trial Motions Judge Denied Idenix's Motion for Enhanced Damages, Attorney's; Says Expects Judge to Rule On Outstanding Motions With Relation to Idenix in Late 2017, Early 2018‍​ -10Q",2017-11-07 06:25:00-05:00,GILD,positive
550071.0,"FDA Commissioner Tweets: Today, #FDA finalized guidance to help bring more Hepatitis C treatments to the market https://go.usa.gov/xnbNg",2017-11-06 10:40:00-05:00,GILD,positive
550072.0,Federal Register Issues Guidance: Chronic Hepatitis C Virus Infection; Developing Direct-Acting Antiviral Drugs for Treatment,2017-11-06 10:39:00-05:00,GILD,neutral
550073.0,The Health Care Episode: Reviewing Earnings Season And A CVS/Aetna Merger,2017-11-01 12:48:00-04:00,GILD,positive
550074.0,45 Stocks Moving In Friday's Mid-Day Session,2017-10-27 12:32:00-04:00,GILD,neutral
550075.0,32 Stocks Moving In Friday's Pre-Market Session,2017-10-27 08:04:00-04:00,GILD,neutral
550076.0,14 Stocks Moving In Thursday's After-Hours Session,2017-10-26 17:42:00-04:00,GILD,neutral
550077.0,"Gilead Sciences Reports Q3 Adj. EPS $2.27 vs $2.13 Est., Sales $6.512B vs $6.39B Est.",2017-10-26 16:02:00-04:00,GILD,neutral
550078.0,It's A Bad Day For Biotechs,2017-10-26 10:30:00-04:00,GILD,negative
550079.0,"Earnings Scheduled For October 26, 2017",2017-10-26 04:20:00-04:00,GILD,neutral
550080.0,Healthcare ETFs Set To Soar As Q3 Earnings Unfold,2017-10-24 12:35:00-04:00,GILD,neutral
550081.0,Gilead Announces GS-0976 In Phase 2 Study Showed Statistically Significant Efficacy Compared To Placebo,2017-10-24 08:41:00-04:00,GILD,positive
550082.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,GILD,positive
550083.0,Alpine Immune Sciences and Kite Extend Research Term of Collaboration for CAR-T and TCRs,2017-10-23 07:09:00-04:00,GILD,positive
550084.0,Gilead Sciences Reports Phase 2 And 3 Studies Of Its Approved HCV And HBV Medicines At The 2017 Liver Meeting,2017-10-20 08:05:00-04:00,GILD,positive
550085.0,"Senator Bernie Sanders Tweets: Gilead, one of the greediest pharmaceutical corporations in the world, is once again gouging people dealing with life-threatening illness.",2017-10-19 16:29:00-04:00,GILD,negative
550086.0,32 Stocks Moving In Thursday's Mid-Day Session,2017-10-19 12:59:00-04:00,GILD,neutral
550087.0,"Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug",2017-10-19 12:22:00-04:00,GILD,negative
550088.0,Gilead Volatile After Kite Pharma's Yescarta Gets FDA Approval,2017-10-19 10:42:00-04:00,GILD,positive
550089.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-10-19 08:08:00-04:00,GILD,neutral
550090.0,Gilead Subsidiary Kite Announces FDA Approval For Yescarta,2017-10-18 17:44:00-04:00,GILD,positive
550091.0,13 Stocks Moving In Wednesday's After-Hours Session,2017-10-18 17:38:00-04:00,GILD,neutral
550092.0,How To Use Options During Earnings Season,2017-10-12 10:25:00-04:00,GILD,neutral
550093.0,"Barclays Reinstates Overweight on Gilead Sciences, Announces $90.00",2017-10-11 07:33:00-04:00,GILD,negative
550094.0,These Were The Most Bought And Sold Stocks In September,2017-10-10 16:12:00-04:00,GILD,neutral
550095.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,GILD,positive
550096.0,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,2017-10-09 15:56:00-04:00,GILD,positive
550097.0,Watch These 7 Huge Put Purchases In Monday Trade,2017-10-09 04:29:00-04:00,GILD,positive
550098.0,Gilead Option Alert: Oct 20 $81.5 Puts Sweep (23) at the Ask: 507 @ $1.191 vs 329 OI; Ref=$82.05,2017-10-06 12:25:00-04:00,GILD,positive
550099.0,Life (Science) Lessons: The Hows And Whos To Play Biotech,2017-10-06 11:09:00-04:00,GILD,positive
550100.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2017",2017-10-05 09:26:00-04:00,GILD,positive
550101.0,Oppenheimer Initiates Coverage On Gilead Sciences with Perform Rating,2017-10-05 07:44:00-04:00,GILD,neutral
550102.0,"Gilead Report No Patients In bictegravir Treatment Arm Demonstrated Treatment-Emergent Resistance Through 48 Weeks, Was Found To Be Non-Inferior To Boosted Protease Inhibitor Based Regiments",2017-10-04 08:03:00-04:00,GILD,neutral
550103.0,"Jefferies Reinstates Hold on Gilead Sciences, Announces $93.00 Price Target",2017-10-04 07:19:00-04:00,GILD,neutral
550104.0,Gilead Announces New License Agreement With UN-Backed Medicines Patent Pool for Access to Bictegravir,2017-10-04 04:05:00-04:00,GILD,positive
550105.0,Gilead Sciences COO Kevin YOung CBE To Retire Effective Early 2018,2017-09-27 16:30:00-04:00,GILD,positive
550106.0,"Gilead, Kite Pharma Report Expiration Of HSR Waiting Period",2017-09-26 08:30:00-04:00,GILD,neutral
550107.0,Gilead's Sovaldi Approved by the China FDA for Treatment of Chronic Hepatitis C Virus Infection,2017-09-25 07:55:00-04:00,GILD,positive
550108.0,"AMD, Bank Of America, Gilead, Intel: Fast Money Picks For September 19",2017-09-19 08:59:00-04:00,GILD,neutral
550109.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,GILD,neutral
550110.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,GILD,neutral
550111.0,Najarian Brothers See Unusual Options Activity In Tripadvisor And Gilead,2017-09-07 16:44:00-04:00,GILD,neutral
550112.0,Pro: Biotech Is The Hottest ETF Of 2017 With Plenty Of Upside Ahead,2017-09-07 09:38:00-04:00,GILD,neutral
550113.0,"Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ",2017-09-06 09:13:00-04:00,GILD,neutral
550114.0,Why It's Useful To Know A Company's Competitors When Trading,2017-09-05 11:26:00-04:00,GILD,positive
550115.0,Vetr Urges Hold On Gilead After Kite Merger,2017-09-02 10:46:00-04:00,GILD,neutral
550116.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,GILD,neutral
550117.0,Sell In May And Go Away? Doing So With These Stocks Was A Mistake,2017-09-01 12:09:00-04:00,GILD,negative
550118.0,Watch These 5 Huge Put Purchases In Friday Trade,2017-09-01 04:15:00-04:00,GILD,positive
550119.0,A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers,2017-08-31 16:37:00-04:00,GILD,neutral
550120.0,S-3 From Gilead Shows Registration For Mixed Securities Shelf Offering,2017-08-31 16:22:00-04:00,GILD,positive
550121.0,Benzinga's Option Alert Recap From August 31,2017-08-31 16:22:00-04:00,GILD,positive
550122.0,Gilead Option Alert: Feb 16 $80 Puts Sweep (2) at the Bid: 1000 @ $3.9 vs 111 OI; Ref=$83.870,2017-08-31 15:49:00-04:00,GILD,positive
550123.0,iShares NASDAQ Biotech ETF At Highest Since Level Since December 2015,2017-08-31 14:57:00-04:00,GILD,neutral
550124.0,Street Puts Stamp Of Approval On Gilead's  Kite Pharma Takeover,2017-08-31 14:40:00-04:00,GILD,positive
550125.0,18 Biggest Mid-Day Gainers For Thursday,2017-08-31 12:28:00-04:00,GILD,neutral
550126.0,Gilead Gets An Upgrade Amid 'Game-Changing' Kite Deal,2017-08-31 09:48:00-04:00,GILD,neutral
550127.0,"Benzinga's Top Upgrades, Downgrades For August 31, 2017",2017-08-31 09:34:00-04:00,GILD,positive
550128.0,Argus Upgrades Gilead Sciences to Buy,2017-08-31 09:02:00-04:00,GILD,neutral
550129.0,Watch These 7 Huge Put Purchases In Thursday Trade,2017-08-31 06:06:00-04:00,GILD,positive
550130.0,Watch These 7 Huge Call Purchases In Thursday Trade,2017-08-31 06:05:00-04:00,GILD,positive
550131.0,Benzinga's Option Alert Recap From August 30,2017-08-30 16:13:00-04:00,GILD,positive
550132.0,Gilead Option Alert: Sep 8 $81 Calls Sweep (12) at the Ask: 502 @ $1.221 vs 20 OI; Ref=$80.93,2017-08-30 15:20:00-04:00,GILD,positive
550133.0,Gilead Option Alert: Sep 15 $77 Puts Sweep (30) at the Ask: 514 @ $1.078 vs 92 OI; Ref=$78.11,2017-08-30 10:07:00-04:00,GILD,positive
550134.0,The Market In 5 Minutes,2017-08-30 08:09:00-04:00,GILD,neutral
550135.0,Brian Stutland Sees Unusual Options Activity In Juno Therapeutics,2017-08-30 07:26:00-04:00,GILD,neutral
550136.0,Analysts Weigh In On Gilead-Kite Pharma Deal,2017-08-29 12:07:00-04:00,GILD,neutral
550137.0,Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade,2017-08-29 12:01:00-04:00,GILD,positive
550138.0,5 Biggest Price Target Changes For Tuesday,2017-08-29 09:57:00-04:00,GILD,neutral
550139.0,"Wall Street's M&A Chatter From August 28: Gilead-Kite Pharma, Enzymotec-Frutarom, MaxPoint-Valassis",2017-08-29 07:31:00-04:00,GILD,neutral
550140.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-08-29 04:59:00-04:00,GILD,positive
550141.0,Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge,2017-08-28 14:30:00-04:00,GILD,positive
550142.0,Adam Feuerstein Tweets: $GILD should be more worried about $NVS undercutting CAR-T pricing than any NIH-loving ninny.,2017-08-28 13:23:00-04:00,GILD,negative
550143.0,18 Biggest Mid-Day Gainers For Monday,2017-08-28 12:35:00-04:00,GILD,neutral
550144.0,Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher,2017-08-28 12:13:00-04:00,GILD,negative
550145.0,Juno Therapeutics Jumps 17% After Gilead's Purchase Of Kite Pharma,2017-08-28 12:01:00-04:00,GILD,neutral
550146.0,Mid-Morning Market Update: Markets Mostly Higher; Gilead Sciences To Buy Kite Pharma,2017-08-28 10:14:00-04:00,GILD,neutral
550147.0,Gilead Option Alert: Sep 29 $76 Calls Sweep (34) at the Ask: 1751 @ $1.353 vs 389 OI; Ref=$75.15,2017-08-28 09:48:00-04:00,GILD,positive
550148.0,Gilead Seeks Diversification Into Immuno-oncology Space With $11.9 Billion Kite Pharma Acquisition,2017-08-28 08:59:00-04:00,GILD,neutral
550149.0,"Gilead CEO On Conf. Call Says Co. Is Not Going Quiet After This Deal, Will Search For More Opportunities",2017-08-28 08:20:00-04:00,GILD,positive
550150.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-28 08:16:00-04:00,GILD,neutral
550151.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of International Trade Data,2017-08-28 07:13:00-04:00,GILD,negative
550152.0,"Gilead to Acquire Kite Pharma for $11.9B Cash, $180/Share",2017-08-28 07:00:00-04:00,GILD,neutral
550153.0,Gilead to Acquire Kite Pharma for $180/Share According to Dow Jones,2017-08-28 06:35:00-04:00,GILD,neutral
550154.0,Gilead to Buy Kite Pharma for ~$11B in Cash -DJ,2017-08-28 06:33:00-04:00,GILD,neutral
550155.0,5 Biggest Price Target Changes For Friday,2017-08-18 09:45:00-04:00,GILD,neutral
550156.0,"A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Wal-Mart, Alibaba Earnings",2017-08-17 06:48:00-04:00,GILD,neutral
550157.0,Gilead Receives Approval For Vosevi,2017-08-17 06:05:00-04:00,GILD,positive
550158.0,"Gilead Reports FDA Priority Review Designation For Fixed-Dose Combo Of Bictegravir, Emtricitabine, Tenofovir Alafenamide For Treatment Of HIV",2017-08-10 16:03:00-04:00,GILD,neutral
550159.0,Morgan Stanley Expects Galapagos Shares To Rise 10%,2017-08-10 11:36:00-04:00,GILD,positive
550160.0,Gilead Shares Up ~$0.40 Over Last Min. As Traders Circulating Chatter Of Activist Interest,2017-08-09 10:40:00-04:00,GILD,positive
550161.0,"Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics",2017-08-07 07:19:00-04:00,GILD,positive
550162.0,"United Therapeutics Shares Up 7.7% On M&A Chatter; GSK, Gilead, Novartis Said To Be Possibly Considering Deal For Co.",2017-08-04 09:40:00-04:00,GILD,positive
550163.0,"UK Evening Standard Reports GSK, Gilead, Novartis Could Pay Up to $200/Share for United Therapeutics",2017-08-04 08:00:00-04:00,GILD,positive
550164.0,FDA Approves Expanded Labeling For Gilead's Epclusa,2017-08-01 16:05:00-04:00,GILD,positive
550165.0,3 ETFs To Watch Out For On Biotech Earnings,2017-08-01 12:41:00-04:00,GILD,neutral
550166.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,GILD,neutral
550167.0,EC Grants Marketing Authorization for Gilead's Vosevi for the Treatment of All Genotyes of Chronic Hepaptitis C,2017-07-28 05:58:00-04:00,GILD,positive
550168.0,"Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National",2017-07-27 07:24:00-04:00,GILD,neutral
550169.0,"Gilead, Juniper, United, Wynn: Fast Money Picks For July 27",2017-07-27 07:07:00-04:00,GILD,positive
550170.0,"15 Stocks To Watch For July 17, 2017",2017-07-27 05:12:00-04:00,GILD,neutral
550171.0,"Gilead Sciences, Inc. Reports Q2 Adj. EPS $2.56 vs $2.15 Est., Sales $7.141B vs $6.35B Est.",2017-07-26 16:01:00-04:00,GILD,neutral
550172.0,"Gilead Sciences, Verizon Communications, And MGM Resorts Report Q2 Results This Week",2017-07-26 15:37:00-04:00,GILD,neutral
550173.0,Redburn Initiates Coverage On Gilead Sciences with Buy Rating,2017-07-26 09:16:00-04:00,GILD,neutral
550174.0,"12 Stocks To Watch For July 26, 2017",2017-07-26 05:02:00-04:00,GILD,neutral
550175.0,"Earnings Scheduled For July 26, 2017",2017-07-26 04:22:00-04:00,GILD,neutral
550176.0,2 Ways To Trade This Week's Healthcare Earnings,2017-07-24 11:51:00-04:00,GILD,neutral
550177.0,"Adam Feuerstein Tweets: $GILD — HIV is the new (old) profit driver, which is why bictegravir (new data today) is so important. —> statnews.com/2017/07/24/hiv…",2017-07-24 07:49:00-04:00,GILD,positive
550178.0,Gilead Presenting Phase 3 Bictegravir Data At Int'l AIDS Society Conf. Today,2017-07-24 06:44:00-04:00,GILD,neutral
550179.0,Gilead Reports FDA Approved Vosevi For Re-Treatment Of Adults With Chronic Hep C,2017-07-18 13:35:00-04:00,GILD,positive
550180.0,"Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock",2017-07-17 12:52:00-04:00,GILD,positive
550181.0,"Jim Cramer Advises His Viewers On Seagate, Centurylink And Gilead",2017-07-14 06:39:00-04:00,GILD,neutral
550182.0,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",2017-07-13 14:43:00-04:00,GILD,positive
550183.0,"EMA Validates Gilead's Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV",2017-07-13 06:57:00-04:00,GILD,positive
550184.0,J&J To Commence Pharma Q2 Earnings Season: What's Up?,2017-07-12 14:44:00-04:00,GILD,neutral
550185.0,"Benzinga's Top Upgrades, Downgrades For July 11, 2017",2017-07-11 09:27:00-04:00,GILD,positive
550186.0,"Jefferies Assumes Gilead Sciences at Hold, Announces price target $80.00",2017-07-11 07:40:00-04:00,GILD,neutral
550187.0,"Spring Bank Pharma Reports Collaboration With Gilead For Hep B Phase 2 Study Exploring Combo Treatment Of SB 9200, Vemlidy",2017-07-10 08:35:00-04:00,GILD,neutral
550188.0,"Barron's Picks And Pans: Canadian Stocks, NCR, Gilead And More",2017-06-24 16:03:00-04:00,GILD,neutral
550189.0,Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold,2017-06-23 09:54:00-04:00,GILD,neutral
550190.0,"Benzinga's Top Upgrades, Downgrades For June 23, 2017",2017-06-23 09:23:00-04:00,GILD,positive
550191.0,Gilead Reports European CHMP Adopted Positive Opinion For Co.'s Vosevi For Treatment Of All Chronic Hep C Genotypes,2017-06-23 07:40:00-04:00,GILD,positive
550192.0,"Deutsche Bank Initiates Coverage On Gilead Sciences with Buy Rating, Announces $79.00 Price Target",2017-06-23 07:32:00-04:00,GILD,neutral
550194.0,"Wall Street's M&A Chatter From June 20: Calpine, Parexel, Gilead, Spherix-Hoth Therapeutics, Norsat-Hytera",2017-06-21 07:10:00-04:00,GILD,neutral
550196.0,Gilead Shares Spike ~$0.45 Off Session Lows As Traders Circulating Takeover Chatter,2017-06-20 10:00:00-04:00,GILD,positive
550197.0,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,2017-06-19 07:57:00-04:00,GILD,neutral
550198.0,Gilead Receives Approval in Canada for VEMLIDY  for the Treatment of Chronic Hepatitis B Virus Infection,2017-06-19 06:03:00-04:00,GILD,positive
550199.0,Gilead Sciences Receives FDA Orphan Designation for Tybost in Treatment of HIV-1 Infection in Pediatric Patients,2017-06-18 22:14:00-04:00,GILD,neutral
550202.0,"Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes",2017-06-15 08:52:00-04:00,GILD,neutral
550204.0,"Wall Street's M&A Chatter From June 13: Brookdale, Etsy, Roche-Tesaro",2017-06-14 06:53:00-04:00,GILD,neutral
550205.0,Tesaro Is A Top Rumor Mill Stock Right Now; Here Is A Timeline Of The Chatter,2017-06-13 12:24:00-04:00,GILD,positive
550206.0,"Wall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant",2017-06-13 07:03:00-04:00,GILD,neutral
550207.0,"Gilead Reports Submission Of NDA For Fixed-Dose Combo Of Bictegravir, Emtricitabine, Tenofovir Alafenamide For HIV",2017-06-12 08:15:00-04:00,GILD,neutral
550208.0,"What Do To With Starbucks, Amgen, Costco, Twilio, Gilead and Kroger?",2017-06-12 06:47:00-04:00,GILD,neutral
550209.0,"Gilead, Roche Shares Largely Unimpacted Following Headlines the World Health Organization Expert Committee Said Could Delete Oseltamivir from Next List of Recommended Medicines as General Treatment for Flu Pandemics",2017-06-06 10:09:00-04:00,GILD,positive
550210.0,"Gilead Sciences Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies; U.S. NDA Submission Planned For Q2",2017-05-30 08:34:00-04:00,GILD,neutral
550211.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-05-30 04:58:00-04:00,GILD,positive
550212.0,Benzinga's Option Alert Recap From May 26,2017-05-26 17:01:00-04:00,GILD,positive
550214.0,"Bank Of America Health Care Conference Concludes Today; Presenters Include Boston Scientific, Humana, Universal Health, Chemed, Community Health, Eagle Pharma, Alnylam, Gilead, & Illumina",2017-05-18 08:53:00-04:00,GILD,positive
550215.0,"U.S. Health Officials Say New Cases Of Hep. C Rose ~300% From 2010 to 2015, Fueled By Spike In Heroin and Other Injection Drugs",2017-05-11 15:13:00-04:00,GILD,negative
550216.0,Analysts On Gilead: We Think They're Mobilizing For A Deal,2017-05-04 11:53:00-04:00,GILD,neutral
550217.0,"Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price",2017-05-03 11:46:00-04:00,GILD,positive
550218.0,"In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad",2017-05-03 09:10:00-04:00,GILD,negative
550219.0,"Adam Feuerstein Tweets: No $GILD M&A Yet, but CEO Offers Hint of Deals to Come —> thestreet.com/story/14116282…",2017-05-03 08:57:00-04:00,GILD,negative
550220.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-05-03 08:05:00-04:00,GILD,neutral
550221.0,"15 Stocks To Watch For May 3, 2017",2017-05-03 05:31:00-04:00,GILD,neutral
550222.0,"Meg Tirrell Tweets: $GILD CEOs says a number of partnerships, acquisitions could play out this year",2017-05-02 17:18:00-04:00,GILD,positive
550223.0,Gilead Reaffirms FY17 Outlook,2017-05-02 16:02:00-04:00,GILD,neutral
550224.0,"Gilead Reports Q1 Adj. EPS $2.23 vs $2.28 Est., Sales $6.505B vs $6.62B Est.",2017-05-02 16:01:00-04:00,GILD,neutral
550225.0,"12 Stocks To Watch For May 2, 2017",2017-05-02 05:06:00-04:00,GILD,neutral
550226.0,"Earnings Scheduled For May 2, 2017",2017-05-02 04:31:00-04:00,GILD,neutral
550227.0,"Earnings Preview: Q1 Results From Pfizer, Merck, And Gilead Sciences This Week",2017-05-01 10:56:00-04:00,GILD,neutral
550228.0,Benzinga's Option Alert Recap From April 26,2017-04-26 16:54:00-04:00,GILD,positive
550229.0,Option Alert: Gilead May 69.0 Calls Sweep: 1000 @  ASK  $1.57: 2284 traded vs 196 OI:  Earnings 5/2 After Close  $68.48 Ref,2017-04-26 11:13:00-04:00,GILD,positive
550230.0,Watch These 10 Huge Call Purchases In Friday Trade,2017-04-21 04:00:00-04:00,GILD,positive
550231.0,Benzinga's Option Alert Recap From April 20,2017-04-20 16:34:00-04:00,GILD,positive
550232.0,Option Alert: Gilead May 65.0 Calls: 979 @  Above Ask!  $2.65: 1086 traded vs 3760 OI:  Earnings 5/2 After Close  $66.29 Ref,2017-04-20 09:39:00-04:00,GILD,positive
550233.0,"Gilead Shares Turn Positive Over Last Few Mins, Now Up 0.1% as Traders Circulating Rumor Mentioning JANA",2017-04-18 09:45:00-04:00,GILD,positive
550234.0,Apple Team Working on Secret Diabetes Treatment -CNBC,2017-04-12 20:02:00-04:00,GILD,neutral
550235.0,Watch These 6 Huge Put Purchases In Tuesday Trade,2017-04-11 07:11:00-04:00,GILD,positive
550236.0,"Gilead Announces FDA Has Approved New Indications for Harvoni, Sovaldi in Patients 12 Years, Older with Chronic Hep C Infection",2017-04-07 10:11:00-04:00,GILD,positive
550237.0,Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger,2017-04-06 16:01:00-04:00,GILD,neutral
550238.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,GILD,negative
550239.0,Feuerstein Throws BioMarin Into Gilead Takeover Speculation,2017-04-05 11:28:00-04:00,GILD,neutral
550240.0,"Feuerstein on Possibilities of Gilead Takeover Interest: Notes A Lot of Sources Have Talked About TESARO as Target, But Feels BioMarin is a Co. Which Has Better Chance to Move the Needle at Gilead",2017-04-05 09:03:00-04:00,GILD,positive
550241.0,Feuerstein on Possibilities of Gilead Takeover Interest: Likes BioMarin as a Target,2017-04-05 09:01:00-04:00,GILD,positive
550242.0,Galapagos Announces Three New Phase 2 Proof-of-Concept Studies Investigating Filgotinib in Sjögren's Syndrome with Collaboration Partner Gilead,2017-04-04 04:04:00-04:00,GILD,neutral
550243.0,Option Alert: Gilead Apr 69.5 Calls: 1500 @  ASK  $0.58: 1520 traded vs 942 OI:  Earnings 4/27 After Close (est)  $68.22 Ref,2017-03-31 11:10:00-04:00,GILD,positive
550244.0,Here's What You Missed On PreMarket Prep Today,2017-03-30 11:00:00-04:00,GILD,negative
550245.0,Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst',2017-03-30 08:46:00-04:00,GILD,positive
550246.0,Option Alert: Gilead May 67.5 Calls: 1500 @  ASK  $2.38: 1955 traded vs 4929 OI:  Earnings 4/27 After Close (est)  $67.38 Ref,2017-03-29 11:06:00-04:00,GILD,positive
550247.0,STAT News Reporting Gilead Faces European Hepatitis C Drug Patent Challenge Filed By Medecins du Monde and Doctors Without Borders,2017-03-27 15:44:00-04:00,GILD,positive
550248.0,"Jefferies Says Gilead's GS-0976 Novel Mechanism Has Good Scientific Rationale, May Likely Be Playing Out In Phase 2 Study",2017-03-20 12:53:00-04:00,GILD,positive
550249.0,Incyte Shares Spike Over $148 Level as Hearing Traders Circulating Unconfirmed Chatter of Gilead Interest,2017-03-16 14:26:00-04:00,GILD,positive
550250.0,Gilead Looking To Buy Incyte? It Makes Sense,2017-03-14 10:55:00-04:00,GILD,neutral
550251.0,"Barclays Global Healthcare Conference Begins Today; Presenters Include Johnson & Johnson, Alnylam, Axovant, Paraxel, Gilead, bluebird bio, Envision Healthcare, & Tenet Healthcare",2017-03-14 08:20:00-04:00,GILD,neutral
550252.0,Adam Feuerstein Tweets: Barclays Healthcare Conference: $GILD CEO John Milligan 9 am Tues. $INCY CEO Herve Hoppenot 2:30 pm Weds. Both STILL ON SCHEDULE.,2017-03-13 08:52:00-04:00,GILD,neutral
550253.0,Wall Street's M&A Chatter From March 10-12,2017-03-13 07:01:00-04:00,GILD,neutral
550254.0,Incyte Spikes to High of $149.28,2017-03-10 15:47:00-05:00,GILD,neutral
550255.0,Hearing Unconfirmed Chatter Gilead Near Bid for Incyte,2017-03-10 15:23:00-05:00,GILD,negative
550256.0,"Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease",2017-03-10 14:33:00-05:00,GILD,neutral
550257.0,"Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump",2017-03-10 11:32:00-05:00,GILD,negative
550258.0,Barclays Analyst Pens Open Letter To Gilead Board And Management,2017-03-10 10:22:00-05:00,GILD,neutral
550259.0,Feuerstein Highlighting Several Points Why Gilead Has Been Struggling Recently,2017-03-10 09:09:00-05:00,GILD,negative
550260.0,Feuerstein on Benzinga's PreMarket Prep Discussing Stocks Which Could Be Impacted by Drug Pricing Changes: Believes Worst Case Scenario Would Create Vulnerabilities for Drugs with High Levels of Competition,2017-03-10 09:04:00-05:00,GILD,negative
550261.0,Galapagos Announces New Phase 2 Studies with Filgotinib in Small Bowel and Fistulizing Crohn's Disease,2017-03-10 04:34:00-05:00,GILD,neutral
550262.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2017",2017-03-09 09:42:00-05:00,GILD,positive
550263.0,UBS Downgrades Gilead Sciences To Neutral,2017-03-09 06:21:00-05:00,GILD,neutral
550264.0,RBC Hints At Potential M&A For Kite Pharma,2017-03-06 13:10:00-05:00,GILD,neutral
550265.0,Traders Circulating Rumor Of Icahn Involvement In Gilead,2017-03-02 09:48:00-05:00,GILD,neutral
550266.0,Hearing Starboard Has Built $2.6B Activist Stake In Gilead,2017-02-28 11:14:00-05:00,GILD,neutral
550267.0,EU Medicines Agency Recommends Approval of Gilead's Descovy For HIV Treatment,2017-02-24 07:27:00-05:00,GILD,positive
550268.0,Gilead Sciences Canada To List Epclusa On Public Drug Plan To Treat All 6 Genotypes Of Hep. C Infection,2017-02-22 11:41:00-05:00,GILD,positive
550269.0,"RBC Capital Markets Healthcare Conference Begins Today, Day 1 Of 2; Presenters Include Tesaro, Axovant, Gilead, And Puma Biotechnology",2017-02-22 08:24:00-05:00,GILD,neutral
550270.0,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?,2017-02-21 16:48:00-05:00,GILD,neutral
550271.0,Gilead Receives Canada Approval For Odefsey For Treatment Of HIV-1 Infection,2017-02-16 11:31:00-05:00,GILD,positive
550272.0,Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers,2017-02-15 14:26:00-05:00,GILD,negative
550273.0,Gilead Announces Higher Rates of Virologic Suppression in 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults,2017-02-15 04:22:00-05:00,GILD,positive
550274.0,Hearing Gilead Will Face New Patent Challenges Related to Hep C Drugs In India; Shares Unaffected,2017-02-14 11:31:00-05:00,GILD,positive
550275.0,Curing Disease Is Bad For Business: How Do Big Pharma Companies Continue Their Growth?,2017-02-14 08:55:00-05:00,GILD,negative
550276.0,Wall Street's M&A Chatter From February 13,2017-02-14 07:01:00-05:00,GILD,neutral
550277.0,Gilead Sciences Says Bictegravir in Combination With FTC/TAF Showed 97% Rates of Virologic Suppression in Phase 2 Study,2017-02-13 18:51:00-05:00,GILD,neutral
550278.0,Hearing Carl Icahn Has Taken Stake In Gilead,2017-02-13 09:57:00-05:00,GILD,neutral
550279.0,20 Biggest Mid-Day Losers For Wednesday,2017-02-08 13:09:00-05:00,GILD,negative
550280.0,Oil Weakness A Possible Drag On Market As Earnings Season Keeps Rolling,2017-02-08 10:57:00-05:00,GILD,negative
550281.0,8 Biggest Price Target Changes For Wednesday,2017-02-08 10:50:00-05:00,GILD,neutral
550282.0,Gilead's 2017 Guidance Sank Shares To A New Bottom,2017-02-08 10:40:00-05:00,GILD,positive
550283.0,Martin Shkreli: I Would Buy Gilead Shares,2017-02-08 09:59:00-05:00,GILD,positive
550284.0,"Benzinga's Top Upgrades, Downgrades For February 8, 2017",2017-02-08 09:51:00-05:00,GILD,positive
550285.0,"The Market In 5 Minutes: Disney, Gilead Investors Not Too Pleased",2017-02-08 09:03:00-05:00,GILD,negative
550286.0,"Yesterday Night, Martin Shrkeli Said He Would Be A Buyer Of Gilead On Weak Quarter Results, Believes Stock Is Worth $125/Share",2017-02-08 08:54:00-05:00,GILD,negative
550287.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-02-08 08:28:00-05:00,GILD,neutral
550288.0,"Citigroup Downgrades Gilead Sciences To Neutral, Lowers Price Target To $76",2017-02-08 06:29:00-05:00,GILD,negative
550289.0,12 Stocks You Should Be Watching Today,2017-02-08 05:29:00-05:00,GILD,neutral
550290.0,Gilead Touches Lowest Level Since 2014 Following Q4 Report,2017-02-07 16:42:00-05:00,GILD,negative
550291.0,"Adam Feuerstein  @adamfeuerstein Tweet: $GILD  Just Kitchen-Sinked 2017 Guidance, Worse Than Anyone Expected —> thestreet.com/story/13993572",2017-02-07 16:21:00-05:00,GILD,negative
550292.0,Gilead Raises Qtr Dividend From $0.47/Share To $0.52/Share,2017-02-07 16:21:00-05:00,GILD,neutral
550293.0,Gilead Science Sees FY17 Product Sales $22.5B-$24.5B,2017-02-07 16:03:00-05:00,GILD,neutral
550294.0,"Gilead Sciences Reports Q4 Adj EPS $2.70 vs $2.61 Est, Revenus $7.32B vs $7.15B Est",2017-02-07 16:02:00-05:00,GILD,neutral
550295.0,"Keep an Eye on These 12 Stocks for February 7, 2017",2017-02-07 05:44:00-05:00,GILD,neutral
550296.0,"Earnings Scheduled For February 7, 2017",2017-02-07 05:04:00-05:00,GILD,neutral
550297.0,Q4 2016 Real-Time Call Brief,2017-02-06 19:00:00-05:00,GILD,neutral
550298.0,"Jim Cramer Gives His Opinion On CSX, JetBlue, Gilead And Burlington Stores",2017-02-02 06:39:00-05:00,GILD,neutral
550299.0,"JJ Kinahan Walks Us Through The Most Traded Stocks Among TDA Clients In 2016: Apple, Bank of America & More",2017-01-27 12:23:00-05:00,GILD,positive
550300.0,Gilead Defends Hepatitis C Treatments On Reports Of Side Effects,2017-01-26 08:18:00-05:00,GILD,neutral
550301.0,"Gilead Responds to Report Of Lack Of Efficacy From Harvoni Treatment, Points to Extensive Data Showing Failure Rates 'low but given large numbers of patients treated...not unexpected to see reports of some patients failing these treatments'",2017-01-25 17:09:00-05:00,GILD,negative
550302.0,"UPDATE: Gilead Says It Has Worked Closely With FDA To Share Data On Liver Failure Cases, Has Found No Suggestion Of Causal Relationship Between Harvoni And Liver Failure, No Product Updates Deemed Necessary",2017-01-25 16:58:00-05:00,GILD,negative
550303.0,"Gilead Responds To Reports Of Side Effects From Harvoni Hepatitis Treatment, Tells Benzinga Safety Is Highest Priority, Co. Continuously Monitors Safey Information To Inform Appropriate Use",2017-01-25 16:54:00-05:00,GILD,positive
550304.0,Traders Circulating Stat News Report Posted 5 Hrs Ago Suggesting Safety Concerns In Gilead's Hepatitis Drugs,2017-01-25 14:46:00-05:00,GILD,positive
550305.0,Watch These 10 Huge Call Purchases In Wednesday Trade,2017-01-25 04:05:00-05:00,GILD,positive
550306.0,Benzinga's Option Alert Recap From January 24,2017-01-24 17:26:00-05:00,GILD,positive
550307.0,Option Alert: Gilead May 70.0 Calls Sweep: 2173 @  ASK  $3.953: 12k traded vs 1798 OI:  Earnings 2/7 After Close  $70.12 Ref,2017-01-24 10:49:00-05:00,GILD,positive
550308.0,Technical Alert: Gilead Sciences Makes New For Move,2017-01-20 12:31:00-05:00,GILD,positive
550309.0,EMA Validates Gilead's Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir,2017-01-20 05:51:00-05:00,GILD,positive
550310.0,"Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors",2017-01-19 12:29:00-05:00,GILD,positive
550311.0,BZ NOTE: Gilead Has Been Mentioned as a Rumor Stock by Traders At Least Twice Over the Last 2 Months,2017-01-18 11:49:00-05:00,GILD,positive
550312.0,"Hearing Gilead, Pfizer CEOs Currently Meeting At Davos, Traders Speculating M&A Talks",2017-01-18 11:46:00-05:00,GILD,neutral
550313.0,Orphan Drugs Among 2015's Top 10 Best-Selling Medications,2017-01-18 10:40:00-05:00,GILD,positive
550314.0,Adam Feuerstein Tweets: $GILD told analysts at mtg today they might separate out HCV and/or HIV product guidance for 2017 on upcoming earnings call.,2017-01-11 17:41:00-05:00,GILD,neutral
550315.0,"Watching Weakness In Amgen,Biogen, Gilead, Mylan, Pfizer And Other Biotechs After Pres. Elect Trump Negative Statement On Drug Pricing",2017-01-11 11:25:00-05:00,GILD,negative
550316.0,Gilead Granted Marketing Authorization From European Commission for Vemlidy,2017-01-11 06:53:00-05:00,GILD,positive
550317.0,"GM, Gilead, Barracuda And Freeport-McMoRan: Fast Money Picks For January 11",2017-01-11 06:42:00-05:00,GILD,neutral
550318.0,Gilead Says Slowdown In Patients Starting Hepatitis C Therapies To Continue Into 2017,2017-01-09 14:27:00-05:00,GILD,neutral
550319.0,Adam Feuerstein Tweets: $GILD breakout. The full force of co.'s HIV power is being applied to bictegravir pgm. They sound really confident about this drug. #JPM17,2017-01-09 14:05:00-05:00,GILD,positive
550320.0,Gilead CEO Says Planning Phase 3 Trials Of Nash Drug In Patients With Advanced Fibrosis,2017-01-09 13:53:00-05:00,GILD,positive
550321.0,The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know,2017-01-09 06:33:00-05:00,GILD,neutral
550322.0,Hearing Carl Icahn Considering Activist Stake In Gilead,2017-01-06 09:41:00-05:00,GILD,neutral
550323.0,Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets,2017-01-05 16:10:00-05:00,GILD,neutral
550324.0,Jim Cramer Gives His Opinion On SYSCO And Gilead,2017-01-04 06:52:00-05:00,GILD,neutral
550325.0,January Will Feature Some Of The Market's Most Influential Events,2016-12-30 15:36:00-05:00,GILD,positive
550326.0,Japan to Review Drug Prices Each Year vs Every Two Years Previously -Reuters,2016-12-19 04:17:00-05:00,GILD,neutral
550327.0,"Japan's Ministry of Health, Labour and Welfare Approves Gilead's Vemlidy for Patients With Chronic Hepatitis B Virus Infection",2016-12-19 04:11:00-05:00,GILD,positive
550328.0,"CNBC Meg Tirrell Tweets: $GILD says it plans to ""vigorously challenge"" verdict ordering it to pay $MRK $2.54B in hepatitis C royalties",2016-12-15 17:00:00-05:00,GILD,positive
550329.0,Gilead To Pay Merck $2.54B In Hep. C Royalties,2016-12-15 16:30:00-05:00,GILD,negative
550330.0,Galapagos Reports Publication of Phase 2 Study with Filgotinib in Crohn's Disease in The Lancet,2016-12-15 04:40:00-05:00,GILD,neutral
550331.0,"Najarian Brothers See Unusually High Options Activity In KeyCorp, Gilead Sciences",2016-12-14 15:59:00-05:00,GILD,neutral
550332.0,"10 Notable Stocks Trading Ex-Dividend Tuesday, December 13",2016-12-12 11:38:00-05:00,GILD,neutral
550333.0,"Express Scripts Hep. C Cure Program Expands To Cover Treatments To Include Viekira Pak, Harvoni In 2017",2016-12-12 07:09:00-05:00,GILD,positive
550334.0,Stocks Hitting 52-Week Lows,2016-12-08 14:46:00-05:00,GILD,negative
550335.0,Endeavor Funds' Jerome Dodson Defends 3 Stocks Beaten Down In 2016,2016-12-08 14:02:00-05:00,GILD,negative
550336.0,Gilead Submits NDA to FDA for Sofosbuvir,2016-12-08 08:12:00-05:00,GILD,neutral
550337.0,"Gilead Sciences Nears 30-Month Low, Attempts To Rebound",2016-12-07 11:15:00-05:00,GILD,negative
550338.0,PRAC Warns Of Risk Of Hepatitis B Re-activation With Direct-acting Antivirals For Hepatitis C,2016-12-02 09:38:00-05:00,GILD,negative
550339.0,"PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio",2016-11-29 08:53:00-05:00,GILD,neutral
550340.0,UPDATE: Galapagos Says Start of DIVERSITY Study Triggers $50M Milestone Payment from Gilead,2016-11-22 16:04:00-05:00,GILD,neutral
550341.0,Assessing The Legitimacy Of The Biotech ETF Bounce,2016-11-18 11:56:00-05:00,GILD,neutral
550342.0,How Incyte Just Became A Major M&A Target,2016-11-17 13:10:00-05:00,GILD,neutral
550343.0,"Incyte Shares Trading Up 5.3%, Traders Attributing Strength To Multiple Analyst Notes Highlighting Gilead's Unlikely Approval Of SIMPLIFY-1 and SIMPLIFY-II, Combined With Repatriation Holiday, Make Incyte More Attractive As M&A Target",2016-11-17 11:10:00-05:00,GILD,positive
550344.0,Gilead's Full Top-Line Results From Two Phase 3 Studies,2016-11-16 16:17:00-05:00,GILD,neutral
550345.0,Gilead Announces SIMPLIFY-1 Study Achieved Its Primary Endpoint In Phase 3 Study,2016-11-16 16:16:00-05:00,GILD,neutral
550346.0,Gilead Announces SIMPLIFY-2 Did Not Achieve Its Primary Endpoint In Phase 3 Study,2016-11-16 16:16:00-05:00,GILD,neutral
550347.0,Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price,2016-11-14 16:57:00-05:00,GILD,positive
550348.0,Gilead Reports Phase 2 Data for Selonsertib in NASH Showed Results Demonstrate Improvement in Fibrosis Stage among NASH Patients with Moderate to Severe Fibrosis,2016-11-14 16:31:00-05:00,GILD,positive
550349.0,Gilead Responding To CMS Blog Post Highlighting The Cost Increase For Hep-C Treatment Harvoni Tells Benzinga The VA And Medicaid Currently Receive Discounts Of 50%+ On Harvoni,2016-11-14 16:14:00-05:00,GILD,positive
550350.0,Several Key Catalysts Lay Ahead For Gilead Sciences In The Next Year,2016-11-14 16:00:00-05:00,GILD,neutral
550351.0,CMS Criticizes Gilead's Harvoni Price Increases,2016-11-14 14:04:00-05:00,GILD,negative
550352.0,Benzinga's Top Initiations,2016-11-14 09:16:00-05:00,GILD,positive
550353.0,The Market In 5 Minutes: A Couple Of Pharma Stocks Move 70% In Opposite Directions,2016-11-14 09:04:00-05:00,GILD,neutral
550354.0,"Stifel Nicolaus Initiates Coverage On Gilead Sciences, Inc. - Common Stock at Buy, Announces $100.00",2016-11-14 06:38:00-05:00,GILD,neutral
550355.0,Technical Alert: Gilead Sciences Lower Despite Favorable EU Ruling,2016-11-11 11:34:00-05:00,GILD,negative
550356.0,"EU Medicines Agency Announces Positive Opinion from CHMP for Gilead's Chronic Hep B Treatment, Vemlidy",2016-11-11 07:07:00-05:00,GILD,positive
550357.0,U.S. Food and Drug Administration Approves Gilead's Vemlidy for the Treatment of Chronic Hepatitis B Virus Infection,2016-11-10 13:06:00-05:00,GILD,positive
550358.0,Wednesday's Loser: Hospital Stocks,2016-11-09 15:12:00-05:00,GILD,negative
550359.0,Biotech Is Getting A Big Boost Following Clinton's Loss,2016-11-09 08:38:00-05:00,GILD,positive
550360.0,"UPDATE: Jefferies Comments on Gilead: 'ALXN's actions interpreted by some as suggesting they are in play.'; BZ NOTE: Note is Focused on Gilead, Not Necessarily Alexion; Jefferies Maintains Gilead is 'Undervalued'",2016-11-08 14:56:00-05:00,GILD,positive
550361.0,UPDATE: Jefferies Note Highlighting Gilead for Alexion Titled 'Another Look At Our Hypothetical M&A Scenario Analysis',2016-11-08 14:52:00-05:00,GILD,neutral
550362.0,"Hearing Jefferies Defending Alexion, Says Gilead Could Buy Co.",2016-11-08 14:49:00-05:00,GILD,neutral
550363.0,The Market In 5 Minutes: Election Day Has Finally Arrived,2016-11-08 09:00:00-05:00,GILD,neutral
550364.0,"Mizuho Initiates Coverage On Gilead Sciences, Inc. - Common Stock at Buy, Announces $88.00",2016-11-08 05:43:00-05:00,GILD,neutral
550365.0,"Gilead Shares Spike to Session Highs as Traders Passing Around Vague, Unconfirmed Chatter in Name; Shares Up 2% for Session",2016-11-04 10:51:00-04:00,GILD,positive
550366.0,Near-Term Headwinds And Long-Term Promise For Gilead Sciences,2016-11-02 13:35:00-04:00,GILD,positive
550367.0,Gilead Sciences Price Target Trimmed Following A Sobering Q3,2016-11-02 12:59:00-04:00,GILD,negative
550368.0,Benzinga's Top Upgrades,2016-11-02 09:10:00-04:00,GILD,positive
550369.0,"The Market In 5 Minutes: Alibaba, Brocade And A Game 6",2016-11-02 09:05:00-04:00,GILD,neutral
550370.0,"BMO Capital Upgrades Gilead Sciences, Inc. - Common Stock to Outperform",2016-11-02 06:50:00-04:00,GILD,neutral
550371.0,12 Stocks You Should Be Watching Today,2016-11-02 04:50:00-04:00,GILD,neutral
550372.0,"Adam Feuerstein @adamfeuerstein Tweet: Summary of analyst reaction to $GILD quarter: ""Whew, they didn't guide down again.""   Sad to say, but that is a positive.",2016-11-01 16:47:00-04:00,GILD,positive
550373.0,Gilead Ticks Lower On Earnings Miss,2016-11-01 16:18:00-04:00,GILD,negative
550374.0,"Gilead Reports Q3 Adj. EPS $2.75 vs $2.86 Est., Sales $7.5B vs $7.45B Est.",2016-11-01 16:01:00-04:00,GILD,neutral
550375.0,ContraVir CEO Talks Hep. B Treatment's Future,2016-11-01 12:11:00-04:00,GILD,neutral
550376.0,Nerves Start To Fray Ahead Of Election As Investors Scramble For Protection,2016-11-01 11:37:00-04:00,GILD,negative
550377.0,The Election Can't Come Soon Enough For Biotechs,2016-11-01 10:39:00-04:00,GILD,neutral
550378.0,"Earnings Scheduled For November 1, 2016",2016-11-01 04:52:00-04:00,GILD,neutral
550379.0,"Keep an Eye on These 10 Stocks for November 1, 2016",2016-11-01 04:27:00-04:00,GILD,neutral
550380.0,Option Alert: GILD Feb17 82.5 Calls: 3530 @  Above Ask!  $2.00: 4948 traded vs 774 OI:  Earnings 11/1 After Close  $75.25 Ref,2016-10-26 10:13:00-04:00,GILD,positive
550381.0,"Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated",2016-10-25 14:47:00-04:00,GILD,positive
550382.0,Gilead Reports FTC/TAF-Based Regimens Demonstrate Comparable Efficacy and Improved Renal and Bone Laboratory Parameters Compared to Truvada,2016-10-24 06:26:00-04:00,GILD,positive
550383.0,"Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients",2016-10-20 10:09:00-04:00,GILD,neutral
550384.0,UPDATE: Gilead Says Separate Phase 2 Study of Selonsertib Did Not Meet Primary Endpoint for PAH or DKD; Gilead Will Not Pursue Phase 3 Studies for PAH or DKD at This Time,2016-10-20 10:07:00-04:00,GILD,neutral
550385.0,UPDATE: Gilead Says Selonsertib Showed 'Anti-Fibrotic Activity in Open-Label Phase 2 NASH Study; Data Support Plans to Advance GS-4997 into Phase 3 Clinical Trials',2016-10-20 10:05:00-04:00,GILD,positive
550386.0,"Gilead Reports Top-Line Phase 2 Results from Selonsertib in NASH, PAH, DKD",2016-10-20 10:05:00-04:00,GILD,neutral
550387.0,"Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space",2016-10-18 13:32:00-04:00,GILD,positive
550388.0,"20-Week Data From Filogtinib Phase 2 ""Fitzroy"" STudy In Crohn's Disease Expected To Be Presented During United European Gastroenterology Week",2016-10-17 08:27:00-04:00,GILD,positive
550389.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-10-17 02:56:00-04:00,GILD,positive
550390.0,Option Alert: GILD May $65 Put; 1100 @Bid @$3.40 vs 275 OI,2016-10-14 11:42:00-04:00,GILD,positive
550391.0,Theravance Biopharma's Valuation Has Gotten A Little Carried Away,2016-10-12 13:21:00-04:00,GILD,neutral
550392.0,Analysts Share Their Low Forward P/E Picks,2016-10-12 06:52:00-04:00,GILD,neutral
550393.0,Technical Alert: Gilead Sciences Lower For Fourth Day In A Row,2016-10-11 14:38:00-04:00,GILD,neutral
550394.0,Technical Alert: Gilead Sciences Makes New Low For Move,2016-10-07 13:45:00-04:00,GILD,neutral
550395.0,"Gilead, Bank Of America, Costco: Fast Money Picks For September 28",2016-09-28 06:32:00-04:00,GILD,neutral
550396.0,"Gilead Sciences, WHO Report 5 Year Leishmaniasis Partnership",2016-09-27 16:06:00-04:00,GILD,neutral
550397.0,Galapagos Reports Successful Completion Of Discussions With US And European Authorities To Initiate Phase 3 Crohn's Disease Study,2016-09-27 16:06:00-04:00,GILD,positive
550398.0,15 Biggest Mid-Day Losers For Tuesday,2016-09-27 12:58:00-04:00,GILD,negative
550399.0,The Drug Price Increase Debate: Separating The Winners From The Losers,2016-09-27 11:23:00-04:00,GILD,positive
550400.0,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed",2016-09-27 09:06:00-04:00,GILD,neutral
550401.0,Benzinga's Top Downgrades,2016-09-27 09:01:00-04:00,GILD,positive
550402.0,Leerink Swann Downgrades Gilead Sciences to Market Perform,2016-09-27 06:30:00-04:00,GILD,neutral
550403.0,"Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98",2016-09-26 12:40:00-04:00,GILD,neutral
550404.0,"Sell Twitter, Buy Gilead And More Fast Money Picks For September 23",2016-09-23 06:48:00-04:00,GILD,neutral
550405.0,Cramer Advises His Viewers On Gilead Sciences And Monsanto,2016-09-23 06:46:00-04:00,GILD,neutral
550406.0,Gilead Valuation Only Minimally Effected By Drug Trial Stoppage,2016-09-22 15:38:00-04:00,GILD,neutral
550407.0,Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters',2016-09-22 14:43:00-04:00,GILD,neutral
550408.0,Benzinga's Top Initiations,2016-09-22 09:49:00-04:00,GILD,positive
550409.0,The Market In 5 Minutes: No Interest Rate Hike...Yet,2016-09-22 09:04:00-04:00,GILD,positive
550410.0,Berenberg Initiates Coverage on Gilead Sciences at Buy,2016-09-22 07:47:00-04:00,GILD,neutral
550411.0,Can You Guess This Chart?,2016-09-22 07:31:00-04:00,GILD,neutral
550412.0,Gilead Reports Termination of Phase 2/3 Study of GS-5745 in Patients Ulcerative Colitis,2016-09-21 17:00:00-04:00,GILD,neutral
550413.0,The Street's Adam Feuerstein Tweets: $AGN ($94B) is not buying $GILD ($107B)  Please shut up.,2016-09-21 10:30:00-04:00,GILD,positive
550414.0,Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers',2016-09-21 10:30:00-04:00,GILD,positive
550415.0,Traders Highlighting Barron's Article On Gabelli Note Speculating Allergan Possibly Preparing Bid For Gilead,2016-09-21 09:46:00-04:00,GILD,neutral
550416.0,Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma,2016-09-21 07:21:00-04:00,GILD,neutral
550417.0,Technical Alert: Gilead Sciences Tests Resistance At $82 Area,2016-09-20 15:03:00-04:00,GILD,positive
550418.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,GILD,positive
550419.0,The 5 Top-Selling Drugs In The World,2016-09-20 12:09:00-04:00,GILD,neutral
550420.0,TESARO Shares Trading Up ~2% in Otherwise Down Tape on No News; Some Traders Getting Anxious Following News of Gilead $5B Senior Notes Offering Announced Thurs. Evening,2016-09-16 11:33:00-04:00,GILD,negative
550421.0,"Adam Feuerstein @adamfeuerstein $GILD Drug Pipeline, Maligned by Investors is Still Packed with Q4 Clinical Trial Readouts thestreet.com/story/13741594… 9 clinical trials in Q4.",2016-09-15 11:26:00-04:00,GILD,neutral
550422.0,"Adam Feuerstein Tweets: $GILD Drug Pipeline, Maligned by Investors, is Still Packed with Q4 Clinical Trial Readouts thestreet.com/story/13741594… 9 clinical trials in Q4.",2016-09-15 11:26:00-04:00,GILD,neutral
550423.0,Credit Suisse Cuts Gilead Price Target To $95,2016-09-14 10:48:00-04:00,GILD,positive
550424.0,7 Biggest Price Target Changes For Wednesday,2016-09-14 09:50:00-04:00,GILD,neutral
550425.0,"The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A",2016-09-14 09:17:00-04:00,GILD,positive
550426.0,Can You Guess This Chart?,2016-09-14 07:29:00-04:00,GILD,neutral
550427.0,Watch These 7 Huge Put Purchases In Wednesday Trade,2016-09-14 02:16:00-04:00,GILD,positive
550428.0,Option Alert: GILD Jun 16 $72.5 Puts at the bid: 2000 @ 5.651 vs. Open Interest 136,2016-09-13 11:59:00-04:00,GILD,positive
550429.0,Recent Strength In TESARO Being Attributed To Gabelli Research Report Of Potential Gilead Interest In TESARO,2016-09-13 10:25:00-04:00,GILD,positive
550430.0,Benzinga's Top Initiations,2016-09-12 09:02:00-04:00,GILD,positive
550431.0,The Market In 5 Minutes: Hillary Clinton Falls Ill With The Global Stock Markets,2016-09-12 08:55:00-04:00,GILD,negative
550432.0,Berenberg Initiates Coverage on Gilead Sciences at Buy,2016-09-12 06:23:00-04:00,GILD,neutral
550433.0,Traders Attributing Strength in TESARO Shares to Comment from Gilead Exec Mgmt is 'Absolutely Willing' to Take Risk with Right PARP Product,2016-09-08 10:28:00-04:00,GILD,positive
550434.0,"Hearing Gilead Exec at Wells Fargo Healthcare Conference Has Said Mgmt is Feeling 'an Urgency to Do Deals,' But is Not Desperate",2016-09-08 10:09:00-04:00,GILD,positive
550435.0,Benzinga's Top Upgrades,2016-09-06 08:52:00-04:00,GILD,positive
550436.0,The Market In 5 Minutes: Stocks Return Higher From Three-Day Weekend,2016-09-06 08:34:00-04:00,GILD,neutral
550437.0,Jefferies Upgrades Gilead To Buy Citing Bullish Prospects For HIV Franchise,2016-09-06 07:39:00-04:00,GILD,positive
550438.0,Jefferies Upgrades Gilead Sciences to Buy,2016-09-06 01:43:00-04:00,GILD,neutral
550439.0,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",2016-08-30 12:16:00-04:00,GILD,positive
550440.0,Technical Alert: Gilead Sciences Makes New Low For Move And Attempts To Rebound,2016-08-29 11:48:00-04:00,GILD,neutral
550441.0,Here Are All The Big Biotech Mergers In 2016,2016-08-27 18:36:00-04:00,GILD,neutral
550442.0,Galapagos NV Reports Initiation of Global Phase 3 Program Investigating filgotinib In Rheumatoid Arthritis,2016-08-22 16:12:00-04:00,GILD,neutral
550443.0,European Commission Grants Marketing Authorization For Once-Daily Truvada To Reduce Risk Of Sexually Acquired HIV-1,2016-08-22 11:50:00-04:00,GILD,negative
550444.0,"Must Watch Stocks for August 22, 2016",2016-08-22 05:05:00-04:00,GILD,neutral
550445.0,Benzinga's Weekend M&A Chatter,2016-08-21 20:59:00-04:00,GILD,neutral
550446.0,"UPDATE: Reuters Says Merck, Sanofi, Pfizer, Gilead, Celgene Have Each Submitted Expressions of Interest for Medivation",2016-08-17 12:55:00-04:00,GILD,positive
550447.0,The Least Popular Stocks This 13F Season,2016-08-16 12:08:00-04:00,GILD,negative
550448.0,"13F from Soros' Soros Fund Mgmt Shows Liquidated Positions in Apple, Netflix, Gilead, Gap, Synchrony Financial, United Continental",2016-08-15 16:23:00-04:00,GILD,positive
550449.0,13F from Cooperman's Omega Shows Liquidated Stake in Gilead,2016-08-15 09:50:00-04:00,GILD,neutral
550450.0,"Gilead Shares Tick Lower; Traders Circulating Stat News Article ""IRS is urged to investigate Gilead for 'dodging' US taxes""",2016-08-11 13:41:00-04:00,GILD,neutral
550451.0,"Gilead Shares Indicated Higher, Up ~0.4%; BZ NOTE: Co. Was Discussed as a Possible Takeover Candidate for Bristol-Myers, as Recently as Aug. 1",2016-08-05 08:05:00-04:00,GILD,positive
550452.0,UPDATE: Free Cash-Flow For Bristol-Myers Squibb Has Been Negative For 2 Straight Quarters,2016-08-01 11:30:00-04:00,GILD,positive
550453.0,"UPDATE: In Early July Citigroup Said Gilead Would Not Seek Mega-Merger, Said Co Was Comfortable With 'their lean size'",2016-08-01 11:25:00-04:00,GILD,positive
550454.0,Gilead Spikes to High; Hearing Unconfirmed Market Chatter Co Talking With BMY Regarding Merger,2016-08-01 11:22:00-04:00,GILD,negative
550455.0,Jefferies Ponders Whether Gilead Sciences Should Experiment With An HCV Spinoff,2016-08-01 09:25:00-04:00,GILD,neutral
550456.0,The Market In 5 Minutes: Amazon And Google Continue To Dominate,2016-07-29 08:52:00-04:00,GILD,positive
550457.0,Argus Research Downgrades Gilead Sciences to Hold,2016-07-29 07:09:00-04:00,GILD,neutral
550458.0,Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings,2016-07-27 09:12:00-04:00,GILD,positive
550459.0,15 Biggest Mid-Day Losers For Tuesday,2016-07-26 12:53:00-04:00,GILD,negative
550460.0,Technical Alert - Gilead Sciences Falls Into Limited Support Zone After Q2 Report,2016-07-26 10:44:00-04:00,GILD,positive
550461.0,Benzinga's Top Downgrades,2016-07-26 09:10:00-04:00,GILD,positive
550462.0,"The Market In 5 Minutes: Apple And Twitter And McDonald's, Oh My!",2016-07-26 08:55:00-04:00,GILD,neutral
550463.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-07-26 08:29:00-04:00,GILD,neutral
550464.0,Needham Downgrades Gilead Sciences to Hold,2016-07-26 07:38:00-04:00,GILD,neutral
550465.0,Wait On The DNC Before Going Long Biotech ETFs,2016-07-26 06:43:00-04:00,GILD,neutral
550466.0,"Keep an Eye on These 12 Stocks for July 26, 2016",2016-07-26 04:28:00-04:00,GILD,neutral
550467.0,4 Stocks Moving In Monday's After-Hours Session,2016-07-25 17:14:00-04:00,GILD,neutral
550468.0,"After-Hours Losers: CRME down 14.91%, SANM 9.06%, GBR 4.50%, CMP 2.75%, GILD 3.67, CDNS 2.45%, FCCY 2.50%",2016-07-25 16:45:00-04:00,GILD,negative
550469.0,"Gilead Misses Revenue Estimates, Cuts Guidance",2016-07-25 16:21:00-04:00,GILD,negative
550470.0,Gilead Shares Down 4.5%,2016-07-25 16:13:00-04:00,GILD,positive
550471.0,Gilead Cuts FY16 Rev. From $30-$31B To $29.5-$30.5B,2016-07-25 16:09:00-04:00,GILD,negative
550472.0,Gilead Sciences Cuts Sales Guidance,2016-07-25 16:08:00-04:00,GILD,negative
550473.0,"Gilead Reports Q2 EPS $3.08 vs. Est. $3.02, Rev. $7.776B vs. Est. $7.79B",2016-07-25 16:08:00-04:00,GILD,neutral
550474.0,Technical Alert - Gilead Sciences Testing Major Resistance Ahead Of Q2 Report,2016-07-25 13:05:00-04:00,GILD,positive
550475.0,"The Market In 5 Minutes: Yahoo, Outerwall Highlight Merger Monday",2016-07-25 08:53:00-04:00,GILD,positive
550476.0,"Earnings Scheduled For July 25, 2016",2016-07-25 04:55:00-04:00,GILD,neutral
550477.0,8 Stocks You Should Be Watching Today,2016-07-25 04:28:00-04:00,GILD,neutral
550478.0,"Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences",2016-07-24 16:03:00-04:00,GILD,neutral
550479.0,Scott Bauer's Gilead Sciences Trade,2016-07-24 15:38:00-04:00,GILD,neutral
550480.0,Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada,2016-07-22 12:38:00-04:00,GILD,positive
550481.0,Gilead Sciences Reports Position Opinion from CHMP Related to Type II Variation App for Truvada for Reducing Risk of Sexually-Acquired HIV,2016-07-22 07:17:00-04:00,GILD,negative
550482.0,Gilead's Odefsey Meets Primary 48-Week Objective in Two Phase 3b Studies,2016-07-21 16:31:00-04:00,GILD,neutral
550483.0,Here Are The 14 Stocks Morgan Stanley Wants You To Focus On During Q2 Earnings,2016-07-19 08:30:00-04:00,GILD,neutral
550484.0,"Barron's Picks And Pans: Madison Square Garden, Cigna, Kennedy-Wilson And More",2016-07-17 13:36:00-04:00,GILD,neutral
550485.0,SWEEP (SELL) - GILD Sep $87.5 Put - 842 @ 3.801 in 37 orders. 907 traded. OI: 449,2016-07-15 10:29:00-04:00,GILD,neutral
550486.0,Gilead Receives Approval in Canada for Epclusa for Treatment of Chronic Hepatitis C,2016-07-14 07:54:00-04:00,GILD,positive
550487.0,10 Stocks Cramer's Watching To See If The Market Rebound Is Sustainable,2016-07-12 15:03:00-04:00,GILD,neutral
550488.0,Ligand Reaches OmniAb Platform License Agreement with Gilead,2016-07-08 11:12:00-04:00,GILD,positive
550489.0,Gilead Receives European Commission Marketing Authorization For Epclusa,2016-07-08 09:34:00-04:00,GILD,neutral
550490.0,Ligand Enters into OmniAb Platform License Agreement with Gilead Sciences,2016-07-08 09:01:00-04:00,GILD,positive
550491.0,Gilead Announces European Commission Marketing Authorization For Epclusa For Hepatitis C,2016-07-08 06:51:00-04:00,GILD,neutral
550492.0,"Jim Cramer Shares His Thoughts On Gilead Sciences, Inc. And Citigroup Inc",2016-07-01 08:16:00-04:00,GILD,positive
550493.0,Fast Money Traders Share Their Biotech Picks,2016-07-01 08:10:00-04:00,GILD,positive
550494.0,"Buying Nike, Gilead And PayPal: Fast Money Picks For June 29",2016-06-29 06:32:00-04:00,GILD,neutral
550495.0,Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold,2016-06-28 16:27:00-04:00,GILD,negative
550497.0,Gilead Rallies Off Epclusa Approval,2016-06-28 11:42:00-04:00,GILD,positive
550498.0,Gilead Gets FDA Approval For Epclusa (Sofosbuvir/Velpatasvir) for All Genotypes Of Chronic Hepatitis C Treatment,2016-06-28 11:40:00-04:00,GILD,positive
550499.0,"Adam Feuerstein @adamfeuerstein Tweet: $GILD I'm surprised at the Epclusa WAC price of $74,760 — a lot lower than I expected.",2016-06-28 11:03:00-04:00,GILD,negative
550500.0,FDA Approves Gilead's Epclusa for Treatment of Chronic Hepatitis C Virus Infection,2016-06-28 10:10:00-04:00,GILD,positive
550501.0,Option Alert:  SWEEP (BUY) - GILD July 8 $81 Call - 739 @ 1.559 in 18 orders. 753 traded. OI: 11,2016-06-24 14:47:00-04:00,GILD,positive
550502.0,Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey,2016-06-23 11:30:00-04:00,GILD,positive
550503.0,"As Buybacks Soar, Buyback ETF Tries To Get Its Groove Back",2016-06-23 08:48:00-04:00,GILD,neutral
550504.0,European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey for the Treatment of HIV,2016-06-23 07:55:00-04:00,GILD,positive
550505.0,Biotechs Are Ripping Following IPAB Ruling,2016-06-22 11:31:00-04:00,GILD,neutral
550506.0,Gilead Sciences Approaches Major Support Level,2016-06-21 13:59:00-04:00,GILD,positive
550507.0,"Gilead Reports Prelim. Data on Bictegravir, Says Now Being Evaluated in Phase 3 Studies",2016-06-20 08:30:00-04:00,GILD,neutral
550508.0,Arbutus Biopharma Taken Off Of Chardan's Sell List,2016-06-16 09:29:00-04:00,GILD,neutral
550509.0,"At William Blair Growth Conference, Gilead Says They Cured 2 People With Ebola Treated With GS-5734",2016-06-14 09:26:00-04:00,GILD,positive
550510.0,Gilead's HCV Franchise Erosion Here To Stay; Leerink Cuts Price Target,2016-06-13 12:45:00-04:00,GILD,negative
550511.0,Biogen And Gilead Sciences Buck Biotech Short Interest Trend,2016-06-12 14:35:00-04:00,GILD,positive
550512.0,Hold The Phone On Biotech,2016-06-09 07:07:00-04:00,GILD,neutral
550513.0,"Gilead Shares Spiking, Traders Passing Around Comments Of Possible ValueAct Stake",2016-06-08 09:54:00-04:00,GILD,positive
550514.0,"Merck Says Ruling Reversal in Gilead Case 'Doesn't Reflect the Facts,' Co. Will Appeal Ruling Overturn",2016-06-07 15:53:00-04:00,GILD,neutral
550515.0,US Judge Rules Gilead Won't have to Pay $200M Jury Verdict to Merck in Hepatitis C Patent Dispute -Reuters,2016-06-06 20:17:00-04:00,GILD,negative
550516.0,TD Ameritrade's IMX Growth Hits Record High In May: Check Out Clients' Picks & Pans,2016-06-06 17:50:00-04:00,GILD,positive
550517.0,"Gilead Shares Trading HOD, Seeing Sweep Action In The Weekly 87.5 Calls Expiring July 1",2016-06-06 11:16:00-04:00,GILD,positive
550518.0,"What's The Single Best $10,000 Investment To Hold For The Next 25 Years?",2016-06-04 14:54:00-04:00,GILD,positive
550519.0,Benzinga's Top Initiations,2016-06-01 09:45:00-04:00,GILD,positive
550520.0,Gabelli & Co Initiates Coverage on Gilead Sciences at Buy,2016-06-01 09:03:00-04:00,GILD,neutral
550521.0,Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How,2016-05-31 09:56:00-04:00,GILD,positive
550522.0,Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C Treatment,2016-05-27 10:57:00-04:00,GILD,positive
550523.0,"European CHMP Adopts Positive Opinion for Gilead's Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C, Expects Target Action Date Under PDUFA Of June 28th, 2016",2016-05-27 07:26:00-04:00,GILD,positive
550524.0,Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?,2016-05-26 13:38:00-04:00,GILD,positive
550525.0,"Benzinga's M&A Chatter for Wednesday May 25, 2016",2016-05-25 21:47:00-04:00,GILD,neutral
550526.0,"Celgene, Gilead Said to Bid for Medivation -Bloomberg",2016-05-25 10:11:00-04:00,GILD,neutral
550527.0,Gilead Names Kevin Young CBE COO,2016-05-24 16:31:00-04:00,GILD,neutral
550528.0,5 Reasons Arrowhead Pharma Is A Hepatitis B Leader,2016-05-19 12:38:00-04:00,GILD,neutral
550529.0,Has A Biotech Recovery Started Yet?,2016-05-17 17:56:00-04:00,GILD,neutral
550530.0,13F From George Soros Shows New Stake In Gilead Sciences,2016-05-16 16:43:00-04:00,GILD,neutral
550531.0,"Leon Cooperman Buys 227,000 Apple Shares, Adds More Microsoft",2016-05-16 15:41:00-04:00,GILD,positive
550532.0,"Jim Cramer Advises Viewers On Schlumberger, Gilead Sciences And Disney",2016-05-04 06:17:00-04:00,GILD,neutral
550533.0,The Next Sector Rotation Will Be To Biotechs,2016-05-03 12:17:00-04:00,GILD,neutral
550534.0,Barron's 500: America's Top Companies,2016-05-01 16:11:00-04:00,GILD,positive
550535.0,"After-Hours Recap: April In Review, Friday Index Movers & After-Hours Runners",2016-04-29 17:23:00-04:00,GILD,neutral
550536.0,Gilead Says European CHMP Adopts Positive Opinion For Its Odefsey For Treating HIV,2016-04-29 09:42:00-04:00,GILD,positive
550537.0,European CHMP Adopts Positive Opinion for Gilead's TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV,2016-04-29 08:32:00-04:00,GILD,positive
550538.0,15 Stocks Moving In Friday's Pre-Market Session,2016-04-29 08:22:00-04:00,GILD,neutral
550539.0,Maxim Group Downgrades Gilead Sciences to Hold,2016-04-29 07:56:00-04:00,GILD,neutral
550540.0,10 Stocks You Should Be Watching Today,2016-04-29 04:52:00-04:00,GILD,neutral
550541.0,Gilead Reaffirms FY16 Sales $30B-$31B vs $31.8B Est.,2016-04-28 16:24:00-04:00,GILD,neutral
550542.0,"Gilead Sciences Reports Q1 Adj EPS $3.03 Vs Est $3.14, Sales $7.79B Vs Est $8.11B",2016-04-28 16:02:00-04:00,GILD,neutral
550543.0,Biotech Boom May Continue Through Earnings Season,2016-04-28 12:00:00-04:00,GILD,neutral
550544.0,"Earnings Scheduled For April 28, 2016",2016-04-28 05:00:00-04:00,GILD,neutral
550545.0,"Amazon Earnings, GDP And Other Key Market Data For Thursday",2016-04-27 17:55:00-04:00,GILD,positive
550546.0,"Credit Suisse Maintains Outperform on Gilead Sciences, Raises PT to $120.00",2016-04-26 23:40:00-04:00,GILD,positive
550547.0,Big Biotech In The Earnings Spotlight,2016-04-26 08:08:00-04:00,GILD,neutral
550548.0,Sustainable Investing With A New ETF,2016-04-25 14:04:00-04:00,GILD,neutral
550549.0,Gilead Gets European Commission Marketing Authorization For HIV-1 Infection Drug,2016-04-25 08:30:00-04:00,GILD,neutral
550550.0,Gilead Announces European Commission Grants Marketing Authorization For 2 Doses Of Descovy For HIV Treatment,2016-04-25 07:12:00-04:00,GILD,positive
550551.0,Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hep C Therapies at ILC,2016-04-16 10:06:00-04:00,GILD,neutral
550552.0,Gilead Presents New Data Highlighting Progress in Liver Fibrosis at ILC,2016-04-16 10:04:00-04:00,GILD,positive
550553.0,"Adam Feuerstein @adamfeuersteinTweet:  Investor source (long $GILD) at EASL: ""$RGLS isn't going anywhere. This is the $GILD show. Literally half the posters are abt GILD's drugs.""",2016-04-15 10:34:00-04:00,GILD,neutral
550554.0,Gilead Sciences' Two Phase Three Trials Meet Primary Endpoints,2016-04-15 06:53:00-04:00,GILD,neutral
550555.0,Gilead Announces Two Phase 3 Studies Evaluating Tenofovir Alafenamide for Patients With Chronic Hep B Infection Both Met their Primary Endpoints of Non-inferiority to Gilead's Viread,2016-04-15 04:38:00-04:00,GILD,neutral
550556.0,"SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position",2016-04-13 13:44:00-04:00,GILD,positive
550557.0,Cancer Drug Stocks Are The Picture Of Health,2016-04-12 17:12:00-04:00,GILD,negative
550558.0,"Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term",2016-04-12 10:06:00-04:00,GILD,positive
550559.0,How One Analyst Is Playing The Biotech Rebound This Week,2016-04-07 15:45:00-04:00,GILD,positive
550560.0,"BMO Capital Initiates Coverage on Gilead Sciences at Market Perform, Announces $102.00 PT",2016-04-05 17:31:00-04:00,GILD,neutral
550561.0,Gilead Sciences Acquires Nimbus Apollo for $400M,2016-04-04 16:39:00-04:00,GILD,neutral
550562.0,Gilead Announces FDA Has Approved Descovy,2016-04-04 14:58:00-04:00,GILD,positive
550563.0,"Gilead Reports Purchase of Nimbus Therapeutics' ACC Program for NAS, Other Liver Diseases; Made $400M Upfront Payment, Potential to Receive Added $800M in Development-Related Milestones Over Time",2016-04-04 08:32:00-04:00,GILD,neutral
550564.0,"IBM, Micron, Gilead: Fast Money Picks For March 31",2016-03-31 06:47:00-04:00,GILD,neutral
550565.0,Gilead Submits NDA to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide for Patients with Chronic Hepatitis B Infection,2016-03-31 04:43:00-04:00,GILD,neutral
550566.0,ContraVir Pharma Says Its CMX157 Outperformed Gilead's Drug in Trial,2016-03-29 06:02:00-04:00,GILD,neutral
550567.0,Data Shows Gilead's HCV Franchise Is Surviving New Competition,2016-03-28 10:47:00-04:00,GILD,positive
550568.0,"Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck",2016-03-24 15:20:00-04:00,GILD,positive
550569.0,"Gilead, FedEx And Other Fast Money Picks For March 24",2016-03-24 06:39:00-04:00,GILD,neutral
550570.0,Jury Rules Merck Patents Valid…Bad For Gilead?,2016-03-23 10:58:00-04:00,GILD,neutral
550571.0,Gilead -2.5% Premarket Following Verdict Tuesday Validating Merck's Hep C Patents,2016-03-23 06:30:00-04:00,GILD,positive
550572.0,"Credit Suisse Maintains Outperform on Gilead Sciences, Lowers PT to $116.00",2016-03-23 04:10:00-04:00,GILD,positive
550573.0,"Wedbush Downgrades Infinity Pharma To Underperform, Slashes Target To $3",2016-03-22 13:31:00-04:00,GILD,negative
550574.0,Potent Value In This Large-Cap ETF,2016-03-18 08:20:00-04:00,GILD,positive
550575.0,A Rare Opportunity With A Biotechnology ETF,2016-03-17 07:54:00-04:00,GILD,positive
550576.0,Gilead Shares Down 0.7% @$89.90 Pre-Market After Gilead Decided To Stop Zydelig Trials Due To Serious Adverse Events,2016-03-15 08:28:00-04:00,GILD,negative
550577.0,Factor Fun With This ETF,2016-03-10 07:52:00-05:00,GILD,positive
550578.0,"The Market In 5 Minutes: Tuesday, March 8, 2016",2016-03-08 12:26:00-05:00,GILD,neutral
550579.0,Leerink Raises Gilead Target To $130 On New HIV Outlook,2016-03-08 09:52:00-05:00,GILD,neutral
550580.0,Gilead Vs. Merck: What To Know,2016-03-07 15:19:00-05:00,GILD,neutral
550581.0,The 5 Most Notable Insider Sells Of The Week,2016-03-07 15:02:00-05:00,GILD,neutral
550582.0,Gilead Shares Fall to Low of $87.65 on Volume; May be  Attributed to Insider Sales Filings,2016-03-03 15:21:00-05:00,GILD,neutral
550583.0,"Leerink Positive On GILD Outlook, Likes Co's Substantial Cash Generation, Maintains Outperform And $125 PT",2016-03-03 08:04:00-05:00,GILD,positive
550584.0,NY State AG Subpoenas Health Insurers Requesting Documents Explaining How Decide Which Hep C Drugs to Cover -Bloomberg,2016-03-03 04:39:00-05:00,GILD,neutral
550585.0,Gilead Reports FDA Approval of Second TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV-1 Infection,2016-03-01 14:06:00-05:00,GILD,positive
550586.0,Gilead's 'R&D Day' Points To Upside For Shareholders,2016-03-01 09:37:00-05:00,GILD,neutral
550587.0,3 Mega Biotechs Leerink Loves,2016-02-29 13:25:00-05:00,GILD,positive
550588.0,Health Canada Issues Notice Of Compliance for Gilead's Truvada for Reducing Risk of Sexually Acquired HIV Infection,2016-02-29 07:05:00-05:00,GILD,negative
550589.0,European CHMP Adopts Positive Opinion for Gilead's Fixed-Dose Combination Descovy for the Treatment of HIV,2016-02-26 07:52:00-05:00,GILD,positive
550590.0,"Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover",2016-02-25 08:51:00-05:00,GILD,neutral
550591.0,Citigroup Initiates Coverage on Gilead Sciences at Buy,2016-02-25 06:49:00-05:00,GILD,neutral
550592.0,Gilead Offers New Preclinical Study Data Evaluating Investigational TLR7 Agonist in SIV-Infected Monkeys,2016-02-24 12:12:00-05:00,GILD,neutral
550593.0,"Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President And Dems Win Senate Majority",2016-02-24 11:00:00-05:00,GILD,positive
550594.0,Will Merck Encroach On Gilead's Harvoni Territory?,2016-02-23 11:36:00-05:00,GILD,neutral
550595.0,"8,383 Patients Contacted to Arrange Blood Test Following Possible Exposure to ex-NHS Worker with Hepatitis C -Sky News",2016-02-23 05:41:00-05:00,GILD,neutral
550596.0,Gilead Launches New Grants Program to Support HIV Cure,2016-02-22 08:33:00-05:00,GILD,positive
550597.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-02-17 16:32:00-05:00,GILD,neutral
550598.0,Gilead Reports FDA Has Approved Two Supplemental Indications for Harvoni in Chronic Hep C Patients with Advanced Liver Disease,2016-02-16 08:31:00-05:00,GILD,positive
550599.0,Schroer: Biotech Will Turn Around,2016-02-13 22:12:00-05:00,GILD,neutral
550600.0,Benzinga's Top Initiations,2016-02-11 09:47:00-05:00,GILD,positive
550601.0,"Oppenheimer Initiates Coverage on Gilead Sciences at Outperform, Abb $120.00 PT",2016-02-11 08:07:00-05:00,GILD,neutral
550602.0,Zika Virus Spreading: Here's How To Play It Again,2016-02-10 13:49:00-05:00,GILD,positive
550603.0,"Icahn, Gilead, GE Lead Top Insider Trades Of The Week",2016-02-09 16:07:00-05:00,GILD,positive
550604.0,"Celgene, Gilead Spike to Highs; May be Attributed to CMS Memo",2016-02-09 14:10:00-05:00,GILD,neutral
550605.0,Rebound For Big Biotech ETF Will Require Some Patience,2016-02-09 08:05:00-05:00,GILD,neutral
550606.0,"Cramer Shares His Thoughts On Chipotle Mexican Grill, Inc. And Gilead Sciences, Inc.",2016-02-09 07:49:00-05:00,GILD,positive
550607.0,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,2016-02-08 15:56:00-05:00,GILD,positive
550608.0,"Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts",2016-02-08 15:27:00-05:00,GILD,neutral
550609.0,How To Invest In An Aging World With The 'Live Long & Prosper' ETF,2016-02-08 10:53:00-05:00,GILD,neutral
550610.0,Barron's: Here Comes $20 Oil,2016-02-07 11:12:00-05:00,GILD,neutral
550611.0,"Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More",2016-02-07 10:49:00-05:00,GILD,positive
550612.0,Leerink Is Back On Board The Biotech Train,2016-02-05 10:32:00-05:00,GILD,neutral
550613.0,Leerink Swann Initiates Coverage on Gilead Sciences at Outperform,2016-02-05 04:08:00-05:00,GILD,neutral
550614.0,25 Companies That Could Still Buy Back Mountains Of Stock,2016-02-04 12:39:00-05:00,GILD,neutral
550615.0,Gilead Sciences Rallies Off Q4 Report,2016-02-03 15:10:00-05:00,GILD,neutral
550616.0,Zika-Related Social Media Chatter Is Picking Up,2016-02-03 13:40:00-05:00,GILD,neutral
550617.0,Is Big Pharma Hinting At A SMID-Cap Biotech Rally?,2016-02-03 13:16:00-05:00,GILD,neutral
550618.0,Joe McCann: Here's How To Play Biotech Market In Earnings Season,2016-02-03 11:48:00-05:00,GILD,positive
550619.0,Ronnie Moas Initiates Gilead At Buy; Models Show It's A Top 10 S&P Stock,2016-02-03 10:37:00-05:00,GILD,positive
550620.0,Benzinga's Top Initiations,2016-02-03 09:45:00-05:00,GILD,positive
550621.0,Credit Suisse Not Expecting GILD To Face Significantly Lower HCV Discounts From New Competitor,2016-02-03 08:25:00-05:00,GILD,positive
550622.0,"Credit Suisse Maintains Outperform on Gilead Sciences, Lowers PT to $118.00",2016-02-03 08:24:00-05:00,GILD,positive
550623.0,"Standpoint Research Initiates Coverage on Gilead Sciences at Buy, Announces $110.00 PT",2016-02-03 08:04:00-05:00,GILD,neutral
550624.0,"Keep an Eye on These 10 Stocks for February 3, 2016",2016-02-03 04:28:00-05:00,GILD,neutral
550625.0,Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.,2016-02-02 17:17:00-05:00,GILD,neutral
550626.0,Earnings Recap For February 2,2016-02-02 16:45:00-05:00,GILD,neutral
550627.0,Gilead To Increase Qtr. Dividend From $0.43 To $0.47/Share,2016-02-02 16:01:00-05:00,GILD,positive
550628.0,Gilead Reports $12B Additional Buyback,2016-02-02 16:01:00-05:00,GILD,neutral
550629.0,Gilead Sees FY16 Rev. $30B-$31B v.s Est. $32.26B,2016-02-02 16:01:00-05:00,GILD,neutral
550630.0,"Gilead Sciences Reports Q4 EPS $3.32 Vs Est $2.99, Sales $8.51B Vs Est $8.13B",2016-02-02 16:00:00-05:00,GILD,neutral
550631.0,Gilead Faces Its Great Hep C Threat: Will It Change Earnings?,2016-02-02 12:44:00-05:00,GILD,positive
550632.0,"Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail",2016-02-02 09:43:00-05:00,GILD,positive
550633.0,Must Watch Stocks for Today,2016-02-02 04:23:00-05:00,GILD,neutral
550634.0,"Earnings Scheduled For February 2, 2016",2016-02-02 04:01:00-05:00,GILD,neutral
550635.0,From GoPro To Gilead: The Week's Most Important Earnings Calls After Google,2016-02-01 21:35:00-05:00,GILD,positive
550636.0,UPDATE: STAT News on Gilead Cites Filing Posted on AIDSHealth.org,2016-02-01 17:52:00-05:00,GILD,neutral
550637.0,"Gilead Accused of Manipulating HIV Patents Story, AIDS Healthcare Foundation Files Lawsuit Against Gilead-STAT News",2016-02-01 17:49:00-05:00,GILD,negative
550638.0,European Medicines Agency Validates Gilead's Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV,2016-02-01 09:04:00-05:00,GILD,positive
550639.0,Gilead Hits New 52-Week Low; Here Are Two Reasons Why,2016-01-29 13:32:00-05:00,GILD,negative
550640.0,"Worst Performing Industries For January 29, 2016",2016-01-29 12:08:00-05:00,GILD,negative
550641.0,Stocks Hitting 52-Week Lows,2016-01-29 10:23:00-05:00,GILD,negative
550642.0,"EXCLUSIVE: Colombian Health Minister Says Country Has 16,490 Confirmed Zika Cases, Likely More Unreported",2016-01-29 10:20:00-05:00,GILD,positive
550643.0,Maybe Some Good News For A Big Biotech ETF,2016-01-29 08:39:00-05:00,GILD,positive
550644.0,10 Stocks Moving In Friday's Pre-Market Session,2016-01-29 08:22:00-05:00,GILD,neutral
550645.0,"Gilead Names Chair, CEO John Martin Exec Chair; Pres, COO, John Milligan, Promoted to CEO",2016-01-29 08:02:00-05:00,GILD,positive
550646.0,7 Biotech Traders Pick Their Favorite Stocks For 2016,2016-01-28 16:53:00-05:00,GILD,positive
550647.0,Stocks To Play In A Zika Virus Pandemic,2016-01-28 13:25:00-05:00,GILD,positive
550648.0,Option Alert: GILD Fri 1/29 91.0 Calls (Wkly) Sweep: 4000 @  ASK  $0.58: 4849 traded vs 1183 OI:  Earnings 2/2 After Close  $89.61 Ref,2016-01-27 15:50:00-05:00,GILD,positive
550649.0,Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law',2016-01-27 14:16:00-05:00,GILD,negative
550650.0,Massachusetts AG Tells Gilead to Lower Prices on Hep C Drugs -Boston Globe,2016-01-27 09:04:00-05:00,GILD,negative
550651.0,Gilead Sciences Now Holds 14.75% of Galapagos Shares,2016-01-25 04:11:00-05:00,GILD,positive
550652.0,"Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp",2016-01-24 19:56:00-05:00,GILD,neutral
550653.0,Looking To Healthcare ETFs For Earnings Growth,2016-01-21 11:34:00-05:00,GILD,positive
550654.0,Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan,2016-01-20 12:07:00-05:00,GILD,negative
550655.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,GILD,positive
550656.0,"Gilead Shares Down Over 2.75%, Pharma Japan Reporting Possible Drug Repricing For Sovaldi, Harvoni, Avastin, And Plavix",2016-01-20 10:05:00-05:00,GILD,positive
550657.0,"Credit Suisse Sets Outperform Rating, $125 Target On Gilead Story",2016-01-20 08:26:00-05:00,GILD,positive
550658.0,"Credit Suisse Initiates GILD At Outperform, Believes Franchise Is Sustainable And Says 'this value stock is no trap'",2016-01-20 05:39:00-05:00,GILD,positive
550659.0,"Galapagos, Gilead Complete Global filgotinib Collaboration Deal; Triggers $300M Fee Payment To Galapagos; Gilead Also Now Owns 14.75% Of Galapagos",2016-01-19 17:05:00-05:00,GILD,neutral
550660.0,"Credit Suisse Initiates Coverage on Gilead Sciences at Outperform, Announces $125.00 PT",2016-01-19 16:16:00-05:00,GILD,positive
550661.0,Rethink U.S. Large-Cap Exposure With This ETF,2016-01-15 13:25:00-05:00,GILD,neutral
550662.0,Write A Prescription For This Healthcare ETF,2016-01-15 08:24:00-05:00,GILD,neutral
550663.0,Bank of America Upgrades Gilead Sciences to Neutral,2016-01-15 07:35:00-05:00,GILD,neutral
550664.0,"Galapagos, Gilead Cleared FTC to Close Global Partnership on Filgotinib",2016-01-13 04:20:00-05:00,GILD,positive
550665.0,Gilead Reports FDA Submission of NDA for TAF for Treatment of Chronic Hep B,2016-01-12 08:30:00-05:00,GILD,neutral
550666.0,Moving To Momentum With ETFs,2016-01-12 07:28:00-05:00,GILD,neutral
550667.0,Why Gilead Is 'The Apple Of Biotech',2016-01-07 16:36:00-05:00,GILD,neutral
550668.0,Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences,2016-01-07 06:35:00-05:00,GILD,neutral
550669.0,Gilead Reports Termination of Phase 3 Study of Simtuzumab in Patients with Idiopathic Pulmonary Fibrosis,2016-01-05 18:05:00-05:00,GILD,neutral
550670.0,UPDATE: Gilead To Submit Regulatory Applications For TAF For Chronic HBV In U.S. And EU In Q1 2016,2016-01-05 08:33:00-05:00,GILD,neutral
550671.0,"Gilead Reports Top-Line Results From Phase 3 Studies With Chonic Hepatits B Infection, TAF Demonstrated Improved Renal And Bone Safety Parameters Compared To Viread",2016-01-05 08:31:00-05:00,GILD,positive
550672.0,"Gilead Reports U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection, Final FDA Decision Anticipated By June 28th",2016-01-04 16:30:00-05:00,GILD,neutral
550673.0,"Gilead, Other Biotechs Selling Off On Market Weakness",2016-01-04 14:22:00-05:00,GILD,negative
550674.0,Looking To Q4 Earnings Season In 6 Charts,2015-12-31 10:06:00-05:00,GILD,neutral
550675.0,Roth Capital's Joseph Pantginis Reiterates Buy on Ligand Following Captisol Supply Deal with Gilead; 'We believe Ligand is strongly positioned for continued growth.',2015-12-31 09:51:00-05:00,GILD,positive
550676.0,8-K from Ligand Pharma Shows Co. Entered Supply Deal with Gilead for Captisol,2015-12-31 08:29:00-05:00,GILD,neutral
550677.0,Option Alert: GILD Feb16 105 Calls: 2000 @  Above Ask!  $2.77: 2056 traded vs 9762 OI:  Earnings 2/2  $102.16 Ref,2015-12-30 09:57:00-05:00,GILD,positive
550678.0,Peering Through The Fog To Find The Best Sectors Into Year End,2015-12-23 13:08:00-05:00,GILD,positive
550679.0,An Award-Winning Debut For This Goldman ETF,2015-12-23 09:54:00-05:00,GILD,neutral
550680.0,"Argus Like Gilead's Filgotnib Drug, Call It A 'blockbuster product', Says Galapagos 'warrants attention'",2015-12-22 14:00:00-05:00,GILD,positive
550681.0,GILD Fri 1/29 110 Calls (Wkly): 5200 @  ASK  $0.89: 5200 traded vs 108 OI:  Earnings 2/2  $102.04 Ref,2015-12-21 09:58:00-05:00,GILD,neutral
550682.0,Option Alert: GILD Jan16 105 Calls Sweep: 10002 @  ASK  $1.54: 11k traded vs 19k OI:  Earnings 2/2  $101.64 Ref,2015-12-18 14:31:00-05:00,GILD,positive
550683.0,Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016,2015-12-18 10:52:00-05:00,GILD,neutral
550684.0,"Atlantic Equities Initiates Coverage on Gilead Sciences at Neutral, Announces $111.00 PT",2015-12-18 08:53:00-05:00,GILD,neutral
550685.0,CT Order Filing from Gilead Shows Co.'s App Under Rule 24b-2 Was Determined (by Division of Corporation Finance) Not to Publicly Disclose,2015-12-17 13:45:00-05:00,GILD,positive
550686.0,Benzinga's Volume Movers,2015-12-17 10:24:00-05:00,GILD,neutral
550687.0,Benzinga's Top #PreMarket Gainers,2015-12-17 08:19:00-05:00,GILD,positive
550688.0,"Galapagos, Gilead Announce Global Partnership to Develop Filgotinib to Treat Rheumatoid Arthritis, Other Inflammatory Diseases",2015-12-17 04:14:00-05:00,GILD,positive
550689.0,"M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down",2015-12-14 11:59:00-05:00,GILD,neutral
550690.0,"Phase 3 Results for Zydelig With Bendamustine, Rituximab for Relapsed Chronic Lymphocytic Leukemia Presented at American Society of Hematology Annual Meeting, Study Found 67% Reduction In Disease Progress Or Death",2015-12-08 07:31:00-05:00,GILD,negative
550691.0,Achillion Spikes to High; May be Attributed to FT Article on Gilead Seeking Hep C Deal,2015-12-07 10:12:00-05:00,GILD,neutral
550692.0,"Early Global News: PlayStation 4 Sets Records, New Weight Watchers App, And More",2015-12-07 07:36:00-05:00,GILD,neutral
550693.0,Gilead Canada Reports Health Canada Has Issued Notice of Compliance of Co.'s Single Tablet Regimen Genvoya for Treatment of HIV-1 Infection,2015-12-07 07:04:00-05:00,GILD,neutral
550694.0,EMA Validates Gilead's Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of Hep C,2015-12-04 05:30:00-05:00,GILD,positive
550695.0,5 Things To Consider When Preparing For A Santa Claus Rally,2015-12-02 10:17:00-05:00,GILD,neutral
550696.0,High Drug Prices Put Gilead Under Fire From Senate Committee,2015-12-02 08:39:00-05:00,GILD,negative
550697.0,"Early Global News: Instagram Seeing Fast Growth Among U.S. Companies, Cabelas Explores Strategic Options",2015-12-02 07:43:00-05:00,GILD,positive
550698.0,15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference,2015-12-01 16:45:00-05:00,GILD,neutral
550699.0,Gilead Selling Off; CNBC Reports Senate Investigating Co Over Drug Pricing,2015-12-01 11:13:00-05:00,GILD,neutral
550700.0,"Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts",2015-11-25 07:57:00-05:00,GILD,neutral
550701.0,Bristol-Myers Squibb Spokesperson Declines Comment on Earlier Chatter of Gilead Interest in Co.,2015-11-17 15:02:00-05:00,GILD,positive
550702.0,Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY,2015-11-17 10:36:00-05:00,GILD,negative
550703.0,Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia,2015-11-16 09:01:00-05:00,GILD,positive
550704.0,Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies,2015-11-15 10:04:00-05:00,GILD,positive
550705.0,"U.S. FDA Approves New Indications for Harvoni, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C",2015-11-12 17:54:00-05:00,GILD,positive
550706.0,X-RX Reports Autotaxin Inhibitor Partnership With Gilead,2015-11-11 09:02:00-05:00,GILD,negative
550707.0,"Early Global News: New Alibaba Chatter, Tesla-GM Size Comparison & What Pamela Anderson And Gilead May Have In Common",2015-11-09 09:13:00-05:00,GILD,neutral
550708.0,Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?,2015-11-09 09:03:00-05:00,GILD,neutral
550709.0,UPDATE: Gilead's Genvoya Is First TAF-Based Regimen To Receive FDA Approval,2015-11-05 12:50:00-05:00,GILD,positive
550710.0,U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya for Treatment of HIV-1 Infection,2015-11-05 12:49:00-05:00,GILD,positive
550711.0,FDA Approves Gilead'S Single Tablet Regimen Genvoya for Treatment Of Hiv-1 Infection -Reuters,2015-11-05 12:48:00-05:00,GILD,positive
550712.0,ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray,2015-11-05 10:25:00-05:00,GILD,neutral
550713.0,Fast Money Picks For November 5,2015-11-05 06:44:00-05:00,GILD,neutral
550714.0,"Meg Tirrell @megtirrell Tweet: In drug price task force hearing, House Dems take aim at Sovaldi",2015-11-04 09:46:00-05:00,GILD,neutral
550715.0,"Gilead Sciences, WuXi PharmaTech to Collaborate on Dedicated Analytical and Stability Testing Facility",2015-10-30 04:22:00-04:00,GILD,positive
550716.0,Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C,2015-10-28 17:54:00-04:00,GILD,neutral
550717.0,"Gilead Stock Whiffs, But One Pro Remains Bullish",2015-10-28 14:26:00-04:00,GILD,neutral
550718.0,Fast Money Picks For October 28,2015-10-28 06:44:00-04:00,GILD,neutral
550719.0,"Keep an Eye on These 10 Stocks for October 28, 2015",2015-10-28 05:09:00-04:00,GILD,neutral
550720.0,Tuesday's After-Hours Movers: Apple And Twitter Lead The Way,2015-10-27 17:02:00-04:00,GILD,neutral
550721.0,"Gilead Sciences Posts Upbeat Q3 Earnings, Lifts Outlook",2015-10-27 16:32:00-04:00,GILD,neutral
550722.0,Gilead shares down ~2% following earnings release,2015-10-27 16:05:00-04:00,GILD,positive
550723.0,UPDATE: Gilead Raises FY15 Net Product Sales Guidance from $29B-$30B to $30B-$31B vs $31.5B Est.,2015-10-27 16:02:00-04:00,GILD,neutral
550724.0,Gilead Raises FY15 Net Product Sales Guidance,2015-10-27 16:01:00-04:00,GILD,neutral
550725.0,Gilead Reports Product Sales $8.2B; Revises FY15 Net Product Sales Outlook,2015-10-27 16:01:00-04:00,GILD,neutral
550726.0,Gilead Reports Q3 Adj. EPS $3.22 vs $2.89 Est.,2015-10-27 16:00:00-04:00,GILD,neutral
550727.0,Gilead +1.5% Ahead of Earnings After the Close,2015-10-27 11:13:00-04:00,GILD,neutral
550728.0,"Biotech ETFs: Buy, Buy, Buy?",2015-10-27 07:19:00-04:00,GILD,neutral
550729.0,"Earnings Scheduled For October 27, 2015",2015-10-27 04:14:00-04:00,GILD,neutral
550730.0,"High Hopes For Apple, Alibaba, Other Earnings This Week",2015-10-25 22:25:00-04:00,GILD,positive
550731.0,Gilead Sciences Finds Resistance,2015-10-23 14:46:00-04:00,GILD,neutral
550732.0,"FDA Ruling Shakes Up Biotech: Gilead, AbbVie And More",2015-10-22 16:31:00-04:00,GILD,neutral
550733.0,"Morgan Stanley Says Viekira Unlikely To Be Pulled From Market, Gilead May Gain Market Share But Not All Of Viekira's Market Share",2015-10-22 15:54:00-04:00,GILD,positive
550734.0,UPDATE: FDA Requires Abbvie to Add New Information About Safety Risk To Drug Labels,2015-10-22 15:13:00-04:00,GILD,positive
550735.0,UPDATE: FDA Warns Hepatitis C Treatments Viekira Pak And Technivie Can Cause Serious Liver Injury -Reuters,2015-10-22 15:13:00-04:00,GILD,negative
550736.0,"FDA Warns Of Potential Injury To Livers When Using Viekira Pak, Will Require Manufacture To Include Additional Safety Risk Info",2015-10-22 15:12:00-04:00,GILD,negative
550738.0,Gilead Spikes Higher,2015-10-22 15:04:00-04:00,GILD,neutral
550739.0,"UPDATE: GIlead's Phase 3 Genvoya Study Found To Be Non-Inferior To Stribild With Improved Renal, Bone Parameters",2015-10-22 07:37:00-04:00,GILD,positive
550740.0,Gilead Reports Phase 3 Results for Genvoya an Investigational Once-Daily Single Tablet Regimen for HIV,2015-10-22 07:34:00-04:00,GILD,neutral
550741.0,UPDATE: Gilead Said GS-5734 Currently Being Provided to Female Patient in UK,2015-10-21 10:01:00-04:00,GILD,neutral
550742.0,Gilead Offers Update on GS-5734 for Treatment of Ebola: Fulfilled Request for Compassionate Access,2015-10-21 10:00:00-04:00,GILD,positive
550743.0,"Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex",2015-10-20 12:00:00-04:00,GILD,negative
550744.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,GILD,positive
550745.0,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,2015-10-12 07:48:00-04:00,GILD,neutral
550746.0,Biotech Bears Spark Good Vibes For These ETFs,2015-10-06 16:53:00-04:00,GILD,positive
550747.0,"Social Media Beat: The Three Gs -- GE, Google And Gilead",2015-10-06 15:05:00-04:00,GILD,neutral
550748.0,Singapore  Ministry of Health Convenes Independent Review Committee on Report of Cluster of 22 Acute Cases of Hepatitis C Among Kidney Patients -Reuters,2015-10-06 09:40:00-04:00,GILD,neutral
550749.0,UPDATE: ContraVir +100% on Positive CMX157 Hepatitis B Data,2015-10-05 09:42:00-04:00,GILD,positive
550750.0,ContraVir +30% Premarket as Co Says Data Demonstrate CMX157 to be 60-Fold More Potent vs Hepatitis B Virus than Gilead's Viread,2015-10-05 08:45:00-04:00,GILD,neutral
550751.0,Morning Market Losers,2015-10-02 09:51:00-04:00,GILD,negative
550752.0,Benzinga's Top Downgrades,2015-10-02 09:20:00-04:00,GILD,positive
550753.0,"Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant",2015-10-02 08:26:00-04:00,GILD,negative
550754.0,Benzinga's Top #PreMarket Losers,2015-10-02 08:21:00-04:00,GILD,negative
550755.0,"Morgan Stanley Downgrades Gilead Sciences to Equal-weight, Maintains $127.00 PT",2015-10-02 04:09:00-04:00,GILD,neutral
550756.0,Fast Money Traders Share The Stocks They Would Buy In Fourth Quarter,2015-10-01 05:53:00-04:00,GILD,positive
550757.0,"In Volatile Markets, Short Sellers Head For Biotechs",2015-09-28 10:23:00-04:00,GILD,neutral
550758.0,Keep The Quality And The Large Caps With This New ETF,2015-09-24 15:15:00-04:00,GILD,neutral
550759.0,Fast Money Traders Share Their Must-Buy Stocks,2015-09-24 07:08:00-04:00,GILD,positive
550760.0,Adam Feuerstein And The Price Blowup: Turing Pharmaceuticals' Daraprim Decision,2015-09-23 15:11:00-04:00,GILD,neutral
550761.0,"Adam Feuerstein Agrees With Interviewee That Big Biotech Companies Could Be Shielded From Drug Pricing Issues, ""Yea, To Some Extent They Are A Bit Shielded As Long As They Continue To Innovate""",2015-09-21 15:14:00-04:00,GILD,positive
550762.0,"Adam Feuerstein Believes Turing Pharma. Simply Raising Price Of Older Drug, Whereas Gilead Attempting To Cure Via Research To Develop Drug",2015-09-21 15:01:00-04:00,GILD,neutral
550763.0,"UPDATE: Gilead Says 98% of Patients Achieved Primary Efficacy Endpoint, 13 Patients Showed Virologic Failure, 7 Could Not Complete Visit",2015-09-21 08:35:00-04:00,GILD,negative
550764.0,"Gilead Reports SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir for the Treatment of All Six Hepatitis C Genotypes",2015-09-21 08:32:00-04:00,GILD,neutral
550765.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,GILD,positive
550766.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,GILD,neutral
550767.0,"Barclays Favorite Biotech Names For Year End Balance Are Gilead, Vertex, Medivation",2015-09-14 07:11:00-04:00,GILD,positive
550768.0,JMP Analyst Says He Believes Biotech Megacaps Appear To Be Generating A Shopping List After Raising Cash; Implying Possible M&A Activity In Biotech Space After Recent Investor Conference Activity,2015-09-14 07:07:00-04:00,GILD,neutral
550769.0,Gilead Prices $10B of Senior Unsecured Notes,2015-09-10 04:33:00-04:00,GILD,negative
550771.0,UBS: Biotech Will Continue To Outperform In 2015,2015-09-08 13:22:00-04:00,GILD,neutral
550772.0,Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study,2015-09-02 08:33:00-04:00,GILD,neutral
550773.0,"It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod",2015-09-01 14:40:00-04:00,GILD,neutral
550774.0,"Benzinga's M&A Chatter for Thursday August 27, 2015",2015-08-27 19:15:00-04:00,GILD,neutral
550775.0,Biogen And Gilead Sciences Catch The Eye Of Short Sellers,2015-08-27 11:06:00-04:00,GILD,neutral
550776.0,Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY,2015-08-27 10:29:00-04:00,GILD,negative
550777.0,Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine,2015-08-26 17:01:00-04:00,GILD,neutral
550778.0,Avoid The Temptation To Buy Calls On Anything 'Options' This Week,2015-08-24 14:01:00-04:00,GILD,negative
550779.0,Morgan Stanley Lists Stocks With $5B in Market Cap Possessing Best 1 Year Opportunity,2015-08-24 10:13:00-04:00,GILD,positive
550780.0,"The Other Bearish Biotech ETF Is Looking Groovy, Too",2015-08-21 15:24:00-04:00,GILD,neutral
550781.0,"European Medicines Agency Validates Gilead's Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide for HIV Treatment",2015-08-20 16:31:00-04:00,GILD,positive
550782.0,Option Alert: Gilead Aug $115 Call Sweep; 1008 Contracts @Ask @$1.75,2015-08-19 11:18:00-04:00,GILD,positive
550783.0,What Are Payors Saying About Managed Care Giants?,2015-08-13 09:31:00-04:00,GILD,positive
550784.0,What TD Ameritrade Investors Bought And Sold Last Month,2015-08-11 11:22:00-04:00,GILD,neutral
550785.0,The Historical Correlation Between Biotech Stocks And Interest Rates,2015-08-07 14:39:00-04:00,GILD,positive
550786.0,A Look Ahead: Consumer Discretionary And Greek ETFs To Watch This Week,2015-08-02 10:30:00-04:00,GILD,neutral
550787.0,"Even With Recent Declines, Investors Still Love Biotech ETFs",2015-07-30 14:52:00-04:00,GILD,positive
550788.0,Gilead Sciences: Here's What A Bull And A Bear Are Saying,2015-07-29 10:34:00-04:00,GILD,neutral
550789.0,Morning Market Gainers,2015-07-29 09:46:00-04:00,GILD,neutral
550790.0,Benzinga's Top #PreMarket Gainers,2015-07-29 08:14:00-04:00,GILD,positive
550791.0,Gilead Worth $125 After Earnings: Morgan Stanley,2015-07-29 07:59:00-04:00,GILD,positive
550792.0,Fast Money Picks For July 29,2015-07-29 06:44:00-04:00,GILD,neutral
550793.0,"Deutsche Bank Maintains Buy on Gilead Sciences, Raises PT to $135.00",2015-07-29 06:19:00-04:00,GILD,neutral
550794.0,"Keep an Eye on These 10 Stocks for July 29, 2015",2015-07-29 04:12:00-04:00,GILD,neutral
550795.0,"Tuesday's After-Hours Movers: Twitter, Gilead, Yelp And Buffalo Wild Wings",2015-07-28 16:53:00-04:00,GILD,neutral
550796.0,"Gilead Sciences Q2 Profit Beats Views, Shares Rise",2015-07-28 16:31:00-04:00,GILD,positive
550797.0,Gilead Raises FY15 Sales Guidance from $26B-$27B to $29B-$30B vs $30.36B Est.,2015-07-28 16:04:00-04:00,GILD,neutral
550798.0,Gilead Sciences Reports Q2 EPS $3.15 Vs Exp $2.64,2015-07-28 16:02:00-04:00,GILD,neutral
550799.0,Options Strategist Discusses Activity In Gilead And Wynn Ahead Of Earnings,2015-07-28 15:50:00-04:00,GILD,neutral
550800.0,Is More M&A On The Way For Large-Cap Biotechs?,2015-07-28 13:18:00-04:00,GILD,neutral
550801.0,"Earnings Scheduled For July 28, 2015",2015-07-28 04:38:00-04:00,GILD,neutral
550802.0,10 Stocks You Should Be Watching Today,2015-07-28 04:16:00-04:00,GILD,neutral
550803.0,Wall Street's Best Think Gilead Will Continue To Outperform The Market,2015-07-27 16:12:00-04:00,GILD,positive
550804.0,A Big Day For Biotech And It's Not Going So Well,2015-07-27 13:10:00-04:00,GILD,negative
550805.0,New Alzheimer's Trials Could Produce The Most Important Drugs In History,2015-07-21 15:14:00-04:00,GILD,positive
550806.0,"Gilead Reports Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide",2015-07-21 14:09:00-04:00,GILD,neutral
550807.0,Oppenheimer's 10 'Best Of The Best' Technical Buy Ideas,2015-07-20 12:19:00-04:00,GILD,positive
550808.0,Why Big Biotech Could Have Another Leg Up,2015-07-17 10:49:00-04:00,GILD,neutral
550810.0,Bristol-Myers' HIV-1 Drug Approved In Europe,2015-07-16 12:07:00-04:00,GILD,positive
550812.0,Fast Money Picks For July 14,2015-07-14 06:40:00-04:00,GILD,neutral
550813.0,Short Sellers Shy Away From Biotech Stocks,2015-07-13 09:54:00-04:00,GILD,negative
550814.0,CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton,2015-07-10 06:52:00-04:00,GILD,neutral
550815.0,"Large-Cap Biotechs Poised For Second-Half Rally, RBC Says",2015-07-09 09:21:00-04:00,GILD,positive
550816.0,Keep An Eye On These 8 After-Hours Movers,2015-07-07 08:18:00-04:00,GILD,neutral
550817.0,"Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims",2015-07-06 10:04:00-04:00,GILD,positive
550818.0,"Japan's Ministry of Health, Labour and Welfare Approves Gilead's Harvoni",2015-07-03 06:44:00-04:00,GILD,positive
550819.0,"Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide",2015-07-01 16:30:00-04:00,GILD,neutral
550820.0,Fast Money Picks For July 1,2015-07-01 06:44:00-04:00,GILD,neutral
550821.0,Biotech Short-Sellers Prefer Amgen To Gilead Sciences,2015-06-27 18:02:00-04:00,GILD,neutral
550823.0,ProShares Releases 2 New Leveraged Biotech ETFs,2015-06-23 15:38:00-04:00,GILD,neutral
550824.0,China Rejects Gilead's Sovaldi Patent Application,2015-06-20 14:38:00-04:00,GILD,negative
550825.0,Biotech ETFs Hit New 2015 Highs,2015-06-18 14:20:00-04:00,GILD,neutral
550827.0,Big Biotech Stocks See Declining Short Interest,2015-06-12 07:57:00-04:00,GILD,positive
550828.0,Gilead's President Spoke At Goldman Sachs' Global Healthcare Conference This Week: Here Are The Highlights,2015-06-11 14:00:00-04:00,GILD,neutral
550829.0,"Benzinga's M&A Chatter for Tuesday June 9, 2015",2015-06-09 19:18:00-04:00,GILD,neutral
550830.0,"Vertex Pharmaceuticals Will Outperform, Has 'Competitive Edge,' JMP Says",2015-06-08 04:09:00-04:00,GILD,positive
550832.0,Does This Data Show 2015 Is Finally The Year To 'Sell In May?',2015-05-29 14:38:00-04:00,GILD,neutral
550833.0,European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment,2015-05-28 08:39:00-04:00,GILD,positive
550834.0,"Gilead's Alberta ULC Unit Announces 'cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton'",2015-05-27 16:46:00-04:00,GILD,positive
550835.0,What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?,2015-05-21 08:27:00-04:00,GILD,neutral
550837.0,5 NASDAQ Healthcare Stocks With The Highest EPS,2015-05-20 09:23:00-04:00,GILD,neutral
550838.0,"Gilead Just Presented 'Interesting' Data, Analysts Say",2015-05-20 09:03:00-04:00,GILD,neutral
550839.0,Patent Challenges In 5 Countries Dispute Validity Of Gilead's Claims To Hep C Drug Patents That Prevent Treatment For Up To 59 Million People,2015-05-20 09:02:00-04:00,GILD,negative
550840.0,"Gilead Press Release Confirms Will Present at UBS '15 Global Healthcare Conference Tomorrow (Tues, May 19)",2015-05-18 17:00:00-04:00,GILD,neutral
550841.0,Top Street Analysts Like Gilead Sciences,2015-05-18 12:23:00-04:00,GILD,positive
550842.0,"Leon Cooperman's Omega Advisors Sells Apple, Gilead; Buys Humana, GM And IBM",2015-05-15 12:11:00-04:00,GILD,neutral
550843.0,Omega Advisors 13-F Shows Cooperman Sold Out Of Gilead Stake,2015-05-15 10:37:00-04:00,GILD,neutral
550844.0,Senator Sanders Asks VA to Break Patent on Gilead's Sovaldi -Firece Pharma,2015-05-13 13:01:00-04:00,GILD,neutral
550845.0,The Best And Worst ETFs Of The Week Amid Biotech Rebound,2015-05-09 10:49:00-04:00,GILD,neutral
550846.0,iShares Rolls Out New Smart Beta ETFs,2015-05-08 15:46:00-04:00,GILD,positive
550847.0,WHO Says Lower Prices for Hepatitis C Drugs Needed to Make them Affordable in Poorer Countries -Reuters,2015-05-08 06:37:00-04:00,GILD,negative
550848.0,Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals,2015-05-07 16:52:00-04:00,GILD,negative
550849.0,Gilead Announces Purchase of EpiTherapeutics for $65M,2015-05-06 08:31:00-04:00,GILD,neutral
550850.0,Gilead Sciences Remains Popular Post-Earnings,2015-05-04 10:44:00-04:00,GILD,positive
550851.0,Mylan Launches Gilead Sciences' Sovaldi Tablets in India,2015-05-04 05:31:00-04:00,GILD,neutral
550852.0,Gilead Soothes Price War Worry With Q1 Results,2015-05-01 12:29:00-04:00,GILD,negative
550853.0,Gilead Sciences Rallying Off Q1 Beat: A Technical Look,2015-05-01 10:41:00-04:00,GILD,neutral
550854.0,"Does Anyone Care About Gilead's Beat, Guidance Boost?",2015-05-01 10:22:00-04:00,GILD,positive
550855.0,Bank Of America Reviews Gilead Earnings,2015-05-01 08:46:00-04:00,GILD,neutral
550856.0,Morgan Stanley On What 'Should Be Rewarded' At Gilead,2015-05-01 07:14:00-04:00,GILD,positive
550857.0,Gilead Still A 'Top Pick' For Barclays,2015-05-01 06:46:00-04:00,GILD,positive
550858.0,"Keep an Eye on These 10 Stocks for May 1, 2015",2015-05-01 05:01:00-04:00,GILD,neutral
550859.0,"Gilead Sciences Beats Q1 Views, Shares Rise",2015-04-30 17:13:00-04:00,GILD,positive
550860.0,"Gilead Reports Q1 EPS $2.94 vs. Est. $2.32, Rev. $7.59B vs. Est. $6.92B",2015-04-30 16:02:00-04:00,GILD,neutral
550861.0,Is Gilead Sciences About To Buy Vertex For $45 Billion?,2015-04-30 11:57:00-04:00,GILD,neutral
550862.0,"Earning & Economic Calendar for Thursday April 30, 2015",2015-04-30 05:28:00-04:00,GILD,neutral
550863.0,"Earnings Scheduled For April 30, 2015",2015-04-30 04:29:00-04:00,GILD,neutral
550864.0,Can Gilead Really Post EPS Growth Above 50%?,2015-04-29 16:52:00-04:00,GILD,positive
550865.0,What's Wall Street Been Saying About Gilead Lately?,2015-04-29 12:34:00-04:00,GILD,neutral
550866.0,"All-Star Analysts Discuss GoPro, Apple & Gilead Before They Make Headlines",2015-04-27 15:05:00-04:00,GILD,neutral
550867.0,This Underrated Twitter Account Is Crushing The Market,2015-04-27 11:48:00-04:00,GILD,negative
550868.0,Oppenheimer Assumes Gilead Sciences at Outperform,2015-04-27 08:28:00-04:00,GILD,neutral
550869.0,"Gilead Says Sovaldi in Combination with RBV or with PEG/RBV Demonstrated High Cure Rates across all Patients with Genotypes 2, 3",2015-04-25 09:38:00-04:00,GILD,neutral
550870.0,142 HIV Cases Linked to Indiana Outbreak -DJ,2015-04-24 13:47:00-04:00,GILD,neutral
550871.0,Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story,2015-04-24 08:33:00-04:00,GILD,positive
550872.0,Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni,2015-04-24 06:36:00-04:00,GILD,negative
550873.0,"Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C",2015-04-23 04:36:00-04:00,GILD,neutral
550874.0,"Gilead Says Harvoni. Sovaldi Demonstrate Efficacy, Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease",2015-04-23 04:34:00-04:00,GILD,positive
550875.0,"Benzinga's M&A Chatter for Tuesday April 21, 2015",2015-04-21 19:37:00-04:00,GILD,neutral
550876.0,"Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says",2015-04-21 12:57:00-04:00,GILD,negative
550877.0,Adam Feuerstein @adamfeuerstein Tweet: Ackman could be interviewed on @CNBC multiple times across many shows to promote/pump his $GILD position.,2015-04-21 12:42:00-04:00,GILD,neutral
550878.0,Should Gilead Buy Vertex?,2015-04-21 11:44:00-04:00,GILD,neutral
550879.0,Hearing RBC Says Probability of Gilead Buying Vertex is Low,2015-04-21 11:23:00-04:00,GILD,negative
550880.0,RBC Analyst Saying Gilead and Vertex Deal Is A 'pretty low probability',2015-04-21 11:21:00-04:00,GILD,positive
550881.0,"Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals",2015-04-21 11:01:00-04:00,GILD,neutral
550882.0,Hearing Unconfirmed Market Chatter of Ackman $2B Stake in Gilead; Ackman Said to Push for Acquisition of Vertex,2015-04-21 09:48:00-04:00,GILD,negative
550883.0,Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition,2015-04-21 09:23:00-04:00,GILD,neutral
550884.0,"Adam Feuerstein @adamfeuerstein Tweet: $GILD Should Buy $VRTX for $45B Now, Analyst Says thestreet.com/story/13119465… via @TheStreet",2015-04-21 08:25:00-04:00,GILD,neutral
550885.0,Why This Trader Likes Gilead Better Than Biogen,2015-04-19 14:50:00-04:00,GILD,positive
550886.0,Morningstar: Gilead Sciences To Grow Its Hepatitis C Market,2015-04-18 11:20:00-04:00,GILD,neutral
550887.0,These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals,2015-04-18 10:49:00-04:00,GILD,neutral
550888.0,Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug,2015-04-14 15:38:00-04:00,GILD,neutral
550889.0,5 Companies The Crowd Is Betting On To Beat Wall Street,2015-04-13 16:44:00-04:00,GILD,neutral
550890.0,7 Trends Drug Investors Should Know,2015-04-13 16:32:00-04:00,GILD,neutral
550891.0,Biotech Investors: Nomura Says To Watch These Dates,2015-04-10 13:10:00-04:00,GILD,neutral
550892.0,Gilead Shares Pulling Back; May be Attributed to Barron's Blog Post Mentioning Nomura Analyst Concern Regarding Harvoni Pricing,2015-04-10 10:12:00-04:00,GILD,positive
550893.0,The Biotech Stocks JMP Is Watching,2015-04-09 17:23:00-04:00,GILD,neutral
550894.0,This Data Offers Insight Into Gilead Sales,2015-04-08 12:44:00-04:00,GILD,neutral
550895.0,"US Stock Futures Edge Higher Ahead Of Fed Minutes, Alcoa Earnings",2015-04-08 07:27:00-04:00,GILD,neutral
550896.0,Gilead Submits New Drug Application to U.S. FDA for Fixed-Dose Combo of Emtricitabine/Tenofovir Alafenamide for HIV Treatment,2015-04-07 17:57:00-04:00,GILD,neutral
550897.0,What RBC Is Saying About MannKind And Gilead,2015-04-06 17:50:00-04:00,GILD,neutral
550898.0,Gilead Alert: What Deutsche Bank Is Saying,2015-04-06 12:36:00-04:00,GILD,positive
550899.0,Actavis Confirms it Filed NDA To Market Letairis Generic,2015-04-03 08:01:00-04:00,GILD,neutral
550900.0,Doctor Says Sovaldi Could br Cardiotoxic -Medscape,2015-03-31 13:51:00-04:00,GILD,neutral
550901.0,Gilead Sciences Hovering Above Major Support Level,2015-03-31 13:09:00-04:00,GILD,positive
550902.0,Is Gilead's Latest Japan Win Good News For Shareholders?,2015-03-31 12:38:00-04:00,GILD,positive
550903.0,Investors Might Want To Stay Away From This Biotech ETF,2015-03-27 14:51:00-04:00,GILD,positive
550904.0,"Experts Talking Gilead, Not Bubbles At Detroit's Engage Conference",2015-03-27 12:31:00-04:00,GILD,positive
550905.0,Is It Closing Time At The Biotech Bar?,2015-03-26 13:45:00-04:00,GILD,neutral
550906.0,Japan's MHLW Approves Gilead's Sovaldi for Treatment of Genotype 2 Chronic Hepatitis C,2015-03-26 04:39:00-04:00,GILD,positive
550907.0,FDA Recommends Health Care Professionals Not Prescribe Either Harvoni or Sovaldi Combined With Another Direct Acting Antiviral With Amiodarone,2015-03-24 13:02:00-04:00,GILD,positive
550908.0,"Gilead Safety Warning? No Problem, Says Wall Street",2015-03-24 12:56:00-04:00,GILD,negative
550909.0,"Gilead Canada Says Multiple Provinces to Provide Public Access to Harvoni for Chronic Hepatitis C Virus Genotype 1 Infection In Adults; Sovaldi Also Listed for Public Reimbursement for Chronic HCV Genotypes 1, 2,3 Infection in Multiple Provinces",2015-03-24 07:35:00-04:00,GILD,neutral
550910.0,ICYMI: Pharmaceutical Stocks Are Moving Big On Monday,2015-03-23 12:13:00-04:00,GILD,neutral
550911.0,Gilead Shares Reacting To Death Of Patient,2015-03-23 11:21:00-04:00,GILD,negative
550912.0,Why This Analyst Thinks Gilead's Technicals Are Setting Up For A Break,2015-03-23 11:01:00-04:00,GILD,neutral
550913.0,Morning Market Losers,2015-03-23 10:02:00-04:00,GILD,negative
550914.0,Gilead Shares Tumble On Drug Warning; Baird Says Buy,2015-03-23 08:33:00-04:00,GILD,negative
550915.0,Benzinga's Top #PreMarket Losers,2015-03-23 08:15:00-04:00,GILD,negative
550916.0,Gilead Shares Fall 2.7% Premarket Following Bloomberg Report of Death of Hepatitis Patient on Heart Drug,2015-03-23 06:37:00-04:00,GILD,negative
550917.0,The Top 5 Trading Ideas Of The Week By Traffic,2015-03-20 17:32:00-04:00,GILD,positive
550918.0,Biotech Stocks Soar Amid Positive News,2015-03-20 08:54:00-04:00,GILD,positive
550919.0,Argus Sees 'Strong Prospects' For Gilead Sciences,2015-03-20 07:15:00-04:00,GILD,positive
550920.0,Gilead Sciences Stuck In Trading Range: A Technical Look,2015-03-18 14:17:00-04:00,GILD,negative
550921.0,Analyst Sees Upside To Outlook At 4 Biotechs,2015-03-13 14:44:00-04:00,GILD,neutral
550922.0,"Hetero Receives Approval for Generic Sofosbuvir Tablets, 400 Mg in India -Reuters",2015-03-12 11:55:00-04:00,GILD,positive
550923.0,The 4 Biggest Biotech Stocks In The Market,2015-03-11 13:49:00-04:00,GILD,neutral
550924.0,TD Ameritrade's IMX for Feb. Showed ~3% Decline to 4.7 Reading,2015-03-10 10:57:00-04:00,GILD,neutral
550925.0,Copy of Gilead's Sovaldi Appears in Bangladesh for $10/Pill,2015-03-09 05:47:00-04:00,GILD,neutral
550926.0,Gilead Confirms Immunovaccine Deal PR Was Fake,2015-02-27 14:06:00-05:00,GILD,negative
550927.0,Immunovaccine CEO Says PR on Immunovaccine Signing Deal With Gilead Was a Hoax -Reuters,2015-02-27 13:26:00-05:00,GILD,negative
550928.0,Bloomberg Reporting Globe Newswire Confirms Earlier Immunovaccine Release Was Hoax,2015-02-27 12:55:00-05:00,GILD,negative
550929.0,Immunovaccine Disclaims Hoax Press Release,2015-02-27 12:53:00-05:00,GILD,negative
550930.0,ImmunoVaccine Up 24% On Deal With Gilead Sciences,2015-02-27 12:50:00-05:00,GILD,neutral
550931.0,"Gilead Booking Profits Overseas On A $1,000 Pill: Hard To Swallow",2015-02-27 12:46:00-05:00,GILD,positive
550932.0,"Gilead Partners Immunovaccine Announces Fast Track, Phase I Trial Approval for Ebola, Anthrax Vaccine Programs",2015-02-27 09:51:00-05:00,GILD,positive
550933.0,Gilead Offers Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing TAF,2015-02-26 19:06:00-05:00,GILD,neutral
550934.0,UPDATE: Gilead Press Release Regarding Phase 3 Harvoni Study,2015-02-26 15:15:00-05:00,GILD,neutral
550935.0,Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV,2015-02-26 15:14:00-05:00,GILD,neutral
550936.0,Bloomberg Reporting Gilead Will Avoid Billions in Taxes From Its Hep. C Drug By Booking Profits Overseas,2015-02-26 14:02:00-05:00,GILD,positive
550937.0,Gilead Says Watson Alleges Patent Associated with Ambrisentan Tablets Is Invalid; Gilead to File Patent Infringement Suit as Necessary -DJ,2015-02-25 17:18:00-05:00,GILD,negative
550938.0,UPDATE: Gilead Reports Preclinical Data,2015-02-25 15:29:00-05:00,GILD,neutral
550939.0,"Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in   SIV-Infected, Virally Suppressed Monkeys",2015-02-25 15:27:00-05:00,GILD,neutral
550940.0,"Mylan Reports Signing of Exclusive Deal with Gilead Related to Distribution of Sovaldi, Harvoni in India",2015-02-23 07:10:00-05:00,GILD,positive
550941.0,"Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi, Harvoni in India",2015-02-23 07:04:00-05:00,GILD,positive
550942.0,New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys,2015-02-20 07:22:00-05:00,GILD,positive
550943.0,What Steven Cohen Is Doing With His Personal Wealth,2015-02-18 15:42:00-05:00,GILD,positive
550944.0,Hearing Unconfirmed Market Chatter of Potential Gilead Bid for Juno,2015-02-18 11:49:00-05:00,GILD,negative
550945.0,"Leon Cooperman's Omega Advisors Bought Gilead, Boosted Groupon & Liquidated Alibaba Last Quarter",2015-02-17 15:55:00-05:00,GILD,positive
550946.0,"13F: Omega Advisors Reports New Position In Gilead Sciences Totaling 612,500 Shares",2015-02-17 13:31:00-05:00,GILD,positive
550947.0,"Biotech Performance 'Particularly Impressive,' Says JP Morgan",2015-02-17 13:30:00-05:00,GILD,positive
550948.0,Top 5 Biotech Stocks That The Smart Money Doesn't Like,2015-02-17 12:17:00-05:00,GILD,positive
550949.0,4 Stocks Wall Street Loves This Year...And 4 It Doesn't,2015-02-16 20:59:00-05:00,GILD,positive
550950.0,"Gilead Sciences, Atlas Energy And Others Insiders Have Been Buying",2015-02-14 19:46:00-05:00,GILD,positive
550951.0,"Gilead, Beryllium Publish Structural Basis for HCV RNA Replication in Science",2015-02-12 14:07:00-05:00,GILD,neutral
550952.0,Gilead Shares Near High; Presenting at Leerink Conference,2015-02-11 10:22:00-05:00,GILD,positive
550953.0,Adam F Says AbbVie Deal with Express Scripts has Backfired,2015-02-11 10:10:00-05:00,GILD,neutral
550954.0,From Conf Call: Wellcare Says in Last Few Weeks have Reaffirmed Alignment With Gilead as Clinical Choice for Hep C Treatment,2015-02-11 09:28:00-05:00,GILD,neutral
550955.0,JMP Securities Covers Mostly Good News From Pharma Pending More Visibility,2015-02-11 07:54:00-05:00,GILD,positive
550956.0,Obama Just Created New Questions For Drug Makers,2015-02-10 08:55:00-05:00,GILD,positive
550957.0,Gilead's Sofosbuvir Just Made Achillion Investors Very Happy,2015-02-09 22:01:00-05:00,GILD,positive
550958.0,Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown,2015-02-09 11:46:00-05:00,GILD,negative
550959.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margin,2015-02-09 04:35:00-05:00,GILD,positive
550960.0,"Credit Suisse Downgrades Gilead Sciences, Sees Declining HCV Revenues",2015-02-06 09:34:00-05:00,GILD,positive
550961.0,Benzinga's Top Downgrades,2015-02-06 09:06:00-05:00,GILD,positive
550962.0,Credit Suisse Downgrades Gilead Sciences To Neutral,2015-02-06 07:53:00-05:00,GILD,positive
550963.0,"Credit Suisse Downgrades Gilead Sciences to Neutral, Lowers PT to $115.00",2015-02-06 04:17:00-05:00,GILD,positive
550964.0,The S&P 500 Got A Boost From These Earnings,2015-02-04 17:40:00-05:00,GILD,positive
550965.0,Cigna Signs Agreement with Gilead to Include Harvoni as Only Preferred Brand for Customers with Hep C Genotype 1,2015-02-04 16:38:00-05:00,GILD,positive
550966.0,UBS Just Boosted Aetna By 8% Because Of This,2015-02-04 13:37:00-05:00,GILD,positive
550967.0,J.P. Morgan Is Watching This 'Curve Ball' At Gilead,2015-02-04 12:27:00-05:00,GILD,neutral
550968.0,Gilead Sciences Getting Crushed On Mixed Results,2015-02-04 11:59:00-05:00,GILD,negative
550969.0,5 Reasons Deutsche Bank Still Likes Gilead Stock,2015-02-04 11:39:00-05:00,GILD,positive
550970.0,Morgan Stanley On Gilead: 'It's All About Price (Again)',2015-02-04 11:12:00-05:00,GILD,neutral
550971.0,Nomura Just Cut Its Price Target On Gilead,2015-02-04 10:56:00-05:00,GILD,negative
550972.0,Morning Market Losers,2015-02-04 09:54:00-05:00,GILD,negative
550973.0,"Wednesday Morning Movers: Gilead Sciences, Myriad Genetics Tumble Following Earnings",2015-02-04 09:39:00-05:00,GILD,neutral
550974.0,Benzinga's Top #PreMarket Losers,2015-02-04 08:16:00-05:00,GILD,negative
550975.0,"Tuesday's After-Hours Movers: Gilead, Wynn Resorts And Chipotle Fall Following Earnings",2015-02-03 17:53:00-05:00,GILD,neutral
550976.0,"Gilead Sciences Beats Q4 Views But Outlook Disappoints, Shares Fall",2015-02-03 17:45:00-05:00,GILD,negative
550977.0,Gilead Sciences conference call ends.,2015-02-03 17:36:00-05:00,GILD,neutral
550978.0,"Company has never been in better shape and will continue to look forward and invest in share buybacks, dividends and continued product strength.",2015-02-03 17:36:00-05:00,GILD,positive
550979.0,"Gilead has a large, sustainable market in Europe that will continue with healthy growth in the coming years.",2015-02-03 17:32:00-05:00,GILD,positive
550980.0,The timing of our dividend reflects our confidence in our cash flow and balance sheet. Does not in any way prevent the company from investing in its business pipeline or M&A. We do not feel constrained in any way by issuing this dividend.,2015-02-03 17:22:00-05:00,GILD,positive
550981.0,Gilead sales team has been a lot of time securing access in 2014 and will shift to drive demand in 2015.,2015-02-03 17:21:00-05:00,GILD,positive
550982.0,"Harvoni has proven to be effective on a much wider range of patients than previously thought, we are not concerned about future competition and this represents a very strong category for Gilead based on this profile.",2015-02-03 17:19:00-05:00,GILD,positive
550983.0,70% of patients in 2014 came from the private sector,2015-02-03 17:05:00-05:00,GILD,neutral
550984.0,We are confident that we will see a large increase in patients across the US based on our goals to achieve greater accessibility.,2015-02-03 16:59:00-05:00,GILD,positive
550985.0,"Intentions for dividend are to grow over time, but at the moment they will still use share repurchases as the larger portion of the share returns in the near future.",2015-02-03 16:58:00-05:00,GILD,positive
550986.0,Gilead conference call Q&A begins,2015-02-03 16:57:00-05:00,GILD,neutral
550987.0,"CFO Washington: Expecting 2015 product sales to be $26-27B, increase of 6-10% over 2014",2015-02-03 16:55:00-05:00,GILD,positive
550988.0,CFO Washington: Repaid $1B in outstanding debt in Q4,2015-02-03 16:54:00-05:00,GILD,positive
550989.0,"CFO Washington: HCV product sales $12.4B for 2014, helped by continued launches of Sovaldi and Harvoni and geographic expansion",2015-02-03 16:52:00-05:00,GILD,neutral
550990.0,Gilead Estimates 2015 Gross to Net Hepatitis C Drug Adjustments at 46% vs 22% at End  of 2014,2015-02-03 16:51:00-05:00,GILD,negative
550991.0,CFO Washington: Cash flow will keep company strong and well positioned for any forthcoming M&A opportunities,2015-02-03 16:51:00-05:00,GILD,positive
550992.0,"CFO Washington: Annual yield of 1.6%, based on Monday's closing stock price",2015-02-03 16:50:00-05:00,GILD,neutral
550993.0,"EVP Carter: HIV: In 2014, Gilead continues clinical and commercial success, $1.9B in sales in the Q4 and $6.3B in sales for the whole year, lead by Complera and Stribild",2015-02-03 16:48:00-05:00,GILD,positive
550994.0,"EVP Carter: 80% of new HIV patients started treament on a Gilead product, 70% of which were on Truvada",2015-02-03 16:48:00-05:00,GILD,neutral
550995.0,"EVP Carter: We aim to streamline the process of access to treatment and therapy to at least 250,000 patients across all genotypes",2015-02-03 16:46:00-05:00,GILD,neutral
550996.0,"EVP Carter: We expect 2015 gross to net adjustments in product in the US to be 46%, over double in 2014 which was 22%",2015-02-03 16:46:00-05:00,GILD,negative
550997.0,EVP Carter: Sovaldi contributed $1.5B to European sales in 2014,2015-02-03 16:44:00-05:00,GILD,neutral
550998.0,"EVP Carter: 140,000 have started HCV therapy on a Gilead product in the United States.",2015-02-03 16:42:00-05:00,GILD,positive
550999.0,"CEO Martin: Board has approved quarterly cash dividend program and $15B, 5-year repurchase. 2015 will be as busy as 2014, and will continue to provide collaboration and medication to those in need. I am proud of our progress thus far.",2015-02-03 16:41:00-05:00,GILD,positive
551000.0,CEO Martin: GS-57945 Phase 2 studies are planned in Crohn's disease,2015-02-03 16:39:00-05:00,GILD,neutral
551001.0,"CEO Martin: Progress continues in oncology and inflammation. Additional hires have been made to oncology, respiratory and inflammatory studies and departments.",2015-02-03 16:38:00-05:00,GILD,positive
551002.0,"CEO John Martin: Sovaldi has been approved in India and currently has 15,000 under treatment",2015-02-03 16:36:00-05:00,GILD,positive
551003.0,Gilead Sciences Announces Initial Dividend Of $0.43/share,2015-02-03 16:07:00-05:00,GILD,neutral
551004.0,Gilead Sciences Announces $15B Buyback Program,2015-02-03 16:07:00-05:00,GILD,neutral
551005.0,"Gilead Reports Q4 Adj. EPS $2.43 vs $2.21 Est., Sales $7.31B vs $6.74B Est.",2015-02-03 16:06:00-05:00,GILD,neutral
551006.0,Gilead Sciences Q4 Conference Call Play-By-Play Recap,2015-02-03 16:05:00-05:00,GILD,neutral
551007.0,"Notable Earnings After The Close: GILD, DIS, CMG",2015-02-03 15:47:00-05:00,GILD,neutral
551008.0,Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key,2015-02-03 14:13:00-05:00,GILD,neutral
551009.0,"Catamaran Corp Says Gilead's Hepatitis C Treatments, Harvoni, Sovaldi Are Exclusive Options on Cos National, Value Formularies",2015-02-03 12:35:00-05:00,GILD,positive
551010.0,Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations,2015-02-03 11:28:00-05:00,GILD,neutral
551011.0,The Key Level In Gilead Sciences You Need To Watch For,2015-02-03 10:31:00-05:00,GILD,neutral
551012.0,"Here's What To Watch At Gilead Sciences, Chipotle & Twitter",2015-02-03 10:01:00-05:00,GILD,neutral
551013.0,From Conf Call: Aetna CFO Says Part of Increase in 2015 Earnings Outlook Based on Lower Price on Gilead's Hepatitis C Drugs,2015-02-03 08:39:00-05:00,GILD,neutral
551014.0,"Earning & Economic Calendar for Tuesday February 3, 2015",2015-02-03 05:24:00-05:00,GILD,neutral
551015.0,"Earnings Scheduled For February 3, 2015",2015-02-03 04:59:00-05:00,GILD,neutral
551016.0,Must Watch Stocks for Today,2015-02-03 04:09:00-05:00,GILD,neutral
551017.0,Gilead Could Miss Earnings (Hint: Watch Drug Sales),2015-02-02 22:27:00-05:00,GILD,negative
551018.0,"Energy, TIPs And Biotechnology ETFs To Watch This Week",2015-02-02 07:34:00-05:00,GILD,positive
551019.0,"Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching",2015-02-01 21:14:00-05:00,GILD,positive
551020.0,"Earnings Expectations For The Week Of February 2: Disney, Exxon, GM And More",2015-02-01 13:38:00-05:00,GILD,neutral
551021.0,Why The Biotech Boom Is Still In The 1st Inning,2015-02-01 12:35:00-05:00,GILD,neutral
551022.0,Fast Money Halftime Report Final Trade From January 30,2015-01-31 12:16:00-05:00,GILD,neutral
551023.0,What Investors Are Watching For In Regulus Therapeutics' Next Data Release,2015-01-30 14:32:00-05:00,GILD,neutral
551024.0,Baird Remains Buyers Of Gilead Before Earnings Release,2015-01-29 14:18:00-05:00,GILD,neutral
551025.0,"Gilead Promotes Andrew Cheng To EVP HIV Therapeutics and Development Operations; Taiyin Yang To EVP, President Pharmaceutical Development and Manufacturing",2015-01-28 16:31:00-05:00,GILD,positive
551026.0,Alibaba Is A Favorite Holding Even For U.S.-Focused Funds,2015-01-26 14:22:00-05:00,GILD,positive
551027.0,US Stock Futures Signal Lower Start On Wall Street,2015-01-26 07:14:00-05:00,GILD,negative
551028.0,Gilead Expands Hepatitis C Generic Licensing Agreements to Include GS-5816,2015-01-26 04:37:00-05:00,GILD,positive
551029.0,Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences,2015-01-21 16:27:00-05:00,GILD,neutral
551030.0,The 5 Biggest Biotech Stocks,2015-01-20 16:43:00-05:00,GILD,neutral
551031.0,Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year,2015-01-20 16:21:00-05:00,GILD,neutral
551032.0,From Aetna Newsroom: 'Aetna and Gilead agree to discount pricing for hepatitis C drugs',2015-01-16 14:49:00-05:00,GILD,positive
551033.0,Aetna Says Gilead's Harvoni And Sovaldi Are Preferred Treatment For Its 20 Mln Commercial Customers,2015-01-16 14:36:00-05:00,GILD,neutral
551034.0,Nomura's Takeaways From Meeting With Gilead Sciences' Management,2015-01-16 10:17:00-05:00,GILD,neutral
551035.0,Kite CEO Says Learning from Gilead's Pricing Playbook for their Own Experimental Cancer Treatment -Reuters,2015-01-15 14:53:00-05:00,GILD,negative
551036.0,Gilead Sciences' Sovaldi Patent Application Rejected In India,2015-01-14 13:08:00-05:00,GILD,negative
551037.0,'India Rejects Gildead Patent Request For Hep C Drug',2015-01-14 12:34:00-05:00,GILD,negative
551038.0,"Aetna CEO Bertolini Says Co Has Not Made Decision Regarding Gilead's, Abbvie's Hepatitis C Drugs -Reuters",2015-01-13 17:18:00-05:00,GILD,neutral
551039.0,Gilead Begins Presentation At JPM Conference,2015-01-13 11:31:00-05:00,GILD,neutral
551040.0,A Look At 3 Biotech Stocks With Upside Potential,2015-01-12 16:25:00-05:00,GILD,neutral
551041.0,"Prime Therapeutics Enters Agreements With AbbVie, Gilead",2015-01-12 14:05:00-05:00,GILD,positive
551042.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,GILD,neutral
551043.0,Adam Feuerstein @adamfeuerstein Tweet: $GILD Buying $VRTX Among Bold Biotech Stock Predictions for 2015 thestreet.com/story/13006004… @dsobek peers into his Cajun crystal ball...,2015-01-09 10:55:00-05:00,GILD,positive
551044.0,"Anthem, Gilead Sign Deal For Hep. C Drug",2015-01-08 15:32:00-05:00,GILD,neutral
551045.0,Gilead Sciences Just Received Orphan Drug Status For Liver Treatment,2015-01-07 11:27:00-05:00,GILD,neutral
551046.0,Gilead Receives Orphan Drug Status For Simtuzumab,2015-01-07 10:06:00-05:00,GILD,neutral
551047.0,J.P Morgan Just Chimed In With Ratings On Biotech Stocks,2015-01-06 16:34:00-05:00,GILD,neutral
551048.0,Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market,2015-01-06 12:21:00-05:00,GILD,positive
551049.0,"UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'",2015-01-06 09:08:00-05:00,GILD,neutral
551050.0,Gilead Sciences Announces Purchase of Phenex Pharma's Development Program for NASH,2015-01-06 08:31:00-05:00,GILD,neutral
551051.0,"Barclays Initiates Coverage on Gilead Sciences at Overweight, Announces $125.00 PT",2015-01-06 06:17:00-05:00,GILD,negative
551052.0,CNBC's Stock Pops & Drops From January 5,2015-01-05 19:36:00-05:00,GILD,neutral
551053.0,Gilead Sciences Spikes Amid CVS Formulary Status,2015-01-05 12:32:00-05:00,GILD,neutral
551054.0,CVS Health Corp. Gives Preferred Formulary Status to Gilead Sciences' Drugs Harvoni and Sovaldi,2015-01-05 11:43:00-05:00,GILD,neutral
551055.0,These Were The 10 Most Traded Stocks Of 2014,2015-01-03 15:08:00-05:00,GILD,neutral
551056.0,The Struggles Of Gilead Sciences,2014-12-31 13:38:00-05:00,GILD,negative
551057.0,"Gilead Spokesperson Says GoodRx Coupon for Harvoni Tablets Was Not Sponsored by Gilead and Co Cannot Comment on Pricing, As they do Not Sell Directly to Consumers",2014-12-30 13:32:00-05:00,GILD,neutral
551058.0,Discount Coupon for Gilead's Harvoni from GoodRx,2014-12-30 10:19:00-05:00,GILD,neutral
551059.0,Mid-Afternoon Market Update: Crude Oil Slides 3%; Gilead Sciences Shares Spike Higher,2014-12-29 15:27:00-05:00,GILD,negative
551060.0,"Morgan Stanley Upgrades Gilead Sciences, Says It Will Maintain 75% Market Share",2014-12-29 15:08:00-05:00,GILD,positive
551061.0,Morning Market Movers,2014-12-29 09:51:00-05:00,GILD,neutral
551062.0,Benzinga's Top Upgrades,2014-12-29 08:37:00-05:00,GILD,positive
551063.0,"#PreMarket Primer: Monday, December 29: Controversial Film 'The Interview' Makes Millions Online",2014-12-29 08:34:00-05:00,GILD,negative
551064.0,Gilead Reports Amended Deals with J&J's Janssen to Develop PREZISTA-Based Single-Tablet Regimen for Treatment of People Living with HIV,2014-12-29 08:31:00-05:00,GILD,neutral
551065.0,Benzinga's Top #PreMarket Gainers,2014-12-29 08:04:00-05:00,GILD,positive
551066.0,"Morgan Stanley Upgrades  Gilead Sciences To Overweight, Shares Rise",2014-12-29 07:31:00-05:00,GILD,negative
551067.0,UPDATE: Gilead Shares Rise ~2% Premarket Follwing Morgan Stanley Upgrade to Overweight,2014-12-29 07:29:00-05:00,GILD,negative
551068.0,US Stock Futures Down; Crude Oil Rises,2014-12-29 07:00:00-05:00,GILD,negative
551069.0,Morgan Stanley Upgrades Gilead Sciences to Overweight,2014-12-29 06:02:00-05:00,GILD,negative
551070.0,CNBC's Stock Pops & Drops From December 26,2014-12-27 14:08:00-05:00,GILD,neutral
551071.0,#Premarket Prep Technical Update - Gilead Sciences Higher,2014-12-26 12:22:00-05:00,GILD,neutral
551072.0,Morning Market Movers,2014-12-26 09:57:00-05:00,GILD,neutral
551073.0,Why Shares Of Gilead Sciences Are Trading Higher,2014-12-26 09:22:00-05:00,GILD,positive
551074.0,RBC: Gilead could launch $10B+ accelerated buyback,2014-12-26 08:26:00-05:00,GILD,neutral
551075.0,How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge Funds,2014-12-24 11:27:00-05:00,GILD,neutral
551076.0,Benzinga's Top #PreMarket Losers,2014-12-24 08:16:00-05:00,GILD,negative
551077.0,3 Charts That Show Why There's Gilead Sciences...And Then There's Everybody Else,2014-12-23 17:26:00-05:00,GILD,neutral
551078.0,"Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact",2014-12-23 16:13:00-05:00,GILD,negative
551079.0,Health Care And Biotech Sector Looking Sick,2014-12-23 15:42:00-05:00,GILD,neutral
551080.0,#Premarket Prep Technical Update - Gilead Sciences Continues Lower,2014-12-23 14:01:00-05:00,GILD,negative
551081.0,CNBC's Meg Tirrell Breaks Down The AbbVie/Express Scripts Deal,2014-12-23 13:01:00-05:00,GILD,neutral
551082.0,Deutsche Bank Analyst Sees Gilead Sciences Vs. AbbVie 'Price War',2014-12-23 10:56:00-05:00,GILD,negative
551083.0,"Fast Money Picks For December 23: Gilead Sciences, Starbucks, CVS Health",2014-12-23 07:30:00-05:00,GILD,neutral
551084.0,AbbVie Takes A Bite Out Of Gilead Sciences' Hepatitis C Market Share,2014-12-22 16:52:00-05:00,GILD,positive
551085.0,"Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing War",2014-12-22 15:04:00-05:00,GILD,negative
551086.0,"Option Alert: GIlead Jan $105 Call; 4,504 Contract Trade Above Ask @$1.45; Currently $94.64",2014-12-22 14:43:00-05:00,GILD,positive
551087.0,"Bank of America Downgrades Gilead Sciences to Underperform, Lowers PT to $87.00",2014-12-22 14:33:00-05:00,GILD,negative
551088.0,"Mid-Day Losers From December 22: Gilead, Ocwen Financial And More",2014-12-22 13:21:00-05:00,GILD,negative
551089.0,Mid-Morning Market Update: Markets Open Higher; Caesars Entertainment To Buy Caesars Acquisition,2014-12-22 10:41:00-05:00,GILD,positive
551090.0,Monday's Biggest Social Media Movers,2014-12-22 10:35:00-05:00,GILD,neutral
551091.0,Morning Market Losers,2014-12-22 10:01:00-05:00,GILD,negative
551092.0,Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts,2014-12-22 09:46:00-05:00,GILD,neutral
551093.0,"Monday's #PreMarket Movers: Caesars, Enta, Twitter And More",2014-12-22 09:06:00-05:00,GILD,neutral
551094.0,Benzinga's Top #PreMarket Losers,2014-12-22 08:18:00-05:00,GILD,negative
551095.0,"Express Scripts to Cover AbbVie Hepatitis C Drug Viekira Pak, Drops Coverage on Gilead's Sovaldi Due to Significantly Lower Price of AbbVie Treatment -CNBC",2014-12-22 05:57:00-05:00,GILD,negative
551096.0,"ONO, Gilead Announce Exclusive License Agreement to Develop ONO-4059 for Treatment of B-cell Malignancies and Other Diseases",2014-12-19 05:08:00-05:00,GILD,positive
551097.0,"Gilead Sciences Announces Philippe Bishop, MD Will Join Gilead As SVP Hematology, Oncology Therapeutics",2014-12-15 08:31:00-05:00,GILD,positive
551098.0,These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market,2014-12-12 11:44:00-05:00,GILD,neutral
551099.0,Gilead Sciences Bucks Trend In Biotech Short Interest,2014-12-11 12:06:00-05:00,GILD,positive
551100.0,6 Strong Analyst Recommendations That You Should Know,2014-12-11 11:49:00-05:00,GILD,positive
551101.0,"Septa Lawsuit Seeks Class-Action Status, Monetary Damages From Gilead for Price Gouging on Sovaldi -DJ",2014-12-10 13:27:00-05:00,GILD,negative
551102.0,UPDATE: Morgan Stanley Raises PT on Gilead Sciences Following AlphaWise Survey,2014-12-09 11:10:00-05:00,GILD,neutral
551103.0,"Morgan Stanley Maintains Equal-weight on Gilead Sciences, Inc., Raises PT to $100.00",2014-12-09 04:32:00-05:00,GILD,neutral
551104.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,GILD,neutral
551105.0,Gilead Presents Follow-up Data from Zydelig Registrational Studies At 56th American Society of Hematology Annual Meeting,2014-12-08 10:01:00-05:00,GILD,neutral
551106.0,Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C,2014-12-05 10:50:00-05:00,GILD,neutral
551107.0,Earnings Season In Review: Who's Winning?,2014-12-04 11:07:00-05:00,GILD,positive
551108.0,"Great News For Biogen, But What's Next For The Stock?",2014-12-03 12:36:00-05:00,GILD,positive
551109.0,"8-K from Gilead Sciences Shows UK Court Invalidated Idenix 489 Patent, Trials Will Be Held on Merck's Idenix Patents in Canada in Jan.",2014-12-01 14:40:00-05:00,GILD,neutral
551110.0,Mylan Reports Deal with Gilead for Enhancement of Access to TAF-Based HIV Treatments in Developing Countires,2014-12-01 07:02:00-05:00,GILD,neutral
551111.0,"#PreMarket Primer: Wednesday, November 26: Big Retailers Gear Up For Black Friday",2014-11-26 08:13:00-05:00,GILD,neutral
551112.0,Hearing Unconfirmed Market Chatter of Icahn Stake in Gilead,2014-11-20 11:16:00-05:00,GILD,negative
551113.0,CNBC's Stock Pops & Drops From November 19,2014-11-20 07:38:00-05:00,GILD,neutral
551114.0,"French Ministry of Health Announces Final Negotiated Price for Gilead's Sovaldi is €41,000 for 12 Weeks -Reuters",2014-11-20 07:10:00-05:00,GILD,neutral
551115.0,Gilead Sciences Announces That The European Commission Has Granted Marketing Authorization for Gilead's Harvoni,2014-11-18 10:09:00-05:00,GILD,positive
551116.0,Julian Robertson's Tiger Management 13F Reveals Huge Alibaba Stake,2014-11-15 09:57:00-05:00,GILD,positive
551117.0,"CNBC's Stock Pops & Drops From November 13: King Digital, Alibaba, SanDisk, Gilead Sciences",2014-11-14 07:25:00-05:00,GILD,neutral
551118.0,"#PreMarket Primer: Friday, November 14: Tensions At All-Time High For G20 Summit",2014-11-14 07:22:00-05:00,GILD,negative
551119.0,Gilead Sciences In Correction Mode,2014-11-13 13:37:00-05:00,GILD,neutral
551120.0,The Top 25 Analysts On Wall Street,2014-11-13 10:47:00-05:00,GILD,positive
551121.0,Hearing Cleveland Research Cautious on Gilead,2014-11-13 09:35:00-05:00,GILD,negative
551122.0,Gilead Prices $4B Offering Of Senior Unsecured Notes,2014-11-12 18:00:00-05:00,GILD,negative
551123.0,"Fast Money Halftime Report Final Trade From November 12: Twitter, Dunkin Brands, Gilead Sciences",2014-11-12 15:58:00-05:00,GILD,neutral
551124.0,"#PreMarket Primer: Wednesday, November 12: Banks Fined More Than $3 Billion For Role In Forex Manipulation",2014-11-12 07:44:00-05:00,GILD,negative
551125.0,Gilead Reports Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for Treatment of Chronic Hep C,2014-11-11 08:06:00-05:00,GILD,neutral
551126.0,Gilead Announces Phase 2 Data For Investigational All-Oral Regimen Of Sofosbuvir Plus GS-5816 For The Treatment Of Chronic Hepatitis C,2014-11-11 08:03:00-05:00,GILD,neutral
551127.0,RBC Sees Weak Merck Data As Positive For Gilead,2014-11-10 09:29:00-05:00,GILD,positive
551128.0,Gilead Submits New Drug Application To FDA For Tenofovir Alafenamide ,2014-11-06 08:33:00-05:00,GILD,neutral
551129.0,"CNBC's Stock Pops & Drops From November 3: GoPro, Gilead Sciences And More",2014-11-03 20:17:00-05:00,GILD,neutral
551130.0,"#PreMarket Primer: Monday, November 3: Commercial Space Travel Questioned After Failed Flights",2014-11-03 07:55:00-05:00,GILD,negative
551131.0,"Edward Jones Initiates Coverage on Gilead Sciences, Inc. at Hold",2014-10-31 15:34:00-04:00,GILD,neutral
551132.0,"Fast Money Traders Comment On Stocks Making Headlines On Wednesday: Panera Bread, Hershey And More",2014-10-29 16:15:00-04:00,GILD,neutral
551133.0,Express Scripts Says May Change Drug Formulary in Mid-2015 to Favor Less Expensive Hepatitis C Drugs vs Gilead's Sovaldi -Reuters,2014-10-29 09:36:00-04:00,GILD,positive
551134.0,"#PreMarket Primer: Wednesday, October 29: Fed Likely To End Bond Purchases",2014-10-29 07:50:00-04:00,GILD,neutral
551135.0,Gilead Sciences Reports Softer Sovaldi Revenues,2014-10-28 17:15:00-04:00,GILD,neutral
551136.0,Gilead Boosts FY14 Product Sales Guidance from $21-$23B Previously to $22-$23B,2014-10-28 16:22:00-04:00,GILD,positive
551137.0,"Gilead Sciences, Inc. Reports Q3 EPS of $1.84 vs $1.92 Est; Revenue of $6.04B vs $6.06B Est; Narrowing Guidance",2014-10-28 16:06:00-04:00,GILD,neutral
551138.0,Gilead Earnings Implied Volatility ~70%; Expecting $6.30 Move,2014-10-28 15:52:00-04:00,GILD,neutral
551139.0,"#PreMarket Primer: Tuesday, October 28: CDC Warns That Involuntary Quarantines Could Discourage Progress On Ebola",2014-10-28 08:00:00-04:00,GILD,negative
551140.0,"Earnings Scheduled For October 28, 2014",2014-10-28 05:25:00-04:00,GILD,neutral
551141.0,"#PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations",2014-10-27 08:19:00-04:00,GILD,negative
551142.0,"#PreMarket Primer: Monday, October 20: Fed To Tread Softly At October Meeting",2014-10-20 08:05:00-04:00,GILD,neutral
551143.0,Gilead Announces Health Canada Has Issued Notice of Compliance Related to Harvoni for Genotype 1 Chronic Hep C,2014-10-16 13:32:00-04:00,GILD,neutral
551144.0,Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark',2014-10-15 16:42:00-04:00,GILD,neutral
551145.0,Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone,2014-10-14 13:59:00-04:00,GILD,neutral
551146.0,"Deutsche Bank Just Out with Mid-Day Defense on Gilead, 'weakness on Irish tax, JNJ comments is overdone'",2014-10-14 11:13:00-04:00,GILD,negative
551147.0,Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level,2014-10-13 16:57:00-04:00,GILD,negative
551148.0,"FBR Capital Maintains Outperform on Gilead Sciences, Inc., Raises PT to $133.00",2014-10-13 09:09:00-04:00,GILD,neutral
551149.0,Big Swings in Biotech Short Interest,2014-10-13 08:32:00-04:00,GILD,positive
551150.0,5 Companies That Could Develop An Enterovirus Treatment,2014-10-13 08:07:00-04:00,GILD,neutral
551151.0,Release Confirms Gilead's Approval For Combination Hep C Product,2014-10-10 13:56:00-04:00,GILD,positive
551152.0,Gilead Has Won US Approval for Combination Hep C Product,2014-10-10 13:37:00-04:00,GILD,positive
551153.0,Shares of Achillion Pharma at Session Highs as Traders Passing Around Mid-Day Note from FBR Showing Indication from Co. (via Abstract) of '100% of Patients Dosed for Eight Weeks Remained Cured',2014-10-08 12:50:00-04:00,GILD,positive
551154.0,"#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed",2014-10-01 07:42:00-04:00,GILD,neutral
551155.0,"AIFA, Gilead Have Agreed to Reimburse Sovaldi for Hep C Treatment",2014-09-30 14:16:00-04:00,GILD,positive
551156.0,"Gilead Sciences, Inc. Consolidating Gains?",2014-09-29 15:30:00-04:00,GILD,positive
551157.0,"Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26",2014-09-27 10:33:00-04:00,GILD,positive
551158.0,Gilead Release Confirms European CHMP Positive Opinion for Harvoni for Treatment of Chronic Hep C Infection in Adults,2014-09-26 07:19:00-04:00,GILD,positive
551159.0,EMA Announces Positive Recommendation for Gilead's Harvoni -DJ,2014-09-26 07:15:00-04:00,GILD,positive
551160.0,Gilead Shares Volatile This Morning Following FDA Approval of VITEKTA in HIV,2014-09-25 10:07:00-04:00,GILD,positive
551161.0,Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies ,2014-09-24 08:31:00-04:00,GILD,neutral
551162.0,Gilead Submits NDA in Japan for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection ,2014-09-24 00:59:00-04:00,GILD,neutral
551163.0,US Stock Futures Signal Higher Start On Wall Street,2014-09-19 07:22:00-04:00,GILD,neutral
551164.0," Gilead Gets EC Approval for Zydelig in Chronic Lymphocytic Leukemia, Follicular Lymphoma",2014-09-19 06:26:00-04:00,GILD,positive
551165.0,2 Columbia Growth Funds Notch Impressive Three-Month Performance,2014-09-18 10:52:00-04:00,GILD,positive
551166.0,This Top Growth Fund Leans Heavily On Large-Cap Tech,2014-09-17 09:28:00-04:00,GILD,positive
551167.0,Gilead Says Addition of Simtuzumab to Gemcitabine Didn't Significantly Increase Progression-Free Survival,2014-09-17 06:02:00-04:00,GILD,negative
551168.0,"Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks",2014-09-16 08:19:00-04:00,GILD,neutral
551169.0,Benzinga's Top #PreMarket Losers ,2014-09-16 08:11:00-04:00,GILD,negative
551170.0,Morning Market Losers ,2014-09-15 09:48:00-04:00,GILD,negative
551171.0,Benzinga's Top #PreMarket Losers,2014-09-15 08:15:00-04:00,GILD,negative
551172.0,"#PreMarket Primer: Monday, September 15: Cameron Vows To Destroy ISIS",2014-09-15 07:54:00-04:00,GILD,negative
551173.0,UPDATE: Gilead Announces Licensing Agreements for Generic Sovaldi,2014-09-15 06:33:00-04:00,GILD,positive
551174.0,Mylan In Pact With Gilead To Accelerate Access To Hepatitis C,2014-09-15 06:31:00-04:00,GILD,neutral
551175.0,"UPDATE: Gilead Says Licensees to Set Prices for Generic Version of Sovaldi, Will Pay Gilead a Royalty on Sales",2014-09-15 05:51:00-04:00,GILD,negative
551176.0,"Gilead Licenses Hep C Drug Sovaldi to 7 Companies Including Mylan, Ranbaxy",2014-09-15 05:48:00-04:00,GILD,neutral
551177.0,"#PreMarket Primer: Friday, September 12: US Allies Vague About Participation In Syrian Airstrikes",2014-09-12 07:40:00-04:00,GILD,negative
551178.0,"Gilead Sciences, Inc. Could Be Taking A Break Before Even More Upside",2014-09-10 15:05:00-04:00,GILD,neutral
551179.0,Have We Seen The Market's Top?,2014-09-09 14:40:00-04:00,GILD,positive
551180.0,Hearing Cleveland Research Says Gilead Recently Started Cutting Pricing 8% for Sovaldi,2014-09-09 09:36:00-04:00,GILD,negative
551181.0,"Gilead Reports First-Line Combo Study of Ambrisentan, Tadalafil Met Primary Endpoint, Expecting to Submit Ambition Data by End of 2014",2014-09-08 08:47:00-04:00,GILD,neutral
551182.0,"CNBC's Stock Pops & Drops From September 5: Control4 Corp, Priceline Group Inc & More",2014-09-06 18:32:00-04:00,GILD,neutral
551183.0,"Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead",2014-09-06 17:28:00-04:00,GILD,positive
551184.0,"Fast Money Halftime Report Final Trade From September 5: American Eagle Outfitters, Delta Air Lines, Inc. & More",2014-09-06 17:26:00-04:00,GILD,neutral
551185.0,"A Word On Healthcare Mutual Funds, And One Sector's 'Fittest' Segment",2014-09-05 10:22:00-04:00,GILD,neutral
551186.0,Markets Edge Lower; Zumiez Issues Weak Outlook,2014-09-05 10:21:00-04:00,GILD,negative
551187.0,"Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding ",2014-09-05 09:27:00-04:00,GILD,positive
551188.0,"Biotechnology, Oil And Brazil ETFs To Watch This Week",2014-09-02 10:05:00-04:00,GILD,neutral
551189.0,Mike Khouw's Gilead Sciences Trade,2014-08-30 11:20:00-04:00,GILD,neutral
551190.0,What You Need to Know About the Roche-InterMune Deal,2014-08-29 15:51:00-04:00,GILD,neutral
551191.0,"Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)",2014-08-27 15:22:00-04:00,GILD,neutral
551192.0,"Seeing Very High Social Activity on Gilead Shares as Stock Crosses $108 Level, Shares Up 2%",2014-08-27 12:35:00-04:00,GILD,positive
551193.0,"#PreMarket Primer: Wednesday, August 27: Israel And Hamas To Resume Peace Talks In Cairo",2014-08-27 07:08:00-04:00,GILD,positive
551194.0,"Deutsche Bank Has Added Gilead, Celgene to 'Short-Term Buy' List - Bloomberg",2014-08-26 11:19:00-04:00,GILD,neutral
551195.0,"#PreMarket Primer: Tuesday, August 26: US Gathers Intelligence In Syria",2014-08-26 06:37:00-04:00,GILD,positive
551196.0,InterMune's Roche Deal Sends Peer Group Up,2014-08-25 11:38:00-04:00,GILD,neutral
551197.0,CNBC's Stock Pops & Drops From August 22,2014-08-24 19:02:00-04:00,GILD,neutral
551198.0,"#PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention",2014-08-18 07:12:00-04:00,GILD,neutral
551199.0,CNBC's Stock Pops & Drops From August 15,2014-08-16 15:16:00-04:00,GILD,neutral
551200.0,Markets Close The Week On Negative Note As Ukraine Worries Mount,2014-08-15 17:01:00-04:00,GILD,negative
551201.0,"Gilead Shares Rise in Premarket as UK's National Institute for Health and Care Excellence Recommends English Health System Pays for Sovaldi, Also Gets Favorable Ruling vs Roche in Arbitration",2014-08-15 08:25:00-04:00,GILD,positive
551202.0,"Shares of Intercept Moving Higher; Report of Tweet Mentioning Potential Deal by Gilead being Passed Around, Totally Unconfirmed",2014-08-14 14:34:00-04:00,GILD,positive
551203.0,"#PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods",2014-08-07 07:03:00-04:00,GILD,negative
551204.0,Top 4 Stocks In The Biotechnology Industry With The Highest Revenue,2014-08-07 04:24:00-04:00,GILD,positive
551205.0,Why Investors Should Closely Watch Celgene,2014-08-06 16:53:00-04:00,GILD,neutral
551206.0,"TD Ameritrade Client Activity Jumped In July, Back To March Levels",2014-08-04 14:55:00-04:00,GILD,neutral
551207.0,"#PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise",2014-07-28 06:59:00-04:00,GILD,negative
551208.0,EU Medicines Agency Recommends Gilead Leukemia Drug Idelalisib ,2014-07-25 07:11:00-04:00,GILD,positive
551209.0,Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug,2014-07-24 06:50:00-04:00,GILD,positive
551210.0,Markets Mostly Higher As Earnings Season Continues To Impress,2014-07-23 16:55:00-04:00,GILD,positive
551211.0,"Shares of Gilead Resume Trade, Trading Very Slightly Lower, Down ~0.5% from Close",2014-07-23 16:26:00-04:00,GILD,neutral
551212.0, Gilead Reports Q2 Sovaldi Sales $3.48B,2014-07-23 16:11:00-04:00,GILD,neutral
551213.0,PREVIEW: Gilead Sciences  to Resume Trading at 4:30 PM ET,2014-07-23 16:10:00-04:00,GILD,neutral
551214.0,"Gilead Sciences, Inc. Sees FY2014 Sales $21.0B-23.0B vs $22.63B Est",2014-07-23 16:06:00-04:00,GILD,neutral
551215.0,"Gilead Sciences, Inc. Reports Q2 EPS of $2.36 vs $1.79 Est; Revenue of $6.53B vs $5.86B Est",2014-07-23 16:05:00-04:00,GILD,neutral
551216.0,Gilead Halted Ahead of Earnings,2014-07-23 16:01:00-04:00,GILD,neutral
551217.0,Statement from FDA Confirms Approval of Gilead's Zydelig,2014-07-23 11:46:00-04:00,GILD,positive
551218.0,FDA Statement Shows Approval for Gilead's Zydelig - Bloomberg,2014-07-23 11:32:00-04:00,GILD,positive
551219.0,"Earnings Scheduled For July 23, 2014",2014-07-23 05:26:00-04:00,GILD,neutral
551220.0,Investors Focus On Earnings Rather Than Geopolitical Tensions,2014-07-18 18:08:00-04:00,GILD,negative
551221.0,Biotech Enters Reporting Season With Large Caps Central To Sector Performance,2014-07-18 15:40:00-04:00,GILD,neutral
551222.0,2 Biotech Stocks That Crushed On Earnings,2014-07-14 14:35:00-04:00,GILD,negative
551223.0,Markets Close Higher Ahead Of Busy Earnings Season,2014-07-11 16:40:00-04:00,GILD,neutral
551224.0,Stocks Hitting 52-Week Highs,2014-07-11 10:13:00-04:00,GILD,neutral
551225.0,Wyden and Grassley Seek Details on Gilead's Solvaldi Pricing,2014-07-11 09:46:00-04:00,GILD,neutral
551226.0,J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views,2014-07-10 16:31:00-04:00,GILD,neutral
551227.0,FDA Warns Gilead on Marketing oF Hepatitis B Drug Viread,2014-07-07 12:39:00-04:00,GILD,negative
551228.0,Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector,2014-07-03 12:26:00-04:00,GILD,neutral
551229.0,"Option Alert: Gilead Aug $95 Call; 9,227 Contracts Traded vs 3,595 OI; Currently $87.67",2014-07-02 12:21:00-04:00,GILD,positive
551230.0,UPDATE: Morgan Stanley Reiterates On Gilead Sciences On EM Sovaldi,2014-06-30 08:53:00-04:00,GILD,neutral
551231.0,Gilead Submits NDA to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C ,2014-06-27 05:27:00-04:00,GILD,neutral
551232.0,Gilead Shares Spiker Lower; May be Attributed to Congressional Probe into Sovaldi Pricing,2014-06-19 11:41:00-04:00,GILD,neutral
551233.0,"Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks",2014-06-18 09:38:00-04:00,GILD,positive
551234.0,"Benzinga's M&A Chatter for Monday June 16, 2014",2014-06-16 20:53:00-04:00,GILD,neutral
551235.0,Gilead Phase 3 Data Show Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response Among Patients with Chronic Hepatitis C in Japan ,2014-06-15 21:15:00-04:00,GILD,neutral
551236.0,Are Gilead Shares Overreacting To Merck's Idenix Acquisition?,2014-06-09 14:34:00-04:00,GILD,positive
551237.0,Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle To Buy Hillshire Brands For $63/Share,2014-06-09 10:12:00-04:00,GILD,positive
551238.0,Hepatitis C Stocks Move After Idenix Rockets Up 235%,2014-06-09 08:59:00-04:00,GILD,neutral
551239.0,Benzinga's Top #PreMarket Losers,2014-06-09 08:08:00-04:00,GILD,negative
551240.0,"UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70%",2014-06-03 08:33:00-04:00,GILD,neutral
551241.0,"Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70%",2014-06-03 08:30:00-04:00,GILD,neutral
551242.0,Value Of U.S. Equity Buybacks In May Drops,2014-06-02 13:53:00-04:00,GILD,positive
551243.0,"Option Alert: Gilead Jun $87.5 Call; 7,432 Contracts Traded vs 3.026 OI; Currently $82.41",2014-05-28 11:43:00-04:00,GILD,positive
551244.0,"UPDATE: Gilead Reports Investigational GS-5806 Reduces Viral Load, Clinical Syptoms in Phase 2 RSV Study, Says Study Reached Primary, Secondary Endpoints",2014-05-20 17:02:00-04:00,GILD,positive
551245.0,"Gilead Reports Investigational GS-5806 Reduces Viral Load, Clinical Syptoms in Phase 2 RSV Study, Says Study Reached Primary, Secondary Endpoints",2014-05-20 17:01:00-04:00,GILD,positive
551246.0,Breaking Biotech: Gilead's Phase 2 Study Results,2014-05-12 12:37:00-04:00,GILD,neutral
551247.0,Gilead Phase 2 Study Shows Reduction in Atrial Fibrillation Burden with Investigational Combination of Ranolazine and Low-Dose Dronedarone ,2014-05-10 18:47:00-04:00,GILD,negative
551248.0,Gilead Announces Phase 1 Data For Investigation Therapy,2014-05-09 16:30:00-04:00,GILD,neutral
551249.0,Gilead Announces $5B Buyback Plan,2014-05-07 17:17:00-04:00,GILD,neutral
551250.0,U.S.-Russia Tensions Over Ukraine Could Make This An Interesting Weekend,2014-04-25 15:37:00-04:00,GILD,neutral
551251.0,"Biogen Raises Full-Year Earnings, But Is That The Entire Picture?",2014-04-24 17:03:00-04:00,GILD,neutral
551252.0,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",2014-04-23 16:46:00-04:00,GILD,positive
551253.0,#Premarket Technical Update - Gilead Sciences Trading Higher,2014-04-23 15:01:00-04:00,GILD,neutral
551254.0,Morning Market Movers ,2014-04-23 09:44:00-04:00,GILD,neutral
551255.0,How Did Analysts Get Gilead's Earnings Completely Wrong?,2014-04-23 09:19:00-04:00,GILD,negative
551256.0,Benzinga's Top #PreMarket Gainers,2014-04-23 08:09:00-04:00,GILD,positive
551257.0,"ETF Outlook For Wednesday, April 23, 2014 (MGC, IYZ, TAN, BBH, GILD, T)",2014-04-23 07:41:00-04:00,GILD,neutral
551258.0,"Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to $130.00",2014-04-23 07:31:00-04:00,GILD,neutral
551259.0,"Gilead Crushes On Earnings, Quickly Gives Up Gains",2014-04-22 17:46:00-04:00,GILD,negative
551260.0,"Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive",2014-04-22 16:52:00-04:00,GILD,positive
551261.0,"Gilead Beats Q1 Estimates, Stock Halted Briefly",2014-04-22 16:41:00-04:00,GILD,neutral
551262.0,"Gilead Sciences Shares Resume Trade, Up 5%",2014-04-22 16:30:00-04:00,GILD,positive
551263.0,Gilead Sciences Shares to Resume Trade at 4:30PM EDt,2014-04-22 16:10:00-04:00,GILD,positive
551264.0,"Gilead Sciences, Inc. Reports Q1 EPS of $1.48 vs $0.92 Est; Revenue of $5.0B, Up 98% YOY",2014-04-22 16:02:00-04:00,GILD,neutral
551265.0,Gilead Sciences Halted Ahead of Earnings,2014-04-22 16:00:00-04:00,GILD,neutral
551266.0,CAFC Says Gilead Has Lost Appeals Court Ruling Related to Patent Over TAmiflu,2014-04-22 11:09:00-04:00,GILD,negative
551267.0,"Earnings Scheduled For April 22, 2014",2014-04-22 05:14:00-04:00,GILD,neutral
551268.0,Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA,2014-04-21 16:30:00-04:00,GILD,positive
551269.0,Bloomberg Report Says CVS May Try to Slow the Uptake of Gilead's New Drug; Says CVS Wants Price Competition to Gilead's Hepatitis C Drug,2014-04-21 14:25:00-04:00,GILD,neutral
551270.0,Gilead Receives FDA Orphan Status for Chronic Lymphocytic Leukemia - Bloomberg,2014-04-15 15:01:00-04:00,GILD,neutral
551271.0,Markets Falling? Get Your Defense Ready,2014-04-14 15:47:00-04:00,GILD,positive
551272.0,US Stock Futures Slip Ahead Of Consumer Sentiment Report,2014-04-11 07:41:00-04:00,GILD,neutral
551273.0,Gilead Announces Sovaldi Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease ,2014-04-11 05:39:00-04:00,GILD,positive
551274.0,Market Wrap For April 10: Wednesday's Rally Completely Forgotten,2014-04-10 16:33:00-04:00,GILD,negative
551275.0,Five Star Stock Watch: Gilead Sciences,2014-04-10 10:35:00-04:00,GILD,neutral
551276.0,Natco Pharma Files to Block Grant Of India Patent On Gilead's Hepatitis C Drug Sovaldi -Reuters,2014-04-10 08:28:00-04:00,GILD,negative
551277.0,"Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to $121.00",2014-04-10 07:30:00-04:00,GILD,neutral
551278.0,Gilead Announces Phase 2 Results for Investigational All-Oral Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C ,2014-04-10 05:43:00-04:00,GILD,neutral
551279.0,Biotechs Struggling To Find A Bottom,2014-04-08 10:24:00-04:00,GILD,negative
551280.0,Morning Market Losers ,2014-04-08 09:46:00-04:00,GILD,negative
551281.0,Benzinga's Top #PreMarket Losers,2014-04-08 08:35:00-04:00,GILD,negative
551282.0,"Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016",2014-04-08 08:11:00-04:00,GILD,neutral
551283.0,UPDATE: TD Ameritrade Says IMX for Mar. Up to 5.87,2014-04-07 12:47:00-04:00,GILD,neutral
551284.0,"Gilead Sets US FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combo Tablet, Sets PDUFA Date for Oct. 10th",2014-04-07 08:33:00-04:00,GILD,neutral
551285.0,"Gilead Says Results of Phase 3 Study of Sofosbuvir Confirm Efficacy, Safety",2014-04-02 16:30:00-04:00,GILD,positive
551286.0,Gilead's HepC Drug Sales May Be More Resilient Than Feared,2014-04-02 11:10:00-04:00,GILD,negative
551287.0,"Despite S&P 500's New High, Stocks Face Challenges ",2014-04-01 10:44:00-04:00,GILD,positive
551288.0,Market Wrap For March 27: Markets Lower Following Mixed Economic Data,2014-03-27 17:39:00-04:00,GILD,negative
551289.0,UPDATE: Gilead Sciences' LDV/SOF Receives Accelerated Assessment,2014-03-27 16:13:00-04:00,GILD,neutral
551290.0,EMA Validates Gilead's Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection,2014-03-27 16:12:00-04:00,GILD,positive
551291.0,Morgan Stanley's Top Biotech Pick is Biogen,2014-03-27 15:57:00-04:00,GILD,positive
551292.0,"Morgan Stanley Initiates Coverage on Gilead Sciences, Inc. at Equal-weight, Announces $75.00 PT",2014-03-27 07:05:00-04:00,GILD,neutral
551293.0,Morgan Stanley Starts Gilead Sciences With Equal-Weight;  $75 PT,2014-03-26 16:25:00-04:00,GILD,neutral
551294.0,Have We Seen The Top Of The Market?,2014-03-24 14:32:00-04:00,GILD,positive
551295.0,Idenix to Appeal Norway District Court Decision Regarding Patent Invalidity Case ,2014-03-24 07:02:00-04:00,GILD,neutral
551296.0,"Market Wrap For March 21: Markets End Friday On A Negative Note, But Still Positive For The Week",2014-03-21 16:38:00-04:00,GILD,positive
551297.0,U.S. Lawmakers Ask For Briefing From Gilead Sciences onn Price Of New Hepatitis C Drug Sovaldi,2014-03-21 10:28:00-04:00,GILD,neutral
551298.0,Market Wrap For March 14: Ukraine Tension Drag Markets Lower,2014-03-14 17:17:00-04:00,GILD,negative
551299.0,US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report,2014-03-14 07:25:00-04:00,GILD,neutral
551300.0,Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe ,2014-03-14 07:04:00-04:00,GILD,negative
551301.0,"UPDATE: TD Ameritrade's IMX Sentiment for Feb. Gains, Now at 5.74",2014-03-10 12:42:00-04:00,GILD,positive
551302.0,Market Wrap For March 6: Investors Find Positives In Jobless Claims,2014-03-06 17:06:00-05:00,GILD,positive
551303.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2014-02-26 04:18:00-05:00,GILD,negative
551304.0,Constructing A Hedged Portfolio Around A Position In Priceline.com,2014-02-24 10:16:00-05:00,GILD,neutral
551305.0,"Gilead Sciences VP Bischofberger Sells 90,000 Shares -Form 4",2014-02-19 14:14:00-05:00,GILD,positive
551306.0,A High Expected Return Watch List,2014-02-19 10:17:00-05:00,GILD,neutral
551307.0,Gilead Files for US Approval of Ledipasivr/Sofosbuvir Fixed-Dose Combo,2014-02-10 16:08:00-05:00,GILD,positive
551308.0,"Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)",2014-02-10 09:13:00-05:00,GILD,neutral
551309.0,Market Wrap For February 5: Markets Unsure Of Which Direction To Take,2014-02-05 16:47:00-05:00,GILD,negative
551310.0,"Stifel Nicolaus Maintains Buy on Gilead Sciences, Inc., Raises PT to $92.00",2014-02-05 07:24:00-05:00,GILD,neutral
551311.0,Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat,2014-02-04 16:46:00-05:00,GILD,neutral
551312.0,Market Wrap For February 4: Investors And Traders Go Bargain Hunting,2014-02-04 16:40:00-05:00,GILD,positive
551313.0,From Gilead Call: CEO Martin Highlighting FDA Priority Review for Idelalisib in CLL,2014-02-04 16:40:00-05:00,GILD,neutral
551314.0,"Gilead Sciences, Inc. Sees FY2014 Product Sales $11.30B-11.50B",2014-02-04 16:05:00-05:00,GILD,neutral
551315.0,"Gilead Sciences, Inc. Reports Q4 EPS of $0.55 vs $0.50 Est; Revenue of $3.12B vs $2.85B Est",2014-02-04 16:05:00-05:00,GILD,neutral
551316.0,"Baird Upgrades Gilead Sciences, Inc. to Outperform",2014-02-04 08:11:00-05:00,GILD,neutral
551317.0,"Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to $119.00",2014-02-04 07:31:00-05:00,GILD,neutral
551318.0,"#PreMarket Primer for Tuesday, February 4: Will The Plunge Continue?",2014-02-04 06:58:00-05:00,GILD,neutral
551319.0,Mylan Selected as Gilead's Exclusive Branded Medicines Business Partner for India ,2014-01-31 05:36:00-05:00,GILD,positive
551320.0,Idenix to Challenge Decision by USPTO Patent Trial and Appeal Board in First Patent Interference ,2014-01-29 18:05:00-05:00,GILD,positive
551321.0,Ian Estepan Tweet: Patent Office Website Indicates That $GILD Has Prevailed In Interference Proceeding Between '572 Patent And $IDIX '868 Application,2014-01-29 13:05:00-05:00,GILD,neutral
551322.0,"Deutsche Bank Boosts Target on Gilead to $132, on Celgene to $190, on Biogen to $415, Says We Would Be Buyers on Weakness",2014-01-28 08:07:00-05:00,GILD,negative
551323.0,Deutsche Bank Adds Gilead to 'Short-Term Buy' List,2014-01-23 14:31:00-05:00,GILD,neutral
551324.0,Gilead Announces EC Has Granted Marketing Authorization for Sovaldi,2014-01-17 09:09:00-05:00,GILD,positive
551325.0,Is The Market On Drugs?,2014-01-16 14:30:00-05:00,GILD,neutral
551326.0,FDA Accepts NDA for Gilead's Idelalisib for Treatment of Refractory Indolent Non-Hodgkin's Lymphoma ,2014-01-13 08:33:00-05:00,GILD,positive
551327.0,"Nomura Initiates Coverage on Gilead Sciences, Inc. at Buy, Announces $118.00 PT",2014-01-08 07:46:00-05:00,GILD,neutral
551328.0,"Targets on Gilead Raised from $87 to $96 at Citi, from $80 to $102 at UBS",2014-01-06 09:37:00-05:00,GILD,neutral
551329.0,"Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)",2013-12-26 13:26:00-05:00,GILD,positive
551330.0,UPDATE: Idenix Pharmaceuticals Spokesperson Says IDX20963 Still on Hold; Preclinical Work is Ongoing to Characterize the Genotoxicity Signal in Single Ames in vitro Test; No Update on Litigation,2013-12-24 13:10:00-05:00,GILD,negative
551331.0,Market Wrap For December 18: Markets Surge Following the Fed's Taper Announcement,2013-12-18 16:46:00-05:00,GILD,neutral
551332.0,"JP Morgan Lifts Target on Gilead from $85 to $100, Maintains Overweight",2013-12-18 10:10:00-05:00,GILD,neutral
551333.0,Gilead Sciences Says High Cure Rates Observed With Single Tablet Regimen May Eliminate Interferon And Ribavirin From Hcv Therapy For Genotype 1 Patients,2013-12-18 08:41:00-05:00,GILD,neutral
551334.0,"Gilead Issues SVR12 Rates from Three Phase 3 STudies, Says Ion-1 Rate 97.7%, NDA Submission Planned for Q1'14",2013-12-18 08:39:00-05:00,GILD,neutral
551335.0,Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013,2013-12-17 09:38:00-05:00,GILD,positive
551336.0,Market Wrap For December 16: Dow Posts Triple Point Gain Ahead of Fed Meeting,2013-12-16 16:55:00-05:00,GILD,positive
551337.0,Gilead Announces Health Canada Notice of Compliance for Sovaldi for Treatment of Chronic Hepatitis C ,2013-12-16 08:39:00-05:00,GILD,neutral
551338.0,FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera®   for Patients Switching from a Stable Regimen; Also Approved by European Comission,2013-12-13 16:32:00-05:00,GILD,positive
551339.0,The One True Sector Bubble: Profits Here When It Crashes Soon,2013-12-11 10:17:00-05:00,GILD,positive
551340.0,"Bloomberg Reporting Express Scripts' Miller in Phone Interview Said Aiming to Cut Costs for Hep C Drugs, Planning to Pit Gilead Against Other Drugmakers",2013-12-10 12:09:00-05:00,GILD,negative
551341.0,"Stocks to Watch for December 10, 2013",2013-12-10 11:28:00-05:00,GILD,neutral
551342.0,Market Wrap For December 9: Investors Digest Further Clues Hinting at An Upcoming Taper,2013-12-09 16:45:00-05:00,GILD,neutral
551343.0,Moody's Revises Gilead Outlook to Positive on Sovaldi Approval,2013-12-09 14:43:00-05:00,GILD,positive
551344.0,USA TD Ameritrade's Investor Movement Index for Nov 5.42 vs 5.07 Prior,2013-12-09 12:31:00-05:00,GILD,neutral
551345.0,Benzinga's Top #PreMarket Gainers,2013-12-09 08:08:00-05:00,GILD,positive
551346.0,Gilead Announces Phase 2 Study Results for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH ,2013-12-08 18:36:00-05:00,GILD,neutral
551347.0,Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia ,2013-12-07 20:03:00-05:00,GILD,positive
551348.0,Bloomberg First Word Reporting Gilead Has Won FDA Approval for Sofosbuvir,2013-12-06 16:15:00-05:00,GILD,positive
551349.0,"Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences ",2013-12-02 07:08:00-05:00,GILD,negative
551350.0,UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns,2013-11-27 11:16:00-05:00,GILD,positive
551351.0,10 Stocks To Be Thankful For This Thanksgiving,2013-11-27 11:12:00-05:00,GILD,positive
551352.0,"Piper Jaffray Reinstates Overweight on Gilead Sciences, Inc.",2013-11-26 16:22:00-05:00,GILD,negative
551353.0,UPDATE: Bank of America Increased Gilead Sciences PT,2013-11-22 15:23:00-05:00,GILD,positive
551354.0,EMA Says Gilead Sciences Granted Marketing Authorization for Sofosbuvir,2013-11-22 08:35:00-05:00,GILD,positive
551355.0,UPDATE: Citigroup Reiterates on Gilead Sciences on Positive Outlook,2013-11-20 10:15:00-05:00,GILD,positive
551356.0,"Citigroup Maintains Buy on Gilead Sciences, Inc., Raises PT to $87.00",2013-11-20 07:08:00-05:00,GILD,neutral
551357.0,"Gilead Says Idelalisib Significantly Reduced Rate of Disease Progression or Death in Phase 3 Trial, Met Primary, Secondary Endpoints",2013-11-18 09:18:00-05:00,GILD,negative
551358.0,UPDATE: Gilead Says Working on Resubmitting Vitekta to FDA as Single Agent,2013-11-18 08:15:00-05:00,GILD,neutral
551359.0,"European Commission Approves Gilead's Vitekta, HIV-1 Infection Treatment",2013-11-18 08:00:00-05:00,GILD,positive
551360.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,GILD,positive
551361.0,"J&J, Gilead Report HCV Combo Shows 93% SVR12 Rate Prior Null Responders, Says Medivir Showed No Benefit from Ribavirin, 12-Week Regimen Similar to 24",2013-11-04 16:34:00-05:00,GILD,positive
551362.0,Benzinga's Top #PreMarket Losers,2013-11-04 08:37:00-05:00,GILD,negative
551363.0,Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV ,2013-11-02 17:15:00-04:00,GILD,positive
551364.0,Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients,2013-11-02 17:12:00-04:00,GILD,positive
551365.0,Argus' Market Digest Summary,2013-11-01 10:47:00-04:00,GILD,neutral
551366.0,"Market Wrap for October 30: Fed Worries Push Stocks Lower, Facebook Earnings Raise Concerns",2013-10-30 16:52:00-04:00,GILD,negative
551367.0,Deutsche Bank Adds Gilead Sciences to 'Short-Term Buy' List,2013-10-30 11:13:00-04:00,GILD,neutral
551368.0,UPDATE: BMO Capital Markets Reiterates on Gilead Sciences Following Solid 3Q13 Results,2013-10-30 10:31:00-04:00,GILD,positive
551369.0,"Gilead Sciences, Inc. Reports Q3 EPS of $0.52 vs $0.48 Est; Revenue of $2.78B vs $2.72B Est",2013-10-29 16:02:00-04:00,GILD,neutral
551370.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,GILD,positive
551371.0,Gilead's Stribild Demonstrates Durable Viral Suppression in Two Phase 3 Studies,2013-10-16 06:00:00-04:00,GILD,neutral
551372.0,FDA Reporting Gilead Wins Orphan Drug Designation for Idealalisib,2013-10-15 18:05:00-04:00,GILD,positive
551373.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,GILD,neutral
551374.0,UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit ,2013-10-09 16:20:00-04:00,GILD,positive
551375.0,UPDATE: Gilead Says Planning to File Idelaisib in EU Later This Year,2013-10-09 16:19:00-04:00,GILD,neutral
551376.0,"Gilead Says Will Stop Phase 3 Study 116 of Idelalisib in CLL, Says Will Engage in Dialogue with FDA",2013-10-09 16:18:00-04:00,GILD,positive
551377.0,"Biotech ETFs Plummeting (XBI, IBB, BBH)",2013-10-08 12:42:00-04:00,GILD,neutral
551378.0,"Playing Momentum With ETFs (PDP, PIE, MTUM)",2013-10-07 15:52:00-04:00,GILD,positive
551379.0,Shares of Gilead Bouncing Off Lows; Several Analysts Making Reassuring Comments,2013-10-07 11:47:00-04:00,GILD,positive
551380.0,Gilead Wins Orphan Drug Status for Lymphoma Treatment,2013-09-27 13:05:00-04:00,GILD,positive
551381.0,European Commission Gives Okay on Gilead's Tybost for HIV Therapy,2013-09-25 16:32:00-04:00,GILD,positive
551382.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,GILD,positive
551383.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,GILD,positive
551384.0,Some New ETFs Off To Impressive Starts,2013-09-12 13:18:00-04:00,GILD,positive
551385.0,UPDATE: Gilead Says Will File for EU Approval of Idelalisib in Q4,2013-09-11 16:18:00-04:00,GILD,positive
551386.0,Gilead Submits NDA to FDA for Idealalisib for Treatment of NHL,2013-09-11 16:17:00-04:00,GILD,neutral
551387.0,Biotech Breakout Highlights Flawed ETF Thinking,2013-09-05 14:31:00-04:00,GILD,neutral
551388.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,GILD,positive
551389.0,How Much Does It Cost To Develop A New Drug?,2013-08-14 09:32:00-04:00,GILD,neutral
551390.0,AHF Wins Major Ruling against FDA on Gilead Prevention Pill ,2013-08-07 13:30:00-04:00,GILD,positive
551391.0,"Three Soaring, But Overlooked Health Care ETFs",2013-08-02 14:19:00-04:00,GILD,positive
551392.0,Three ETFs That Have Blown Past Their 200-Day Lines,2013-07-30 12:48:00-04:00,GILD,neutral
551393.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,GILD,positive
551394.0,"Baird Downgrades Gilead Sciences, Inc. to Neutral",2013-07-26 09:58:00-04:00,GILD,neutral
551395.0,Atlantic Equities Upgrades Gilead Sciences to Overweight,2013-07-26 07:32:00-04:00,GILD,negative
551396.0,Gilead Sciences Rises After Q2 Report (GILD),2013-07-25 20:32:00-04:00,GILD,neutral
551397.0,"Gilead Sciences, Inc. Reports Q2 EPS of $0.50, Inline; Revenue of $2.66B vs $2.66B Est",2013-07-25 16:06:00-04:00,GILD,neutral
551398.0,"Economic Calendar for Thursday July 25, 2013",2013-07-25 06:18:00-04:00,GILD,neutral
551399.0,Benzinga's Top Pre-Market Losers,2013-07-22 08:22:00-04:00,GILD,negative
551400.0,"Kris Jenner of Rock Springs Capital Mentioning Vertex, Gilead, Pharmacyclics",2013-07-17 15:52:00-04:00,GILD,neutral
551401.0,"Benzinga's M&A Chatter for Tuesday July 16, 2013",2013-07-16 19:42:00-04:00,GILD,neutral
551402.0,Gilead Not Commenting on Potential Bid for Onyx,2013-07-16 13:54:00-04:00,GILD,neutral
551403.0,"UPDATE: Amgen, Pfizer, Bristol-Myers Squibb, Gilead Among Companies that May Submit Bids for Onyx, According to Sources",2013-07-16 12:19:00-04:00,GILD,neutral
551404.0,Health Care ETFs Looking Healthy Ahead of Earnings,2013-07-15 15:43:00-04:00,GILD,positive
551405.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,GILD,positive
551406.0,ETFs For an Onyx Takeover Battle,2013-07-01 13:02:00-04:00,GILD,negative
551407.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,GILD,positive
551408.0,Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results,2013-06-17 11:15:00-04:00,GILD,neutral
551409.0,Gilead Interim Phase 2 Data for Idelalisib Shows Response in Refractory Indolent Non-Hodgkin's Lymphoma ,2013-06-17 06:08:00-04:00,GILD,neutral
551410.0,"Argus Research Upgrades Gilead Sciences, Inc. to Buy, Announces $62.00 PT",2013-06-13 09:05:00-04:00,GILD,neutral
551411.0,Gilead Shares Unaffected Following Headlines Viread Study Shows Reduced HIV Risk Among 49% of Patients,2013-06-12 15:00:00-04:00,GILD,neutral
551412.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,GILD,positive
551413.0,Benzinga's Top Pre-Market Gainers,2013-06-10 08:20:00-04:00,GILD,positive
551414.0,"Gilead Gets FDA Priority Review for Sofosbuvir for Hep C, Says PDUFA Date Dec. 8th",2013-06-07 17:20:00-04:00,GILD,neutral
551415.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,GILD,positive
551416.0,"European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection",2013-05-28 08:37:00-04:00,GILD,positive
551417.0,Gilead Receives MAA for Hep C Treatment,2013-05-21 16:31:00-04:00,GILD,neutral
551418.0,Gilead Offers Response Data from Phase 2 Study of Idelalisib,2013-05-15 18:32:00-04:00,GILD,neutral
551419.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,GILD,positive
551420.0,S&P Highlights Biotech ETFs,2013-05-10 07:39:00-04:00,GILD,neutral
551421.0,"Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data",2013-05-03 16:28:00-04:00,GILD,positive
551422.0,Three Sector ETFs Up 20% or More YTD,2013-05-03 08:09:00-04:00,GILD,neutral
551423.0,"Gilead Sciences, Inc. Reports Q1 EPS of $0.48 vs $0.50 Est; Revenue of $2.53B vs $2.58B Est",2013-05-02 16:05:00-04:00,GILD,neutral
551424.0,"Benzinga Market Primer: Thursday, May 2",2013-05-02 06:53:00-04:00,GILD,neutral
551425.0,Illumina and Other Bargain Biotech Stocks Worth a Look Now,2013-05-01 12:57:00-04:00,GILD,positive
551426.0,"Gilead Receives CRL from FDA for Elvitegravir, Cobicistat",2013-04-29 08:31:00-04:00,GILD,neutral
551427.0,Earnings Expectations for the Week of April 29,2013-04-28 17:31:00-04:00,GILD,neutral
551428.0,A Look Ahead: This Week's ETFs to Watch,2013-04-28 17:28:00-04:00,GILD,neutral
551429.0,Weekly Preview: Focus Shifts from Earnings to Economy,2013-04-26 16:35:00-04:00,GILD,neutral
551430.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,GILD,neutral
551431.0,"Gilead Hep-C Combo Cures 100% of Patients in Study, Results Presented in Amsterdam",2013-04-25 11:55:00-04:00,GILD,neutral
551432.0,"Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to $63.00",2013-04-23 13:33:00-04:00,GILD,negative
551433.0,"Gilead, Bristol Hepatitis-C Drug Combination Suppresses Virus in Study, Helps Those Who Fail Other Drugs",2013-04-23 07:38:00-04:00,GILD,negative
551434.0,Gildead Presents Data from Phase 3 Studies of Sofosbuvir for Hepatitis C ,2013-04-23 06:10:00-04:00,GILD,neutral
551435.0,Gilead Sciences Target Boosted Sharply from $48 to $97 at Maxim,2013-04-22 14:39:00-04:00,GILD,positive
551436.0,Biotech Mutual Funds Show ETFs Are The Place to Be,2013-04-22 12:41:00-04:00,GILD,neutral
551437.0,UPDATE: Morgan Stanley Raises PT on Gilead Sciences on Multiple Positive Factors,2013-04-22 10:59:00-04:00,GILD,positive
551438.0,"Morgan Stanley Maintains Overweight on Gilead Sciences, Inc., Raises PT to $65.00",2013-04-22 07:45:00-04:00,GILD,negative
551439.0,A Look Ahead: This Week's ETFs to Watch,2013-04-21 18:22:00-04:00,GILD,neutral
551440.0,"Weekly Preview: Earnings Season Continues, Apple In Focus",2013-04-19 16:38:00-04:00,GILD,neutral
551441.0,Vertex News Lifts Biotech ETFs,2013-04-19 10:52:00-04:00,GILD,neutral
551442.0,UPDATE: Deutsche Bank Raises PT on Gilead Sciences on Monthly HCV Market Model,2013-04-16 11:06:00-04:00,GILD,neutral
551443.0,"Deutsche Bank Maintains Buy on Gilead Sciences, Inc., Raises PT to $69.00",2013-04-16 08:21:00-04:00,GILD,neutral
551444.0,"Leerink Swann Maintains Outperform on Gilead Sciences, Inc., Raises PT to $70.00",2013-04-15 08:59:00-04:00,GILD,neutral
551445.0,A Look Ahead: This Week's ETFs to Watch ,2013-04-14 19:52:00-04:00,GILD,neutral
551446.0,"UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to $59.00",2013-04-12 10:20:00-04:00,GILD,neutral
551447.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,GILD,negative
551448.0,Under The Hood: An Unheralded Biotech ETF,2013-04-11 13:53:00-04:00,GILD,neutral
551449.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,GILD,neutral
551450.0,Gilead Hep C Drug Likely to be Launched in Q1 2014,2013-04-09 14:14:00-04:00,GILD,positive
551451.0,These Are the 100 Highest-Paid CEOs in Business Today,2013-04-08 16:30:00-04:00,GILD,neutral
551452.0,Gilead Submits NDA to FDA for Sofosbuvir for Hep C,2013-04-08 16:30:00-04:00,GILD,neutral
551453.0,Some Companies Aren't Evil... And Some Even Save Lives,2013-04-05 09:28:00-04:00,GILD,positive
551454.0,"Benzinga's M&A Chatter for Thursday April 4, 2013",2013-04-04 17:54:00-04:00,GILD,neutral
551455.0,"Credit Suisse Maintains Outperform on Gilead Sciences, Inc., Raises PT to $60.00",2013-04-04 11:48:00-04:00,GILD,positive
551456.0,Hearing Chatter Dan Loeb Has Taken Significant Stake in Gilead,2013-04-04 10:09:00-04:00,GILD,positive
551457.0,Biotech Breakout Boosting ETFs,2013-03-28 15:21:00-04:00,GILD,positive
551458.0,Stocks Hitting 52-Week Highs,2013-03-28 10:21:00-04:00,GILD,neutral
551459.0,"Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences",2013-03-28 08:18:00-04:00,GILD,negative
551460.0,Benzinga's Top Pre-Market Gainers,2013-03-27 08:06:00-04:00,GILD,positive
551461.0,Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients ,2013-03-26 08:31:00-04:00,GILD,neutral
551462.0,Moving Averages Indicate These Sector ETFs Could be Stretched,2013-03-25 17:33:00-04:00,GILD,neutral
551463.0,Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost,2013-03-25 15:37:00-04:00,GILD,positive
551464.0,"Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results",2013-03-25 13:11:00-04:00,GILD,neutral
551465.0,"Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit",2013-03-25 11:03:00-04:00,GILD,positive
551466.0,Morning Market Losers,2013-03-25 10:15:00-04:00,GILD,negative
551467.0,Benzinga's Top Pre-Market Losers,2013-03-25 08:39:00-04:00,GILD,negative
551468.0,Gilead Confirms Positive CHMP Opinion for Stribild,2013-03-22 08:37:00-04:00,GILD,positive
551469.0,"EMA Gives Positive Opinion's on Baxter's Hyqvia, ARIAD Pharma's Iclusig, Gilead's Stribild",2013-03-22 08:28:00-04:00,GILD,positive
551470.0,"Citigroup Maintains Buy on Gilead Sciences, Inc., Raises PT to $60.00",2013-03-18 06:32:00-04:00,GILD,neutral
551471.0,"Three Top Performing BRIC Stocks (CBPO, GSH, VIPS)",2013-03-17 15:13:00-04:00,GILD,positive
551472.0,Exploring No Man's Land ETFs,2013-03-15 14:23:00-04:00,GILD,negative
551473.0,Report of 14 Adults 'Cured' of HIV -NewScientist,2013-03-15 06:27:00-04:00,GILD,neutral
551474.0,UPDATE: Oppenheimer Raises Gilead PT on Promising Oncology Pipeline,2013-03-14 11:21:00-04:00,GILD,positive
551475.0,"Oppenheimer Maintains Outperform on Gilead Sciences, Inc., Raises PT to $50.00",2013-03-14 08:04:00-04:00,GILD,neutral
551476.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,GILD,positive
551477.0,"Deutsche Bank Reiterates Buy Rating, $48 PT on Gilead Sciences on IMS Weekly Script Analysis",2013-03-11 10:50:00-04:00,GILD,neutral
551478.0,A Look Ahead: This Week's ETFs to Watch ,2013-03-11 07:12:00-04:00,GILD,neutral
551479.0,Study Shows Gilead's Ranexa Reduces Angina Frequency in Chronic Angina Patients With Type 2 Diabetes ,2013-03-10 15:36:00-04:00,GILD,neutral
551480.0,"If Stocks Keep Soaring, Get to Know These Leveraged ETFs",2013-03-08 14:16:00-05:00,GILD,neutral
551481.0,UPDATE: Piper Jaffray Raises PT to $50 on Gilead Sciences on Positive Data,2013-03-05 12:59:00-05:00,GILD,positive
551482.0,Gilead Reports Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel TAF,2013-03-05 12:16:00-05:00,GILD,positive
551483.0,"Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to $50.00",2013-03-05 08:32:00-05:00,GILD,negative
551484.0,AHF Seeking FDA Reversal on Gilead's HIV Prevention Pill for Women,2013-03-05 07:36:00-05:00,GILD,neutral
551485.0,An HIV Cure Is Great News For These Drug Manufacturers,2013-03-04 15:22:00-05:00,GILD,positive
551486.0,HIV Infected Baby 'Cured' with Aggressive Drug Treatment -NYT,2013-03-03 17:50:00-05:00,GILD,negative
551487.0,"Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)",2013-02-28 15:13:00-05:00,GILD,positive
551488.0,Gilead Shares Moving Higher as BofA Merrill Added to 'US 1 List',2013-02-25 09:17:00-05:00,GILD,positive
551489.0,Gilead's Sofosbuvir Meets Primary Endpoint in Fourth Pivotal Phase 3 Study,2013-02-19 08:33:00-05:00,GILD,neutral
551490.0,"Credit Suisse Upgrades Gilead Sciences, Inc. to Outperform, Raises PT to $55.00",2013-02-19 08:31:00-05:00,GILD,positive
551491.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,GILD,positive
551492.0,"UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to $48.00",2013-02-05 11:30:00-05:00,GILD,neutral
551493.0,"Atlantic Equities Downgraded Gilead Sciences, Inc. to Neutral, Raised PT to $41.00",2013-02-05 11:25:00-05:00,GILD,neutral
551494.0,YM Biosciences Wins Final Court Order Approving Plan of Arrangement with Gilead,2013-02-05 10:48:00-05:00,GILD,positive
551495.0,Stocks Hitting 52-Week Highs,2013-02-05 10:05:00-05:00,GILD,neutral
551496.0,"Jefferies Maintains Hold on Gilead Sciences, Inc., Raises PT to $40.00",2013-02-05 08:27:00-05:00,GILD,neutral
551497.0,"Stifel Nicolaus Maintains Buy on Gilead Sciences, Inc., Raises PT to $49.00",2013-02-05 07:55:00-05:00,GILD,neutral
551498.0,UPDATE: Gilead Posts Upbeat Q4 Results,2013-02-05 01:37:00-05:00,GILD,neutral
551499.0,"Gilead Sciences, Inc. Reports Q4 EPS of $0.50 vs $0.48 Est; Revenue of $2.59B vs $2.43B Est",2013-02-04 16:05:00-05:00,GILD,neutral
551500.0,Morgan Stanley Reiterates Overweight Rating on Gilead Sciences on Phase III Data,2013-02-04 13:22:00-05:00,GILD,negative
551501.0,"Piper Jaffray Reiterates Overweight Rating, $44 PT on Gilead Sciences",2013-02-04 12:22:00-05:00,GILD,negative
551502.0,Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir,2013-02-04 08:40:00-05:00,GILD,neutral
551503.0,US Stock Futures Flat Ahead Of Factory-Orders Data,2013-02-04 05:47:00-05:00,GILD,neutral
551504.0,"Earnings Scheduled For February 4, 2013",2013-02-04 01:16:00-05:00,GILD,neutral
551505.0,"UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences",2013-01-30 14:18:00-05:00,GILD,negative
551506.0,"UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to $47.00",2013-01-30 10:19:00-05:00,GILD,neutral
551507.0,"Deutsche Bank Maintains Buy on Gilead Sciences, Inc., Lowers PT to $48.00",2013-01-30 09:27:00-05:00,GILD,negative
551508.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,GILD,positive
551509.0,Friday January 25th Watchlist,2013-01-24 21:31:00-05:00,GILD,neutral
551510.0,"Morgan Stanley Sees Possible Near-Term Increase in M&A, Unveils 'Acquisition Likelihood Estimate Ranking Tool'",2013-01-22 10:07:00-05:00,GILD,positive
551511.0,One Biotech Stock Investors are Unfairly Ignoring,2013-01-15 09:00:00-05:00,GILD,negative
551512.0,4 Health Care ETFs Your Broker Forgot to Mention,2013-01-07 15:52:00-05:00,GILD,positive
551513.0,Gilead Offers Update on Hep C Development Plans,2013-01-07 08:33:00-05:00,GILD,neutral
551514.0,MacroGenics Enters License Agreement with Gilead Sciences to Develop and Commercialize Four DART Products ,2013-01-07 07:31:00-05:00,GILD,positive
551515.0,"Baird Initiates Coverage on Gilead Sciences, Inc. at Outperform, Announces $86.00 PT",2013-01-03 18:21:00-05:00,GILD,neutral
551516.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,GILD,positive
551517.0,"UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to $87.00",2012-12-18 10:40:00-05:00,GILD,neutral
551518.0,UPDATE: Bloom Burton Downgrades YM BioSciences to Hold Post Gilead Acquisition  ,2012-12-17 13:10:00-05:00,GILD,neutral
551519.0,"Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to $88.00",2012-12-14 10:03:00-05:00,GILD,negative
551520.0,"Goldman Sachs Reinstates Neutral on Gilead Sciences, Inc., Announces $81.00 PT",2012-12-13 06:16:00-05:00,GILD,neutral
551521.0,"Benzinga's M&A Chatter for Wednesday December 12, 2012",2012-12-12 17:59:00-05:00,GILD,neutral
551522.0,J.P. Morgan Reiterates Overweight Rating on Gilead Sciences,2012-12-12 13:18:00-05:00,GILD,negative
551523.0,These ETFs Are Awash in 2013 Takeover Targets,2012-12-12 13:01:00-05:00,GILD,neutral
551524.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,GILD,positive
551525.0,Morning Market Movers,2012-12-12 09:53:00-05:00,GILD,neutral
551526.0,UPDATE: Gilead to Buy YM BioSciences for $2.95/Share in Cash,2012-12-12 08:38:00-05:00,GILD,neutral
551527.0,Gilead Sciences to Buy YM Biosciences for $2.95/Share in Cash,2012-12-12 08:32:00-05:00,GILD,neutral
551528.0,Gilead Board Approves Two-for-One Stock Split  ,2012-12-10 16:16:00-05:00,GILD,positive
551529.0,"A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)",2012-12-08 23:17:00-05:00,GILD,positive
551530.0,"Barclays Maintains Overweight on Gilead Sciences, Inc., Raises PT to $76.00",2012-12-04 14:27:00-05:00,GILD,negative
551531.0,"BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November",2012-12-02 20:29:00-05:00,GILD,positive
551532.0,"RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November",2012-12-01 13:38:00-05:00,GILD,positive
551533.0,"EC Approves Gilead's Viread for HIV-1 Infection in Children, Adolescents",2012-11-27 16:32:00-05:00,GILD,positive
551534.0,Gilead Shares Continuing Higher After Teva Says Won't Offer Gilead Generics Til June 1st or Court Ruling,2012-11-27 14:09:00-05:00,GILD,positive
551535.0,Gilead Announces Sustained Virologic Response Rate of 78% from Phase 3 Study of Sofosbuvir,2012-11-27 08:35:00-05:00,GILD,neutral
551536.0,Gilead Announces Results from Two Phase 3  Stribild HIV Studies ,2012-11-15 07:25:00-05:00,GILD,neutral
551537.0,UPDATE: BMO Capital Markets Reiterates Gilead Sciences at Outperform on Positive ELECTRON Data Results,2012-11-14 11:21:00-05:00,GILD,positive
551538.0,UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data  ,2012-11-13 14:17:00-05:00,GILD,neutral
551539.0,UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data  ,2012-11-13 11:07:00-05:00,GILD,neutral
551540.0,Stocks Hitting 52-Week Highs,2012-11-13 10:10:00-05:00,GILD,neutral
551541.0,"Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from $80 to $85",2012-11-13 07:50:00-05:00,GILD,neutral
551542.0,"Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from $75 to $95",2012-11-13 07:37:00-05:00,GILD,neutral
551543.0,Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further,2012-11-12 16:04:00-05:00,GILD,negative
551544.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,GILD,positive
551545.0,Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower,2012-11-12 12:49:00-05:00,GILD,negative
551546.0,Stocks Hitting 52-Week Highs,2012-11-12 11:02:00-05:00,GILD,neutral
551547.0,Mid-Morning Market Update: Markets Continue Cautious Rally; Jefferies Acquired by Leucadia ,2012-11-12 10:21:00-05:00,GILD,negative
551548.0,Benzinga's Top Pre-Market Gainers,2012-11-12 08:13:00-05:00,GILD,positive
551549.0,Gilead Sciences Rises 10% Pre-Market on Positive Hepatitis C Data,2012-11-12 07:41:00-05:00,GILD,positive
551550.0,Gilead Announces Positive Hepatitis C Data,2012-11-12 07:38:00-05:00,GILD,positive
551551.0,Gilead's Once-Daily Novel Prodrug for the Treatment of HIV Meets 24-Week Primary Objective in Phase 2 Study,2012-10-31 08:14:00-04:00,GILD,positive
551552.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,GILD,positive
551553.0,S&P Likes a Trio of Biotech ETFs ,2012-10-24 16:09:00-04:00,GILD,positive
551554.0,"UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Gilead Sciences",2012-10-24 12:43:00-04:00,GILD,positive
551555.0,"UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences",2012-10-24 10:41:00-04:00,GILD,neutral
551556.0,"BMO Capital Markets Maintains Gilead Sciences at Outperform, raises PT from $67 to $89",2012-10-24 07:56:00-04:00,GILD,neutral
551557.0,"Credit Suisse Maintains Gilead Sciences at Neutral, Raises PT from $54 to $65",2012-10-24 07:42:00-04:00,GILD,positive
551558.0,"Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from $55 to $59",2012-10-24 07:26:00-04:00,GILD,neutral
551559.0,Gilead Sciences Reports Q3 EPS $1 vs $0.94 Est; Revenues $2.43B vs $2.34B Est,2012-10-23 16:02:00-04:00,GILD,neutral
551560.0,"Barclays Maintains Gilead Sciences at Overweight, Raises PT from $65 to $73",2012-10-15 12:11:00-04:00,GILD,negative
551561.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)",2012-10-15 06:59:00-04:00,GILD,positive
551562.0,"Piper Jaffray Maintains Gilead Sciences at Overweight, Raises PT from $69 to $85",2012-10-08 10:11:00-04:00,GILD,negative
551563.0,"Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)",2012-10-03 14:57:00-04:00,GILD,positive
551564.0,"UBS Maintains Gilead Sciences at Buy, Raises PT from $65 to $80",2012-10-03 10:25:00-04:00,GILD,neutral
551565.0,Bernstein Upgraded Gilead Sciences from Market Perform to Outperform,2012-10-01 09:26:00-04:00,GILD,neutral
551566.0,"Bank of America Maintains Gilead Sciences at Buy, Raises PO from $64 to $86",2012-09-27 06:46:00-04:00,GILD,negative
551567.0,"Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)",2012-09-26 13:22:00-04:00,GILD,positive
551568.0,"UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Gilead Sciences",2012-09-19 10:32:00-04:00,GILD,neutral
551569.0,Long set-ups for Wednesday,2012-09-19 10:23:00-04:00,GILD,neutral
551570.0,"Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from $68 to $75",2012-09-19 06:18:00-04:00,GILD,neutral
551571.0,Top Narrow Based Indexes For September 17,2012-09-17 10:48:00-04:00,GILD,positive
551572.0,Stocks Hitting 52-Week Highs,2012-09-17 10:27:00-04:00,GILD,neutral
551573.0,"JP Morgan Maintains Gilead Sciences at Overweight, Raises PT from $70 to $75",2012-09-17 07:01:00-04:00,GILD,neutral
551574.0,Gilead Accelerates Expiration of Rights Pact,2012-09-14 16:07:00-04:00,GILD,neutral
551575.0,Short Sellers Shy Away from Biotech Firms,2012-09-13 13:34:00-04:00,GILD,negative
551576.0,Gilead Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-09-12 18:31:00-04:00,GILD,positive
551577.0,Gilead Reiterates Its FY12 Forecast for Net Product Sales $8.8-9B,2012-09-12 12:29:00-04:00,GILD,neutral
551578.0,Gilead Sciences Begins Presentation at Morgan Stanley Conference,2012-09-12 12:12:00-04:00,GILD,neutral
551579.0,"Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)",2012-09-05 15:34:00-04:00,GILD,positive
551580.0,"UBS Maintains Gilead Sciences at Buy, Raises PT from $61 to $65",2012-08-30 10:31:00-04:00,GILD,neutral
551581.0,UPDATE: Stifel Nicolaus Raises PT to $68 on Gilead Sciences,2012-08-28 13:21:00-04:00,GILD,neutral
551582.0,"Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from $65 to $68",2012-08-28 08:36:00-04:00,GILD,neutral
551583.0,"Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from $53 to $55",2012-08-28 06:49:00-04:00,GILD,neutral
551584.0,Gilead Quad Pill Wins FDA Approval to Treat Patients with HIV -Bloomberg,2012-08-27 17:02:00-04:00,GILD,positive
551585.0,Short Interest in Biotech Firms on the Rise,2012-08-27 15:21:00-04:00,GILD,positive
551586.0,Bristol-Myers' Trash is Gilead Sciences' Treasure,2012-08-24 09:16:00-04:00,GILD,positive
551587.0,Idenix Shares Plunge After Hepatitis Drug Study Put on Hold ,2012-08-17 09:43:00-04:00,GILD,positive
551588.0,"Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from $65 to $68",2012-08-15 06:22:00-04:00,GILD,neutral
551589.0,Short Sellers Shy Away from Biotech Firms,2012-08-13 06:18:00-04:00,GILD,negative
551590.0,Barclays Upgrades Gilead Sciences from Equal-weight to Overweight,2012-08-02 11:55:00-04:00,GILD,negative
551591.0,Mylan Signs Agreement with Gilead to Accelerate Access to Generic Single and Fixed-Dose Combination ARVs Containing Emtricitabine ,2012-08-02 10:21:00-04:00,GILD,positive
551592.0,Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries   ,2012-08-02 09:24:00-04:00,GILD,positive
551593.0,"Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from $57 to $65",2012-08-02 06:06:00-04:00,GILD,neutral
551594.0,Possible Hepatitis C Outbreak Could Lift This ETF,2012-07-30 06:53:00-04:00,GILD,neutral
551595.0,UPDATE: Jefferies Raises PT on Gilead Science from $48 to $53,2012-07-27 11:38:00-04:00,GILD,neutral
551596.0,"Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from $55 to $60",2012-07-27 08:52:00-04:00,GILD,neutral
551597.0,"Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from $48 to $53",2012-07-27 06:29:00-04:00,GILD,neutral
551598.0,Gilead Sciences Reports Q2 EPS $0.99 vs $0.95 Est; Revenues $2.41B vs $2.29B Est,2012-07-26 16:07:00-04:00,GILD,neutral
551599.0,Gilead's Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens   ,2012-07-24 11:01:00-04:00,GILD,neutral
551600.0,Gilead's Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study   ,2012-07-24 11:00:00-04:00,GILD,positive
551601.0,UPDATE: U.S. Food and Drug Administration Approves Gilead's Truvada® for Reducing the Risk of Acquiring HIV,2012-07-16 12:47:00-04:00,GILD,positive
551602.0,Gilead Wins FDA Approval for Truvada to Prevent HIV Risk,2012-07-16 12:36:00-04:00,GILD,positive
551603.0,Glaxo HIV Drug Beats Gilead's Atripla In Study -IBD,2012-07-11 12:34:00-04:00,GILD,neutral
551604.0,Small-Cap Corner: A Forgotten Biotech ETF,2012-07-05 18:11:00-04:00,GILD,negative
551605.0,Heating Positive Chatter in Achillion Pharmaceuticals,2012-06-29 09:38:00-04:00,GILD,positive
551606.0,Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat   ,2012-06-28 16:30:00-04:00,GILD,positive
551607.0,Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients   ,2012-06-27 16:30:00-04:00,GILD,negative
551608.0,European Medicines Agency Validates Gilead's Marketing Application for Elvitegravir for Treatment of HIV Infection,2012-06-18 16:32:00-04:00,GILD,positive
551609.0,"Gilead Sciences Says Very Robust Pipeline in Phase 2, Phase 3",2012-06-13 09:04:00-04:00,GILD,positive
551610.0,Gilead Sciences Presentation Begins at William Blair Growth Stock Conference,2012-06-13 09:02:00-04:00,GILD,positive
551611.0,"PREVIEW: Gilead Sciences, Scotts Miracle-Gro to Present at William Blair Growth Stock Conference at 9:00am",2012-06-13 07:45:00-04:00,GILD,positive
551612.0,FDA Delays Decision on Gilead's Truvada to Prevent HIV -Bloomberg,2012-06-08 14:28:00-04:00,GILD,neutral
551613.0,"The Definitive Biotech ETF Guide (IBB, XBI, FBT)",2012-05-21 13:35:00-04:00,GILD,neutral
551614.0,"J.P. Morgan Reiterates Overweight Rating, $65 PT for Gilead Sciences",2012-05-16 12:12:00-04:00,GILD,negative
551615.0,"Third Point Initiates Stake in Gilead Sciences, Hollyfrontier, Newell Rubbermaid, Potash",2012-05-15 17:42:00-04:00,GILD,neutral
551616.0,"S&P Bullish On Biotech ETFs (FBT, IBB, XBI)",2012-05-15 14:31:00-04:00,GILD,neutral
551617.0,HIV Drug Maker Gilead Sciences Scores Two Wins,2012-05-14 12:14:00-04:00,GILD,positive
551618.0,UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV   ,2012-05-11 15:31:00-04:00,GILD,positive
551619.0,FDA Advisory Panel Votes 13-1 to Recommend Gilead's Quad,2012-05-11 14:42:00-04:00,GILD,positive
551620.0,From Earlier: FDA Advisory Committee Supports Approval of Gilead's Truvada® for Reducing the Risk of Acquiring HIV  ,2012-05-11 08:52:00-04:00,GILD,positive
551621.0,FDA Staff Saying Research Shows Gilead's Quad to Be Non-Inferior to Comparator Groups with Respect to Efficacy -Reuters ,2012-05-09 08:41:00-04:00,GILD,positive
551622.0,UPDATE: Gilead's HIV Quad Drug Faces FDA Panel Review Friday,2012-05-09 07:57:00-04:00,GILD,neutral
551623.0,Gilead Initiates Phase 3 Clinical Trial of GS-1101 for the Treatment of Chronic Lymphocytic Leukemia,2012-05-01 18:01:00-04:00,GILD,neutral
551624.0,Gilead Sciences Reports Q1 EPS $0.91 vs $0.94 Est; Revenues $2.21B vs $2.20B Est,2012-04-26 16:55:00-04:00,GILD,neutral
551625.0,"Hedge Fund Shkreli Making Negative Comments on Gilead Sciences, Shorting Shares",2012-04-19 11:53:00-04:00,GILD,negative
551626.0,Notable Options Activity in Gilead Sciences Inc,2012-04-19 10:13:00-04:00,GILD,neutral
551627.0,Benzinga's Top Pre-Market Gainers,2012-04-19 08:05:00-04:00,GILD,positive
551628.0,"Financial Breakfast: Morning News Summary for April 19, 2012",2012-04-19 07:38:00-04:00,GILD,neutral
551629.0,Gilead Sciences Rises 15% on Release of Phase 2 Hepatitis C Data,2012-04-19 07:23:00-04:00,GILD,neutral
551630.0,From Earlier: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients  ,2012-04-19 07:22:00-04:00,GILD,neutral
551631.0,Hearing UBS Positive on Gilead Sciences,2012-04-04 13:59:00-04:00,GILD,positive
551632.0,Brean Murray Carret Discusses Gilead's Potential Competitor,2012-04-03 09:09:00-04:00,GILD,neutral
551633.0,"UPDATE: Stifel Nicolaus Resumes Buy, $57 PT on Gilead Sciences",2012-03-15 11:43:00-04:00,GILD,neutral
551634.0,Idenix Pharmaceuticals Spokesperson Says Resolution in Patent Interference Claim Against Gilead Could Take Up to 2 Years,2012-03-13 10:45:00-04:00,GILD,neutral
551635.0,Hearing Leering Says Gilead Will Have to Pay Licensing Fee to Idenix,2012-03-13 09:34:00-04:00,GILD,negative
551636.0,The Portfolio Bids Adieu to Gilead and Banco Itau,2012-03-13 04:01:00-04:00,GILD,neutral
551637.0,Gilead Launching New Single Tablet AIDS Drug This Year,2012-03-09 14:08:00-05:00,GILD,neutral
551638.0,"Gilead Analyst: The Abstract Stated That Total Cholesterol and LDL Increases Are Significantly Lower for Quad.  Some HIV Medicines Have Been Linked to an Increase in Cholesterol, Which Can Lead to Heart Attacks.",2012-03-07 15:35:00-05:00,GILD,negative
551639.0,Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study,2012-03-07 15:01:00-05:00,GILD,neutral
551640.0,Morgan Stanley Updates Gilead Sciences Model,2012-03-07 09:26:00-05:00,GILD,neutral
551641.0,"Researcher Says 8 Of The 9 ""null"" Hepatitis C Patients Who Have Reached 4 Weeks Post-Treatment In Trial Of Gilead's GS-7977 Have Relapsed -Reuters ",2012-03-06 10:47:00-05:00,GILD,positive
551642.0,"Hearing Goldman Sachs Reiterating Gilead Sciences as Top Pick for 2012, Making Positive Comments",2012-03-05 10:48:00-05:00,GILD,positive
551643.0,"Option Alert: Gilead Sciences April 50 Call; Block Trade, 3,835 Contracts",2012-03-02 10:05:00-05:00,GILD,negative
551644.0,"Deutsche Bank Reiterates Buy, $57 PT on Gilead Sciences",2012-02-27 09:48:00-05:00,GILD,neutral
551645.0,Morgan Stanley: 7977 Will Be Vital in All-Oral HCV Therapy,2012-02-27 09:06:00-05:00,GILD,positive
551646.0,UPDATE: Deutsche Bank Cuts Target to $57 on Gilead Sciences,2012-02-24 10:29:00-05:00,GILD,negative
551647.0,JP Morgan Remains Bullish on Gilead Sciences,2012-02-23 10:30:00-05:00,GILD,positive
551648.0,Hearing Deutsche Bank Making Negative Comments on Gilead Sciences,2012-02-22 15:07:00-05:00,GILD,negative
551649.0,"Friday Slide: Opportunity Or Red Flag For Biotech ETFs? (GILD, IBB, XBI)",2012-02-17 15:10:00-05:00,GILD,positive
551650.0,Gilead Analyst: The Gilead News is Positive for Vertex Investor Sentiment.  It Casts Doubt Over the Thesis That Invicek's Market Share Will Go to Zero in 2014.,2012-02-17 13:42:00-05:00,GILD,positive
551651.0,Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish,2012-02-17 12:30:00-05:00,GILD,negative
551652.0,UPDATE: Analyst Mark Schoenebaum Discusses Gilead Sciences on CNBC,2012-02-17 10:29:00-05:00,GILD,neutral
551653.0,"Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix",2012-02-17 07:54:00-05:00,GILD,negative
551654.0,Achillion Pharmaceuticals Spiking Higher on Gilead Hep C Data,2012-02-17 07:47:00-05:00,GILD,neutral
551655.0,Deutsche Bank Sees Buying Opportunity on Gilead Share Weakess,2012-02-17 07:41:00-05:00,GILD,positive
551656.0,Vertex Pharmaceuticals Seeing Strength this Morning after Gilead's Negative Results,2012-02-17 07:37:00-05:00,GILD,negative
551657.0,Idenix Pharmaceuticals Seeing Weakness this Morning on Gilead's Negative Results,2012-02-17 07:24:00-05:00,GILD,negative
551658.0,Gilead Sciences Falls 23% Pre-Market on Disappointing Hep C Data,2012-02-17 07:06:00-05:00,GILD,negative
551659.0,Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study; Viral Relapse Seen Post Treatment with GS-7977 Plus Ribavirin   ,2012-02-17 06:52:00-05:00,GILD,neutral
551660.0,From Earlier: U.S. FDA Grants Priority Review for Truvada for Reducing the Risk of Acquiring HIV Infection  ,2012-02-14 09:10:00-05:00,GILD,negative
551661.0,"Morgan Stanley Initiates Coverage on Gilead Sciences at Overweight, Announces PT of $65",2012-02-10 06:41:00-05:00,GILD,negative
551662.0,Gilead Sciences Hits 52-Week High of $54.90,2012-02-06 09:32:00-05:00,GILD,neutral
551663.0,"Gilead Sciences Soars On ""Striking"" Clinical Trial Data",2012-02-03 13:33:00-05:00,GILD,neutral
551664.0,Gilead Sciences Surging on Clinical Trial Data,2012-02-03 10:50:00-05:00,GILD,neutral
551665.0,UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences,2012-02-03 09:36:00-05:00,GILD,positive
551666.0,Gilead Sciences Hits 52-Week High of $53.42,2012-02-03 09:30:00-05:00,GILD,neutral
551667.0,Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit ,2012-02-03 09:07:00-05:00,GILD,positive
551668.0,Brean Murray Maintains Sell on Idenix,2012-02-03 09:02:00-05:00,GILD,neutral
551669.0,UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences,2012-02-03 07:13:00-05:00,GILD,neutral
551670.0,JP Morgan Raises PT on Gilead Sciences to $65,2012-02-03 06:59:00-05:00,GILD,positive
551671.0,Gilead Guides 2012 Product Sales $8.6-8.8B,2012-02-02 17:31:00-05:00,GILD,neutral
551672.0,Gilead Sciences Reports Q4 EPS $0.97 vs $1.05 Est; Revenues $2.20B vs $2.18B Est	 			,2012-02-02 16:06:00-05:00,GILD,neutral
551673.0,Gilead Sciences Hits 52-Week High of $49.40,2012-02-02 10:03:00-05:00,GILD,neutral
551674.0,Gilead Sciences Hits 52-Week High of $49.06,2012-02-01 09:33:00-05:00,GILD,neutral
551675.0,Brean Murray Carret & Co. Raises Gilead Sciences PT To $60,2012-01-26 16:00:00-05:00,GILD,neutral
551676.0,Gilead Sciences Hits 52-Week High of $47.87,2012-01-25 10:51:00-05:00,GILD,neutral
551677.0,"Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV  ",2012-01-24 16:06:00-05:00,GILD,positive
551678.0,BioLineRx Surges after Hep C License Agreement,2012-01-24 10:23:00-05:00,GILD,positive
551679.0,Gilead Sciences Hits 52-Week High of $47.56,2012-01-24 09:30:00-05:00,GILD,neutral
551680.0,Achillion's Hep C Pipeline Likely Can't Compete,2012-01-19 09:03:00-05:00,GILD,neutral
551681.0,From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV  ,2012-01-19 06:54:00-05:00,GILD,positive
551682.0,J.P. Morgan Gives Gilead Sciences HIV Monthly Rx Update ,2012-01-18 10:53:00-05:00,GILD,neutral
551683.0,Gilead Sciences Hits 52-Week High of $46.51,2012-01-18 09:53:00-05:00,GILD,neutral
551684.0,6 Stocks that worth watching,2012-01-17 18:04:00-05:00,GILD,positive
551685.0,"Gilead Enters into $1.25B, 5 Year Credit Pact; Funds Will Partially Cover Pharmasset Acquisition",2012-01-17 11:38:00-05:00,GILD,positive
551686.0,Gilead Sciences Hits 52-Week High of $45.05,2012-01-17 09:30:00-05:00,GILD,neutral
551687.0,Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?,2012-01-10 14:54:00-05:00,GILD,neutral
551688.0,Just What The Doctor Ordered: 4 ETFs For Biotech M&A,2012-01-09 15:49:00-05:00,GILD,neutral
551689.0,"Forget Dendreon, Inhibitex is the New Biotech Success Story",2012-01-09 13:26:00-05:00,GILD,positive
551690.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin,2011-12-29 03:21:00-05:00,GILD,positive
551691.0,"Citigroup Reiterates Buy, $49 Target on Gilead Sciences",2011-12-28 07:09:00-05:00,GILD,neutral
551692.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,GILD,positive
551693.0,"Citigroup Reiterates Buy, $49 Target on Gilead Sciences",2011-12-27 10:34:00-05:00,GILD,neutral
551694.0,"Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infectio",2011-12-20 16:30:00-05:00,GILD,neutral
551695.0,Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition,2011-12-16 16:24:00-05:00,GILD,positive
551696.0,Gilead Says it Remains Committed To Closing Pharmasset Acquisition -DJ,2011-12-16 10:00:00-05:00,GILD,positive
551697.0,JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement,2011-12-16 09:50:00-05:00,GILD,neutral
551698.0,Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada,2011-12-15 16:30:00-05:00,GILD,neutral
551699.0,"Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV  ",2011-12-09 08:42:00-05:00,GILD,negative
551700.0,Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis,2011-12-08 06:56:00-05:00,GILD,neutral
551701.0,"Financial Breakfast: Morning News Summary for December 7, 2011",2011-12-07 07:26:00-05:00,GILD,neutral
551702.0,Gilead Prices $3.7 Billion of Senior Unsecured Notes   ,2011-12-07 06:48:00-05:00,GILD,negative
551703.0,"Deutsche Bank Reiterates Buy, $53 PT on Gilead",2011-12-05 12:16:00-05:00,GILD,neutral
551704.0,"Citi Reiterates Buy, $49 PT on Gilead",2011-12-05 12:11:00-05:00,GILD,neutral
551705.0,J.P. Morgan Reiterates Overweight On Gilead,2011-12-05 12:07:00-05:00,GILD,negative
551706.0,"Gilead's Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study  ",2011-12-05 08:33:00-05:00,GILD,positive
551707.0,"Pharmasset Seeing Weak Tape, Will $11B Deal Go Through?",2011-12-01 13:37:00-05:00,GILD,negative
551708.0,Brean Murray Raises Inhibitex PT to $19 From $12,2011-11-29 12:25:00-05:00,GILD,neutral
551709.0,Gilead Receives European Marketing Authorization for Eviplera,2011-11-28 13:00:00-05:00,GILD,neutral
551710.0,"Deutsche Bank Has Buy, $53 PT On Gilead ",2011-11-28 11:37:00-05:00,GILD,neutral
551711.0,"Investor Ideas' Biotech and Pharma Stock Investor Alert for Aethlon Medical, Vertex, Pharmasset",2011-11-28 11:21:00-05:00,GILD,positive
551712.0,Credit Suisse Downgrades Gilead Sciences to Neutral ,2011-11-28 09:03:00-05:00,GILD,positive
551713.0,Goldman Sachs Adds Gilead Sciences to Conviction Buy List,2011-11-28 07:11:00-05:00,GILD,neutral
551714.0,Investor Ideas' Hepatitis C Virus (HCV) Biotech and Pharma Stock Investor Alert,2011-11-25 12:30:00-05:00,GILD,positive
551715.0,"Fast Money Picks For November 25th (EMB, GILD, PM, DE, TWI)",2011-11-23 19:34:00-05:00,GILD,neutral
551716.0,Argus Downgrades Gilead Sciences to Hold,2011-11-23 07:46:00-05:00,GILD,neutral
551717.0,"Brean Murray Downgrades Pharmasset to ""Hold""",2011-11-22 11:29:00-05:00,GILD,neutral
551718.0,UPDATE: Bank of America Upgrades Gilead Sciences to Buy  ,2011-11-22 09:52:00-05:00,GILD,neutral
551719.0,"Bank of America Upgrades Gilead Sciences to Buy, PO Raised to $55",2011-11-22 09:44:00-05:00,GILD,negative
551720.0,"UDPATE: JP Morgan Maintains Overweight, Raises PT to $55 on Gilead Sciences",2011-11-22 09:18:00-05:00,GILD,neutral
551721.0,Piper Jaffray Reiterates Overweight Rating on Achillion Pharmaceuticals,2011-11-22 07:26:00-05:00,GILD,negative
551722.0,Canaccord Downgrades Pharmasset to Hold,2011-11-22 07:20:00-05:00,GILD,neutral
551723.0,UBS Downgrades Pharmasset to Neutral,2011-11-22 07:19:00-05:00,GILD,neutral
551724.0,BMO Capital Markets Upgrades Gilead Sciences to Outperform,2011-11-22 07:10:00-05:00,GILD,neutral
551725.0,JP Morgan Raises PT on Gilead Sciences to $55,2011-11-22 06:53:00-05:00,GILD,positive
551726.0,Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs,2011-11-22 06:49:00-05:00,GILD,neutral
551727.0,"Fast Money Picks For November 22nd (TOL, GILD, M, GFI, MS)",2011-11-21 19:45:00-05:00,GILD,neutral
551728.0,Pharmasset to Pay Gilead $331.9M Fee if Deal Terminated,2011-11-21 16:53:00-05:00,GILD,negative
551729.0,Pharmasset Agreed Not to Solicit Talks on Other Proposals,2011-11-21 16:52:00-05:00,GILD,positive
551730.0,Afternoon Movers; Healthcare Sector Up Significantly,2011-11-21 16:32:00-05:00,GILD,neutral
551731.0,Hep-C Stocks Soar On M&A News,2011-11-21 13:14:00-05:00,GILD,neutral
551732.0,What's Next for Hep C Drug Stocks Following Gilead's $11B Pharmasset Buy? ,2011-11-21 13:14:00-05:00,GILD,neutral
551733.0,"UPDATE: Piper Jaffray Downgrades Pharmasset to Neutral, PT Raised to $137",2011-11-21 11:10:00-05:00,GILD,neutral
551734.0,GILD Acquires VRUS,2011-11-21 11:00:00-05:00,GILD,neutral
551735.0,Stocks Hitting 52-Week Highs,2011-11-21 10:02:00-05:00,GILD,neutral
551736.0,"Option Alert: Pharmasset December 100 Call Rises 17,300% on Takeover by Gilead Sciences",2011-11-21 09:54:00-05:00,GILD,positive
551737.0,Morning Market Movers,2011-11-21 09:48:00-05:00,GILD,neutral
551738.0,"Jim Cramer says Gilead ""Staggeringly"" Overpaid for Pharmasset",2011-11-21 09:44:00-05:00,GILD,neutral
551739.0,Gilead Sciences Hits 52-Week Low of $35.27,2011-11-21 09:34:00-05:00,GILD,negative
551740.0,J.P. Morgan Maintains Overweight Rating on Gilead Sciences ,2011-11-21 09:23:00-05:00,GILD,negative
551741.0,Inhibitex Rises 29% Pre-Market on Gilead Buyout of Pharmasset,2011-11-21 09:18:00-05:00,GILD,neutral
551742.0,Deutsche Bank Maintains Buy Rating on Gilead Sciences Following Pharmasset Acquisition,2011-11-21 09:09:00-05:00,GILD,neutral
551743.0,Benzinga's Top Pre-Market Losers,2011-11-21 08:18:00-05:00,GILD,negative
551744.0,Benzinga's Top Pre-Market Gainers,2011-11-21 08:12:00-05:00,GILD,positive
551745.0,Gilead Participating in Merger Monday with Massive $11B Deal,2011-11-21 07:55:00-05:00,GILD,neutral
551746.0,Pharmasset Shares Surge In Pre-Market On Acquisition News,2011-11-21 07:37:00-05:00,GILD,positive
551747.0,"Financial Breakfast: Morning News Summary for November 21, 2011",2011-11-21 07:34:00-05:00,GILD,neutral
551748.0,Pharmasset Rises 85% Pre-Market on Gilead Sciences Buyout,2011-11-21 07:32:00-05:00,GILD,neutral
551749.0,"Pharmasset, Gilead Sciences Resume Trading ",2011-11-21 07:31:00-05:00,GILD,neutral
551750.0,"Pharmasset, Gilead Sciences to resume trading at 7:30am",2011-11-21 07:07:00-05:00,GILD,neutral
551751.0,"Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion",2011-11-21 07:00:00-05:00,GILD,neutral
551752.0,JP Morgan Overweight on Positive Rx Data from Gilead Sciences,2011-11-16 09:34:00-05:00,GILD,positive
551753.0,"End-of-Day Market Summary for November 15, 2011",2011-11-15 16:17:00-05:00,GILD,neutral
551754.0,"Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop  and Commercialize a Single-Tablet Regimen of Prezista with Emtriva, GS 7340 and Cobicistat",2011-11-15 16:07:00-05:00,GILD,positive
551755.0,Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista,2011-11-15 16:06:00-05:00,GILD,positive
551756.0,"Third Point Entered Stakes in Yahoo, HollyFrontier Corp, Gilead Sciences, Warnaco Group and Gardner Denver; Exited Stakes in CIT Group, NXP Semiconductors, Pall Corp, Health Net, Safeway and Freeport-McMoran in Q3",2011-11-14 16:46:00-05:00,GILD,neutral
551757.0,Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina  ,2011-11-07 08:33:00-05:00,GILD,neutral
551758.0,Gilead Announces Positive Five-Year Data Showing Effect of Viread on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B,2011-11-05 14:30:00-04:00,GILD,positive
551759.0,Profit Up for Gilead Sciences,2011-10-27 17:07:00-04:00,GILD,positive
551760.0,Gilead Sciences Reports Q3 EPS $1.02 vs $1.01 Est; Revenues $2.12B vs $2.11B Est,2011-10-27 16:07:00-04:00,GILD,neutral
551761.0,"Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet ""Quad"" HIV Regimen   ",2011-10-27 16:04:00-04:00,GILD,neutral
551762.0,Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV   ,2011-10-26 08:30:00-04:00,GILD,positive
551763.0,"Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise",2011-10-25 13:50:00-04:00,GILD,neutral
551764.0,Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection   ,2011-10-24 16:25:00-04:00,GILD,positive
551765.0,"Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-24 08:46:00-04:00,GILD,neutral
551766.0,Standpoint Research Downgraded Gilead Sciences to Hold,2011-10-19 14:37:00-04:00,GILD,neutral
551767.0,Goldman Sachs Comments on Gilead Sciences,2011-10-06 11:50:00-04:00,GILD,neutral
551768.0,Piper Jaffray Comments on Gilead Sciences' Licensing Agreement with Boehringer Ingelheim,2011-10-06 11:32:00-04:00,GILD,positive
551769.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2011-09-26 04:42:00-04:00,GILD,negative
551770.0,Gilead's Second Pivotal Phase 3 Clinical Study of the Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective   ,2011-09-19 16:06:00-04:00,GILD,neutral
551771.0,"Financial Breakfast: Morning News Summary for September 16, 2011",2011-09-16 07:44:00-04:00,GILD,neutral
551772.0,Benzinga's Top Pre-Market Gainers,2011-09-16 07:37:00-04:00,GILD,positive
551773.0,Benzinga's Top Upgrades,2011-09-16 07:30:00-04:00,GILD,positive
551774.0,"Goldman Sachs Upgrades Gilead Sciences To Buy, $46 PT",2011-09-16 05:55:00-04:00,GILD,neutral
551775.0,Citi Maintains Hold on Gilead Sciences,2011-09-12 09:38:00-04:00,GILD,neutral
551776.0,Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials ,2011-09-04 11:47:00-04:00,GILD,neutral
551777.0,Piper Jaffray Looks Long at Gilead Sciences,2011-08-25 07:08:00-04:00,GILD,neutral
551778.0,J.P. Morgan Adding Gilead Sciences To Focus List,2011-08-16 08:17:00-04:00,GILD,neutral
551779.0,JP Morgan Adds Gilead Sciences To Analyst Focus list,2011-08-16 06:15:00-04:00,GILD,positive
551780.0,Hearing UBS Positive on Gilead Sciences,2011-08-15 10:14:00-04:00,GILD,positive
551781.0,Gilead's Antiretroviral Regiment Meets 48-Week Primary Objective in Phase 3 Study,2011-08-15 08:32:00-04:00,GILD,neutral
551782.0,Brean Murray Carret & Co Revises EPS Estimates Of Gilead,2011-08-11 08:53:00-04:00,GILD,neutral
551783.0,J.P. Morgan Reports On FDA Approval For GILD,2011-08-11 08:32:00-04:00,GILD,positive
551784.0,Gilead Sciences Resolves FDA Warning Letter Related to San Dimas Manufacturing Facility  ,2011-08-10 17:01:00-04:00,GILD,negative
551785.0,FDA Approves Gilead Sciences' Complera for HIV-1 Infection in Treatment-Naïve Adults ,2011-08-10 16:06:00-04:00,GILD,positive
551786.0,Gilead Sciences To Purchase Research and Manufacturing Facilities From Genentech ,2011-08-09 07:35:00-04:00,GILD,neutral
551787.0,Gilead Sciences to Purchase Biologics Process Research and Clinical Manufacturing Facility from Genentech ,2011-08-08 16:18:00-04:00,GILD,neutral
551788.0,"AIDS Healthcare Foundation Hosts Protest & ""Die-in"" Over Gilead's AIDS Drug Prices",2011-08-02 21:23:00-04:00,GILD,negative
551789.0,Wednesday's S&P 500 Sector Recap: Hottest and Coldest Sectors,2011-07-27 17:36:00-04:00,GILD,neutral
551790.0,UPDATE: JP Morgan Raises PT on Gilead Sciences from $45 to $50,2011-07-27 09:53:00-04:00,GILD,positive
551792.0,UPDATE: Oppenheimer Raises PT on Gilead Sciences to $46,2011-07-27 07:26:00-04:00,GILD,neutral
551793.0,JP Morgan Raises PT on Gilead Sciences To $50,2011-07-27 07:14:00-04:00,GILD,positive
551794.0,Oppenheimer Raises PT On Gilead Sciences To $46,2011-07-27 06:12:00-04:00,GILD,neutral
551796.0,"Gilead Sciences Reports Profit, Beats Estimates",2011-07-26 17:08:00-04:00,GILD,positive
551797.0,Gilead Sciences Reports Q2 EPS of $1.00 vs. $0.99 Est; Revenues $2.14B vs. $2.07B Est			,2011-07-26 16:06:00-04:00,GILD,neutral
551798.0,"Notable Earnings After the Close: ACE, AMZN, GILD, CHRW, LVS, NSC, BWLD",2011-07-26 15:00:00-04:00,GILD,neutral
551799.0,ISI Group Comments on Gilead Sciences,2011-07-25 14:30:00-04:00,GILD,neutral
551800.0,"Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter",2011-07-25 13:49:00-04:00,GILD,negative
551801.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,GILD,positive
551802.0,"Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter",2011-07-21 13:12:00-04:00,GILD,neutral
551803.0,Gilead Sciences Hits New 52-Week High at $42.94,2011-07-21 13:00:00-04:00,GILD,neutral
551804.0,Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks ,2011-07-20 10:33:00-04:00,GILD,neutral
551805.0,Support Held  07-18-2011,2011-07-18 17:58:00-04:00,GILD,positive
551806.0,WANTED: Buyers  07-18-2011,2011-07-18 13:26:00-04:00,GILD,neutral
551807.0,J.P. Morgan Overweight On Gilead Sciences,2011-07-18 11:59:00-04:00,GILD,negative
551808.0,Options Brief: Gilead Sciences,2011-07-18 10:16:00-04:00,GILD,neutral
551809.0,Bank of America Comments on Gilead Sciences After Research Results,2011-07-18 07:11:00-04:00,GILD,neutral
551810.0,Oppenheimer Discusses Phase III Results From Gilead,2011-07-12 09:20:00-04:00,GILD,neutral
551811.0,Deutsche Banks Reports Gilead Sciences 1Q To Miss,2011-07-11 07:32:00-04:00,GILD,negative
551812.0,UPDATE: Piper Jaffray Upgrades Gilead Sciences to Overweight,2011-06-29 07:31:00-04:00,GILD,negative
551813.0,"Piper Jaffray Upgrades Gilead Sciences To Overweight, Raises PT To $53",2011-06-29 06:28:00-04:00,GILD,negative
551814.0,Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista,2011-06-28 08:32:00-04:00,GILD,positive
551815.0,Health Care Sector Showing Strength,2011-06-13 13:28:00-04:00,GILD,positive
551816.0,Benzinga's Top Pre-Market Losers,2011-06-13 08:19:00-04:00,GILD,negative
551817.0,"US Stock Futures Flat; Crude Oil, Gold Futures Drop ",2011-06-13 06:23:00-04:00,GILD,negative
551818.0,Stocks To Watch For June 13,2011-06-13 04:26:00-04:00,GILD,neutral
551819.0,Gilead Sciences Receives Subpoena from U.S. Department of Justice ,2011-06-10 16:15:00-04:00,GILD,positive
551820.0,Gilead Reigns Supreme In HIV,2011-06-06 08:57:00-04:00,GILD,positive
551821.0,J.P. Morgan Overweight On Gilead Sciences After Meeting With Management,2011-06-03 07:26:00-04:00,GILD,negative
551822.0,Deutsche Bank Reports on Gilead Sciences,2011-05-23 08:37:00-04:00,GILD,neutral
551823.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,GILD,neutral
551824.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy Gilead Sciences (GILD, NGG, NOG, AA, VOD)",2011-05-04 02:18:00-04:00,GILD,negative
551825.0,Deutsche Bank Comments On Gilead Sciences Client Dinner,2011-05-03 09:01:00-04:00,GILD,neutral
551826.0,"Top 5 S&P 500 worst performers for the week – IRM, GILD, HOG, KEY and DV",2011-04-24 06:21:00-04:00,GILD,negative
551827.0,UPDATE: Citi Raising Price Target On Gilead Sciences Inc (GILD),2011-04-21 10:05:00-04:00,GILD,neutral
551828.0,Jefferies Comments On Gilead Sciences 1Q11 Results,2011-04-21 08:22:00-04:00,GILD,neutral
551829.0,J.P. Morgan Maintains Overweight on Gilead Sciences (GILD),2011-04-21 07:56:00-04:00,GILD,negative
551830.0,Citigroup Raises PT On Gilead Sciences To $44,2011-04-21 07:40:00-04:00,GILD,neutral
551831.0,Gilead Sciences Reports EPS $0.87 vs. $0.97 Estimate; Revenues $1.93B vs. $2.04B Estimate (GILD),2011-04-20 16:12:00-04:00,GILD,neutral
551832.0,Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory Syncytial Virus   ,2011-04-20 08:36:00-04:00,GILD,positive
551833.0,Trend Continues to be Your Friend  04-15-2011,2011-04-15 18:52:00-04:00,GILD,positive
551834.0,J.P. Morgan Maintains Overweight on Gilead Sciences (GILD),2011-04-11 07:52:00-04:00,GILD,negative
551835.0,Deutsche Bank Reiterates Buy Rating On GILD,2011-04-04 09:16:00-04:00,GILD,neutral
551836.0,Yale and Gilead Sciences Announce Cancer Research Collaboration   ,2011-03-30 08:30:00-04:00,GILD,negative
551837.0,Drug Stocks Finally Make Their Move ,2011-03-29 13:01:00-04:00,GILD,neutral
551838.0,Wedbush Dropping Coverage Of Gilead Sciences,2011-03-29 07:18:00-04:00,GILD,neutral
551839.0,"Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin (GILD, AMGN, BIIB, CELG)",2011-03-29 01:23:00-04:00,GILD,positive
551840.0,Deutsche Bank Releases GILD Weekly IMS,2011-03-28 09:10:00-04:00,GILD,neutral
551841.0,"Mad Money Lightning Round: Cramer Likes Alcoa, Health Care REIT (AA, SPPI, PANL, PFE, GILD, CELG, MRK, ABT, AGNC, NLY, HCN)",2011-03-28 02:03:00-04:00,GILD,positive
551842.0,"UBS Research Summary (AOL, CCL, CHD, GILD, RCL, SFSF)",2011-03-23 10:00:00-04:00,GILD,neutral
551843.0,Gilead to Offer Senior Notes   ,2011-03-23 09:12:00-04:00,GILD,neutral
551844.0,Gilead Sciences Files Automatic Mixed Securities Shelf,2011-03-23 08:43:00-04:00,GILD,positive
551845.0,Phase III Clinical Trial of Gilead's Investigational Elvitegravir Meets 48-Week Primary Objective   ,2011-03-23 08:32:00-04:00,GILD,neutral
551846.0,Biotech Sector Snapshot HIV Drug Development,2011-03-18 14:13:00-04:00,GILD,neutral
551847.0,Biotech/Pharma Sector Close-Up;  Drug Resistance Potential for HIV Drugs; Can Medical Devices take over when drugs fail?,2011-03-17 14:22:00-04:00,GILD,negative
551848.0,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Lowest PEG Ratio (CELG, TEVA, GILD, GENZ)",2011-03-17 02:29:00-04:00,GILD,negative
551849.0,FDA Modifies Boxed Warning For Gilead Sciences Letairis Drug; Monthly Tests No Longer Required,2011-03-05 15:42:00-05:00,GILD,negative
551850.0,Running Late  03-04-2011,2011-03-04 15:43:00-05:00,GILD,neutral
551851.0,FDA Modifies Boxed Warning For Gilead Sciences Letairis Drug; Monthly Tests No Longer Required ,2011-03-04 15:20:00-05:00,GILD,negative
551852.0," How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GLD)",2011-03-04 11:37:00-05:00,GILD,positive
551853.0,U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis ,2011-03-04 08:32:00-05:00,GILD,negative
551854.0,Deutsche Bank Reports FDA Meta-Analysis On Abacavir Will Not Change Much For Gilead Sciences,2011-03-02 08:49:00-05:00,GILD,neutral
551855.0,Gilead Sciences HIV Franchise Tracking Above Street Consensus Estimates,2011-02-28 10:00:00-05:00,GILD,neutral
551856.0,Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375M,2011-02-22 08:33:00-05:00,GILD,neutral
551857.0,ETF Showdown: A Biotech Battle,2011-02-18 16:05:00-05:00,GILD,negative
551858.0,Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278   ,2011-02-10 16:21:00-05:00,GILD,neutral
551859.0,Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278,2011-02-10 16:11:00-05:00,GILD,neutral
551860.0,"J.P. Morgan Leaves Gilead Sciences Overweight Rating, $45 PT Unchanged (GILD)",2011-02-09 07:54:00-05:00,GILD,negative
551861.0,Gilead Sciences Announces Notification of ANDA Filing for Tamiflu,2011-02-07 17:01:00-05:00,GILD,neutral
551862.0,Gilead Beats by a Penny - Analyst Blog,2011-01-26 10:31:00-05:00,GILD,neutral
551863.0,Gilead Beats by a Penny - Analyst Blog,2011-01-26 10:00:00-05:00,GILD,neutral
551864.0,Gilead Sciences Down Despite Earnings Beat (GILD),2011-01-25 16:36:00-05:00,GILD,neutral
551865.0,Gilead Sciences Repurchases $5B of Common Stock,2011-01-25 16:31:00-05:00,GILD,neutral
551866.0,Gilead Sciences Announces Fourth Quarter and Full Year 2010 Financial Results,2011-01-25 16:10:00-05:00,GILD,neutral
551867.0,Gilead Sciences Reports Q4 EPS of $.95 vs. $.94,2011-01-25 16:09:00-05:00,GILD,neutral
551868.0,Gilead Sciences Receives Refuse to File Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada,2011-01-25 16:06:00-05:00,GILD,negative
551869.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 09:01:00-05:00,GILD,neutral
551870.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 08:30:00-05:00,GILD,neutral
551871.0,"Earnings Scheduled For January 25 (MMM, YHOO, VZ, JNJ, KMB, JNPR, GILD, DD, NSC, COH, AKS, BLK, TRV, ALTR, DV)",2011-01-25 02:51:00-05:00,GILD,neutral
551872.0,Earnings Preview:  Gilead Sciences - Analyst Blog,2011-01-24 12:31:00-05:00,GILD,neutral
551873.0,Earnings Preview:  Gilead Sciences - Analyst Blog,2011-01-24 12:00:00-05:00,GILD,neutral
551874.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 18:01:00-05:00,GILD,neutral
551875.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 17:40:00-05:00,GILD,neutral
551876.0,"J.P Morgan Gives Update On BioTech Stocks (AMGN, BIIB, GILD)",2011-01-21 10:32:00-05:00,GILD,neutral
551877.0,European Market May Open its Doors to This Biotech,2011-01-13 11:08:00-05:00,GILD,neutral
551878.0,European Market May Open its Doors to This Biotech,2011-01-13 11:08:00-05:00,GILD,neutral
551879.0,Jefferies: GILD Is Range-Bound Until There's Clarity On New Pipeline Assets,2011-01-11 08:34:00-05:00,GILD,positive
551880.0,Gilead Ends Letairis Trial for IPF - Analyst Blog,2010-12-23 17:03:00-05:00,GILD,neutral
551881.0,Gilead Ends Letairis Trial for IPF - Analyst Blog,2010-12-23 16:18:00-05:00,GILD,neutral
551882.0,"Stocks To Watch For December 23 (MU, CROX, BBBY, GILD, MON)",2010-12-23 03:37:00-05:00,GILD,neutral
551883.0,"Bed, Bath & Beyond, Micron: After-Hours Trading",2010-12-22 19:00:00-05:00,GILD,neutral
551884.0,2011 Big-Cap Biotech Preview,2010-12-22 07:00:00-05:00,GILD,neutral
551885.0,Gilead to Buy Arresto Biosciences - Analyst Blog,2010-12-21 13:03:00-05:00,GILD,neutral
551886.0,Gilead to Buy Arresto Biosciences - Analyst Blog,2010-12-21 12:30:00-05:00,GILD,neutral
551887.0,Big Pharma in Frenzy of Drug Deals,2010-12-21 11:34:00-05:00,GILD,negative
551888.0,Gilead Sciences Acquires Arresto Biosciences for $225M   ,2010-12-20 08:32:00-05:00,GILD,neutral
551889.0,DoJ declines to intervene in lawsuit against Gilead Sciences regarding Ranexa (GILD),2010-12-16 16:18:00-05:00,GILD,negative
551890.0,"Mad Money Lightning Round: Cramer Prefers EMC To Terremark Worldwide (TMRK, EMC, DWA, GILD, CELG, F)",2010-12-15 05:45:00-05:00,GILD,negative
551891.0,'Mad Money Lightning Round': Ford Rumbles,2010-12-14 19:22:00-05:00,GILD,negative
551892.0,Pfizer Drug Withdrawn from Market - Analyst Blog,2010-12-14 08:03:00-05:00,GILD,neutral
551893.0,Pfizer Drug Withdrawn from Market - Analyst Blog,2010-12-14 07:20:00-05:00,GILD,neutral
551894.0,Wells Fargo Resumes Coverage On Gilead Sciences With $48-52 Valuation Range,2010-12-10 10:28:00-05:00,GILD,positive
551895.0,ETFs For Biotech M&A Mania,2010-12-06 14:05:00-05:00,GILD,neutral
551896.0,Merck Halts Isentress Study - Analyst Blog,2010-11-30 10:00:00-05:00,GILD,neutral
551897.0,Merck Halts Isentress Study - Analyst Blog,2010-11-30 04:28:00-05:00,GILD,neutral
551898.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 18:30:00-05:00,GILD,positive
551899.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 18:00:00-05:00,GILD,neutral
551900.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 18:00:00-05:00,GILD,neutral
551901.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 13:01:00-05:00,GILD,positive
551902.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 12:18:00-05:00,GILD,neutral
551903.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 12:18:00-05:00,GILD,neutral
551904.0,Gilead Drug Shown to Reduce Risk of HIV Infection - Study,2010-11-23 11:06:00-05:00,GILD,negative
551905.0,Gilead Drug Shown to Reduce Risk of HIV Infection - Study,2010-11-23 11:06:00-05:00,GILD,negative
551906.0,Gilead Sciences Submits New Drug Application to U.S. FDA for Once-Daily Single-Tablet Regimen for HIV ,2010-11-23 08:32:00-05:00,GILD,neutral
551907.0,UBS Initiates Buy Rating on Gilead Sciences,2010-11-16 10:45:00-05:00,GILD,neutral
551908.0,"Zacks Industry Outlook Highlights: Bayer, Sanofi-Aventis, Alcon, Gilead Sciences and Biogen Idec   - Press Releases",2010-11-10 10:33:00-05:00,GILD,neutral
551909.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,2010-11-09 17:03:00-05:00,GILD,neutral
551910.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,GILD,neutral
551911.0,Dr. Paul Berg to Retire from Gilead Sciences' Board of Directors   ,2010-11-05 08:39:00-04:00,GILD,neutral
551912.0,"NASDAQ Biotech Market Gainers; (BPAX), (CELG), (GILD) Stocks to Watch ",2010-11-02 14:08:00-04:00,GILD,neutral
551913.0,Deutsche Bank Reviews Gilead's Possible Safety Issues (GILD),2010-11-02 10:12:00-04:00,GILD,positive
551914.0,Time To Buy Gilead Sciences (GILD) ,2010-11-01 12:51:00-04:00,GILD,neutral
551915.0,Gilead Sciences Upgraded to Outperform ,2010-11-01 11:27:00-04:00,GILD,neutral
551916.0,"Zacks.com featured expert Kevin Matras highlights: Domino's Pizza, Inc., Gilead Sciences, Inc., Huntsman Corp., Domtar Corp. and Diodes Inc.  - Press Releases",2010-10-27 16:03:00-04:00,GILD,neutral
551917.0,Gilead Sciences (GILD) - Bull of the Day,2010-10-27 16:03:00-04:00,GILD,neutral
551918.0,"Zacks Bull and Bear of the Day Highlights: Gilead Sciences, Linear Technology, Biogen Idec, Elan and Novartis     - Press Releases",2010-10-27 15:33:00-04:00,GILD,neutral
551919.0,Gilead Sciences: Defying Gravity (GILD),2010-10-22 11:10:00-04:00,GILD,neutral
551920.0,"Biotech Growth Stocks At A Reasonable Price (CBST, CEPH, GILD, TEVA)",2010-10-21 13:49:00-04:00,GILD,positive
551921.0,Antiviral Franchise Drives Gilead - Analyst Blog,2010-10-20 18:54:00-04:00,GILD,neutral
551922.0,Gilead Rising On Heavy Volume After Earnings (GILD),2010-10-20 13:54:00-04:00,GILD,neutral
551923.0,"Gilead Sciences, Inc. (NASDAQ: GILD)",2010-10-20 11:43:00-04:00,GILD,neutral
551924.0,Gilead Sciences Exceeds Wall Street Estimates (GILD),2010-10-19 17:13:00-04:00,GILD,neutral
551925.0,Gilead Up After Reporting Mixed Quarter (GILD),2010-10-19 16:18:00-04:00,GILD,neutral
551926.0,Gilead Sciences Announces Third Quarter Results; EPS $.83,2010-10-19 16:11:00-04:00,GILD,neutral
551927.0,"AAPL and Oil and 7.5% Levels, Oh My  ",2010-10-19 14:12:00-04:00,GILD,neutral
551928.0,Markets Well Off Lows ,2010-10-19 11:52:00-04:00,GILD,positive
551929.0,"Earnings Scheduled For October 19 (GS, BAC, KO, YHOO, UNH, JNPR, SLM, NYT, HOG, JNJ, ITW, EMC, LMT, GILD, BK, MICC, STT, WDC, BSX, MNI, OXY, BTU)",2010-10-19 04:46:00-04:00,GILD,neutral
551930.0,Jefferies & Company Lowers Estimates While Raising Price Target Of Gilead Sciences,2010-10-15 09:11:00-04:00,GILD,negative
551931.0,"Ben Graham Buys in Pharma: Gilead and Teva (GILD, TEVA)",2010-10-14 11:40:00-04:00,GILD,neutral
551932.0,J.P. Morgan Previews Gilead's Earnings (GILD),2010-10-14 07:59:00-04:00,GILD,neutral
551933.0,"Betting on Biotech - Interview with Adam Feuerstein, Senior Columnist and Biotech Analyst of TheStreet.com",2010-10-01 12:46:00-04:00,GILD,neutral
551934.0,"Top 4 NASDAQ Stocks In The Healthcare Sector With The Highest ROE (TRIB, ALXN, GILD, USNA)",2010-09-28 05:56:00-04:00,GILD,positive
551935.0,Jefferies Reiterates Hold Rating on Gilead Sciences (GILD),2010-09-17 09:15:00-04:00,GILD,neutral
551936.0,Gilead Reports Positive Quad Data - Analyst Blog,2010-09-14 15:03:00-04:00,GILD,positive
551937.0,Jefferies Has Hold On Gilead (GILD),2010-09-14 07:23:00-04:00,GILD,neutral
551938.0,"Mad Money Lightning Round: Cramer Doesn't Like Coal Stocks (LINE, RTN, GILD, YZC, BTU, WFC, JPM)",2010-09-12 13:57:00-04:00,GILD,negative
551939.0,"Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ROE (GILD, TLCR, TECH, AMGN)",2010-09-09 07:13:00-04:00,GILD,positive
551940.0,Gilead Files MAA for HIV Drug - Analyst Blog,2010-09-07 17:03:00-04:00,GILD,neutral
551941.0,Gilead Provides Update on $5 Billion Stock Repurchase (GILD),2010-09-01 08:31:00-04:00,GILD,neutral
551942.0,"Benzinga's After Hours Gainers (STX, NFLX, WFMI)",2010-08-31 18:26:00-04:00,GILD,neutral
551943.0,Generic Risk For Gilead's Hepsera  - Analyst Blog,2010-08-23 08:21:00-04:00,GILD,negative
551944.0,"Cautious Outlook On Biotech Stocks (GILD, DNDN, AMGN, CELG, BIIB, GENZ)",2010-08-16 13:53:00-04:00,GILD,negative
551945.0,"Vertex Loss Narrows, Reaffirms Guidance  - Analyst Blog",2010-08-04 16:10:00-04:00,GILD,negative
551946.0,"UTHR Up on Lower Costs, Higher Revs - Analyst Blog",2010-08-03 09:10:00-04:00,GILD,negative
551947.0,"Market Roundup (F, ADBE, BA, GOOG, GILD, CELG, FSLR)",2010-07-28 14:21:00-04:00,GILD,neutral
551948.0,Gilead Repurchasing $1 billion In Stock (GILD),2010-07-26 07:28:00-04:00,GILD,neutral
551949.0,Gilead – Not Your Run of the Mill Mid-Tier Pharma,2010-07-25 02:54:00-04:00,GILD,neutral
551950.0,Near-Term Impact Of New Guidelines Unclear On GILD ,2010-07-21 13:57:00-04:00,GILD,negative
551951.0,"Afternoon Market Update (GILD, CYT)",2010-07-21 13:52:00-04:00,GILD,neutral
551952.0,GILD Shares Reach Bottom Due To Unrealistically Bearish Street View: JP Morgan,2010-07-21 12:02:00-04:00,GILD,positive
551953.0,"Benzinga’s Top Downgrades (GILD, RICK, YHOO, CPLP)",2010-07-21 08:58:00-04:00,GILD,positive
551954.0,"Benzinga’s Top Pre-Market NASDAQ Losers (YHOO, STX, GILD, JASO)",2010-07-21 08:56:00-04:00,GILD,negative
551955.0,RBC Capital Downgrades GILD To Sector Perform,2010-07-21 06:14:00-04:00,GILD,neutral
551956.0,"Gilead Sciences Misses Estimates, Shares Fall 4% (GILD)",2010-07-20 16:37:00-04:00,GILD,positive
551957.0,J.P. Morgan Reiterates Overweight Rating On Gilead (GILD),2010-07-19 12:50:00-04:00,GILD,negative
551958.0,"Piper Jaffray Lowers Price Targets In Biotech Complex (BMRN, GENZ, GILD, CELG, ALXN, HGSI)",2010-07-19 11:39:00-04:00,GILD,negative
551959.0,"Oppenheimer: Earnings Preview Of GILD, CELG, AMGN, GENZ",2010-07-13 16:06:00-04:00,GILD,neutral
551960.0,Standpoint Research Initiates Coverage On Gilead Sciences (GILD),2010-07-13 10:32:00-04:00,GILD,neutral
551961.0,"Top 4 Stocks In The Biotechnology Industry With The Highest Revenue Estimates (AMGN, GILD, GENZ, BIIB)",2010-07-06 06:58:00-04:00,GILD,positive
551962.0,Pharmaceutical ETFs on the Rise ,2010-06-30 14:49:00-04:00,GILD,neutral
551963.0,"June 24, 2010: 21 Large Cap/Low PE Stocks",2010-06-24 19:02:00-04:00,GILD,neutral
551964.0,Options Traders See Gilead Rallying (GILD),2010-06-15 11:22:00-04:00,GILD,neutral
551965.0,"Citi Rates Gilead Sciences ""Buy""",2010-06-09 08:15:00-04:00,GILD,neutral
551966.0,"Very Important Positions to Hedge Funds (AAPL, BIDU, CIT, QQQ, JPM, INTC, QCOM, XRX)",2010-06-08 16:00:00-04:00,GILD,positive
551967.0,"Top 5 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margins (QLTI, PDLI, TECH, GILD, AMGN)",2010-06-03 07:43:00-04:00,GILD,positive
551968.0,"Mad Money Lightning Round: Jim Discusses HUN, GTE, GILD, GS, BAX, CHU, WHR, OC, QCOM",2010-05-27 09:44:00-04:00,GILD,negative
551969.0,J.P. Morgan Reiterates “Overweight” Rating on Gilead (GILD),2010-05-19 09:27:00-04:00,GILD,neutral
551970.0,J.P. Morgan Sees Upside For Gilead Sciences (GILD),2010-05-18 10:00:00-04:00,GILD,neutral
551971.0,"US Stocks End Lower Yesterday After Soaring On Monday, Dow And S&P Down, Nasdaq Bucks Trend",2010-05-12 06:27:00-04:00,GILD,negative
551972.0,Gilead Sciences (GILD) Opts For Share Buyback,2010-05-11 15:48:00-04:00,GILD,positive
551973.0,Gilead Sciences Gaining On High Volume (GILD),2010-05-11 11:32:00-04:00,GILD,positive
551974.0,Gilead To Purchase Back $5 Billion Of Its Stock,2010-05-11 08:49:00-04:00,GILD,neutral
551975.0,"Top 5 NASDAQ Stocks In The Healthcare Sector With The Highest Sales (AMGN, TEVA, GILD, MYL, BIIB)",2010-05-06 07:13:00-04:00,GILD,positive
551976.0,Investors In Gilead Sciences (GILD) Should See Healthy Returns; Barron’s,2010-04-22 10:19:00-04:00,GILD,positive
551977.0,"Stock Market News for April 22, 2010 - Market News",2010-04-22 09:30:00-04:00,GILD,neutral
551978.0,"Benzinga’s Top Pre-Market Losers (VITC, IGTE, CSIQ, KMGB, GILD)",2010-04-21 09:26:00-04:00,GILD,negative
551979.0,Gilead Sciences (GILD) First-Quarter Profit Up By 45%,2010-04-20 17:16:00-04:00,GILD,positive
551980.0,"Benzinga’s Top Pre-Market Losers (HGSI, XTSI, RYAAY, GILD, CLNE)",2010-04-20 09:22:00-04:00,GILD,negative
551981.0,"Benzinga’s Top Pre-Market Losers (HGSI, XTSI, RYAAY, GILD, CLNE)",2010-04-20 09:12:00-04:00,GILD,negative
551982.0,"BIB, BIS: New Biotech 2x ProShares",2010-04-09 03:00:00-04:00,GILD,neutral
551983.0,Low Volume From The Holiday Should Push These Key Market ETFs Higher,2010-03-30 22:56:00-04:00,GILD,positive
551984.0,"Ascendere Long/Short Model Portfolio End of Day Update: March 25, 2010",2010-03-26 00:48:00-04:00,GILD,neutral
551985.0,Before Jumping Into A Single Health Care Stock Consider This ETF,2010-03-23 23:22:00-04:00,GILD,positive
551986.0,"Top 5 Large-Cap Stocks In The Biotechnology Industry With The Highest ROE (GILD, AMGN, CELG, BIIB, GENZ)",2010-03-23 09:09:00-04:00,GILD,positive
551987.0,"Top 5 Large-Cap Stocks In The Biotechnology Industry With The Highest Cash (AMGN, CELG, GILD, BIIB, GENZ)",2010-03-23 07:38:00-04:00,GILD,positive
551988.0,"Top 5 Large-Cap Stocks In Biotechnology Industry With Highest Gross Margins (CELG, BIIB, AMGN, GILD, GENZ)",2010-03-23 07:35:00-04:00,GILD,negative
551989.0,Investors Flock To Healthcare ETFs On Historic Reform,2010-03-22 16:13:00-04:00,GILD,neutral
551990.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,GILD,positive
551991.0,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,2010-03-17 13:42:00-04:00,GILD,neutral
551992.0,"Five Biotech ETFs, Which One Is Worth A Look?",2010-03-09 17:33:00-05:00,GILD,positive
551993.0,"Jim Cramer Comments On PMCS, CSCO, VRTX, GILD, PAL",2010-03-03 19:32:00-05:00,GILD,neutral
551994.0,"Astellas Dips: OSI Pharmaceuticals Inc. Takeover Not Easy (OSIP, GILD)",2010-03-02 09:38:00-05:00,GILD,negative
551995.0,FDA Approves Gilead Sciences (GILD) Cystic-Fibrosis Treatment,2010-02-23 06:12:00-05:00,GILD,positive
551996.0,Gilead Sciences Gets A ‘Sell’ Rating (GILD),2010-02-22 14:55:00-05:00,GILD,neutral
551997.0,"Benzinga’s Top Downgrades (GILD, HME, CVE, SNMX, NETL)",2010-02-22 14:02:00-05:00,GILD,positive
551998.0,"Benzinga’s Top Pre-Market Losers (RIGL, FSLR, GILD, STP, GSK)",2010-02-22 08:52:00-05:00,GILD,negative
551999.0,Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating,2010-02-18 09:53:00-05:00,GILD,neutral
552000.0,Benzinga's Intraday Sector Leaders,2010-02-17 14:19:00-05:00,GILD,neutral
552001.0,"Healthcare Industry Update (CI, PFE, WLP, CEPH, CELG)",2010-02-17 14:04:00-05:00,GILD,neutral
552002.0,GILD Reports Solid Numerical Data For Quad Combo Pill,2010-02-16 13:35:00-05:00,GILD,positive
552003.0,Calls Purchased in Gilead,2010-02-16 10:24:00-05:00,GILD,neutral
552004.0,"A Look At How Different Sectors Will Behave In 2010 (PG, KO, WMT, GSK, GILD, AZN, EXC, D, DUK)",2010-02-09 14:58:00-05:00,GILD,neutral
552005.0,"Lightening Round: NKE, GILD, V, CSCO Rock",2010-02-09 08:18:00-05:00,GILD,neutral
552006.0,"Analyst Shares Top Picks In Biotechnology Sector With CNBC (AMGN, ACOR, DNDN, GILD)",2010-02-09 08:13:00-05:00,GILD,positive
552007.0,"Top 5 Top-Cap NASDAQ Stocks with Highest PEG Ratio (BRCM, CELG, GOOG, GILD, QCOM)",2010-02-09 07:05:00-05:00,GILD,positive
552008.0,GILD To Continue To Outpace Long-Term Street Estimates,2010-01-27 13:12:00-05:00,GILD,neutral
552009.0,"GILD Reports Stellar Reports For 4Q09, Powered By HIV Franchise",2010-01-27 12:31:00-05:00,GILD,neutral
552010.0,Gilead Sciences Inc. (GILD) Gets Buy Rating From Deutsche Bank,2010-01-27 11:41:00-05:00,GILD,neutral
552011.0,"Benzinga’s Top Pre-Market Gainers (YHOO, ALTR, SANM, KTCC, GILD, SIFY)",2010-01-27 08:14:00-05:00,GILD,positive
552012.0,Gilead Beats Wall Street Estimates (GILD),2010-01-26 16:52:00-05:00,GILD,neutral
552013.0,Stock Outlook for Gilead Sciences Inc (GILD),2010-01-25 13:56:00-05:00,GILD,neutral
552014.0,"Bright 2010 Prospects For US Biotechnology (AMGN, BIIB, CELG, GENZ, GILD)",2010-01-21 13:54:00-05:00,GILD,positive
552015.0,"Jim Cramer's Lightning Round (ALSK, AMGN, GILD, CELG, SNDK, T, VZ, TGB, GLD, HAS, NFLX)",2010-01-18 17:47:00-05:00,GILD,neutral
552016.0,Mid Cap Biotechs May Outperform In 2010,2010-01-15 14:11:00-05:00,GILD,neutral
552017.0,"Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK) ",2010-01-14 09:02:00-05:00,GILD,positive
552018.0,Tech ETFs: A Way Out Of Recession,2010-01-12 17:00:00-05:00,GILD,negative
552019.0,Activity In Genzyme (GENZ),2010-01-08 16:03:00-05:00,GILD,neutral
552020.0,Celgene’s (CELG) 2010 Guidance To Set The Trend,2010-01-06 11:22:00-05:00,GILD,neutral
552021.0,"31.8% Return Expected in Gilead Sciences, Further Upside Possible (GILD)",2009-12-29 14:28:00-05:00,GILD,neutral
552022.0,"Top 5 Large-Cap NASDAQ Stocks with Highest ROE (DELL, ESRX, FSLR, GILD, PAYX)",2009-12-23 07:10:00-05:00,GILD,positive
552023.0,Bookkeeping: Beginning Human Genome Sciences (HGSI) Position,2009-12-22 11:52:00-05:00,GILD,neutral
552024.0,Human Genome Sciences (HGSI) Appears Ready to Breakout of 2 Month Base,2009-12-21 15:07:00-05:00,GILD,positive
552025.0,"Top 5 Large-Cap NASDAQ Stocks with Best ROA (GILD, BIDU, FSLR, MSFT, CTSH)",2009-12-11 08:13:00-05:00,GILD,positive
552026.0,"Top 5 Large-Cap NASDAQ Stocks with Best ROE (GILD, PAYX, ESRX, BIDU, MSFT)",2009-12-11 07:56:00-05:00,GILD,positive
552027.0,Deutsche Bank maintains “buy” rating on GILD,2009-11-11 08:19:00-05:00,GILD,neutral
552028.0,Top Franklin Templeton Funds - Mutual Fund Education,2009-11-11 01:28:00-05:00,GILD,positive
552029.0,Time To Make A Long-Term Bet On Healthcare (XLV),2009-11-05 16:18:00-05:00,GILD,neutral
552030.0,"Morgan Stanley's (MS) Swine Flu Pandemic Trades (AMZN, BCRX, CAL, EXPE, GILD, MMM, MS, SFD)",2009-11-02 18:41:00-05:00,GILD,negative
552031.0,"Cramer Says Buy Citigroup, GILD, ETP, CELG and sell ANN, GERN",2009-10-02 06:21:00-04:00,GILD,neutral
552032.0,"Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN) ",2009-09-11 18:26:00-04:00,GILD,positive
552033.0,"TheFortuneFinancial.com Free Market Research on CVBF, ESRX, CTAS, FUQI, JAZZ and GILD",2009-08-17 06:40:00-04:00,GILD,positive
